Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Involving antigen-antibody binding, specific binding protein assay or specific ligand-receptor binding assay

Subclass of:

435 - Chemistry: molecular biology and microbiology

435004000 - MEASURING OR TESTING PROCESS INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITION OR TEST STRIP THEREFORE; PROCESSES OF FORMING SUCH COMPOSITION OR TEST STRIP

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
435700900 Assay in which an enzyme present is a label 1168
435700200 Involving a micro-organism or cell membrane bound antigen or cell membrane bound receptor or cell membrane bound antibody or microbial lysate 1152
435700400 To identify an enzyme or isoenzyme 314
435700800 Involving nonmembrane bound receptor binding or protein binding other than antigen-antibody binding 112
435700720 Assay in which a label present is an enzyme substrate or substrate analogue 48
435700500 Involving avidin-biotin binding 34
435700600 Involving a modified enzyme (e.g., abzyme, recombinant, chemically altered, etc.) 13
435700710 Assay in which a label present is an enzyme inhibitor or functions to alter enzyme activity 2
20080206792Method of identifying compounds useful to treat neuronal degenerative diseases - Methods of identifying agents that inhibit ROS by altering the binding of a GTPase such as Rac to SOD, agents identified by the method, and methods of using compounds that inhibit ROS to inhibit or treat neuronal degenerative diseases, are provided.08-28-2008
20090215093COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus, such as a detectable label. Along with therapeutic utilities, these peptide based compounds can be used in assays useful for screening, monitoring, diagnostic and/or dosing purposes.08-27-2009
Entries
DocumentTitleDate
20100151485REAGENT FOR DETECTION OF ANALYTE AND PROCESS THEREOF - The present disclosure provides a reagent for detection of analyte in a sample and process of preparation of the reagent. The reagent comprises heparin and substrate coated with the analyte-counterpart. The analyte-counterpart of the reagent is capable of binding to said analyte. The present disclosure further provides a process for detection of an analyte in a sample by contacting said sample with said reagent and detecting formation of analyte-analyte counterpart complex. The present disclosure provides a kit for detection of an analyte in a sample.06-17-2010
20100092995FLUORESCENT RUTHENIUM COMPOUNDS FOR DETECTING CALCIUM BINDING PROTEINS - A fluorescent compound exhibiting a high affinity to calcium-binding proteins (CaBP) is provided. The compound, containing ruthenium, enables to detect, identify, and isolate CaBPs involved in cellular signaling and regulation. The compound is employed for diagnosing a disorder associated with CaBPs defects.04-15-2010
20110177524Recombinant Fibrinogen - The present invention relates to nucleotide sequences encoding a fibrinogen alpha, beta or gamma chain. The sequences are optimized for expression in a eukaryotic cell culture system. Such optimized nucleotide sequences allow for the efficient expression of recombinant fibrinogen and variants thereof in intact form in a eukaryotic cell culture system.07-21-2011
20110177523METHODS OF ANALYZING SAMPLES FOR BACTERIA USING WHOLE CELL CAPTURE AND ATP ANALYSIS - The invention relates to methods of capturing bacterial whole cells that includes the use of one or more antibodies having antigenic specificities for one or more distinct analytes characteristic of the specific bacterium, followed by analyzing the target whole cells using a direct or indirect ATP assay.07-21-2011
20090117583EGF-like nucleic acids and polypeptides and uses thereof - The invention provides isolated nucleic acid molecules, designated ELVIS-1, ELVIS-2, and ELVIS-3 (for Epidermal Growth Factor-Like Variant In Skin-1,2, and 3). ELVIS nucleic acid molecules encode wholly secreted and transmembrane proteins with homology to EGF and TGF-α. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.05-07-2009
20090253147Marker for stem cells - Methods and compositions are provided for the identification of stem cells, including neural, muscle and hair follicle stem cells.10-08-2009
20090081697Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals - Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, coordinates defining the 3D atomic structure thereof and methods of utilizing such coordinates for rational design or identification of antibiotics or large ribosomal subunits having desired characteristics are disclosed.03-26-2009
20100062457BIOMARKERS, KITS, AND METHOD FOR DIAGNOSING, MONITORING, AND/OR STAGING ALZHEIMER'S DISEASE - The present invention is directed to a biomarker and kit for diagnosing, monitoring and/or staging Alzheimer's disease comprising redox-reactive autoantibodies. The present invention is also directed to a method for diagnosing, monitoring and/or staging Alzheimer's disease which comprises conducting a blood test using the same.03-11-2010
20100062455Rapid Detection of Cholinesterase Inhibitors - The present invention relates to a rapid, high-throughput detection method for screening of potential casualties exposed to a cholinesterase inhibitor. A kit is provided for conducting the method that requires only a small volume of sample such as blood for detection and has a rapid screening throughput for multiple casualties. The kit is able to detect both free and protein-bound-cholinesterase inhibitors. The method should be able to differentiate asymptomatic exposure from the mass psychogenic illness cases.03-11-2010
20100062449Method Of Measuring PTX3 With High Sensitivity - To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody.03-11-2010
20100021934Perlecan Fragments as Biomarkers of Bone Stromal Lysis - A method for the detection in a body fluid of perlecan polypeptide fragments that are biomarkers of tumor metastasis, and antibodies for detecting these fragments are described. An immunoassay kit for detecting the presence of these biomarkers in a body fluid, such as serum or urine, is also described.01-28-2010
20110129847MICROFLUIDIC CONTROL CHIP AND METHOD OF DETECTING PROTEIN USING THE SAME - Provided is a microfluidic control chip, which includes a filter section having a filter to which anti-immunoglobulin antibodies, which are bound to endogenous antibodies in blood to thereby remove the endogenous antibodies, are immobilized, a first reaction section to which detection antibodies immobilized to fluorescent nano-particles are adsorbed, the detection antibodies being bound to proteins to be detected in blood which is introduced from the filter section with the endogenous antibodies removed therefrom, and a second reaction and detection section including capture antibodies immobilized thereto, binding the capture antibodies to the proteins, which are bound to the detection antibodies introduced from the first reaction section, and detecting a concentration of the proteins based on an intensity of fluorescent light. Thus, the microfluidic control chip can minimize interference of an immune response to maximize the immune response.06-02-2011
20080261236FGF21 upregulates expression of GLUT-1 in a beta Klotho-dependent manner - A method is provided to identify a modulator of βKlotho-dependant glucose transporter-1 (GLUT-1) upregulation that specifically modulates interaction of βKlotho and an FGFR.10-23-2008
20080261235Novel Green and Orange Fluorescent Labels and Their Uses - The present invention provides novel fluorescent compounds and covalent attachment chemistries which facilitate the use of these compounds as labels for ultrasensitive and quantitative fluorescent detection of low levels of biomolecules. In a preferred embodiment, the fluorescent labels of this invention are novel derivatives of the hydroxy-pyrene trisulpbonic and disulphonic acids which may be used in any assay in which radioisotopes, colored dyes or other fluorescent molecules are currently used. Thus, for example, any assay using labeled antibodies, proteins, oligonucleotides or lipids, including fluorescent cell sorting, fluorescence microscopy (including dark-field microscopy), fluorescence polarization assays, ligand, receptor binding assays, receptor activation assays and diagnostic assays can benefit from use of the compounds disclosed herein.10-23-2008
20080261234Peptides and their use in assays for cardiovascular disease - A peptide having affinity for oxidised low density lipoprotein, in cyclised or multimeric form is useful in an enzyme immunosolvent assay, to detect oxLDL which is a marker of coronary heart disease.10-23-2008
20080261233Assessment of Biological Activity of Hepatocyte Growth Factor (Hgf) - In the present invention the methods for recognition of biologically active hepatocyte growth factor efficient for using in therapeutic components are presented. The biological activity can be determined using: i) an in vitro model of restitution of damaged cells, and/or ii) affinity measurements or epitope mapping using SPR, with the C-met receptor, anti-HGF antibodies or polysaccharides such as dextran, and/or iii) an animal model of hair growth rates. By these methods the activity of HGF in body secretions can be evaluated as well.10-23-2008
20080261232Use of Precursors of Enkephalins and/or Their Fragments in Medical Diagnostics - The invention relates to the diagnosis of disease based on the presence of biochemical components in human or animal body fluids, tissues and/or biomaterials. More specifically the invention relates to the use of precursors of enkephalins and/or its fragments isolated from body fluids, tissues or other biomaterials as a marker peptide for detection of a number of diseases/disorders including diseases/disorders of the central nervous system, neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, Huntington's disease, ischemia including myocardiac ishcemica, schizophrenia, disease/disorders of the immune system, diseases/conditions of pain, chronic pain, migraine, tension type headache, tumor diseases/cancer including lymphoblastic leukaemia, malignant brain tumors, adenomas, in particular human pituitary adenomas, disorders of the blood brain barrier, multiple sclerosis, inflammation, chronic arthritis, infectious diseases, bacterial and viral infections, in particular infections of Gram-positive bacteria, borna diseases virus infections, peritonitis, intoxication, AIDS, stress, trauma comprising head trauma, infarction, in particular cerebral infarction, heart and cardiovascular diseases including coronary heart disease, bone and skin disorders, malaria chronic/obstructive pulmonary disease and cerebral damage. The invention further provides antibodies that bind to proenkephalin and its fragments. In accordance with the invention, a kit useful for the above mentioned diagnosis is also provided.10-23-2008
20090203034Reagents for the detection of tyrosine phosphorylation in brain ischemia signaling pathways - The invention discloses 99 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Brain Ischemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: protein kinases, adaptor/scaffold proteins, adhesion proteins, G proteins/GTPase/Guanine nucleotide exchange factors, Calcium binding proteins, cytoskeletal proteins, Channel proteins, Chaperone proteins, Helicases, Motor proteins, Translation proteins, RNA binding proteins, Ubiquitin conjugating system proteins, vesicle proteins and Receptor proteins.08-13-2009
20110189691Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors - The present invention provides protein and gene expression profiles indicative of whether a patient afflicted with non-small cell lung cancer is likely to be responsive to treatment with a therapeutic compound that is a EGFR-TK inhibitor. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and protein expression profiles, and assays for identifying the presence of a gene or protein expression profile in a patient sample.08-04-2011
20100047821CROWN ETHER DERIVATIVES - The invention describes crown ether chelators, including crown ethers having the formula:02-25-2010
20130045486Composition for Cancer Prognosis Prediction Comprising Anti-TMAP/CKAP2 Antibodies - The present invention relates to an antibody which specifically binds to TMAP (tumor associated microtubule associated protein)/CKAP2 (cytoskeleton associated protein 2) or a fragment thereof, and a method for identifying the presence or absence of mitosis and a method for diagnosing cancer prognosis using the same. More specifically, the present invention relates to a composition for diagnosing cancer prognosis comprising an anti-TMAP/CKAP2 antibody or an antigen-binding site thereof, a method for detecting TMAP/CKAP2 using the composition, an anti-TMAP/CKAP2 antibody for diagnosing cancer prognosis, a method for providing information for diagnosing cancer prognosis using the composition, a method for screening a cancer therapeutic agent comprising the step of determining changes in the level of TMAP/CKAP2 antigen-antibody reaction by the treatment of a candidate substance, and a composition for determining cell-division cycles using the composition.02-21-2013
20130045487METHOD FOR DISCOVERING NEUROGENIC AGENTS - A cell line and an assay for discovering neurogenic drugs are described. The assay allows for systematic screening of test agents such as libraries of compounds.02-21-2013
20100151490Antigenic Protein Conjugates and Process for Preparing Same - An improved process for the preparation of antigenic protein conjugates is provided. The conjugates preferably are formed through reaction with one or more free sulfhydryl groups in the antigenic protein. The process of the present invention preferably employs a trialkylphosphine as the reducing agent and allows for reduction of disulfide bonds in the antigenic protein and conjugation with a conjugate moiety, preferably in a single reaction vessel (i.e. “in situ”) because the process optimally does not require the removal of the reducing agent before subsequent addition of the sulfhydryl reactive agent. Antigenic protein conjugates prepared by the in situ process and their use in diagnostic immunoassays are also provided.06-17-2010
20100151484KINASE AND UBIQUINATION ASSAYS - Compositions, including antibodies, polypeptides, and organic molecules, kits, and methods for probing molecular interactions (e.g., deubiquination, ubiquination and kinase activity), e.g., using resonance energy transfer (RET) are provided.06-17-2010
20100151488Rapid Test for Glycated Albumin - A rapid immunochromatographic assay system is provided for measuring the amount of glycated albumin in a blood sample relative to the total level of albumin in the sample. The assay system is comprised of a disposable cassette that contains the test strips and testing reagents, and a measurement device that automatically reads, calculates and displays the test results over a period of time. The test cassette contains two test strips that are used to measure glycated albumin and total albumin respectively. The strips are contiguous beneath the single sample application well so that the same sample is tested simultaneously by both test strips. Part of the sample will migrate thru the glycated albumin test strip where it will react with the glycated albumin test reagents to yield a glycated albumin result, while part of the sample will migrate thru the total albumin test strip where it will react with the total albumin test reagents to yield a total albumin result. The test cassette is placed within a measuring device such as a reflectance spectrometer or fluorometer, that reads, calculates and expresses the result as the percentage of glycated albumin relative to total albumin in the sample. The results of successive testing that are performed over a period of time are stored in the instrument's memory and displayed in a numerical or graphical format so that the individual's glycated albumin levels can be monitored over time.06-17-2010
20100086941Methods for determining aged based accumulation of senescent cells using senescence specific DNA damage markers - One disclosure provides a method for determining a senescence based disorder by detection of cells with senescence specific DNA damage markers which includes the step of providing a sample with one or more cells. It also includes the steps of identifying with immunodetection the presence of activated DNA damage response proteins that are shown to be activated with senescence and identifying with immunodetection the inactivation of DNA damage response proteins that are shown to be inactive in senescence.04-08-2010
20090191571Isolation and Detection of Pathogenic Prions - Peptide reagents that interact preferentially with the PrP07-30-2009
20110195429METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble p-selectin, protein NOV homolog, soluble epidermal growth factor receptor, netrin-4, haptoglobin, heat shock protein beta-1, alpha-1-antitrypsin, leukocyte elastase, soluble tumor necrosis factor receptor superfamily member 6, soluble tumor necrosis factor ligand superfamily member 6, soluble intercellular adhesion molecule 2, active caspase-3, and soluble platelet endothelial cell adhesion molecule as diagnostic and prognostic biomarkers in renal injuries.08-11-2011
20110195428COMPOSITION, KIT, AND METHOD FOR ASSAYING AGEING AND DISEASE ACCOMPANIED WITH VASCULAR DISORDER - The present invention relates to a method for detecting an ageing or a disease accompanied with a vascular disorder such as age-related macular degeneration, comprising measuring one or more of polypeptides comprising any of amino acid sequences shown in SEQ ID NOS: 1 to 21, mutants thereof, or fragments thereof in a biological sample from a subject, and also to a composition or kit for diagnosing an ageing or a disease accompanied with a vascular disorder such as age-related macular degeneration.08-11-2011
20090233314Functional domain and associated molecule of dock2 essentially required in lymphocyte migration - The present invention is related to provide a method for screening a substance interfering in the association of DOCK2 and ELMO1, a method for screening a substance interfering in the association of ELMO1 and Tiam1, and a method for searching a therapeutic agent for immune related diseases such as allergy, autoimmune diseases, GvH, graft rejection with the use of these searching methods, and so on. It was found that in DOCK2-mutant lacking 504 amino acid residues at the N terminus of DOCK2, Rac-activating ability was significantly decreased, and that actin polymerization could not be induced, and ELMO1 was identified as a molecule binding to this domain. It was found that DOCK2 was associated to ELMO1 via SH3 domain. Moreover, it was found that ELMO1 is bound with Tiam1 functioning as Rac-specific GDP/GTP exchange factor (GEF). It was found that DOCK2 activates Rac by recruiting Tiam1 via ELMO1.09-17-2009
20120178099HIGHLY FLUORESCENT CARBON NANOPARTICLES AND METHODS OF PREPARING THE SAME - Highly fluorescent carbon nanoparticles (FCNs), with tunable emission colours of particle size between 1-10 nm also stable in solid form with high quantum yield (>5%) and its method of synthesis thereof yielding said carbon nanoparticles in milligram to gram scale in high synthesis yield (>80%). The present invention also provides for highly fluorescent carbon nanoparticle solution doped with heteroatom (such as oxygen, nitrogen) and its method of synthesis favoring yield of the said doped carbon nanoparticles of even smaller size ranging from 1-5 nm with narrow size distribution, and also provides for functionalized FCNs that are non-toxic, functional, soluble and stable fluorescent carbon nanoparticles with retained fluorescence for variety of end uses in biomedics, imaging applications, and detection techniques.07-12-2012
20090042211Method for the Selective Detection of Pathological Protein Depositions - The invention relates to a method for the selective detection of the presence and/or quantity of pathological protein depositions.02-12-2009
20100120056DIAGNOSIS AND MONITORING OF DISEASES - The present invention relates to the diagnosis and monitoring of diseases and conditions by quantifying markers, including degradation products of disease-associated proteins, such as diketopiperazines composed of the two N-terminal amino acids or the two C-terminal amino acids of such proteins. The methods are useful for diagnosing or monitoring various diseases, including multiple sclerosis, Alzheimer's disease and ischemia. The invention further provides binding partners specific for the markers and compositions and kits for conducting the methods of the invention.05-13-2010
20100120059INSTRUMENT SETUP SYSTEM FOR A FLUORESCENCE ANALYZER - The present invention reagents and methods for setting up an instruments having a multiplicity of detector channels for analyzing a multiplicity of fluorescent dyes. The present invention is particularly applicable in the field of flow cytometry.05-13-2010
20100120058IgE Antibodies to Chimeric or Humanized IgG Therapeutic Monoclonal Antibodies as a Screening Test for Anaphylaxis - The present invention provides an assay for detecting serum IgE antibody levels to cetuximab and to other proteins. The present invention further provides a method for predicting whether a subject will respond adversely to cetuximab treatment. The present further provides a method for detecting sensitivity to compounds comprising galactose-alpha-1,3-galactose.05-13-2010
20100120057METHODS OF REDUCING NON-SPECIFIC INTERACTION IN METAL NANOPARTICLE ASSAYS - The present invention discloses methods of reducing non-specific interactions of interfering species present in a sample in metallic nanoparticle-based assays, thereby increasing the sensitivity of these assays. In particular, the methods entail neutralizing the chemical reactivity of functional groups present in interfering species by addition of a neutralizing agent, such as an alkylating agent or heavy metal ion. The methods are especially useful in assays for the detection of analytes in biological samples. Reagent kits and assay mixtures for the practice of the described methods are also disclosed.05-13-2010
20100120055TYROSINE PHOSPHORYLATION SITES - The invention discloses 318 novel phosphorylation sites identified in carcinoma, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.05-13-2010
20100120054MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES - The present invention concerns monomeric or polymeric linker molecules useful in biological and chemical applications, their synthesis, and the synthesis and use of derivatives of the linkers conjugated to a variety of detectable labels and other substances. The linkers may be used, for example, in conjunction with fluorescent labels, nucleic acid or nucleic acid analog probes, and solid phase systems, and to enhance the solubility of the conjugated molecules.05-13-2010
20130078643DEVICE AND METHOD OF DETECTING TSH - A device for detecting the concentration of biological materials, is formed in a body having a plurality of fluidic paths connectable to a multi-microbalance structure carrying a plurality of microbalances, each microbalance having a sensitive portion facing a reaction chamber. The body and the multi-microbalance structure are configured to be mechanically coupled together and each microbalance is configured to be coupled to a respective fluidic path. Each fluidic path includes an inlet, a duct and a liquid waste, each duct being configured to be coupled with a respective reaction chamber. The plurality of fluidic paths and microbalances form at least one first and one second reference cells and one first sample cell.03-28-2013
20100075338Whole Blood Assay - A method and apparatus to estimate the concentration of a target substance (e.g. Cholesterol or CRP) in the plasma component of awhole blood sample without the need to separate the red blood cells from the plasma prior to testing, thereby simplfying the design and construction of the test device. The invention achieves this by measuring the analyte under investigation in a time dependent (bio-/immuno-) chemical reaction and measuring separately, a marker substance (e.g haemoglobin) for the estimation of red blood cell volume, using a non-time-dependent alteration in physical property of the reaction mixture (in this instance, transmission) attributed to inherent filter effects on sample addition. These non-time- dependent changes are not part of the reaction chemistry, and are resolved from the time dependent alteration in physical property caused by the assay chemistry by continuous measurement and mathematical modelling. Algorithms that combine these two parameters are used to estimate the target substance and compensate for variations in the percentage haematocrit of the sample. The method equalises the assay response for subtle variations in patient sample (e.g. haematocrit).03-25-2010
20100075337METHOD OF IDENTIFICATION OF CELLS THAT SHOW SENSITIVITY TO MODULATION OF SIGNALINGH MEDIATED BY FIBROBLAST GROWTH FACTOR RECEPTOR OR A VARIANT THEREOF - The invention is based on the finding that cells that show (especially tyrosine) phosphorylation of FGF-R substrate 2 (FRS-2), in contrast to cells that lack such phosphorylation, allow a prediction that treatment with a modulator, especially an inhibitor, of Fibroblast Growth Factor-Receptor signaling will be successful in cells e.g. from biological samples from patients that show such phosphorylation. Therefore, the phosphorylation of FRS-2 can serve as a biomarker for the possibility of successful treatment. The invention relates to various methods, uses, kits and reagents useful in applying this biomarker.03-25-2010
20100075340Electrical Detection Of Biomarkers Using Bioactivated Microfluidic Channels - The present disclosure encompasses the manufacture and use of rapid and inexpensive electrical biosensors comprising microelectrodes in a micro-channel. The devices of the disclosure can be used to detect and quantify target cells, protein biomarkers, and nucleic acid biomarkers, and the like, by measuring instantaneous changes in ionic impedance. The micro-channel devices of the disclosure are also suitable for the detection of target protein and oligonucleotide, and small molecule target biomarkers using protein-functionalized micro-channels for the rapid electrical detection and quantification of any type of target protein biomarker in a sample. The biochip microfluidic devices may be combined with an integrated circuitry into a portable handheld device for multiplex high throughput analysis using an array of micro-channels for probing clinically relevant samples, such as the human serum, for multiple protein and nucleic acid biomarkers for disease diagnosis, and the detection of potentially pathogenic organisms.03-25-2010
20120244552Modified Method of Agglutination to Detect Infections Caused by Microorganisms - Provided herein is a modified method of agglutination to detect infections caused by microorganisms including the steps of staining the test serum, plasma or blood or purified antibodies with a protein stain; mixing serum, plasma or blood with stained antibodies with an equal quantity of colored antigen particles on a glass slide; adding diluted Antiglobulin conjugated with Biotin to the mixture; subjecting the mixture to the step of mixing, adding diluted Avidin (preferably tagged with a visible indicator) to the mixture and thoroughly mixing all the ingredients.09-27-2012
20120244550IMAGE-BASED QUANTITATION OF MOLECULAR TRANSLOCATION - The use of an imaging system, cell compartment markers, and molecular markers in methods for correlating the movement of molecules within a cell to a particular compartment are provided, including measuring and correlating molecule movement in adherent and non-adherent cells.09-27-2012
20120244549Detection Method for Methyltransferase Enzymatic Activity - This invention provides methods to determine the activity of methyltransferase enzymes which employ S-adenosylmethionine (SAM) as a substrate and transfer a methyl group to convert this substrate to S-adenosylhomocysteine (SAH), by measuring SAH conversion to AMP.09-27-2012
20120244548Methods Of Determining Skeletal Maturity - The present invention provides methods to determine skeletal maturity.09-27-2012
20120244547BIOSENSOR - Disclosed herein are biosensors for the detection of airborne biomolecules. The biosensors include a housing, a sensing component, and optionally a sample capture component. The biosensors may utilize a gel-based detection platform.09-27-2012
20120244546ANTIBODIES SPECIFIC TO CARBAMAZEPINE - The present disclosure is directed to antibodies specific to carbamazepine, immunogens used to produce the antibodies, and immunoassay kits and methods for using the antibodies.09-27-2012
20100129828METHOD OF ASSAYING LEUKOCYTE ELASTASE INHIBITOR FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Leukocyte Elastase Inhibitor tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.05-27-2010
20130034861EARLY MARKER OF PROTEINURIA IN PATIENTS TREATED WITH AN ANTI-VEGF TREATMENT - This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.02-07-2013
20130034862Methods for Diagnosis, Prognosis and Methods of Treatment - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN.02-07-2013
20130084580CHROMATOGRAPHIC KIT AND CHROMATOGRAPHY METHOD - A chromatographic kit is provided including a labeling substance holding area having a labeling substance modified with a first binding substance of a test substance, and a labeling substance capturing area having a second binding substance of the test substance or a binding substance of the first binding substance in this order from upstream to downstream of a development direction of a test sample including the test substance, and further including an area having a color developing reagent in order to detect a first amplification reagent of two types of amplification reagents used to amplify the signal of the labeling substance when detecting the labeling substance.04-04-2013
20130084579DRUG SUSCEPTIBILITY USING RARE CELL DETECTION SYSTEM - Methods for determining the efficacy of a given drug for a specific patient with cancer in vitro prior to, or after, the initiation of treatment of the patient are disclosed. Blood from the cancer patient is separated into an assay test tube and a control test tube. The blood in the assay test tube is exposed to a cancer drug. The two test tubes are then visually examined and compared to determine the effect of the cancer drug on cancer cells, other rare cells in the blood, or on normal constituents of the blood of a cancer patient.04-04-2013
20130040307METHOD AND APPARATUS FOR AUTOMATED ANALYSIS - A method and apparatus for pretreatment of a sample of whole blood in a discrete fluid analyzing instrument comprises automated means for handling and analyzing the sample and means for performing a pretreatment step on the sample or a sub-sample of the sample. The means for pretreatment are used for immobilizing at least one substance or analyte from the sample or sub-sample wherein the substance or analyte is reversibly immobilized. Usually, the apparatus further comprises means for eluting the substance or analyte from the capture means prior to analysis.02-14-2013
20130040306BACKSCATTERING INTERFEROMETRIC ANALYSIS OF MEMBRANE MATERIALS - Disclosed are improved optical detection methods comprising multiplexed interferometric detection systems and methods for determining a characteristic property of a sample, together with various applications of the disclosed techniques.02-14-2013
20130040308COMPOSITIONS AND METHODS FOR CHARACTERIZING A MYOPATHY - The invention provides compositions, methods, and kits diagnosing, monitoring, and otherwise characterizing a myopathy and for detecting the presence of autoantibodies in a biological sample.02-14-2013
20090155812APOLIPOPROTEIN FINGERPRINTING TECHNIQUE AND METHODS RELATED THERETO - A method for determining the concentration and modifications of apolipoprotein in biological samples including plasma, serum, and lipoprotein fractions, by obtaining a sample from a patient, adding a specific volume of an internal standard to the sample, applying the sample to a surface-enhanced, Protein G-coated, antibody-bound chip and removing unbound sample components, analyzing the sample by mass spectrometry, determining the concentration of the apolipoprotein using values of internal standards, and evaluating the concentration of the apolipoprotein, its isoforms, amino acid substitutions and modifications for use as a tool for diagnosing cancer, diabetes, stroke, stress, Alzheimer's disease, inflammation, neurological disease and cardiovascular diseases.06-18-2009
20090155811Lateral Flow Immunoassay With Encapsulated Detection Modality - A lateral flow immunoassay featuring encapsulated metal particles. The encapsulated particles may use SERS nanotags as the detection modality. The use of encapsulated particles as a detection modality, in particular encapsulated SERS tags increases the sensitivity of an LFI prepared for visual reading and introduces the ability to obtain substantially more sensitive qualitative results or quantitative results through the analysis of a SERS spectrum read from an LFI prepared in accordance with the present invention. The use of SERS as detection modality also enhances the ability of an LFI device to be used for a multiplexed test. Other aspects of the present invention include LFI devices specifically configured to test whole blood, a reader for the detection and interpretation of a multiplexed assay and the hardware and software components used to implement the reader.06-18-2009
20090155810METHODS FOR PRODUCING MEMBERS OF SPECIFIC BINDING PAIRS - A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods.06-18-2009
20090155813Methods and Devices for Diagnosis of Appendicitis - A method is provided for diagnosing appendicitis in a patient that includes identifying at least one symptom of appendicitis in the patient and identifying the presence of at least one molecule differentially associated with appendicitis in a fluid or tissue sample of said patient. MRP-8/14 and haptoglobin are examples of molecules differentially associated with appendicitis. Devices and kits for performing the appendicitis assays of this invention are also provided. In one embodiment, the device is in a flow-through immunoassay format for testing blood samples. Further, methods for screening for molecules differentially associated with appendicitis are provided that include the use of samples from patients being operated on for suspected appendicitis.06-18-2009
20100105074HIGH THROUGHPUT FLOW CYTOMETRY SYSTEM AND METHOD - The invention provides systems, compositions, kits and methods for automated processing of biological samples and analysis using a flow cytometer.04-29-2010
20100105071METHODS FOR PREDICTING THE ONSET OF MENARCHE - Embodiments of the invention provide methods for predicting the onset of menarche, i.e. a females first menstrual period, through the measurement of salivary hormone levels (e.g. 17-β estradiol, testosterone, progesterone, and/or 17 hydroxy-progesterone (17-OHP)). In particular, the methods described herein enable a reliable determination that menarche will, or will not occur, within varied time intervals, e.g. 1 to 30 days, 1 to 45 days, 1 to 60 days and 1 to 90 days. Diagnostic kits and products of manufacture comprising the kits are also provided.04-29-2010
20100105070DIAGNOSIS AND TREATMENT OF PREECLAMPSIA - The present invention relates to biomarkers for preeclampsia as well as treatment of this disease. In particular, the invention relates to methods for diagnosis or aiding in the diagnosis of preeclampsia of a pregnant female mammal to detect elevated levels of free haemoglobin, particularly free fetal haemoglobin. This facilitates and makes possible early diagnosis and clinical intervention when a preeclamptic condition is found. In addition, the invention relates to a method to treat female mammals with preeclampsia with the purpose to reverse the pathological conditions associated with this disease.04-29-2010
20100105067BIOMARKERS FOR OVARIAN CANCER - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as ovarian cancer, ovarian cancer of low malignant potential, benign ovarian disease or other malignant condition. The biomarkers can be detected by SELDI mass spectrometry.04-29-2010
20100105068HYBRIDOMAS PRODUCING ANTIBODIES AGAINST NON FUNCTIONAL P2X7 RECEPTOR - The present invention relates to the production of anti non functional P2X7 receptor monoclonal antibodies from hybridoma cell lines.04-29-2010
20100105072Methods of identifying respondents to hypoxia inducible factor 1-alpha inhibitors - This invention relates to methods of measuring HIF expression and activity, as well as measuring inhibition of HIF following administration of an HIF inhibitor useful in treating HIF related diseases. The present invention further relates to methods of identifying individuals who will respond to HIF inhibitors. The invention also relates to methods of monitoring a patient response to a given dosage of an HIF inhibitor. The invention also includes assays and kits for performing the methods described herein.04-29-2010
20100105073METHOD FOR THE PRODUCTION OF ANTIBODIES - The current invention is related to a method for the production of a human monoclonal antibody from a immunodeficient non-human animal, said method comprising contacting a new borne immunodeficient non-human animal with a human fetal liver stem cell (FL cell) to generate an immune transplanted non-human animal (reconstituted animal), subsequently contacting said reconstituted animal with a antigen, collecting from said reconstituted animal a human cell producing human antibody against said antigen, and isolating said antibody from said antibody producing cell.04-29-2010
20100105069METHOD FOR DETECTING HUMAN PARVOVIRUS ANTIGEN - A method for detecting human parvovirus/erythrovirus antigen in a sample comprises contacting a buffer having a pH in the range 3.0 to 4.0, suitably a citrate/trisodium citrate buffer, with the sample followed by the measurement of the antigen. The measurement of the antigen can be by virus capture enzyme immunoassay. The method is a good indicator of recent infection and can be used in the screening of individual plasma units or pools from which blood products are extracted.04-29-2010
20100041063ANTI-DRUG ANTIBODY ASSAY - The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.02-18-2010
20100041062DEVICES, SYSTEMS, AND METHODS FOR AIDING IN THE DETECTION OF A PHYSIOLOGICAL ABNORMALITY - The present invention comprises a method for identifying the presence or absence of a pulmonary embolism using a combination of tests and brightline thresholds. The first test is a blood based test measuring D-Dimer concentration and the second test is a respiratory analysis that determines a carboximetry ratio. If the measured D-Dimer value is at or above a threshold indicative of concern and the carboximetry value is equal to or less than a carboximetry ratio threshold, pulmonary embolism is present. If the measured D-Dimer value is at or above a threshold indicative of concern and the respiratory analysis yields a carboximetry ratio greater than the carboximetry ratio threshold, test results are inconclusive and additional testing is required to determine whether a pulmonary embolism is present.02-18-2010
20100041061Enhancing Endotoxin Detection - Provided herein are methods for detecting gram negative bacteria or lipopolysaccharide in a sample. Kits for detecting gram negative bacteria or lipopolysaccharide in a sample are provided.02-18-2010
20100041066NON-PRECIPITATING BODILY FLUID ANALYSIS SYSTEM - A bodily fluid analyzer including a dry test strip impregnated with a reagent providing a non-precipitating reaction to exclude non-desired analytes. The reagent complexes the non-desired analytes so they remain in solution but cannot participate in the test reaction. Red blood cells are removed from the detection area by slowing their vertical movement and stopping flow when the detection membrane is saturated.02-18-2010
20100041065DETECTION METHOD, SAMPLE CELL AND KIT FOR DETECTION AND DETECTION APPARATUS - A labeling binding substance in an amount corresponding to the amount of a detection target substance contained in a liquid sample binds to a sensor portion, and the amount of the detection target substance is detected based on the amount of signal light output by excitation of a label of the labeling binding substance in an enhanced optical field on the sensor portion. In this detection method, a labeling substance that includes a light-responsive substance enclosed by a dielectric that transmits light output from the light-responsive substance is used as the label, and the labeling binding substance binds to the sensor portion through a plurality of fragmented antibodies.02-18-2010
20100041064DIAGNOSIS AND RISK STRATIFICATION OF INFECTIONS AND CHRONIC DISEASES OF THE RESPIRATORY TRACT AND LUNGS BY MEANS OF PROVASOPRESSIN, PARTICULARLY COPEPTIN OR NEUROPHYSIN II - The invention relates to a method for diagnosing and/or stratifying the risk of infections or chronic diseases of the respiratory tract and lungs, particularly lower respiratory tract infections and chronic obstructive pulmonary disease. In said method, provasopressin (proAVP) or fragments or partial peptides thereof, especially copeptin or neurophysin II, is/are determined. The invention further relates to suitable biomarker combinations for in-vitro diagnosis.02-18-2010
20110311988POLYMER END GROUP DETECTION - Provided herein are processes of detecting and quantifying the number of polymer end groups in a sample. In particular instances provided herein are processes of detecting.12-22-2011
20110311987OXYGEN DETECTION USING METALLOPORPHYRINS - An oxygen sensor includes a metalloporphyrin for detecting oxygen levels. The oxygen sensors may also include a light source and a detector. The sensors are configured to measure changes in spectra in response to the redox reaction. They can detect a variety of samples for presence and changes in oxygen concentration in both solution and gaseous form.12-22-2011
20100028902LIVING CELL FORCE SENSORS AND METHODS OF USING SAME - Disclosed herein are materials and methods for the efficient and universal fabrication of microcantilevers terminated with living cells. Methods disclosed describe the passive attachment of cells to microcantilevers that represent cells in suspension comprising living cells attached thereto via association with a hydrophobic layer. Also, disclosed are efficient methods for seeding single and multiple cells to cantilevers that represent isolated adherent cells and tissue constructs of tunable confluency.02-04-2010
20100068726ANTIGEN DETECTION METHOD INVOLVING AN OLIGONUCLEOTIDE ENHANCED COLLOIDAL GOLD SIGNAL - The present invention refers to a rapid immunochromatographic test device for antigen detection, comprising a first and a second conjugate releasing pad, wherein the first conjugate pad comprises a gold conjugated protein linked first oligonucleotide and a gold conjugated antigen specific antibody, and the second conjugate pad comprises a gold conjugated protein linked second oligonucleotide, which second oligonucleotide is complementary to the first oligonucleotide. The present invention further refers to a use of such test device for antigen detection in urine or saliva, e.g. human choriogonadotropin (hCG) in urine. Embodiments of the test device are a test strip and a detection cup. The present invention also refers to a method for manufacturing such test device.03-18-2010
20090325191Method for the diagnosis of pathological conditions in animals - A method for diagnosing a disease or pathological condition in a non-human animal. An ion mobility spectrometry measurement (IMS) or a differential mobility spectrometry (DMS) is carried out on a body sample from the animal to determine an amount of ions formed by at least two biogenic amines contained in the sample. A ratio is calculated of the amounts of ions formed by the different biogenic amines in the sample, wherein the ratio is indicative of the presence or absence of the disease or pathological condition.12-31-2009
20100151483REAGENTS FOR THE DETECTION OF PROTEIN PHOSPHORYLATION IN SIGNALING PATHWAYS - The invention discloses novel phosphorylation sites identified in signal transduction proteins and pathways, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: adaptor/scaffold proteins, adhesion/extracellular matrix protein, apoptosis proteins, calcium binding proteins, cell cycle regulation proteins, chaperone proteins, chromatin, DNA binding/repair/replication proteins, cytoskeletal proteins, endoplasmic reticulum or golgi proteins, enzyme proteins, G/regulator proteins, inhibitor proteins, motor/contractile proteins, phosphatase, protease, Ser/Thr protein kinases, protein kinase (Tyr)s, receptor/channel/cell surface proteins, RNA binding proteins, transcriptional regulators, tumor suppressor proteins, ubiquitan conjugating system proteins and proteins of unknown function.06-17-2010
20130029350BI-STABLE OSCILLATOR - In accordance with the present invention there is provided a bi-stable oscillator circuit for detecting a load imparted to a surface. The bi-stable oscillator comprises an electrical amplifier, at least one resonator comprising an electrical transducer having a resonant frequency, a surface of the resonator forming the surface on which the load is to be detected and an impedance network having a resonant frequency. The resonator is arranged to be exposed to an environment under test, and the resonator and the impedance network are connected in parallel with the electrical amplifier such that when a load imparted to the surface exceeds a pre-determined threshold value the oscillator circuit oscillates at the resonant frequency of the impedance network and when a load imparted to the surface is less than the threshold value the oscillator circuit oscillates at the resonant frequency of the resonator, switching of the circuit oscillation frequency being indicative of the load crossing the predetermined threshold value.01-31-2013
20130029349ASSAYS FOR THE DETECTION OF MICROBES - Methods, devices, and kits are provided herein for the accurate and rapid detection of disease causing microbes in a sample by the detection of microbial components of which correlate to the presence of the microbe. Kits include a first binding agent operatively coupled to an immobilized support; and a second binding agent operatively coupled to one or more pH indicating moieties wherein the first and second binding agents bind with sufficient specificity to the microbial component to permit detection of that component which correlates to the presence of the microbe in the sample.01-31-2013
20100092997Method of Enhancing of Binding Activity of Antibody Composition to FcGamma Receptor IIIa - A method for enhancing a binding activity of an antibody composition to Fcγ receptor IIIa, which comprises modifying a complex N-glycoside-linked sugar chain which is bound to the Fc region of an antibody molecule; a method for enhancing an antibody-dependent cell-mediated cytotoxic activity of an antibody composition; a process for producing an antibody composition having an enhanced binding activity to Fcγ receptor IIIa; a method for detecting the ratio of a sugar chain in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chain among total complex N-glycoside-linked sugar chains bound to the Fc region in an antibody composition; an Fc fusion protein composition produced by using a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through α-bond in a complex N-glycoside-linked sugar chain; and a process for producing the same.04-15-2010
20100092994High specificity monoclonal antibody against a protein or a polypeptide having oxidative modification - The present invention provides an antibody, which reacts with a FGA or FGA partial peptide in which a part of prolines in the molecule thereof are hydroxylated, and which does not react with an unmodified FGA or FGA partial peptide.04-15-2010
20100068728POLYSACCHARIDE DERIVATIVES AND USES IN INDUCTION OF AN IMMUNE RESPONSE - The present invention generally provides compositions comprising a polysaccharide derivative, and methods of their preparation and use for the prevention or treatment of diseases caused by 03-18-2010
20090123937Methods of selecting epidermal growth factor receptor (EGFR) binding agents - The present application relates to methods of selecting EGFr binding agents. In certain embodiments, such EGFr binding agents bind to at least a portion of a panitumumab epitope on an EGFr. In certain embodiments, such EGFr binding agents do not bind to a panitumumab epitope on an EGFr.05-14-2009
20100075339SURFACE-ENHANCED RAMAN SCATTERING (SERS) BASED NANOPARTICLE COMPOSITES - Nanoparticle composites and method of use thereof for simultaneously sensing and probing a biological system, comprising providing a nanoparticle composite comprising a nanoparticle comprising a core and a shell; a first ligand bound to the nanoparticle, said first ligand capable of sensing pH; a second ligand bound to the nanoparticle, said second ligand distinct from said first ligand and capable of binding to a target; and bringing the nanoparticle composite into contact with the biological system to produce a first and a second pH-dependent signal; and analyzing the first or the second signal by means of surface-enhanced Raman spectroscopy.03-25-2010
20130052656FRET MEASUREMENT METHOD AND FRET MEASUREMENT DEVICE - Disclosed herein is a method for measuring FRET by irradiating with laser light a measurement sample. FRET is transfer of energy from a first molecule to a second molecule. The first molecule and the second molecule are included in the measurement sample in which ligands are bound to receptors. The method includes the steps of: irradiating the measurement sample with laser light; measuring fluorescence emitted by the measurement sample; calculating a fluorescence lifetime of the first molecule; calculating a binding ratio; setting a binding condition for the measurement sample; and calculating a dissociation constant. In the dissociation constant calculating step, the dissociation constant is determined by using a least-squares method to fit a function having, as variables, a total concentration of the receptor in the measurement sample and the dissociation constant to the binding ratio calculated in the binding ratio calculating step.02-28-2013
20130052655ASSAY UTILIZING IMMUNOCHROMATOGRAPHY, IMMUNOCHROMATOGRAPHIC TEST STRIP, AND ASSAY REAGENT KIT FOR IMMUNOCHROMATOGRAPHY - The present invention provides a measurement method utilizing immunochromatography, an immunochromatographic test strip, and a reagent kit of immunochromatography capable of accurate short-time measurement of an analyte in blood with simple operations as compared to the conventional methods. The present invention provides a method of measurement by immunochromatography in which concentrations of an analyte and hemoglobin in the same sample are measured by immunochromatography to perform hematocrit correction of a measurement value of the analyte by using a measurement value of hemoglobin, as well as a test strip and a reagent kit for immunochromatography.02-28-2013
20130089870METHOD FOR SELECTING HUMAN INDUCED PLURIPOTENT STEM CELLS - The present invention provides a method for selecting human induced pluripotent stem (iPS) cells which can be safely used for transplantation. That is, the present invention provides a method for selecting human iPS cells having reduced differentiation resistance, comprising the steps of: (1) inducing differentiation of human iPS cells; (2) detecting remaining undifferentiated cells after the step (1); and (3) selecting human iPS cells whose rate of remaining undifferentiated cells detected in step (2) is equivalent to or not more than that of control cells.04-11-2013
20130089869Methods For and Uses of Mechanical Stiffness Profiling of Cancer Cells - Methods of predicting the invasiveness or metastatic potential of cancer cells are provided herein. Methods of screening for cancer cells or diagnosing cancer in a subject are also provided. Methods of screening for agents capable of reducing invasiveness or metastasis of cancer cells are also provided. All of the methods rely on analyzing the creep compliance or spring constant of cells.04-11-2013
20100003698Kit of Materials for Decreasing Interference in Results of Immunochemical Methods - A kit of materials is provided for decreasing or eliminating interference from molecules resulting from upstream immunochemical assays, such as Immunoprecipitation, that employ an Immunoglobulin Binding Molecule (an IBM, e.g., Protein A) in subsequent downstream methods, such as Western Blot. The kit may include packing material, a ligand of an immunoglobulin binding molecule, the IBM itself, a solid support for the IBM, dry solids, primary antibodies, secondary antibodies having a reporter molecule, IBMs having a reporter molecule and combinations of the above materials.01-07-2010
20100047817Synaptotagmin and Collapsin Response Mediator Protein as Biomarkers for Traumatic Brain Injury - Collapsin response mediator proteins (CRMPs) decreased in tissue and increased in biological fluids after neural injury from traumatic brain injury (TBI). Significant decreases of CRMP1, CRMP2, CRMP4 and CRMP5 were accompanied by the appearance of distinct 58 kDa (CRMP-2) or 55 kDa (CRMP-4) breakdown products from proteolytic cleavage by calpain. Synaptotagmin breakdown products were also associated with TBI and could be detected along with intact protein in human cerebral spinal fluid (CSF). Both biomarkers were detected in human biofluid and related to recovery from traumatic brain injury.02-25-2010
20080274475HLA-E BINDING - The invention relates to a method of testing a compound for biological activity, which method comprises providing cells expressing one of the CD94/NKG2 family of receptors, contacting the cells with recombinant HLA-E under binding conditions in the presence of the test compound, and determining whether the presence of the compound affects the binding of HLA-E to the cells. The HLA-E property of binding to CD94/NKG2 receptors on NK cells and a subset of CD8+ T cells is useful for targeting CD94/NKG2+ cells for a variety of purposes such as identification, isolation, killing or inactivation.11-06-2008
20090317826MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM2. Monoclonal antibodies having the binding characteristics of an MCM2 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM2 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM2 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM2 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.12-24-2009
20090098569Novel PGC-1 Isoforms and Uses Therefor - The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.04-16-2009
20090042214BETA2-MICROGLOBULIN AND C REACTIVE PROTEIN (CRP) AS BIOMARKERS FOR PERIPHERAL ARTERY DISEASE - The present invention relates to use of β-2-microglobulin (B2M or β2M) and C-reactive protein (CRP) levels as biomarkers of peripheral artery disease and/or atherosclerosis.02-12-2009
20090042210Sensors and methods for detecting diseases caused by a single point mutation - A method for generating antibodies preferable to either a normal protein and a mutated form of the normal protein, respectively, where a mutation associated with the mutated form includes either a single point mutation or a small number of point mutations where the method includes creating first and second antigenic peptides of a predetermined length corresponding respectively to common regions of the normal target protein and the mutated form, where the common regions are identical to one another except for the point mutation of the mutated form, obtaining first and second antibodies by multiplying the first and second antigenic peptides via hybridoma methods, and identifying the respective affinities of the first and second antibodies for the normal target protein and the mutated form. Also included are methods of using the first and second antibodies to detect and quantify respective amounts of a normal target protein and a mutated form of the target protein. Also included are immunological sensors the include the first and second antibodies for determining the presence and quantity of normal target proteins and mutant forms of the normal target proteins.02-12-2009
20110003311DIAGNOSIS SYSTEM FOR DETERMINING THE BIOLOGICALLY EFFECTIVE PARATHYROID HORMONE ACTIVITY IN A SAMPLE - Diagnosis system or immunoassay for the determination of the effective parathyroid hormone activity in a sample, and for a diagnosis and treatment of calcium metabolism disturbances, osteopathies and hyper- or hypoparathyroidisms. The parathyroid hormone activity is measured with the aid of an antibody which binds to an epitope in the region of the receptor binding structure 01-06-2011
20090305301DETECTION OF VENOUS THROMBOEMBOLIC DISEASES BY MEASUREMENT OF D-DIMERS AND SOLUBLE FIBRIN LEVELS - A method and a test for detecting coagulation activation, in particular when it is responsible for thromboembolic venous diseases; employs assaying D-dimers and assaying the soluble fibrin produced during a fibrinolysis process activated in a blood sample. The method of the invention pertains to comparing the level of D-dimers corresponding to degradation of soluble fibrin and the level of D-dimers of the sample with normal threshold values. The test of the invention may also be used to determine whether anti-coagulation is sufficient in a patient.12-10-2009
20090305302MYCOBACTERIAL CULTURE SCREENING TEST FOR MYCOBACTERIUM AVIUM COMPLEX BACTERIA - A method of antigen-capture assays that uses the detection of antigens secreted into liquid culture is provided. Also provided are antibodies to 12-10-2009
20090305300METHODS AND KITS TO DIAGNOSE GROWTH HORMONE DEFICIENCY - A method of assessing growth hormone deficiency in a human or animal subject, the method comprising administering orally to the subject EP 1572 (Formula I) or EP 1573 (Formula II), obtaining a post-administration sample from the subject, determining the level of growth hormone in the sample and assessing whether the level of growth hormone in the sample is indicative of growth hormone deficiency in the subject. Preferably, the GH level in the sample is measured by immunoassay. Also disclosed is a kit of parts constituting a diagnostic kit comprising: (a) EP 1572 or EP 1573 formulated for oral administration; and (b) means for determining the level of growth hormone in a sample.12-10-2009
20090305299Method for Determination of Prognosis of Prostate Cancer, and Diagnostic Agent for Use in the Method - A method for determining probability that prostate cancer will metastasize, as well as a diagnostic reagent used therefor is disclosed. It was discovered that the percentage that NF-κB-p65/RelA has the 254th amino acid threonine which is phosphorylated is significantly higher in the prostate cancer cells in the cases where the bone metastasis was observed than in the cases where bone metastasis was not observed. Thus, the method for determining probability that prostate cancer will metastasize comprises measuring human NF-κB-p65/RelA in which 254th amino acid threonine is phosphorylated, which human NF-κB-p65/RelA is contained in a prostate tissue separated from human.12-10-2009
20090305298Binder for C-Reactive Protein - A polypeptide dimer is provided wherein both protomers have a sequence according to SEQ ID NO: 1 and at least one phosphocholine derivative is attached to the polypeptide. The polypeptide shows a specific binding for C-reactive protein (CRP). The utilization of the polypeptide in assays for determining the concentration of CRP is described. The purification of CRP, and compositions comprising the CRP also are provided.12-10-2009
20090305297Tyrosine phosphorylation sites - The invention discloses 397 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.12-10-2009
20090305296TEST KIT FOR DETECTING PERIODONTAL DISEASE - A test kit is disclosed for diagnosing periodontal disease in a patient by analysing a sample from the oral cavity of the patient. The test kit includes at least a first detection assay for detection of a first substance originating from bacteria and at least a second detection assay for detection of a second substance originating from the immune or inflammatory system of the patient.12-10-2009
20090117581Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS) - The present invention relates to methods for preparing an artificial immune system. The artificial immune system comprises a cell culture comprising T cells, B cells and antigen-primed dendritic cells. The artificial immune system of the present invention can be used for in vitro testing of vaccines, adjuvants, immunotherapy candidates, cosmetics, drugs, biologics and other chemicals.05-07-2009
20080280305Assays for Detecting Hiv-1 Tat Protein in Hiv-1 Infection - A method for detecting or measuring HIV-1 Transactivating (Tat) protein in a biological sample comprising contacting the biological sample with an amount of a basic protein effective to reduce interference with binding between anti-HIV-1 Tat Epitope 2 ligand and Tat that is caused by acidic components within the sample or reagents. A more accurate detection and measurement of the amount of HIV-1 Tat in the sample is obtained by binding between the anti-Epitope 2 antibody and the Tat in the sample when the interference is neutralized. A diagnostic kit for use in practicing the method contains these components.11-13-2008
20100047819MULTIPLEX ASSAY FOR RHEUMATOID ARTHRITIS - Multiplex assays that allow for the detection and quantification of Rheumatoid Factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies in a single reaction mixture are provided.02-25-2010
20100099114ANALYTICAL STRIP AND DETECTING METHOD USING THE SAME - An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are arranged successively. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. A substrate reagent including a saccharide oxidase is localized in the third region.04-22-2010
20090092996MUCOPOLYSACCHARIDOSIS (MPS) DIAGNOSTIC METHODS, SYSTEMS, KITS AND ASSAYS ASSOCIATED THEREWITH - Methods, systems, kits and assays for diagnosing, monitoring or screening for mucopolysaccharidosis (MPS) and methods and systems for assaying test compounds for therapeutic activity are described, whereby MPS marker protein levels are assayed as an indication of MPS.04-09-2009
20090092998MARKER FOR ARRHYTHMIA RISK - The present invention relates to markers and methods for determining risk of ventricular arrhythmia in an individual. By using the markers of the present invention, individual with high risk of ventricular arrhythmia can properly be detected and treated. The present inventors have discovered that IL-6 and/or DROMs have strongly positive correlation with the risk of ventricular arrhythmia.04-09-2009
20090092997MODULATORS THAT PROMOTE CELL SURFACE EXPRESSION OF ODORANT RECEPTORS - The present invention relates to polypeptides capable of promoting odorant receptor cell surface localization and odorant receptor functional expression. The present invention further provides assays for the detection of ligands specific for various odorant receptors. Additionally, the present invention provides methods of screening for odorant receptor accessory protein polymorphisms and mutations associated with disease states, as well as methods of screening for therapeutic agents, ligands, and modulators of such proteins.04-09-2009
20100062450Methods and Kits for Early Detection of Cancer or Predisposition Thereto - Methods and kits for diagnosing cancer or a pre-malignant lesion by determining the presence and/or level of circulating CD24 of a subject are provided. Also provided are methods and kits for determining if a subject is predisposed to gastrointestinal cancer by the determining the presence or absence, in a homozygous or heterozygous form of cancer associated genotype(s) in the CD24 and/or APC nucleic acid sequences. Also provided are methods and kits for monitoring efficacy of cancer therapy by determining the presence and/or level of circulating CD24 of a subject.03-11-2010
20110014628Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy - An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.01-20-2011
20110014627METHOD FOR DETERMINING ANTAGONIST ACTIVITY TO A CYTOKININ RECEPTOR - The present invention provides a method for analyzing agonist-activity to a cytokinin receptor, which comprises (1) bringing an examinee substance into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and, a method for analyzing antagonist activity to a cytokinin receptor, which comprises (1) bringing an examinee substance and a substance having agonist-activity to the cytokinin receptor into contact with a transformed cell into which DNA coding the cytokinin receptor is introduced and (2) measuring the existence or the quantity of intracellular signal transduction from the cytokinin receptor expressed in the transformed cell, and the like.01-20-2011
20120309017PERINUCLEOLAR COMPARTMENT AS A CANCER MARKER - The present invention relates to compositions and methods for cancer diagnostics, prognostics and predictions, including but not limited to, cancer markers. In particular, the present invention provides perinucleolar compartments and their resident molecules as cancer markers.12-06-2012
201203090163D ADCC NK FACS ASSAY - Herein is reported a cell analytical technology based on a three-dimensional spheroid/aggregate co-culture assay, wherein the spheroid or aggregate is formed of tumor and natural killer cells. This method is useful for the in vitro functional analysis of antibodies in single and high-throughput format.12-06-2012
20110065121METHOD FOR THE DETECTION OF APOPTOSIS - Methods for the detection of apoptosis by measuring apoptotic bodies shed by apoptotic cells are provided, as are kits to carry out such methods.03-17-2011
20120190039RAF DIMERS AND USES THEREOF - Disclosed herein are mutated RAF and KSR nucleic acids and polypeptides. Also disclosed are methods of using the mutated RAF and KSR to inhibit the dimerization of RAF/RAF and RAF/KSR. Also disclosed are methods of using the mutated RAF and KSR to screen for inhibitors of dimerization.07-26-2012
20090269782DIAGNOSTIC METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DELIVERY AND REAGENT KIT FOR USE THEREFOR - The invention relates to a diagnostic method for detecting susceptibility to delivery, and to a test kit for this purpose. A low, but higher than baseline level concentration of Insulin-like Growth Factor Binding Protein 1 (IGFBP-1), which is due to leakage from decidual cells, is detected by an immunological assay in a vaginal secretion sample.10-29-2009
20090269780Method for Creating a Standard for Multiple Analytes Found in a Starting Material of Biological Origin - The invention provides a method for creating a standard for multiple analytes comprising treating a portion of a sample to substantially remove analytes of interest to produce a series of specifically deficient samples; and determining and mixing an appropriate amount of the series of specifically deficient samples to create a standard. The analyte may be any substance to be measured.10-29-2009
20090269779Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer - Provided are differential antibodies recognizing the cleaved and non-cleaved forms of matrix metalloproteinases (MMPs), and methods of using the antibodies as surrogate diagnostic markers for the presence of active MMPs in cancer, such as growing breast cancers.10-29-2009
20090269778BIOCOMPATIBLE THREE DIMENSIONAL MATRIX FOR THE IMMOBILIZATION OF BIOLOGICAL SUBSTANCES - The present invention relates to a method of producing a solid coated carrier carrying biological material. Furthermore, the invention relates to a solid coated carrier to which biological material is attached and uses of the solid coated carrier for the preparation of a medical product. Moreover, the invention provides a method for the contacting, filtration or cleaning of blood, lymph or liquor cerebrospinalis of a patient, a method for the diagnosis of a disease and a diagnostic composition.10-29-2009
20090269777IMMUNOASSAYS AND KITS FOR THE DETECTION OF NGAL - The present invention relates to NGAL immunoassays and kits, and to methods of using glycosylated mammalian NGAL and antibodies that bind to mammalian NGAL in immunoassays and kits. Among other things, the methods and kits can be employed to determine the amount of human NGAL monomer in a test sample, as well as to determine the proportion of human NGAL monomer to human NGAL dimer contained in a test sample.10-29-2009
20090269776Magnetic Immunodiagnostic Method for the Demonstration of Antibody/Antigen Complexes especially of blood groups - The invention relates to a magnetic immunodiagnostic method for the demonstration of antibody-antigen complexes. One such method involves the research and/or identification of antibodies or antigens, preferably anti-antigen antibodies or antigens of a blood group, and comprises a suspension of magnetic particles coated with antigens that can be carried by cells such as erythrocytes. The invention also relates to a device and a kit for carrying out one such method.10-29-2009
20090269781Single-Molecule-Format Probe And Utilization Thereof - A single-chain probe of the present invention for detecting a ligand, comprises: a ligand binding protein for binding the ligand; a recognition protein for recognizing that the ligand is bound by the ligand binding protein; and C— and N-terminal fragments, generated by dissecting an enzyme, between the ligand binding protein and the recognition protein, wherein a carboxy terminal end of the C-terminal fragment is located upstream of an amino terminal end of the N-terminal fragment, and the C— and N-terminal fragments vary the enzyme activity via complementation in case where the recognition protein recognizes that the ligand is bound by the ligand binding protein. This makes it possible to achieve detection of a target protein-specific ligand using the single chain with a high efficiency.10-29-2009
20090215075THREE-DIMENSIONAL STRUCTURE OF A DNAB-FAMILY REPLICATIVE HELICASE (G40P), USES THEREOF, AND METHODS FOR DEVELOPING ANTI-BACTERIAL PATHOGENS BY INHIBITING DNAB HELICASES AND THE INTERACTIONS OF DNAB HELICASE WITH PRIMASE - Structure and methods associated with the three-dimensional structure of G40P helicase and other structure models of any DnaB-like helicase obtained by computer modeling that bears similarity with a root-mean-square deviation (RMSD) of 2.0 with at least one of the three domain structures (N-globe, alpha-hairpin and the C-terminal ATPase domains). In one embodiment, a method for identifying a compound that binds to any fragment of a G40P protein is provided. The method including obtaining the three dimensional structure of the G40P hexamer whose sequence consists of SEQ ID NO:1 and identifying or designing one or more compounds that bind, mimic, enhance, disrupt, or compete with the G40P protein whose sequence consists of SEQ ID NO:1 or interactions of the G40P protein with its ligands based on the three dimensional structure of the G40P hexamer whose sequence consists of SEQ ID NO:1.08-27-2009
20130065245Device - Provided is an assay device and kit for detecting the presence or amount of an analyte of interest.03-14-2013
20130164761CARRIER POLYMER PARTICLE, PROCESS FOR PRODUCING THE SAME, MAGNETIC PARTICLE FOR SPECIFIC TRAPPING, AND PROCESS FOR PRODUCING THE SAME - Carrier polymer particles comprising organic polymer particles having a particle diameter of 0.1 to 20 micrometers and a saccharide with which the surface of the organic polymer particles is covered, the organic polymer particles and the saccharide being chemically bonded.06-27-2013
20110020838MOLECULES FOR THE TREATMENT OF LUNG DISEASE INVOLVING AN IMMUNE REACTION TO CONNECTIVE TISSUE FOUND IN THE LUNG - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.01-27-2011
20110020837Method for isolating or identifying a target protein interacting with a lipid in a cell - The invention is in the field of molecular biology and cell biology. It provides tools and methods for studying the interaction of proteins and lipids in vivo as well as in vitro. The invention relates to a method for isolating or identifying a target protein interacting with a lipid in a cell. This method employs novel dual-labeled lipid precursors such as fatty acids or their derivatives. These lipid precurors comprise two functional groups: a photoactivatable group, such as a diazirine ring, as well as a terminal alkyne or azide moiety.01-27-2011
20110020835Device and Method for Detecting Small Quantities of Light, Comprising an Electronic Image Converter Embodied in Semiconductor Technology - The invention relates to a device for detecting small quantities of light, comprising an electronic image converter embodied in semiconductor technology for detecting the photons representing the small quantities of light and an electronic circuit connected to the electronic image converter for reading the electronic image converter and for generating a signal representing the number of photons received by the electronic image converter, wherein the electronic image converter comprises at least 100,000 light-sensitive cells and the electronic circuit is adapted to add together the signals coming from light-sensitive cells placed on the electronic image converter.01-27-2011
20110045492MICROFLUIDIC SYSTEM AND A METHOD OF PERFORMING A TEST - The invention relates to a microfluidic system comprising a microfluidic device having a first and a second opposite surfaces and an optical detector, the microfluidic device comprises a flow channel with a detection channel section having a length of at least about 1 mm, the microfluidic device comprises at least one aperture section comprising at least a part of said detection channel section and a transparent window into said detection channel section, the optical detector is arranged to be in optical communication with said aperture section to determining at least one optical property of said aperture section as a function of time. The flow channel may have capillary dimensions and/or it may wholly or fully be arranged to drive a fluid flow by applying external forces.02-24-2011
20110045491CYCLIC NUCLEOTIDE-SPECIFIC PHOSPHODIESTERASES FROM LEISHMANIA AND USES THEREOF - The present invention, relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite 02-24-2011
20090233313QUANTIFICATION AND AFFINITY CHARACTERIZATION OF ANTIBODIES FOR THE DIAGNOSIS OF DISEASE USING OPTICAL DIFFRACTION - The invention features methods and devices for the detection of antibodies. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease.09-17-2009
20090233311METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.09-17-2009
20090233310PARTICLE AGGLUTINATION IN A TIP - An apparatus and a related method for performing particle agglutination reactions in a single, disposable probe tip are disclosed. The probe tip includes a sample cavity for sample acquisition, at least one flanking cavity for the capture of particles by centrifugation or other means, a transition zone for the mixing of the sample with reagents for agglutination and a detection zone for the optical detection of particle agglutination. A mechanism may be attached to the probe tip for the controlled movement of fluids through the internal volume of the probe tip. The probe tip is particularly useful for the automation of high-throughput agglutination-type assays.09-17-2009
20090047686METHODS FOR IDENTIFYING AND PRODUCING SPECIFIC AMINO ACID DEPENDENT ANTIBODIES AND USES THEREOF - The present invention relates to methods for producing antibodies that are selective for one or two of the N-terminal amino acid residues of PTH, the antibodies made by such methods, and methods of using them to determine PTH levels while avoiding interference from N-terminally truncated PTH peptides.02-19-2009
20090047685ULTRAHIGHLY SENSITIVE DETERMINATION REAGENT FOR C-REACTIVE PROTEIN AND DETERMINATION METHOD - The present invention is related to an ultrahighly sensitive determination reagent for C-reactive protein (CRP) for use in determination of CRP in a test sample with high sensitivity; and a CRP determination method using the reagent. A reagent for determining C-reactive protein containing an insoluble carrier particle loading an antibody directed to the C-reactive protein via an amino acid; and a method for determining a C-reactive protein including the steps of reacting the reagent with an antigenic substance in a test sample, and determining a resulting aggregate.02-19-2009
20120115163MARKED PEPTIDES AND USE THEREOF FOR ASSAYING CIRCULATING IRAP - A method for the assay of the circulating extracellular portion of the IRAP protein (“insulin responsive aminopeptidase”) includes at least one stage of quantitative assay of the purified, secreted, extracellular portion of IRAP, via at least one labelled peptide, the labelled peptide interacting specifically with the extracellular portion of IRAP.05-10-2012
20120115162ANTI-FATTY ACID AMIDE HYDROLASE-2 ANTIBODIES AND USES THEREOF - Antibodies that specifically bind to fatty acid amide hydrolases and methods of using the antibodies are provided herein.05-10-2012
20120115161COMPOSITIONS AND METHODS FOR DEMONSTRATING SECRETORY IMMUNE SYSTEM REGULATION OF STEROID HORMONE RESPONSIVE CANCER CELL GROWTH - Serum-containing and serum-free immunoglobulin inhibitors of steroid hormone responsive cancer cell growth are disclosed, along with their methods of production. Also disclosed are defined cell culture media, assay protocols, and model systems using the inhibitors for demonstrating steroid hormone growth effects of natural and synthetic substances, and other cell culture applications. The disclosed compositions and methods employing the immunoglobulin inhibitors are also useful as reagents in research, and for the diagnosis, treatment and prevention of mucus epithelial cancers.05-10-2012
20120115160METHOD FOR DETECTING INVASIVE MICROVESCLES DERIVED FROM TUMOR CELLS - The present application relates to the isolation and analysis of populations of microvesicles, such as populations of microvesicles that are shed by tumor cells and contain the protein ARF6. Invasive microvesicles from tumor cells contain a variety of specific proteins, including ARF6.05-10-2012
20090275046Complement factor H protein as a biomarker of Parkinson's disease - The present invention relates to a Complement Factor H protein as a biomarker for neurodegenerative disease, including Parkinson's disease, and the related diseases. More specifically, the present invention relates to the identification of a Complement Factor H protein, useful for the screening, diagnosis, and differentiation between neurodegenerative diseases.11-05-2009
20100009380COMPOSITIONS AND METHODS FOR CHARACTERIZATION OF CYSTEINE OXIDATIVE STATES - The present invention relates to compositions and methods for characterization of cysteine oxidative states. In particular, the present invention provides cysteine-oxidative-state-specific labeling agents and uses thereof.01-14-2010
20100021926METHOD FOR RAPID DETECTION OF LYMPHATIC FILARIASIS - There is provided by this invention a specific and sensitive diagnostic method for rapid detection of lymphatic filariasis. The method employs a combination of SXP/SXP-recombinant antigen, mouse monoclonal anti-human IgG4 antibody conjugated to a detection reagent and the technique of immunochromatography.01-28-2010
20090011429Diagnosis of Pre-Eclampsia - The present invention relates to a method of predicting pre-eclampsia (PE). The present invention also relates to a diagnostic kit for performing a method of predicting PE. In particular, the method determining the level of two or more markers selected from placenta growth factor (P1GF), plasminogen activator inhibitor-1 (PAI-1), plasminogen activator inhibitor-2 (PAI-2) and leptin.01-08-2009
20090011427ASSAYS FOR PREIMPLANTATION FACTOR AND PREIMPLANTATION FACTOR PEPTIDES - The present invention relates to assay methods used for detecting the presence of PIF, and to PIF peptides identified using this assay. In particular, the present invention relates to flow cytometry assays for detecting PIF. It is based, at least in part, on the observation that flow cytometry using fluorescently labeled anti-lymphocyte and anti-platelet antibodies demonstrated an increase in rosette formation in the presence of PIF. It is further based on the observation that flow cytometry demonstrated that monoclonal antibody binding to CD2 decreased in the presence of PIF. The present invention further relates to PIF peptides which, when added to Jurkat cell cultures, have been observed to either (i) decrease binding of anti-CD2 antibody to Jurkat cells; (ii) increase expression of CD2 in Jurkat cells; or (iii) decrease Jurkat cell viability. In additional embodiments, the present invention provides for ELISA assays which detect PIF by determining the effect of a test sample on the binding of anti-CD2 antibody to a CD2 substrate.01-08-2009
20090011426Methods of Diagnosis and Treatment of M.Tuberculosis Infection and Reagents Therefor - The present invention provides diagnostic, prognostic and therapeutic reagents for infection of an animal subject such as a human by 01-08-2009
20090011425Incubation Device for Serology and Histology Slides - This application relates to an incubation device for serology or histology supports. It also relates to any apparatus comprising one such device, and to the use of said apparatuses and/or devices in analysis or diagnosis methods.01-08-2009
20100086939DETERMINATION METHOD FOR ALLERGIC DISEASE - It is to provide a method for determining allergic diseases with a high sensitivity and accuracy which enables multilateral and global analysis with a minute amount of sample, even using body fluid other than blood such as saliva, nasal discharge and tears as a sample, particularly by suppressing nonspecific reaction as much as possible. A chemically modified diamond/DLC (Diamond-like Carbon) chip is activated with a reacting reagent, a coupling reaction with a peptide comprising allergen or allergen epitope is conducted, and a sample such as saliva, tears, and nasal discharge which has undergone pressure filtration with a low protein-adsorbing filter, is contacted with an allergen determination chip to which washing and blocking operations have been performed on unreacted active groups, and an allergen recognizing antibody in the sample captured by the allergen determination chip is detected by immunoassay using a labeled secondary antibody, wherein a glycine-containing solution is used for a washing solution and/or blocking solution used in the washing and blocking operations, is used.04-08-2010
20100086940Polynucleotide encoding an autoantigen associated with endometriosis - This invention provides a polynucleotide encoding Repro-EN-1.0 and IB1, polypeptides associated with endometriosis. Auto-antibodies against Repro-EN-1.0 and IB1 have been found in subjects diagnosed with endometriosis. This invention also provides methods of using this polynucleotide and polypeptide.04-08-2010
20100086942COMPOUNDS - The present invention relates to binding members, especially antibody molecules, for CXCL13. The binding members are useful for the treatment of disorders associated with CXCL13, including arthritic disorders such as rheumatoid arthritis.04-08-2010
20120244551PORPHYRINIC COMPOUNDS FOR USE IN FLOW CYTOMETRY - The present invention provides a method of detecting (e.g., by flow cytometry) a target compound, cell or particle, wherein the target is labelled with a detectable luminescent compound. The method comprises utilizing as the detectable luminescent compound a compound comprising a porphyrinic macrocycle such as a porphyrin, chlorin, bacteriochlorin, or isobacteriochlorin. In particular embodiments, the detectable luminescent compound comprises a compound of the formula A-A′-Z-B′-B, wherein: A is a targeting group or member of a specific binding pair that specifically binds the detectable luminescent compound to the target compound, cell or particle; A′ is a linker group or covalent bond; B′ is a linker group or covalent bond; B is a water-soluble group; and Z is the porphyrinic macrocycle.09-27-2012
20130164759COMPOSITIONS AND METHODS FOR SCREENING FOR LYME DISEASE - The invention provides compositions, methods, and kits for the diagnosis or detection of infection by a pathogen that causes Lyme disease in a subject.06-27-2013
20130164760METHODS AND COMPOSITIONS FOR PREPARING SAMPLES FOR IMMUNOSTAINING - Compositions and methods for preparing a sample for immunological staining are provided. Compositions include kits comprising a first solution comprising a surfactant and a second solution comprising a chaotropic agent. Methods comprise contacting a sample, such as cells or tissues, with a first solution comprising a surfactant and then contacting the sample with a second solution comprising a chaotropic agent. The method does not require extreme heat for antigen retrieval and therefore, maintains the cellular morphology of the sample.06-27-2013
20120237945CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME - A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes.09-20-2012
20120237944DETECTION DEVICE FOR THE IN VIVO AND/OR IN VITRO ENRICHMENT OF SAMPLE MATERIAL - The present invention refers to a detection device for the in vivo and/or in vitro enrichment of sample material, the detection device comprising a functional surface equipped with detection receptors. To further improve the enrichment of sample material by using a detection device of the aforementioned type, it is provided according to the invention that the functional surface has a three-dimensional structure with mutually facing functional sections which form spaces that can be filled with a sample liquid. Furthermore, the present invention provides for a use and for a method for the use of the detection device.09-20-2012
20120270229DEVICE FOR DETECTION OF ANALYTES AND USES THEREOF - Devices and methods for the detection of antigens are disclosed. Devices and methods for detecting food-borne pathogens are disclosed.10-25-2012
20120156687NANOPARTICLES WITH MOLECULAR RECOGNITION ELEMENTS - A method of multiple protein biomarker detection, comprising providing at quantum dot-antibody conjugates that have an affinity for at least two different protein biomarkers; contacting the conjugates with a sample from a subject; allowing the proteins to bridge the antibodies, forming protein biomarker/quantum dot-antibody conjugate agglomerates; detecting the presence of the biomarkers by excitation of the agglomerates.06-21-2012
20080206781Assay and kit for drug efflux transporter activity - The present invention relates to high-throughput cell-based assays for real-time monitoring of multi-resistant drug protein activity. The present invention is an improvement over existing assays in that in addition to a fluorescent drug efflux probe as an indicator of MDR protein activity, the instant assays provide an o-tolidine-based dye for quenching extracellular fluorescence of the probe.08-28-2008
20090017466SEPARATION-FREE ASSAY METHOD - This invention relates to a separation-free assay method employing a binding partner label and a nonspecifically binding label, wherein a signal from said binding partner label or said nonspecifically binding label is measured in a binding event, said method comprising the use of a) two or more binding partners, and a directly luminescent binding partner label adsorbed and/or covalently coupled to at least one of said binding partners; and b) said nonspecifically binding label, wherein i) said nonspecifically binding label is able to affect the signal of said binding partner label, or ii) said binding partner label is able to affect the signal of said nonspecifically binding label; and wherein at least one of said binding partners is a mobile binding partner and at least one other of said binding partners is a labeled ligand.01-15-2009
20090280504NS1-NP Diagnostics of Influenza Virus Infection - The present application describes methods for assessing influenza infection, including prognosis. An assay that determines the amount of the NS1 and NP proteins of influenza virus shows enhanced sensitivity and reliability compared to either antigen alone. Many formats employ pan-specific antibodies (i.e., that react with all or at least with multiple strains within an influenza type).11-12-2009
20110003310ORAL FLUID RAPID IMMUNOCHROMATOGRAPHY TEST - The present invention relates to an oral fluid rapid immunochromatography test. More particularly, the present invention relates to an oral fluid collection swab separate from a lateral flow immunochromatography strip for detecting an analyte in oral fluid, consisting essentially of a sample pad, a conjugate pad, a test zone and control zone pad made of at least one matrix material, wherein the conjugate pad lies downstream of the sample pad, and is striped with a conjugate; the test and control zone pad lies downstream of the conjugate pad, wherein the test zone is immobilized with an specific binding reagent that specifically binding to the target analyte; and the control zone, downstream of the test zone, is immobilized with a second capture reagent. The invention also relates to a method for manufacturing the strip, a lateral flow immunochromatography method for detecting an analyte in oral fluid by using the strip, and kits containing the strip.01-06-2011
20100062458MONOCLONAL AND POLYCLONAL ANTIBODIES TO EQUINE ALBUMIN AND HEMOGLOBIN AND APPARATUS AND METHODS USING THE ANTIBODIES IN THE IDENTIFICATION AND LOCALIZATION OF ULCERS AND OTHER DIGESTIVE TRACT BLEEDING IN EQUINES - A diagnostic and testing apparatus and related methods for the use of the same are disclosed which derive and use antibodies to equine albumin and equine hemoglobin in testing apparatus, kits, and methods for detecting and localizing gastric and colonic ulcers or bleeding in horses. Fecal droppings from a horse to be tested are placed in a container together with a buffered liquid solution and mixed thoroughly, following which several drops of liquid from the container are placed into a test kit. Visual markers in the test kits signify the detection of the indicators equine hemoglobin and equine albumin, which are respectively indicative of the presence of gastric and/or colonic ulcers or bleeding.03-11-2010
20090170116IL-13 Production Inhibitor - The present invention provides a screening method/screening kit for an IL-13 production inhibitor, which comprises using (a) a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or its partial peptide, or a salt thereof; and (b) a ligand capable of specifically binding to the protein; an IL-13 production inhibitor which is obtainable by said screening, and the like. The IL-13 production inhibitor which can be obtained by the screening of the present invention is useful as a prophylactic/therapeutic agent for, e.g., respiratory disease, etc.07-02-2009
20080213797IMMUNOASSAYS EXHIBITING A REDUCTION IN PROZONE PHENOMENA - The present invention relates to immunoassays for detecting or quantifying at least one analyte of interest in a test sample. Specifically, the immunoassays of the present invention exhibit a reduction in prozone phenomena.09-04-2008
20100267050METHODS AND COMPOSITIONS FOR TARGETING POLYUBIQUITIN - Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.10-21-2010
20100267048METHOD FOR MEASUREMENT OF HEMOGLOBIN AND HEMOGLOBIN DERIVATIVE, AND MEASUREMENT KIT - Hemoglobin in a sample solution is quickly and reliably denatured; at the same time, quick and accurate measurement of hemoglobin and a hemoglobin derivative is realized. In a method for measuring hemoglobin and a hemoglobin derivative, and a reagent composition, a measurement kit, an analysis device, and an analysis system used in the method, a sample solution containing a blood component is treated with a nonionic surfactant, an oxidizing agent, and a metal salt to denature hemoglobin in the sample solution to measure the hemoglobin, and thereafter the amount of a hemoglobin derivative in the sample is measured by an immunological method using an antibody specifically binding to a denatured site of the denatured hemoglobin derivative.10-21-2010
20100330584LONG WAVELENGTH FLUOROGENIC INTRACELLULAR ION INDICATORS THAT ARE WELL RETAINED IN THE CYTOSOL - Cell permeable metal ion indicator compounds and methods of their use and synthesis are described. The compound comprises a metal chelating moiety (M12-30-2010
20130022991CELL FREE CD4 QUANTITATION AND METHODS OF USE - The present invention provides a low-cost cell-free assay, the α-test, that provides point-of-care CD4 enumeration using a single platform assay thereby eliminating the need for high-end instrumentation, calibrated pipetting, and specialized technical training. The number of CD4 T cells in blood is driven by the concentration of the protein α1proteinase inhibitor (α1PI, α1antitrypsin, serpin A1). The invention features, in part, methods for determining the number of CD4+ T cells in a sample comprising determining the concentration of alpha 1 proteinase inhibitor (α1PI) in a sample; wherein the number of CD4+ T-cells is related to the concentration of α1PI.01-24-2013
20130022990CELLULAR LABELING FOR NUCLEAR MAGNETIC RESONANCE TECHNIQUES - This disclosure provides, in part, fluorocarbon imaging reagents and formulations for the ex vivo labeling of cells. Labeled cells may be detected in vivo or ex vivo by a nuclear magnetic resonance technique, such as magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS). The disclosure additionally provides methods for using the imaging reagents in a variety of clinical procedures.01-24-2013
20130022989DENTAL STEM CELL REPROGRAMMING - Provided is dental stem cell comprising an Oct3/4 transgene. Also provided is a method of making a pluripotent stem cell. Additionally, a method of preparing an insulin-secreting cell is provided. Further provided is an insulin-secreting cell prepared by that method. A method of preparing a chondrocyte-like cell is also provided, as is a chondrocyte-like cell prepared by that method. Additionally provided is a method of preparing a myocyte-like cell. Also, a myocyte-like cell prepared by that method is provided. A method of preparing a hair follicle-like cell is additionally provided, as is a hair follicle-like cell prepared by that method. A method of preparing a neuron-like cell is additionally provided, as is a neuron-like cell prepared by that method.01-24-2013
20110281278High Throughput Assay for Discovering New Inhibitors of the GIRK1/4 Channel - In certain embodiments of the present disclosure, a method for determining an inhibitor of acetylcholine-activated potassium channel is described. The method includes incubating a cardiac cell in a solution comprising a test compound. The method further includes adding a muscarine (M2) receptor agonist to the cardiac cell in the solution and monitoring the cardiac cell for a change in membrane potential. A statistically insignificant change in the membrane potential following addition of the muscarine (M2) receptor to the solution signifies that the test compound is a K11-17-2011
20110136135APPARATUS AND METHOD FOR PROCESSING BIOLOGICAL SAMPLES - A method and an automated apparatus for processing at least one biological sample arranged on a slide. At least one capillary staining module has a slide rack holder configured to detachably hold a slide rack configured to hold slides, and a capillary lid rack holder configured to detachably hold a capillary lid rack configured to hold capillary lids, wherein the slide rack can be removed independently of removing the capillary lid rack. A first fluid container has a first fluid. The apparatus being configured to automatically rotate the one or more slides, and to move the lids towards the slides to automatically form a capillary gap between each slide and each capillary lid, said capillary gap functioning as a capillary chamber; and to supply an amount of the first fluid to the slide.06-09-2011
20110287446IMMUNOANALYTICAL METHOD AND SYSTEM USING MASS SPECTROMETRY TECHNOLOGY - An immunoanalytical system in which, after a sample such as a patient's serum is subjected to a pretreatment by an immunological pretreatment device, the sample is subjected to light detection by an immunological photometric detection system. Subsequently, the mass spectrometric pretreatment device performs a pretreatment, and the mass spectrometric detection system performs mass spectrometry. The mass spectrometric detection system performs mass spectrometry on components contained in a supernatant. A signal intensity and peak area for each of components are calculated from an obtained chromatograph. A quantitative value measured based on the immunoanalytical method is calculated for each of the components on the basis of the relative ratios of the components.11-24-2011
20090081691METHOD OF IDENTIFYING TRANSMEMBRANE PROTEIN-INTERACTING COMPOUNDS - A method for screening compounds for their ability to interact with transmembrane proteins is provided. Also provided is a method for determining whether proteins such as transmembrane proteins are able to oligomerise.03-26-2009
20100143935c-KIT Phosphorylation in Cancer - An antibody is disclosed for the detection of phosphorylated c-KIT. A method of diagnosing and monitoring cancers responsive to treatment using an anti-phospho-c-KIT antibody are also disclosed. A diagnostic kit is also provided for the detection and monitoring of cancers responsive to tyrosine phosphorylation inhibitor treatment.06-10-2010
20120088250DEVICES, SYSTEMS, AND METHODS FOR THE COLLECTION OF BODY FLUIDS - Devices, systems, and methods for the collection of biological samples. In at least one exemplary embodiment, a device comprises a collection medium having top and bottom surfaces and a predetermined size and shape, the top surface comprising a position marker and at least one binding site operable to bind a biological sample, a protective facing substantially impermeable to the biological sample, the protective facing coupled to the top surface of the collection medium and having a size and shape substantially similar to the predetermined size and shape of the collection medium. The protective facing being sized and shaped to define a first void positioned to allow for the transfer of the biological sample through the protective facing and onto the at least one binding site of the collection medium, and a second void positioned to expose the position marker for alignment of the collection medium.04-12-2012
20100021929DETECTION OF A BIOMARKER OF ABERRANT CELLS OF NEUROECTODERMAL ORIGIN IN A BODY FLUID - Assays and kits for detecting aberrant cells of neuroectodermal origin in a body fluid of an individual, comprising testing for expression of GLAST1b as a biomarker of the cells are disclosed. Intact GLAST1b and/or fragments thereof may be detected in the fluid. Alternatively, another analyte indicative of the expression of GLAST1b by the cells may be detected. The assay is particularly suitable for detecting expression of aberrant neuronal populations such as resulting from brain hypoxia. The fluid can be cerebrospinal fluid (CSF).01-28-2010
20120107831METHOD FOR DETECTING AFFERENT LYMPH VESSEL INFLOW REGIONS AND METHOD FOR IDENTIFYING SPECIFIC CELLS - Regions where metastatic cancer cells can exist are detected with high accuracy in a sentinel lymph node. Quantum dots are injected into the vicinity of a cancer in a living body, thereby identifying the location of the sentinel lymph node by means of fluorescence. Subsequently, the sentinel lymph node is extracted. With respect to the sentinel lymph node extracted with quantum dots injected, structural analysis is conducted by means of precision fluorescence measurement which uses a confocal fluorescence microscope for monomolecular observation. Specifically, the fluorescence intensity is measured with respect to each of multiple areas in the sentinel lymph nodes, and out of the multiple areas measured, one or more areas are detected as afferent lymph vessel inflow regions in descending order of fluorescence intensity.05-03-2012
20100003695MICROWAVE TRIGGER METAL-ENHANCED CHEMILUMINESCENCE (MT MEC) AND SPATIAL AND TEMPORAL CONTROL OF SAME - The present invention relates to a method of imaging structures and features using plasmonic emissions from metallic surfaces caused by chemiluminescence based chemical and biological reactions wherein imaging of the reactions is enhanced by the use of microwave energy and further enhanced by using metallic geometric structures for spatially and temporally controlling the biological and chemical reactions.01-07-2010
20110300555ASSAY DEVICE COMPRISING BUBBLE-FORMING MEANS - Disclosed is a method for determining the presence and/or amount Oran analyte of interest in a liquid sample comprising the steps of: contacting the liquid sample suspected of containing analyte with a gas generating means (eg. catalase and peracid or peroxygen compound), which gas generating means forms a gas dependent upon the presence, absence or amount of analyte, which gas creates one or more bubbles in the liquid sample which act to alter the flow of liquid along a flow path; and determining an alteration of flow in the liquid wherein the alteration of flow of liquid along the flow path is indicative of the presence and/or amount of analyte in the liquid sample.12-08-2011
20110065123Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression - Cell-based methods for rapid real time assay of a presence of 03-17-2011
20110039276IDENTIFYING ORGAN DAMAGE - The present invention provides methods for identifying whether or not a patient has, or is at risk of developing drug induced organ damage and methods of treating patients having drug induced organ damage. In particular, the invention relates to a method for identifying whether or not a patent has, or is at risk of developing paracetamol induced liver damage.02-17-2011
20100297663METHODS AND SYSTEMS FOR ASSAYING, MAINTAINING, AND ENHANCING THE ACTIVITY OF THE IMMUNE SYSTEM OF A SUBJECT - A method for non-invasively assessing a subject's health includes evaluating a state of a subject's immune response. Such a method may include obtaining a salivary sample from the subject and assaying the salivary sample for IgA. The state of a component of the subject's immunity may be evaluated in conjunction with the administration of one or more substances known to elicit a cell-mediated immune response to the subject to determine the effect of the one or more substances on the subject's humoral, or antibody-mediated, immune response. Assay methods may also be used to optimize the dosage of an immune support component to be administered to a particular subject. Systems that include assays for evaluating the state of a subject's immune response and nutraceuticals are also disclosed.11-25-2010
20110287448DIAGNOSTIC METHOD FOR DISEASES BY SCREENING FOR HEPCIDIN IN HUMAN OR ANIMAL TISSUES, BLOOD OR BODY FLUIDS AND THERAPEUTIC USES THEREFOR - The present invention concerns methods and kits for diagnosing a disease condition characterized by non-physiological levels of hepcidin, comprising obtaining a tissue or fluid sample from a subject; contacting the sample with an antibody or fragment thereof that specifically binds to a polypeptide corresponding to the mid-portion or C terminus of a hepcidin protein, and quantifying the hepcidin level using an assay based on binding of the antibody and the polypeptide; wherein the non-physiological level of hepcidin is indicative of the disease condition. The present invention also concerns diagnostic methods and kits for applications in genetic technological approaches, such as for overexpressing or downregulating hepcidin. The present invention further concerns therapeutic treatment of certain diseases by treatment of subjects with hepcidin and agonists or antagonists of hepcidin.11-24-2011
20110287447APPARATUS FOR AND METHOD OF AUTOMATED PROCESSING OF BIOLOGICAL SAMPLES - Provided herein is a bioprocessing device, bioprocessing card, and fluidics cartridge for performing automated bioprocessing of a sample. The bioprocessing card may include a plurality of pipette tips; and at least one pump in fluid communication with the plurality of pipette tips. In some embodiments, the pumps and the pipette tips are in fluid communication through a processing channel which may be a microscale channel. Also provided herein is an automated bioprocessing device comprising: at least one bioprocessing card; at least one fluidic cartridge; and an automated control system configured to control automated bioprocessing of a sample. Further provided herein are methods of use of the device, card, and cartridge.11-24-2011
20110287445Mutant ROS Expression In Human Cancer - The invention provides the identification of the presence of mutant ROS protein in human cancer. In some embodiments, the mutant ROS are FIG-ROS fusion proteins comprising part of the FIG protein fused to the kinase domain of the ROS kinase. In some embodiments, the mutant ROS is the overexpression of wild-type ROS in cancerous tissues (or tissues suspected of being cancerous) where, in normal tissue of that same tissue type, ROS is not expressed or is expressed at lower levels. The mutant ROS proteins of the invention are anticipated to drive the proliferation and survival of a subgroup of human cancers, particularly in cancers of the liver (including bile duct), pancreas, kidney, and testes. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS polypeptides (e.g., a FIG-ROS(S) fusion polypeptide), probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The identification of the mutant ROS polypeptides enables new methods for determining the presence of these mutant ROS polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention.11-24-2011
20110287444IMMUNOASSAY METHOD FOR HUMAN CXCL1 PROTEIN - An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein: 11-24-2011
20110287443HIGH LEVEL EXPRESSION OF RECOMBINANT TOXIN PROTEINS - The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and 11-24-2011
20100285491USE OF IGFBP-7 IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.11-11-2010
20100028904WAY TO OBTAIN HIGH EXPRESSION CLONES OF MAMMALIAN CELLS USING A METHYLCELLULOSE WITH FLUORESCENT PROTEIN A OR G AND FLUORESCENT SCREENING METHOD - The invention provides a genetic screening method for identifying a transfected cell expressing the polypeptide of interest. The methods allows for high throughput screening of recombinant cells for elevated levels of expression of the polypeptide of interest using methylcellulose comprising fluorescent protein A or G to improve detection and cloning. The invention also provides capture media, formulations and methods of making and using thereof.02-04-2010
20110294136BIOMARKER FOR DIAGNOSING PANCREATIC CANCER - The invention relates to a method for diagnosing pancreatic cancer (PaCa) or the precursor diseases and/or concomitant diseases thereof, in particular pancreatic ductal adenocarcinoma (PDAC), pancreatic intraepithelial neoplasia (PanIN), pancreatic lesions, chronic pancreatitis (CP), including endocrine pancreatic tumors. In said method, the diagnosis is performed using selected biomarkers. The invention further relates to biomarker combinations suitable for carrying out said method, particularly for in vitro diagnosis.12-01-2011
20110294139DISPOSABLE CHIP-TYPE FLOW CELL AND FLOW CYTOMETER USING SAME - The present invention provides an apparatus for analyzing particles in a solution including a unit configured to place a flow cell having a flow path for flowing a sample solution containing the particles; a unit configured to illuminate the sample solution flowing through the flow path of the flow cell; a photodetector that detects a scattered light and/or fluorescence generated from the particles in the sample solution; and a unit configured to analyze the particles based on their signal intensities detected by the photodetector, wherein the flow cell has the flow path formed in a substrate, a reflection plane is formed on the side surface of the flow path, the reflection plane leads the lights generated in the flow path of the flow cell and advancing in the substrate in-plane direction to a specified region of the surface of the flow cell, and the photodetector detects the light exiting from the specified region to the outside.12-01-2011
20110294140Lysis Reagent For Use With Capture-In-Solution Immunoassay - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and non-specific animal immunoglobulins. Other aspects of the invention include related immunoassays and test kits.12-01-2011
20110294138METHODS FOR SIMULTANEOUSLY MEASURING THE IN VIVO METABOLISM OF TWO OR MORE ISOFORMS OF A BIOMOLECULE - The present invention encompasses methods for the simultaneous measurement of the in vivo metabolism of two or more isoforms of a biomolecule. The biomolecule is typically produced in the central nervous system.12-01-2011
20110143364CENTRIFUGAL MICRO-FLUIDIC STRUCTURE FOR MEASURING GLYCATED HEMOGLOBIN, CENTRIFUGAL MICRO-FLUIDIC DEVICE FOR MEASURING GLYCATED HEMOGLOBIN, AND METHOD FOR MEASURING GLYCATED HEMOGLOBIN - Disclosed are a centrifugal micro-fluidic structure for measuring glycated hemoglobin, a centrifugal micro-fluidic device for measuring glycated hemoglobin, and a method for measuring glycated hemoglobin. According to the disclosure, immunosorbent assay and affinity measurements are simultaneously conducted using only a single device in order to detect hemoglobin variants or interfering substances and, therefore, the detected results are applied to analysis of measurement results so as to eliminate and/or compensate for, or calibrate errors in measurement of, glycated hemoglobin, thereby more accurately measuring the glycated hemoglobin.06-16-2011
20110143365METHODS AND DEVICES TO ENHANCE SENSITIVITY AND EVALUATE SAMPLE ADEQUACY AND REAGENT REACTIVITY IN RAPID LATERAL FLOW IMMUNOASSAYS - Methods and devices for rapid lateral flow immunoassays to detect specific antibodies within a liquid sample while also validating the adequacy of the liquid sample for the presence of immunoglobulin and the integrity and immunoreactivity of the test reagents that detect the antibodies of interest, without requiring instrumentation. The methods and devices provide for delivery of a diluted liquid sample to a single location that simultaneously directs the liquid flow along two or more separate flow paths, one that serves as a positive control to confirm that all critical reagents of the test are immunoreactive, and that the sample being tested is adequate, and the other to detect specific antibodies if present.06-16-2011
20100068725DIRECT DETERMINATION OF VITAMIN D IN SERUM OR PLASMA - A method for quantitating vitamin D metabolites directly in blood plasma or serum, without the need for prior purification of the vitamin D metabolites, comprising a digestion of the serum proteins with a serine protease such as proteinase K and sequence of steps for inhibiting the proteinase K activity in the competitive binding analysis. The advantages of this method are its high accuracy over the whole range of physiologically relevant values and that it can be easily adapted for a fully automated analysis of serum and plasma samples.03-18-2010
20110294137Sensor - The invention relates to an ADP binding molecule comprising a polypeptide, said polypeptide comprising amino acid sequence corresponding to at least amino acids 11 to 310 of SEQ ID NO:1, wherein said polypeptide comprises a substitution relative to SEQ ID NO:1 at amino acid C287, and wherein said polypeptide comprises a further cysteine residue for attachment of at least one reporter moiety, and wherein said polypeptide has at least 68% sequence identity to SEQ ID NO:1 at the amino acid residues corresponding to those shown in column III of table A.12-01-2011
20100055710Novel Carbohydrate Profile Compositions From Human Cells and Methods for Analysis and Modification Thereof - The invention describes methods for production of novel composition of glycans, glycomes, from human multipotent stem cells. The invention is further directed to methods for modifying the glycomes and analysis of the glycomes and the modified glycomes. Furthermore the invention is directed to stem cells carrying the modified glycomes on their surfaces.03-04-2010
20110033869Enzyme Triggered Redox Altering Chemical Elimination (E-Trace) Immunoassay - The present invention is directed to electronic methods of detecting target analytes such that upon binding of the target analyte a shift in electrochemical potential is seen. This assay relies on the use of an electroactive moiety (“EAM”) that is attached to an electrode and comprises a self-immolative moiety, whose presence gives the EAM a first E0, and whose absence, upon irreversible cleavage gives the EAM a second E0. This difference is detected, and if such change occurs, it is an indication of the presence of a target analyte.02-10-2011
20090280505METHOD FOR DETECTING LYSOSOMAL STORAGE DISEASES - A method for detecting lysosomal storage diseases including the steps of performing an assay for a single species of glycosaminoglycan contained in a specimen and correlating results of the assay with lysosomal storage diseases. A body fluid such as urine or blood can be employed as a specimen. The assay can be performed by use of a polypeptide that is capable of specifically binding to a glycosaminoglycan-containing molecule. The polypeptide may be an antibody, or a polypeptide having an antigen-binding site of an antibody.11-12-2009
20100221743Methods for Diagnosing and Treating Endoplasmic Reticulum (ER) Stress Diseases - The present invention provides methods and reagents to quantify endoplasmic reticulum stress (ER stress) levels, and methods and compounds for treating ER stress disorders such as diabetes. Methods for quantifying ER stress in mammalian cells are exemplified.09-02-2010
20080293074Hemoglobin Derivative Measurement Method, and Reagent Composition, Measurement Kit, Analysis Device and Analysis System for Use in the Method - A sample solution including blood components is processed with a denaturalization reagent comprising a nonionic surface-activating agent and an oxidizing agent to denaturalize a hemoglobin derivative in the sample solution, and thereafter, an immunoassay is performing utilizing an antibody that is specific to a denaturalized site of the hemoglobin derivative to measure the amount of the hemoglobin derivative in the sample. Therefore, when performing assay of hemoglobin derivative, denaturalization of hemoglobin can be performed speedily and reliably while minimizing adverse effects of the denaturalization reagent on immune reaction.11-27-2008
20110189693Methods for Cancer Diagnosis, Anti-Cancer Drug Screening, and Test of Drug Effectiveness on the Basis of Phoshorylation of Ras at Thr-144 and Thr-148 - Methods of diagnosing cancer and screening for an anti-cancer drug using Ras are provided. Ras has a very significant role as a prevalent proto-oncogene which has abnormalities in most forms of cancer, and thus the methods of diagnosing cancer and screening for an anti-cancer drug using Ras may be applied to various forms of cancer. The generation of various forms of cancer in the early stages may be determined by examining whether or not phosphorylation of Ras occurs at Thr-144 and Thr-148 sites, By such a mechanism, an anti-cancer drug having excellent anti-cancer effectiveness may be screened, or the effectiveness of the anti-cancer drug may be tested.08-04-2011
20100035276IDENTIFYING VIRALLY INFECTED AND VACCINATED ORGANISMS - This document provides methods and materials related to assessing organisms for the presence or absence of anti-virus antibodies. For example, this document provides methods and materials that can be used to determine whether or not an organism (e.g., a member of a swine species such as a pig) contains anti-PRRS virus antibodies. In other embodiments, this document provides methods and materials that can be used to determine if a particular organism received a vaccine version of a virus, was infected with a naturally-occurring version of the virus, or is naive with respect to the virus.02-11-2010
20100028903METHOD AND DEVICE FOR EXAMINING THE ATTACHMENT OR DETACHMENT OF LIVING OR DEAD CELLS OR CELL-LIKE PARTICLES OR OTHER SURFACE ACCUMULATIONS ON SURFACES BY MEANS OF PLASMON RESONANCE AND USE OF SAID METHOD AND SAID DEVICE - The invention relates to the examination of the attachment or detachment of living or dead cells, or cell-like particles, or other surface accumulations on surfaces, by means of plasmon resonance. The reflected light is evaluated such that two or more intensity minima of the reflected light occurring within a time frame are registered in a time dependant manner for different incident angles. The registered measurement signals reflect the respective amount of the surface accumulation. In case two intensity minima have occurred at the same time, valuable information about particular processes regarding the surface accumulation, for example regarding the adhesion of cells, can be obtained. Said information is of particular importance in the field of medicine/biology.02-04-2010
20110217718Methods and Kits for Distinguishing Between Specific and Non-Specific Protein Associations - The present invention is method of determining whether or not associations between a given protein and other proteins in a cell are specific. The method comprises (a) providing a first sample of the cells in which the given protein contains a tag, (b) providing a second sample of the same cells, wherein the given protein and the other proteins are metabolically labeled, and wherein neither the given protein nor the other proteins are tagged, (c) mixing and lysing the first cell sample and the second cell sample to provide a mixture of proteins, (d) binding the tag of the given protein to a substrate, (e) isolating proteins associated with the tagged given protein bound to the substrate, whereby the associated proteins comprise: (i) proteins specifically associated with the tagged given protein, (ii) proteins non-specifically associated with the tagged given protein, or (iii) a combination thereof, (f) determining whether each associated protein is unlabeled or a mixture of labeled and unlabeled proteins, wherein if the associated protein is not labeled, then that protein was specifically associated in the cell with the tagged given protein.09-08-2011
20090246795IMMUNOASSAY DEVICE AND METHOD - An immunoassay device capable of assaying amount of an antigen by allowing a labeled antibody to specifically bind to a antigen analyte in a sample and assaying a label of a bound product, an interior of a single device has four regions comprises: (1) a first region where the antigen in the sample reacts with a first antibody that is the labeled antibody capable of specifically binding to the antigen, (2) a second region where first antibody that has not bound to the antigen reacts with a second biotin- or avidin-bound antibody, (3) a third region where, depending on whether the second antibody is biotin-bound antibody or avidin-bound antibody, either avidin or biotin is immobilized by immobilization means so as to be unable to move to the fourth region, and the second antibody is captured by the immobilized avidin or biotin, and (4) a fourth region where the label of the first antibody that has bound to the antigen is detected, being constructed in such a way that a solution can move sequentially through each region, the first antibody, which is the labeled antibody such that an antibody component is an F(ab′) fragment or reduced IgG, the F(ab′) fragment or reduced IgG being bound with the label in a predetermined proportion, is included in the first region or an adjacent region, and the second antibody is a biotin- or avidin-bound antibody, being of anti-idiotype antibody against the first antibody and a type that cannot bind to the bound product of the antigen and first antibody, and is included in the second region or an adjacent region.10-01-2009
20090098570Lxr ligand testing method - A method of easily measuring whether or not an LXR ligand has the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration in a mammal by using the binding activity between LXR and a coactivator, and a method of identifying LXR ligands that do not have the function of effecting, e.g., increasing, plasma triglyceride concentration and/or LDL cholesterol concentration by using the binding activity between LXR and a coactivator.04-16-2009
20090220986ASSESSING NON-ALCOHOLIC FATTY LIVER DISEASE - The document provides methods and materials related to assessing NAFLD in a mammal. For example, methods and materials for determining whether or not a mammal has an NAFLD are provided. In addition, methods and materials for determining whether a mammal with an NAFLD has a severe or mild form of the NAFLD as well as methods and materials for determining whether a mammal with an NAFLD is likely to experience a severe or mild form of the NAFLD are provided.09-03-2009
20090181402COMPOSITIONS AND METHODS FOR COUPLING A PLURALITY OF COMPOUNDS TO A SCAFFOLD - Compositions and methods are provided for coupling a plurality of compounds to a scaffold. Compositions and methods are further provided for catalyzing a reaction between at least one terminal alkyne moiety and at least one azide moiety, wherein one moiety is attached to the compound and the other moiety is attached to the scaffold, forming at least one triazole thereby.07-16-2009
20090170121ASSAY BUFFER, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME - Compositions, reagents, kits, systems, system components, and methods for performing assays. More particularly, the invention relates to the use of novel combinations of reagents to provide improved assay performance.07-02-2009
20090170119METHOD FOR AMPLIFYING VARIATION OF FREQUENCY OF SIGNAL IN PIEZOELECTRICAL BIOSENSOR - Provided is a method for amplifying a frequency variation of a detected signal in a biosensor that is used for detecting a biomolecule by measuring a change in frequency of an oscillating signal the change being caused by pressure a biomolecule applies to a piezoelectric substance. The method for amplifying a frequency variation of a detected signal comprises the steps of: (a) applying a sample to a probe being fixed to an upper portion of a substrate of the biosensor to allow a biomolecule in the sample to be bound to the probe; (b) applying, protein tagged with a metal particle to the biosensor to allow the protein, and the biomolecule to be bound with each other; and (c) applying a metal enhancer to the biosensor to allow the metal enhancer to be bound to the metal, particle having been bound to the protein07-02-2009
20090162869MEMBRANE MOLECULE EXPRESSED SPECIFICALLY IN ACTIVATED PLASMACYTOID DENDRITIC CELL - It is an object of the present invention to identify a membrane molecule that is specifically expressed on activated plasmacytoid dendritic cells, for the purpose of preventing or improving affection or disease such as cancer, autoimmune disease, allergy, or infectious disease by regulating the functions of dendritic cells capable of integrating an immune system. The present invention provides a protein having any one of the following amino acid sequences:06-25-2009
20090253146Methods of expressing integrin beta6 subunits - The present invention provides substantially pure integrins containing a novel β subunit designated as β10-08-2009
20090280502ANTI-2-O-DESULFATED ACHARAN SULFATE ANTIBODY AND ITS APPLICATION - An antibody that reacts with 2-O-desulfated acharan sulfate, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The antibody that reacts with 2-O-desulfated acharan sulfate can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to 2-O-desulfated acharan sulfate.11-12-2009
20100112597Methods for Quantifying Protein Leakage From Protein Based Affinity Chromatography Resins - The present invention provides methods of quantifying protein leakage from a protein based affinity chromatography media (e.g., protein A, protein G and protein L based affinity chromatography media), where such a protein is used for isolating and/or removing a molecule which binds the protein (e.g., an immunoglobulin).05-06-2010
20100167306RAPID TEST FOR GLYCATED ALBUMIN IN SALIVA - This invention describes a rapid immunochromatographic assay for measuring the ratio of glycated albumin to total albumin in saliva. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. Saliva albumin is derived from plasma albumin and therefore contains glycated and non-glycated albumin fractions that can be measured. The ratio of glycated albumin to total albumin in saliva will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period.07-01-2010
20090148856Methods and apparatus for therapeutic drug monitoring using an acoustic device - Methods for therapeutic drug monitoring are provided. A plurality of particles, each of which is coated with a capture agent capable of binding a therapeutic drug of choice is combined with the sample to form a plurality of therapeutic drug-particle complexes. The system also includes a transport arrangement for transporting the sample and/or particles to the sensor surface, and optionally a magnetic field inducing structure constructed and arranged to establish a magnetic field at and adjacent to the sensor surface. The resonant sensor produces a signal corresponding to an amount of therapeutic drug-particle complexes that are bound to the sensor surface.06-11-2009
20080311589METHOD OF HIGH-THROUGHPUT SCREENING OF MOLECULES AND COMPOUNDS FOR THEIR EFFECTS ON BIOLOGICAL AND CHEMICAL PROCESSES - The present invention provides a system for high-throughput analysis of chemical compounds. Assays are performed in a high density platform, and compounds having pre-determined desirable effects are identified. Preferably, the compounds have biological effects, more preferably, the assays and detection are performed on whole cells.12-18-2008
20110262931MAST CELL CARBOXYPEPTIDASE AS A MARKER FOR ANAPHYLAXIS AND MASTOCYTOSIS - The present invention relates to use of mast cell carboxypeptidase as a marker for anaphylaxis or mastocytosis in serum, plasma or saliva samples. Detection of elevated mast cell caroboxypeptidase in for example serum samples is proposed for reducing false negatives in relation to diagnosis of anaphylaxis and various categories of mastocytosis by picking up serum tryptase-negative cases.10-27-2011
20090081692Ceramide Kinase Loop - An isolated polynucleotide of SEQ ID NO:1, an isolated polypeptide of SEQ ID NO:2, e.g. encoded by a polynucleotide of SEQ ID NO:1, a vector comprising such polynucleotide, an expression system, comprising such polynucleotide, a host cell comprising such expression system, the use of a such polypeptide or polynucleotide as a diagnostic reagent, screening assays and methods for identifying an agonist or an antagonist of a ceramide kinase by use of such polypeptide or polynucleotide and an agonist or an antagonist of a ceramide kinase obtained by such screening and their use.03-26-2009
20090148857Method and apparatus for detection of analyte using an acoustic device - Methods for detecting analytes in a sample are provided. A plurality of particles, each of which is coated with a capture agent having an affinity for the analyte, is combined with the sample to form a plurality of analyte-particle complexes. The system also includes a transport arrangement for transporting the sample to the sensor surface, and a magnetic field inducing structure constructed and arranged to establish a magnetic field at and adjacent to the sensor surface. The resonant sensor produces a signal corresponding to an amount of analyte-particle complexes that are bound to the sensor surface.06-11-2009
20090148864METHODS AND COMPOSITIONS FOR THE DETECTION OF CERVICAL DISEASE - Methods and compositions for identifying high-grade cervical disease in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in high-grade cervical disease. In particular claims, the body sample is a cervical smear or monolayer of cervical cells. The biomarkers of the invention include genes and proteins that are involved in cell cycle regulation, signal transduction, and DNA replication and transcription. In particular claims, the biomarker is an S-phase gene. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.06-11-2009
20090148860METHODS OF DIAGNOSING MUSCLE DAMAGE - A method for assessing muscle damage in a biological sample obtained from a subject is disclosed. The method involves obtaining a biological sample from a subject being assessed for muscle damage, and evaluating the sample for the presence or absence of a myofilament protein modification product. The method can also be used to assess the extent and/or type of muscle damage in a subject by studying the profile of myofilament protein modification products detected in the sample taken from the subject. The invention further provides a method for screening for an agent which modulates the level of a myofilament protein modification product present in a biological sample or for a calcium sensitizing agent. The invention is applicable to cardiac muscle and skeletal muscle.06-11-2009
20090148858METHODS FOR CHARACTERIZING BIOLOGICAL MOLECULE MODULATORS - Methods for characterizing a biochemical reaction and analysis of reaction products by establishing continuously variable concentration gradients of one or more reagents of the biochemical reaction are provided. Methods for determining mechanism of inhibition or activation, potency of inhibition or activation, or both of an enzyme inhibitor or activator, respectively, are also provided. The continuously variable concentration gradients can be established in a microfluidic chip.06-11-2009
20100267053AKT3 POLYPEPTIDES - The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.10-21-2010
20100267052COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES - The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.10-21-2010
20100267051ANNEXIN FOR CANCER RISK ASSESSMENT - A method treats urogenital and/or intestinal tract cancer and includes administering a therapeutically effective amount of at least one annexion protein, annexin of A3, to a mammal.10-21-2010
20100267047Test Method on Feline Vaccinated with Feline Immunodeficiency Virus Vaccine, and Antigen for Use in the Test - Since FIV-vaccinated cats produce antibodies against FIV, distinguishing them from FIV-infected cats is difficult by serological diagnostic methods using FIV and FIV-derived substances. The present invention enables tests for determining the presence or absence of a FIV vaccination history in a cat by detecting antibodies that are produced as a result of vaccination of a cat with an FIV vaccine, but not as a result of FIV infection. Using the methods of the present invention, whether an anti-FIV antibody-positive cat is infected with FIV or has been vaccinated can be conveniently distinguished.10-21-2010
20100267046ISOFORM-SELECTIVE INHIBITOR AND ACTIVATORS OF PDE3 CYCLIC NUCLEOTIDE PHOSPHODIESTERASES - The present invention concerns methods and compositions related to type 3 phosphodiesterases (PDE3). Certain embodiments concern isolated peptides corresponding to various PDE3A isoforms and/or site-specific mutants of PDE3A isoforms, along with expression vectors encoding such isoforms or mutants. In specific embodiments, methods for identifying isoform-selective inhibitors or activators of PDE3 are provided, along with methods of use of such inhibitors or activators in the treatment of dilated cardiomyopathy, pulmonary hypertension and/or other medical conditions related to PDE3 effects on cAMP levels in different intracellular compartments.10-21-2010
20080268464Process And Device For Determining The Activity Of Enzymes In Liquids, Or The Concentration And/Or Activity Of Inhibitors In Liquids - A process and device are disclosed to determine the activity of enzymes in liquids in a largely automatic manner. The device for carrying out this process has a column (10-30-2008
20080268462Haptens, hapten conjugates, compositions thereof and method for their preparation and use - A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.10-30-2008
20080268459Anti-Lewis Y Anti-Idiotypic Antibodies and Uses Thereof - This invention provides anti-idiotype antibodies specific for Anti-Lewis Y monoclonal antibodies. The present invention also directed against an ELISA screening method of mAbs produced by hybridoma clones for specific binding to the variable regions of hu3S193 and the ability of the anti-idiotypic mAB to inhibit hu3S193 binding to Lewis Y antigen. Additionally, the present invention provides a hybridoma capable of producing an anti-idiotype antibody specific for anti-Lewis Y monoclonal antibody. A further aspect of the invention is to provide a hybridoma, which is specific for anti-Lewis Y monoclonal antibody selected from the group consisting of LMH-1, LMH-2, LMH-3, or LMH-4. The present invention is also directed against a method to detect HAMA, HACA and HAHA responses using the antibody of the invention.10-30-2008
20120122114IMMUNOASSAY FOR THE DETECTION OF PROCALCITONIN - The present invention relates to an in vitro method for the detection of Procalcitonin or a fragment thereof of at least 20 amino acid residues in length in a biological sample derived from a bodily fluid obtained from a subject, comprising the steps of: (i) contacting said sample with at least two antibodies or functional fragments thereof directed against different epitopes within Procalcitonin, and (ii) qualitatively or quantitatively detecting binding of said at least two antibodies to Procalcitonin or said fragment thereof, wherein binding indicates the presence or concentration of Procalcitonin or said fragment in said sample, wherein at least one antibody or functional fragment thereof is directed against an epitope comprised in the sequence spanning amino acid residues 2 to 52 of Procalcitonin. The invention also pertains to antibodies directed against an N-terminal epitope of Procalcitonin and kits comprising antibodies directed against PCT.05-17-2012
20110124007UTILITY OF HIGH MOLECULAR WEIGHT MELANOMA ASSOCIATED ANTIGEN IN DIAGNOSIS AND TREATMENT OF CANCER - HMW-MAA antibody cocktails and their uses in detecting cancer and isolating cancer cells are disclosed. Also disclosed are methods of detecting cancer based on the presence of an HMW-MAA genomic sequence in circulating DNA, as well as the increased expression of the HMW-MAA gene and the reduced methylation of the HMW-MAA gene promoter in tissues and circulating cells.05-26-2011
20100086937 METHOD TO DETECT TREPONEMA PALLIDUM IMMUNOLOGICAL MARKERS FOR THE DIAGNOSIS OF SYPHILIS - This invention discloses using SPR technology to qualitatively detect the presence of 04-08-2010
20090191570Inhibition of Interaction of PSD93 and PSD95 with nNOS and NMDA Receptors - PSD-95/SAP90 antisense-treated animals not only experience a significant decrease in MAC for isoflurane, but also experience an attenuation in the NMDA-induced increase in isoflurane MAC. PSD-95/SAP90 appears to mediate the role of the NMDA receptor in determining the MAC of inhalational anesthetics. Suppression of the expression of PSD-95/SAP90 in the spinal cord significantly attenuates responses to painful stimuli mediated through the N-methyl-D-aspartate receptor activation. In spinal cord neurons PSD-95/SAP90 interacts with the N-methyl-D-aspartate receptor subunits 2A/2B. Activation of the N-methyl-D-aspartate receptor in spinal hyperalgesia results in association of the N-methyl-D-aspartate receptor with PSD-95/SAP90. PSD-95/SAP90 is required for hyperalgesia triggered via the N-methyl-D-aspartate receptor at the spinal cord level.07-30-2009
20120034618METHODS FOR CULTURE AND PRODUCTION OF SINGLE CELL POPULATIONS OF HUMAN EMBRYONIC STEM CELLS - We used ACCUTASE®, a commercially available cell detachment solution, for single cell propagation of pluripotent hESCs. Unlike trypsin dissociation, ACCUTASE® treatment does not significantly affect the plating efficiency of hESC dissociation into single cells. Cultures dissociated with ACCUTASE® to single cells at each passage maintain a higher proportion of pluripotent cells as compared to collagenase-passaged hESCs. ACCUTASE®-treated hESCs can be grown to a high density as monolayers, and yet retain their pluripotency.02-09-2012
20120142017BIOSENSOR DEVICE AND MANUFACTURING METHOD THEREOF - Disclosed is a biosensor device, comprising: a capillary tube with probe molecules immobilized on the inner wall surface thereof, and a liquid sample containing target molecules, said biosensor device being characterized in that a contact angle between the inner wall surface of the capillary tube and the liquid sample changes because of the specific interaction between the probe molecules and the target molecules, which leads, in turn, to a change in the height of the liquid sample in the capillary tube.06-07-2012
20090087860HIGHLY SENSITIVE SYSTEM AND METHODS FOR ANALYSIS OF PROSTATE SPECIFIC ANTIGEN (PSA) - The invention described herein provides methods, compositions, kits, and systems for the sensitive detection of prostate specific antigen. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of prostate specific antigen.04-02-2009
20090087861Chimeric Tymovirus-like Particles and Process Thereof - The present disclosure relates to chimeric tymovirus-like particles (TVLPs) comprising a fusion protein that further comprises of a first protein that is a truncated tymovirus coat protein and a second protein. These chimeric TVLPs are useful as antigens. The present disclosure provides a highly efficient means for differentiating Foot and Mouth Disease Virus (FMDV) infected animals from vaccinated animals. The present disclosure further provides a process for the production of chimeric TVLPs and a diagnostic kit for the determination of specific antibodies of FMDV to differentiate FMDV infected from vaccinated animals. The present disclosure also provides the use of the chimeric TVLPs for diagnostic purposes.04-02-2009
20090087859Microfluidic device for detecting soluble molecules - The present disclosure provides a microfluidic device that is compatible with standard centrifuges and may be used for point-of-care disease detection. The detection methodology may be based on microELISA.04-02-2009
20100099117DIAGNOSTIC METHOD FOR DETERMINING THE SUSCEPTIBILITY TO DELIVERY AND REAGENT KIT FOR USE THEREFOR - The invention relates to a diagnostic method for detecting susceptibility to delivery, and to a test kit for this purpose. A low, but higher than baseline level concentration of Insulin-like Growth Factor Binding Protein 1 (IGFBP-1), which is due to leakage from decidual cells, is detected by an immunological assay in a vaginal secretion sample.04-22-2010
20100099113MINIMIZED SMALL PEPTIDES WITH HIGH AFFINITY FOR FACTOR VIII AND FACTOR VIII-LIKE PROTEINS - The present invention relates to the composition of small molecules and their use in the field of protein isolation, purification, stabilizing and/or enhancing its activity. In particular, the present invention relates to the synthesis and optimization of compounds comprising small peptides and peptide derivatives with affinity to coagulation Factor VIII and/or Factor VIII-like polypeptides and/or domains thereof. These compounds are useful for labeling, detecting, identifying, isolating and preferably for purifying, stabilizing and enhancing the activity of Factor VIII, Factor VIII-like polypeptides or domains thereof from physiological and non-physiological solutions comprising same. Further, these compounds may be used as ligands, which bind Factor VIII, Factor VIII-like polypeptides or domains thereof in methods of the present invention.04-22-2010
20100086938MASS SPECTROMETRY OF BIOLOGICAL SAMPLE USING IMMUNOPRECIPITATION - It is intended to provide an analysis method for a biological sample with clinical significance, which is a system being simple to such an extent that it can be applied to a clinical field, and capable of capping a molecule ionization suppression in mass spectrometry. Mass spectrometry of a biological sample using immunoprecipitation, comprising the steps of: preparing a sample containing an objective biological molecule; concentrating the biological molecule in the sample by immunoprecipitation using an antibody-bound carrier or a carrier to which a molecule capable of specifically binding to an antibody is bound; washing an immunoprecipitate of the biological molecule by using an aqueous solution containing a charge neutralizing agent as a washing liquid; and detecting the biological molecule by subjecting the washed immunoprecipitate to mass spectrometry.04-08-2010
20110201017LUPUS ANTICOAGULENT TESTING - The present invention relates generally to the field of diagnostic screening and diagnostic assays. In particular, the present invention provides an improved, rapid, and efficient method of screening for antiphospholipid antibodies, such as lupus anticoagulants (LA). The invention also relates to a kit for screening plasma levels for antiphospholipid antibodies in subjects in need thereof, such as those at risk for or suffering from, inter alia, antiphospholipid syndrome (APS) and systemic lupus erythromatosus (SLE).08-18-2011
20110195430HIGH PRESSURE ENZYMATIC DIGESTION SYSTEM FOR PROTEIN CHARACTERIZATION - An on-line method and system for obtaining samples for proteomic analysis that utilizes pressure and a preselected agent to obtain a processing sample in a significantly shorter period of time than prior art methods and which maintains the integrity of the processing sample through the preparatory process, and provides enhanced protein capture. In one embodiment of the invention, a sample and an enzyme are combined and subjected to a pressure, preferably a pressure cycle range that varies between 0 to 35 kpsi, for a period of time of preferably less than 60 seconds. This process results in producing a sample suitable for analysis, which is preferably introduced to another analytical instrument such as a mass spectrometry instrument, or other device.08-11-2011
20100081146METHOD OF REDUCING THE SENSITIVITY OF ASSAY DEVICES - A flow-through assay device for detecting the presence or quantity of an analyte residing in a test sample is provided. The device utilizes a scavenging zone that contains a capture reagent for the analyte of interest. The capture reagent may capture a quantity of the analyte that is less than or equal to a predefined base quantity of the analyte, such as a quantity considered “normal” for a particular test sample. Thus, the capture reagent is able to prevent some of the analyte from being detected. In this manner, the sensitivity of the assay device may be reduced in a simple, inexpensive, yet effective manner.04-01-2010
20120107832METHOD FOR THE DETECTION OF ORGAN OR TISSUE INJURY - This invention relates to methodology for detecting, assessing and/or diagnosing the presence of organ or tissue injury. More specifically, the present invention relates to methodology for detecting particular serum biomarkers that can be used in the detection, assessment and/or diagnosis of organ (e.g. liver) or tissue (e.g. skin) injury.05-03-2012
20090263827Method for determining health status by analyzing analytes - A method to extract information from samples taken at different times from a mammalian. These samples are analyzed with respect to one or more analytes giving one or more responses, creating one or more response curves. From this/these response curves is/are changes in the responses calculated as slope, curvatures or mathematical functions. This is especially useful for early detection of acute myocardial infarction.10-22-2009
20090263823GLYCEROGLYCOLIPID ANTIGEN OF MYCOPLASMA PNEUMONIAE - The present invention provides a novel glyceroglycolipid produced by 10-22-2009
20090263821Ubiquitin Ligase Assays And Related Reagents - The disclosure provides, inter alia, methods and reagents for use in measuring the attachment of ubiquitin and ubiquitin-like proteins to a target protein, particularly an E3 protein.10-22-2009
20090263826MEANS AND METHOD FOR DIAGNOSING HEMOLYTIC ANEMIA - The present invention relates to a method for diagnosing hemolytic anemia or a predis-position thereof. It also relates to a method of determining whether a compound is capable of inducing hemolytic anemia in a subject and to a method of identifying a drug for treating hemolytic anemia. Furthermore, the present invention relates to a data collection comprising characteristic values of metabolites, a data storage medium comprising said data collection, and a system and a device for diagnosing hemolytic anemia. Finally, the present invention pertains to the use of a group of metabolites or means for the determination thereof for the manufacture of a diagnostic device or composition for diagnosing hemolytic anemia in a subject.10-22-2009
20090263824Detection of Neurodegenerative Disease - Provided are methods of assessing the absence or presence of a neurodegenerative disease in a subject comprising characterizing TDP-43 in a tissue sample of the subject. Also disclosed are methods for diagnosing a neurodegenerative disease in a subject, and methods for determining the efficacy of a drug against a neurodegenerative disease. Novel antibodies that bind to TDP-43 are also provided.10-22-2009
20130011854PRESSURE-ASSISTED MOLECULAR RECOVERY (PAMR) OF BIOMOLECULES, PRESSURE-ASSISTED ANTIGEN RETRIEVAL (PAAR), AND PRESSURE-ASSISTED TISSUE HISTOLOGY (PATH) - A method is disclosed for reversing fixation-induced cross-linking in tissue specimens that have been preserved for histological examination. The method involves placing the fixed tissue in a liquid under elevated temperature and pressure conditions that are sufficient to reverse the fixation-induced cross-linking, restore antigenicity to proteins, and permit improved molecular and proteomic analysis of the preserved tissue specimen. Methods are also disclosed for processing tissues for histological examination under elevated pressure conditions that enhance the perfusion of liquid reagents into the tissue and reduce overall processing times.01-10-2013
20130217030INFECTION PROGNOSTIC ASSAY - The invention provides a method of prognosis of a subject with an infection, identifying a subject at greater risk of death from an infection and/or identifying a subject at greater risk of developing an infection, the method comprising detecting an amount of free light chains (FLC) in a sample from the subject, wherein a higher amount of FLC is associated with decreased survival due to the infection and/or increased risk from an infection and/or having an increased risk of developing an infection. A method of monitoring an infection, comprising detecting an amount of free light chains (FLC) in a sample from a patient having an infection and comparing the amount of FLC in the sample with an amount of FLC detected in a sample previously obtained from the patient, wherein an increase in the amount FLC detected, compared to the previous sample, indicates an increase in the infection in the patient, and a decrease in the amount of FLC indicates a decrease in the infection in the patient. Assay kits for use in the method are also provided. Assay kits comprising one or more anti-FLC antibodies and one or more anti-bacterial antigen antibodies are also provided.08-22-2013
20100124754Cloning, Expression And Purification Of Recombinant Porcine Intrinsic Factor For Use In Diagnostic Assay - The present invention relates to a new method of producing functionally active recombinant porcine Intrinsic Factor as well as the protein (i.e., porcine Intrinsic Factor) produced thereby. In particular, the vector comprising the DNA encoding the protein is introduced into a Chinese Hamster Ovary (CHO) host cell under conditions sufficient for optimal expression of functional protein. The expressed protein may then be subjected to three methods ultimately resulting in a protein having at least 97% purity.05-20-2010
20100099116Methods for Analysis of Hedgehog Pathway Inhibitors - One aspect of the present invention relates to a method of ascertaining the inhibitory activity in a mammal of a candidate inhibitor of the hedgehog pathway. In certain embodiments, the candidate inhibitor is administered systemically. In certain embodiments, the mammal is a rodent or primate. In certain embodiments, the mammal is a mouse. In certain embodiments, the candidate inhibitor is a small molecule or natural product.04-22-2010
20100099115SYSTEMS AND METHODS FOR PREPARING AND ANALYZING SAMPLES - The invention relates to systems and methods for preparing and analyzing samples (e.g., mucosal samples) for a microorganism of interest. In particular, the systems and methods are useful for detecting one or more analytes characteristic of a microorganism (i.e., microbe) of interest, such as components of cell walls that are characteristic of a microbe, particularly 04-22-2010
20100099112QUANTITATIVE LATERAL FLOW SYSTEM AND ASSAY - The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid, where the assay is volume independent, and the sample size is less than about 100 μl, where the test strip includes a first membrane such as a sample filter, that is in capillary contact with an optional second membrane, such as a fluid collector, the second membrane, if present is in capillary contact with an optional third membrane, such as a conjugate pad containing a mobilizable detectable agent, or with a fourth membrane, which is a chromatographic strip, which optionally contains a mobilizable detectable agent, all such membranes being in fluid contact with a fifth membrane, such as a buffer pad, a sixth membrane, such as an absorbent pad, optionally a seventh membrane, which is also an absorbent pad, a capture band for capturing the analyte and at least one control band, or alternatively, the chromatographic strip contains the mobilizable detectable agent in place of a conjugate pad, where the test strip is configured to support removal of red blood cells from the sample and to allow uni-directional or bi-directional fluid flow of fluid from the sample filter to the capture band to be retained therein and detected thereon.04-22-2010
20090142773METHODS AND CONTROLS FOR MONITORING ASSAY QUALITY AND ACCURACY IN PARATHYROID HORMONE MEASUREMENT - The present invention relates to the use of control compositions and kits comprising such to evaluate and monitor the consistency of assays utilized to determine parathyroid hormone levels.06-04-2009
20090208974Human Neuronal Attachment Factor-1 - A human F-spondin-like protein and DNA (RNA) encoding such protein and a procedure for producing such protein by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptide for treating spinal cord injuries and damage to peripheral nerves by promoting neural-cell adhesion and neurite extension, inhibiting tumor metastases and tumor angiogenesis, and stimulating wound repair. Antagonists are also disclosed which may be utilized to prevent malaria. Diagnostic assays for identifying mutations in nucleic acid sequence encoding a polypeptide of the present invention and for detecting altered levels of the polypeptide of the present invention for detecting diseases, for example, cancer, are also disclosed.08-20-2009
20110201019Methods and Compositions for Detecting Receptor-Ligand Interactions in Single Cells - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.08-18-2011
20110201018METHODS AND COMPOSITIONS FOR RISK STRATIFICATION - The present invention provides an approach for the simultaneous determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of potentiators of cellular activation allows for characterization of such pathways and cell populations.08-18-2011
20110201016METHOD FOR DETECTING MODULATOR FOR REGULATING ACTIVITY OF CELLULAR COMPONENT IN CELL - A method for detecting a modulator that can regulate biological and/or physiological activity of a cellular component is provided. The method can detect a modulator, after determining whether there is a competitive reaction between a reference substance and a modulator toward the cellular component in a cell by imaging a magnetic pattern magnetized in a direction of a magnetic line of force and a pattern of a label bound to the cellular component. The method has a benefit that since the reaction of a cellular component with a reference substance and a modulator such as a drug occurs in a cell, the competition reaction between the reference substance and the modulator toward the cellular component can reflect the real metabolism occurred in a live cell. It can also allow the result of interaction between the cellular component and the modulator such as a drug to be visualized and to be identified directly in a live cell. Additionally, the method has advantages to screen many modulators using a few reference substances and to detect the functions of the modulator in a cell, e.g., its efficacy without modifying the modulator by introducing the reference substance.08-18-2011
20110201015METHOD FOR MEASURING ENDOTOXIN AND REAGENT KIT FOR MEASURING ENDOTOXIN - A technique which is less likely to be affected by turbid or color of samples and with which prompt and simple detection or concentration measurement of endotoxin can be achieved is provided. A reagent in which proteins contained in LAL are adsorbed or bound onto fine particles dispersed in a previously prepared drug liquid is prepared, and this reagent and a sample containing endotoxin are mixed. By doing this, endotoxin acts on the proteins on the fine particles and the fine particles are associated with one another to form a large aggregate at an early stage. By optically measuring the formation of this aggregate, detection or concentration measurement of endotoxin is performed.08-18-2011
20090136967Peptides for Discrimination of Prions - The aim of the present invention is to provide a non-intrusive way to isolate, concentrate and monitor the TSE disease-related pathogenic prion protein. The invention described several peptides and their ability to capture PrP05-28-2009
20120295278FLUORESCENCE DETECTING METHOD, METHOD FOR PRODUCING FLUORESCENT BEADS, AND FLUORESCENT BEADS - Two or more kinds of fluorescent beads containing at least two kinds of basic fluorochromes different in fluorescence intensity, fluorescence wavelength, and fluorescence relaxation time from each other, wherein a content ratio between the at least two kinds of basic fluorochromes and absolute amounts of contents of the basic fluorochromes are set so as to be different between different kinds of fluorescent beads. The fluorescent beads are used in a flow cytometer for fluorescence detection. This makes it possible to identify a greater variety of beads than before with high accuracy in a single measurement.11-22-2012
20120295277DEVICE AND METHOD FOR DETECTING THE PRESENCE OF HEMOGLOBIN IN A BIOLOGICAL SAMPLE - A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding.11-22-2012
20120295276MASS SPECTRAL ANALYSIS - The invention generally relates to mass spectral analysis. In certain embodiments, methods of the invention involve analyzing a lipid containing sample using a mass spectrometry technique, in which the technique utilizes a liquid phase that does not destroy native tissue morphology during analysis.11-22-2012
20120295274REPORTER VECTOR PRESENTING EXTRACELLULAR BINDING CAPACITY TO METALLIC COMPOUNDS - According to one embodiment, a reporter vector presenting an extracellular binding capacity to metallic compounds contains a nucleotide sequence exhibiting a promoter activity depending on a specific condition, a nucleotide sequence encoding a metallic compound-binding peptide presented extracellularly, and a nucleotide sequence encoding transcription termination signals.11-22-2012
20120295275Monoclonal Antibodies and Uses Thereof - The technology relates to monoclonal antibodies useful in the identification of cancer cells. In one embodiment, mAbs with specificity for tumor antigens are provided. In one embodiment, methods for treating cancer using mAbs are provided. In another embodiment, methods for detecting cancerous cells are provided. In another embodiment, kits for detecting cancerous cells are provided.11-22-2012
20120295273N-ACETYLHEXOSAMINE-CONTAINING N-GLYCANS IN GLYCOPROTEIN PRODUCTS - The present invention provides methods of evaluating a glycoprotein preparation for the absence, presence or amount of an N-acetylhexosamine glycan, e.g., an N-acetylglucosamine glycan.11-22-2012
20090004670METHODS FOR FABRICATING SURFACE ENHANCED FLUORESCENT (SEF) NANOPARTICLES AND THEIR APPLICATIONS IN BIOASSAYS - Embodiments of the invention relate to SEF nanoparticles with increased fluorescence, methods of making SEF nanoparticles, and their application in various bioassays for the detection of target bioanalytes. One embodiment includes the SEF nanoparticle itself, a second embodiment includes the fabrication of SEF nanoparticles, a third embodiment includes methods of using SEF nanoparticles in biodetection assays. A final embodiment includes kits to be used in the fabrication of SEF nanoparticles.01-01-2009
20110171662NON-DENATURING LYSIS REAGENT - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits.07-14-2011
20110171661METHOD FOR DIAGNOSIS OF POST-OPERATIVE RECURRENCE IN PATIENTS WITH HEPATOCELLULAR CARCINOMA - Provided are a method of diagnosing the recurrence or possibility of recurrence of hepa07-14-2011
20100035274Methods for Detecting Symmetrical Dimethylarginine - Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.02-11-2010
20110269149METHOD FOR QUANTIFICATION OF BODY INTERNAL CONCENTRATION OF PROTEIN-BASED DRUG - It is an object of the invention to provide a method for rapid and accurate quantification of a sample in the human body of a patient.11-03-2011
20080241857Netrin receptors - The invention provides methods and compositions relating to vertebrate UNC-5 proteins which function as receptor proteins for netrins, a family of cell guidance proteins. The proteins may be produced recombinantly from transformed host cells from the disclosed vertebrate UNC-5 encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed vertebrate unc-5 gene, vertebrate UNC-5-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.10-02-2008
20090291454Detection method of bio material, fabrication method of chip for detection of bio mateiral, and chip for detecting of bio material - Provided are a method for detecting biomaterials, a method for fabricating a chip for biomaterial detection and a chip for biomaterial detection. The method for detecting biomaterials is characterized by comprising the steps of: (S11-26-2009
20130217032LIGAND FUNCTIONALIZED POLYMERS - Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.08-22-2013
20080206782Methods for Determining the Bivalency of Protein and Antibody Therapeutics - The invention provides methods and kits for detecting or quantitating intact bivalent antibody molecules in a sample and distinguishing those molecules from monovalent fragments.08-28-2008
20090104626METHODS OF ISOLATING BIPOTENT HEPATIC PROGENITOR CELLS - A method of obtaining a mixture of cells enriched in hepatic progenitors is developed which comprises methods yielding suspensions of a mixture of cell types, and selecting those cells that are classical MHC class I antigen(s) negative and ICAM-1 antigen positive. The weak or dull expression of nonclassical MHC class I antigen(s) can be used for further enrichment of hepatic progenitors. Furthermore, the progenitors can be selected to have a level of side scatter, a measure of granularity or cytoplasmic droplets, that is higher than that in non-parenchymal cells, such as hemopoietic cells, and lower than that in mature parenchymal cells, such as hepatocytes. Furthermore, the progeny of the isolated progenitors can express alpha-fetoprotein and/or albumin and/or CK19. The hepatic progenitors, so isolated, can grow clonally, that is an entire population of progeny can be derived from one cell. The clones of progenitors have a growth pattern in culture of piled-up aggregates or clusters. These methods of isolating the hepatic progenitors are applicable to any vertebrates including human. The hepatic progenitor cell population is expected to be useful for cell therapies, for bioartificial livers, for gene therapies, for vaccine development, and for myriad toxicological, pharmacological, and pharmaceutical programs and investigations.04-23-2009
20090104624METHODS AND KITS FOR DETECTING ITA IN A BIOLOGICAL SAMPLE - Methods for detecting invasive trophoblast antigen (ITA) in biological samples comprise screening the samples for ITA using antibodies that bind to the ITA. The methods are useful to detect pregnancy, trophoblastic diseases, and Down's syndrome in fetuses of pregnant women. Some methods include screening the samples with a plurality of capture antibodies that specifically bind ITA. Chemiluminescent immunoassays are disclosed. The methods may be practiced with the diagnostic kits of the invention.04-23-2009
20090104625Homogeneous immunoassays for multiple allergens - A homogeneous immunoassay method and system for quantitative determination of total immunoglobulin E and specific antibody levels to a plurality of allergens, in which a relatively small sampling of blood is required. The method utilizes relatively small microparticles in aqueous suspension. The immunoassay procedure is an immunometric sandwich procedure preferably utilizing biotin-streptavidin signal amplification techniques and R-phycoerytherin fluorescent labels.04-23-2009
20090104623COMPOSITIONS FOR CONTROLLING HAIR GROWTH - FP-1 is a protein that is specifically expressed in the follicular papilla of the hair follicle. The nucleic acid and amino acid sequences of FP-1, as well as antibodies that specifically bind FP-1 are provided. In addition, methods of isolating follicular papilla cells and methods of modulating hair growth are also disclosed.04-23-2009
20090104622Extracellular/Epidermal Growth Factor Like Protein - The present invention discloses an extracellular/epidermal growth factor polypeptides and polynucleotides encoding such polypeptides. Also provided is a procedure for producing such polypeptides by recombinant techniques and therapeutic uses of the polypeptides which include induction of DNA synthesis, stimulating wound healing, treating neurological disorders, treating ocular disorders, treating kidney and liver disorders and stimulating embryogenesis and angiogenesis. Also disclosed are antagonists against such polypeptide and their use as a therapeutic to treat neoplasia. Also disclosed are diagnostic assays for detecting altered levels of the polypeptide of the present invention and mutations in the nucleic acid sequences which encode the polypeptides of the present invention.04-23-2009
20090275048ANTI-ACHARAN SULFATE ANTIBODY AND ITS APPLICATION - An anti-acharan sulfate antibody, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The anti-acharan sulfate antibody can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to acharan sulfate.11-05-2009
20090275047CRYSTAL STRUCTURE OF HUMAN SOLUBLE ADENYLATE CYCLASE - The invention provides the crystal structure of the solAC catalytic domain. The structure is set out in Tables 1 to 5. The structure may be used in to model the interaction of ligands such as pharmaceutical compounds with this protein, and to determine the structure of related adenylate cyclase molecules.11-05-2009
20090280500Assay for generation of a lipid profile using fluorescence measurement - The present invention relates to a method of generating a lipid profile for a sample solution. The method comprising: a first step of determining the concentration of total lipoprotein in a first aliquot of the sample using fluorescence analysis; a second step of determining the concentration of total cholesterol in a second aliquot of the sample using fluorescence analysis; and optionally a third step of determining the concentration of HDL in a third aliquot of the sample using fluorescence analysis. The concentrations of the total lipoprotein, and of total cholesterol may be used to calculate other lipid components and thereby generate a lipid profile. The invention also concerns apparatus that may be used to perform the method of the invention.11-12-2009
20090291455Cynomolgus gp80 Receptor and Uses - Isolated polynucleotides encoding cynomolgus monkey gp80, polypeptides obtainable from expression of these polynucleotides, compositions, recombinant cells, methods of making and using these polynucleotides, polypeptides, and compositions are useful in development of human therapeutics.11-26-2009
20090291456Method for Diagnosing Multiple Sclerosis - Disclosed is a method for diagnosing multiple sclerosis and more particularly to a method for diagnosing multiple sclerosis by measuring levels of antibodies to glycans in a biological sample.11-26-2009
20090148862Evaluation method of organic or bio-conjugation on nanoparticles using imaging of time-of-flight secondary ion mass spectrometry - A method of evaluating conjugation between materials using imaging of time-of-flight secondary ion mass spectrometry (TOF-SIMS) according to the present invention is carried out by following the steps which comprise, a) forming a spontaneous pattern on a substrate with a mixture comprising nanoparticles and a conjugation material selected from organic, bio or inorganic material, b) obtaining an ion detection pattern from said conjugation material and said nanoparticles, respectively, depending on their position on the substrate by using time-of-flight secondary ion mass spectrometry, and c) determining whether the conjugation is formed between said conjugation material and said nanoparticles by comparing the ion detection pattern of said conjugation material with the ion detection pattern of said nanoparticles.06-11-2009
20100003694Biomarkers and Uses Thereof - The present invention provides biomarkers for schizophrenic and bipolar disorders and methods of diagnosis, monitoring and screening associated with the biomarkers and kits for performing such methods.01-07-2010
20100279311METHOD FOR SCREENING OF CELL-PROTECTING AGENT - The invention provides a screening method and screening kit for a cell protecting agent. Specifically, the invention provides a method for screening a cell protecting agent showing an Hsp90-binding activity and a heat shock protein expression-inducing activity but having no Hsp90 client protein degradation-promoting activity. The method comprises the following steps (1) to (3): (1) measuring the binding property of a test compound to Hsp90; (2) measuring the activity of a test compound to induce the expression of a heat shock protein, or measuring the activity of a test compound to disrupt an Hsp90/HSF-1 complex, by using a cell capable of expressing the heat shock protein; and (3) measuring the activity of a test compound to induce the degradation of an Hsp90 client protein by using a cell capable of expressing the Hsp90 client protein. The invention further provides specifically a kit for screening a cell protecting agent, comprising (1) Hsp90; (2) a reagent for measuring the heat shock protein expression-inducing activity; (3) an imidazothiazine derivative; and (4) a reagent for quantifying an Hsp90 client protein.11-04-2010
20100112596KIT FOR DECIDING DEGREE OF MALIGNANCY IN PROSTATE CANCER AND METHOD OF USING THE SAME - The present invention relates to kits and methods for determining (diagnosing) prostate cancer malignancy and to predict patient prognoses. In addition to the Gleason's classification and the TMN classification, the invention kit and methods provide improved procedures with molecular markers. These new diagnostic methods provide methods capable of determining prostate cancer malignancy more accurately and easily through combination with the Gleason's classification via biopsies at an early stage before surgical operation; even when specimens taken through a fine needle examination are used instead of specimens extracted during a surgical operation.05-06-2010
20110269147Methods, Devices, and Systems for Glycated Hemoglobin Analysis - Methods, devices, and systems for measuring the concentration of glycated hemoglobin (HbA11-03-2011
20090170117THREE-DIMENSIONAL STRUCTURE OF FabK PROTEIN AND METHOD OF DEVELOPING A FabK PROTEIN INHIBITOR USING THE SAME - The present invention relates to a FabK (enoyl-acyl carrier protein reductase) protein derived from a 07-02-2009
20090170115Crohn's disease anitbody epitope peptide and reagent for testing crohn's disease - An epitope peptide is provided, which is capable of binding specifically to an antibody characteristic of Crohn's disease that is specifically observed in patients with Crohn's disease, together with a test method for conveniently and rapidly determining whether a subject is affected by Crohn's disease by use of the above peptide. The epitope peptide to the Crohn's disease antibody comprises a peptide having an amino acid sequences represented by any one of SEQ ID NOS: 1 to 3 or a salt thereof. A test reagent and a test method for Crohn's disease are provided, which comprise the peptide as an active ingredient.07-02-2009
20110207145METHODS AND COMPOSITIONS FOR DETECTING RECEPTOR-LIGAND INTERACTIONS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.08-25-2011
20080274474Authentication Method and System for Authenticating Security Documents, Security Document and Security Element - An authentication system for authenticating security documents contains at least an enzyme and a substrate and any co-enzymes and/or co-factors needed, capable of an enzymatic conversion. This conversion leads to a detectable change. The security-document contains at least one of the enzyme and the substrate. According to the invention the genetic information for the enzyme is derived from an extremophilic micro-organism. A security document for use in the authentication system and method is also described.11-06-2008
20090170120Clinical Correlates - A method of assessing an intracellular pathogen infection and/or monitoring an intracellular pathogen infection in an individual comprises determining whether the individual has (a) T-cells that secrete IFN-γ only, (b) T-cells that secrete IL-2 only or (c) T-cells that secrete both IFN-γ and IL-2 in response to an intracellular pathogen antigen and optionally determining any change in this cytokine profile.07-02-2009
20090170118Formation and Encapsulation of Molecular Bilayer and Monolayer Membranes - Disclosed herein are compositions, methods, and devices related to bilayer and monolayer membranes, their encapsulation in a hydrogel, and their formation. Methods of using the disclose compositions and devices are also disclosed.07-02-2009
20080280308G protein coupled receptor signaling modulation - This invention relates to methods for identifying peptides and other compounds which block or enhance G protein coupled receptor mediated signaling with high affinity and specificity and/or which stabilize a particular conformer of a G protein coupled receptor. Assays, methods of treatment and other methods developed in conjunction with these methods also are disclosed.11-13-2008
20080286804MELANOMA ANTIGENS AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC METHODS - The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. This invention further provides immunogenic peptides derived from the MART-1 melanoma antigen or gp100 antigen which have been modified to enhance their immunogenicity. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.11-20-2008
20110269148Nanoaggregate Embedded Beads Conjugated To Single Domain Antibodies - A nanoaggregate embedded bead is formed from an inner core formed of comprising metallic nanoparticles and Raman active reporter molecules, an outer shell, and single-domain antibodies to target the bead to a specific target. The nanoaggregate embedded bead may be used in methods to detect analytes or pathogens in biological or environmental samples using Raman spectroscopy.11-03-2011
20080293073Methods for Assessing CDK5 Activation and Function - As described herein, signaling events occurring in neurons or at neuronal synapses have been identified that involve Cdk5 and various other molecules which bind to, are activated by, and/or activate Cdk5. Of particular relevance are interactions that stimulate calpain cleavage of p35 into p25, which binds Cdk5 in pathologic states. Assays to identify modulators of these interactions are provided.11-27-2008
20080293075Method and Composition for Analyzing A Carbohydrate Polymer - Disclosed is a method for characterizing carbohydrate polymer by identifying at least two binding agents that bind to the carbohydrate polymer. Binding is preferably determined by contacting the carbohydrate polymer with substrate that contains a plurality of first saccharide-binding agents affixed at predetermined locations on the substrate. The carbohydrate polymer is allowed to contact the substrate under conditions that allow for formation of a first complex between the first saccharide-binding agent and the carbohydrate polymer. A second saccharide-binding agent, which preferably includes a label, is also contacted with the carbohydrate polymer under conditions that allow for formation of a second complex between the second binding agent and the first complex. Identification of the first and second binding agent allows for characterization of the polysaccharide.11-27-2008
20100035273METHOD AND DEVICE FOR SMALL SCALE REACTIONS - The present invention relates to a method and a device for small scale reactions, such as sample preparation of a desired substance in a sample. In the method using the device samples mixed with functionalized magnetic particles are magnetically transferred between different working stations on the device. The method uses a hydrophobic surface, such as a Petri dish, provided with hydrophilic spots of, for example, agarose beads located on said hydrophobic surface and provided with buffers, reactants or ligands.02-11-2010
20080305495Methods for determining the redox status of proteins - A method for determining the redox status of a protein sample, the method comprising the steps of: a) contacting the sample with a first label adapted to bind to at least one reduced cysteine group therein; b) contacting the sample with a reducing agent to reduce at least one oxidized cysteine group therein; c) contacting the sample with a second label adapted to bind to any reduced cysteine groups produced in step (b); and d) determining the ratio of the signal from the first label to the signal from the second label wherein the ratio indicates the redox status.12-11-2008
20080305493Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods - Methods for identifying antineoplastic agents by using their ability to modify expression of specific genes or the biological activity of polypeptides encoded by such genes, wherein said genes are located in specific chromosomal regions, called amplicons, or regions of interest, and the presence of such amplified regions within a cancerous cell, are disclosed. Also described are methods for diagnosing cancerous, or potentially cancerous, conditions using these methods. Also encompassed are methods involving determining the modulated expression of the genes in these regions of interest (ROIs), or amplicons, as pharmacodynamic/pharmacogenetic/surrogate markers and/or for patient profiling prior to accrual for clinical trials/treatments based on the identification of these genes as validated gene/drug targets in various cancer tissue types.12-11-2008
20080305494Chemokine Ccl18 as a Biomarker - The invention relates to a diagnostic tool, e.g. to the chemokine CCL12-11-2008
20090263825METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for a membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.10-22-2009
20120295279PRETREATMENT SOLUTION FOR IMMUNOHISTOCHEMICAL STAINING AND CONDENSED SOLUTION THEREOF - Disclosed are a pretreatment solution for immunohistochemical staining, which elutes a paraffin-containing embedding medium from a glass slide with a tissue specimen embedded in the medium, and retrieves antigenicity of the tissue specimen, and which is usable three or more times, and a pretreatment solution concentrate for immunohistochemical staining which allows ready preparation of the pretreatment solution. The pretreatment solution for immunohistochemical staining contains an antigen retrieving agent, particular nonionic surfactants, and cyclodextrin or a derivative thereof, with the balance being not less than 80 mass % of water. The content of the antigen retrieval agent is such that the pH of the pretreatment solution is in a predetermined range, and the content of cyclodextrin or a derivative thereof is a particular amount.11-22-2012
20120142022GLYCOSYLATED MAMMALIAN NGAL AND USE THEREOF - The present invention relates to glycosylated mammalian NGAL, and methods of using said glycosylated mammalian NGAL.06-07-2012
20080274473Amyloid binding assays - Provided herein are amyloid-binding assays that simulate in situ brain conditions by combining binders with various A-beta species on mammalian brain tissue. In general the amyloid-binding assays comprise the steps of (a) contacting a mammalian brain tissue sample with at least one A-beta species; (b) applying a putative binder to the brain tissue sample; and (c) determining whether the putative binder binds to the A-beta species.11-06-2008
20080213794SCREENING FOR GESTATIONAL DISORDERS - The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and/or blood samples and can be conducted prior to the third trimester of pregnancy.09-04-2008
20080206780Antibody Libraries - The invention relates to a composition comprising a plurality of antibody fragments, each comprising a framework region having a murine VH14 heavy chain and a murine VK2 light chain, or homologues thereof, each antibody fragment further comprising at least one different CDR.08-28-2008
20120196298MITOCHONDRIAL FUNCTION OF PROHIBITIN 2 (PHB2) - The present invention relates to a PHB2 gene regulator and a therapeutic drug for mitochondrial-function-related disease containing the same, for example.08-02-2012
20110269146Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating Melanomas - This invention relates to expression vectors comprising VEGF-D and its biologically active derivatives, cell lines stably expressing VEGF-D and its biologically active derivatives, and to a method of making a polypeptide using these expression vectors and host cells. The invention also relates to a method for treating and alleviating melanomas or tumors expressing VEGF-D and various diseases.11-03-2011
20100143934Modified animal lacking functional PYY gene, monoclonal antibodies that bind PYY isoforms and uses therefor - The present invention provides transgenic animals having a reduced level of expression of peptide YY (PYY) and drug screening platforms using the transgenic animals for identifying agonists and antagonists of PYY. The present invention further provides monoclonal antibodies that bind specifically to full-length PYY[1-36] or the processed form thereof i.e., PYY[3-36] and to diagnostic and drug screening platforms using the monoclonal antibodies. The invention has particular utility for the diagnosis of a predisposition or risk of a subject becoming obese, developing one or more pathologies associated with obesity, or developing a disease/disorder of bone tissue.06-10-2010
20100143936Novel Specific Arabinose Transporter from the Yeast Pichia Stipitis, and Uses Thereof - The present invention relates to a polypeptide which has a novel specific arabinose transporter function as well as to nucleic acids coding therefore. The invention further relates to host cells, in particular modified yeast strains which contain the coding nucleic acids and express the polypeptide and functionally integrate it into the plasma membrane and are thus able to absorb L-arabinose. When using modified host cells which express additional proteins of the arabinose metabolic pathway, arabinose can be fermented by these cells, in particular into ethanol. The present invention is therefore relevant, inter alia, in connection with the production of biochemicals from biomass, such as bioethanol for example.06-10-2010
20100143938HIGH SENSITIVITY QUANTITATION OF PEPTIDES BY MASS SPECTROMETRY - The instant invention provides an economical flow-through method for determining amount of target proteins in a sample. An antibody preparation (whether polyclonal or monoclonal, or any equivalent specific binding agent) is used to capture and thus enrich a specific monitor peptide (a specific peptide fragment of a protein to be quantitated in a proteolytic digest of a complex protein sample) and an internal standard peptide (the same chemical structure but including stable isotope labels). Upon elution into a suitable mass spectrometer, the natural (sample derived) and internal standard (isotope labeled) peptides are quantitated, and their measured abundance ratio used to calculate the abundance of the monitor peptide, and its parent protein, in the initial sample06-10-2010
20090029389FLUORESCENT METAL ION INDICATORS WITH LARGE STOKES SHIFTS - The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.01-29-2009
20090029387METHOD FOR EFFECTIVELY MEASURING THE ACTIVITY OF CYTOTOXIC T LYMPHOCYTES IN HUMAN AND OUT-BRED ANIMALS - A method for measuring the activity of cytotoxic T lymphocytes (CTLs) includes preparing peripheral blood mononuclear cells (PBMCs) from blood of an animal; preparing mature dendritic cells by isolating monocytes from the PBMCs, differentiating the monocytes into dendritic cells for presenting an antigen molecule and pulsing dendritic cells with the antigen molecule to obtain the mature dendritic cells; preparing the CTLs as an effector cell by stimulating the PBMCs with the mature dendritic cells to activate and amplify the CTLs; preparing target cells by pulsing the PBMCs, monocytes or B cells with a cytoplasmic transduction peptide (CTP)-antigen complex generated by linking the antigen molecule of step (b) to the CTP; treating the target cells with the effector cells; and analyzing the lysis of the target cells. In addition, a kit for measuring the activity of cytotoxic T lymphocytes is provided.01-29-2009
20090136964NOVEL ANTI-HEPARAN SULFATE ANTIBODY, METHOD FOR DETECTION OF HEPARAN SULFATE, AND KIT FOR DETECTION OF HEPARAN SULFATE - An antibody which reacts with N-acetylheparosan and heparan sulfate that is derived from bovine kidney but does not substantially react with heparan sulfate derived from a murine Engelbreath-Holm-Swam tumor tissue, the antibody being produced with a hybridoma which is prepared using a substance composed of a protein and N-acetylheparosan bound to the protein.05-28-2009
20090081695Methods and Compositions for Detection of Ehrlichia chaffeensis (p120) - The invention provides methods and compositions for the detection of 03-26-2009
20090298090METHODS TO MEASURE IMMUNOSUPPRESSIVE TACROLIMUS, SIROLIMUS, AND CYCLOSPORIN A COMPLEXES IN A BLOOD SAMPLE - The present invention provides methods, diagnostic assays, and diagnostic kits based on said methods, to determine levels of immunosuppressive complexes containing immunosuppressive drugs tacrolimus, sirolimus and cyclosporine A separately and in combination, formed in the blood of a drug-treated patient or in a patient candidate to immunosuppressive drug therapy. These methods, assays and kits are especially useful when using automated systems.12-03-2009
20090162868Gene Markers and Utilization of the Same - [Problems]To provide a gene marker which enables diagnosis of rejection, evaluation of the efficacy of an immunosuppressive agent, and determination of the presence or absence of immunological tolerance; methods that can be performed in a quick, simple, and convenient manner by using the gene marker as an indicator for diagnosing rejection, evaluating the efficacy of an immunosuppressive agent, identifying an immunosuppressive agent, selecting an immunosuppressive agent, determining the dose of an immunosuppressive agent, and judging the presence or absence of immunological tolerance; a kit; and a method for screening for an immunosuppressive agent or an immunological tolerance-inducing agent.06-25-2009
20090136966Normalization of Complex Analyte Mixtures - The present invention relates to methods and compositions for the normalization of complex analyte mixtures. The invention allows the preparation of profiled samples from highly complex analyte mixtures, allowing the identification of relevant targets or biomarkers. The invention also relates to methods for producing devices, such as a support, suitable for normalization of complex analyte samples. The invention can be used for the normalization of any complex mixture, such as immunogenic libraries, particularly of human source, and to identify or produce biomarkers highly relevant to human traits or conditions.05-28-2009
20100151489Method for quantifying biomolecules conjugated to a nanoparticle - Disclosed embodiments concern quantifying a biomolecule conjugated to a nanoparticle. Quantifying typically comprises determining the number of biomolecules per nanoparticle. Any suitable biomolecule can be used, including but not limited to, amino acids, peptides, proteins, haptens, nucleic acids, oligonucleotides, DNA, RNA, and combinations thereof. A single type of biomolecule may be conjugated to the nanoparticle, more than one biomolecule of a particular class may be conjugated to the nanoparticle, or two or more classes of biomolecules may be conjugated to the nanoparticle. Certain disclosed embodiments comprise enzymatically or chemically digesting a biomolecule conjugated to the nanoparticle, or displacing a biomolecule using ligand-exchange chemistry. Where biomolecule concentrations are determined, any technique suitable for determining biomolecule concentration can be used, such as spectrophotometric techniques, including measuring tryptophan fluorescence and using a standard fluorescence intensity versus biomolecule concentration curve.06-17-2010
20090186365Use of 14-3-3- Proteins in Treatment and Prevention of Neurodegeneration - The present disclosure is directed to methods for treatment and prevention of disease states characterized by a decreased 14-3-3 polypeptide expression or activity. In one embodiment, the present disclosure provides methods for the treatment and/or prevention of Parkinson's disease, neurodegeneration and/or diseases characterized, at least in part, by neurodegeneration, by increasing a 14-3-3 polypeptide activity.07-23-2009
2009000467217867, A NOVEL HUMAN AMINOPEPTIDASE - The present invention relates to a newly identified human aminopeptidase. The invention also relates to polynucleotides encoding the aminopeptidase. The invention further relates to methods using the aminopeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in aminopeptidase-related disorders. The invention further relates to drug-screening methods using the aminopeptidase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the aminopeptidase polypeptides and polynucleotides. The invention further relates to procedures for producing the aminopeptidase polypeptides and polynucleotides.01-01-2009
20090004671Marker Protein For Use In Diagnosis Of Pancreatic Cancer - Disclosed herein are a pancreatic carcinoma marker protein that is a blood protein having a molecular weight of 28,080±15, 17,272±9, 17,253±9, 8,766±5, or 14,779±8 (m/z) and a method for detecting pancreatic carcinoma using the marker protein as an indicator.01-01-2009
20080318247Biomarker for cardiac transplant rejection - The invention provides a method of diagnosing a disease or disorder featuring an abnormal level of a ring-containing molecule in a tissue. In one embodiment, a method of diagnosing organ transplant rejection is provided.12-25-2008
20080318248Compositions and Methods of Screening Apoproteins - The present invention is directed to compositions and methods of screening apoproteins for the elucidation of modulators of metalation of apoproteins.12-25-2008
20080318245NANOTUBE STRUCTURES HAVING A SURFACTANT BILAYER INNER WALL COATING - Nanotubes and nanotube array structures comprise (a) a nanotube having an inner wall portion; and (b) a bilayer coating formed on the inner wall portions, with the bilayer coating comprised of surfactants. A secondary compound such as a protein, peptide or nucleic acid may be associated with the bilayer coating. The structures are useful for, among other things, affinity purification, catalysis, and as biochips.12-25-2008
20090246799Detection of Chronic Kidney Disease Patients or Coronary Artery Disease Using Bone Morphogenic Protein-4 - The invention is a method of detecting CAD in a CKD diagnosed human patient or CKD in a diagnosed CAD patient, or detection the presence of both CDK and CAD by assaying a plasma or serum sample of a human patient for elevated levels of BMP-4.10-01-2009
20090246797MEDICAL DEVICE FOR THE ASSESSMENT OF INTERNAL ORGAN TISSUE AND TECHNIQUE FOR USING THE SAME - A system for tissue ischemia detection is provided that may be used to assess markers of tissue ischemia. Such a system may include a sensor that may be used directly on internal tissue to assess ischemic condition. Sensors to be used in conjunction with the provided system may include optical, chemical or electrochemical sensors that may be directly applied or affixed to the tissue, held proximate to the tissue, or spread over the tissue in the form of a gel.10-01-2009
20090246796ISOLATION AND ENUMERATION OF CELLS FROM A COMPLEX SAMPLE MATRIX - The present invention relates to methods and systems for labeling, isolating, detecting and enumerating biological cells, or other biological analytes of interest present in a sample, where the capturing complex may also serve as a labeling agent. In one embodiment, the capture complex is an encoded magnetic bead coupled to antibodies having a specific affinity for a cell surface protein on a cell of interest. The methods and systems of the present invention can be used for quantitative or qualitative detection.10-01-2009
20090325190METHOD FOR QUANTITATIVE DETECTION OF DIABETES RELATED IMMUNOLOGICAL MARKERS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of diabetes related immunological makers in a serum sample, which can be used to diagnose and/or early diagnose diabetes as well as to predict the onset risk of diabetes in first-degree relatives. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antigens and antibodies used for the detection of respective diabetes related immunological makers in a serum sample.12-31-2009
20090325188Method for Detecting IL-16 Activity and Modulation of IL-16 Activity Based on Rantes Proxy Levels - Methods for detecting IL-16 biological activity, detecting modulation of IL-16 biological activity, and diagnosing the presence of or susceptibility of a subject to an IL-16-related disorder involve measuring and comparing the levels of RANTES proxy produced by eukaryotic cells, such as CD4+ and CD9+ cell lines, peripheral blood mononuclear cells, HuT-78 cells, and/or THP-1 cells.12-31-2009
20090325186Method for detecting analytes in a sample - The present invention relates to a method for detecting analytes in a sample comprising the steps of 12-31-2009
20090325187Immunomodulation - Medical use of ILT6 for modulating the immune response, as well as to pharmaceutical compositions containing ILT6.12-31-2009
20110223615Rapid Expression Cloning of Human Monoclonal Antibodies from Memory B Cells - The present application provides methods for producing human monoclonal antibodies without using hybridoma technology, antibodies produced used the described methods, and methods for using the antibodies to treat or prevent disease conditions (e.g., infection by pathogens such as the Human Immunodeficiency Virus).09-15-2011
20130217031GLYCEROGLYCOLIPID ANTIGEN OF MYCOPLASMA PNEUMONIAE - The present invention provides a novel glyceroglycolipid produced by 08-22-2013
20100003696METHOD OF DIAGNOSING AND MONITORING THE PROGRESS OF MULTIPLE SCLEROSIS, AND THE USE OF A TEST KIT THEREFOR - There is a described method and a test kit for diagnosing and monitoring the progress of multiple sclerosis by determining autoantibodies in bodily fluids by determining those antibodies which bind to a spectrin. A typical spectrin is alpha-fodrin.01-07-2010
20090081696LUMINESCENCE ENHANCER AND USE THEREOF - An object of the present invention is to provide a luminescence enhancer by which a luminescence such as chemiluminescence can be enhanced with higher sensitivity and the luminescence can be continued over a prolonged period of time. That is, the present invention provides a luminescence enhancer containing a heteropolymer as an active ingredient, a method for measuring the luminescence using a luminescent substrate and said luminescence enhancer, and a method for analyzing a substance to be measured in a specimen wherein the specimen, an antigen and/or antibody corresponding to a substance to be measured, an antigen and/or antibody labeled-form with an activator and a luminescent substrate are reacted in the presence of said luminescence enhancer to measure the luminescence.03-26-2009
20090075291PEPTIDE-BASED REGULATION OF GAP JUNCTIONS - The present invention relates to proteins and polypeptides that (i) have the formula A-[W03-19-2009
20090053730CHIMERIC HUMAN T1R1 TASTE RECEPTOR POLYPEPTIDES AND COMPOSITIONS CONTAINING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.02-26-2009
20110229909RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies - This invention provides antibodies immunologically specific for ρ1-GABA09-22-2011
20110229908METHODS AND PRODUCTS FOR MEASURING FREE IMMUNOGLOBULIN LIGHT CHAIN MOLECULES - The present invention provides improved methods for measuring the ratio of free K immunoglobulin light chain molecules to free λ immunoglobulin light chain molecules in a test sample, using a monoclonal antibody that specifically binds to free K and a monoclonal antibody that specifically binds to free λ. The application also provides specific monoclonal antibodies that can be used in the method of the invention, as well as kits containing said monoclonal antibodies.09-22-2011
20110229907USE OF CARDIAC HORMONES TO ASSESS RISK OF CARDIOVASCULAR COMPLICATION FROM VOLUME OVERLOAD - The disclosure relates to the use of cardiac hormones, particularly natriuretic peptides, for assessment of risk of suffering from a cardiovascular complication, particularly heart disease or acute coronary syndrome, as a consequence of intravasal volume overload. In particular, the disclosure relates to a method for diagnosing the risk of a patient whose intravasal volume is increased or will be increased of suffering from a cardiovascular complication as a consequence of the increase of intravasal volume, comprising the steps of (a) taking a body fluid or tissue sample, and (b) measuring, preferably in vitro, the level of a cardiac hormone such as NT-proBNP.09-22-2011
20100003697Method and Apparatus for Measuring Analyte Transport Across Barriers - The present invention includes a method and apparatus for measuring the transport of analytes through a cell barrier.01-07-2010
20090087862Chemical Sensing Device - The present invention relates to chemical sensing and in particular to a method for detecting an analyte in a sample of whole blood. The method comprise, in summary, the steps of: exposing the sample to a transducer having a tethered reagent; introducing a labelled reagent; irradiating the sample with a series of pulses of electromagnetic radiation at a wavelength of 600 run or above; and transducing and detecting the electrical signal and the time delay between each pulse. The label on the labelled reagent absorbs the electromagnetic radiation at a level which is at least equal to the absorption of the sample of whole blood at the wavelength of the electromagnetic radiation used.04-02-2009
20110223613METHOD OF IMAGING BY MASS SPECTROMETRY AND NEW MASS TAG ASSOCIATED TRITYL DERIVATIVES - The present invention concerns a method of analyzing at least one specific molecule in a sample using a compound of formula (I″) wherein Z binds specifically to said at least one specific molecule, Y is independently a cleavable single bond, linker atom or group, and R is independently a substituent such as H, C09-15-2011
20090208973Methods to identify compounds useful for the treatment of proliferative and differentiative disorders - The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.08-20-2009
20090053732MICROFLUIDIC DEVICES, METHODS AND SYSTEMS FOR DETECTING TARGET MOLECULES - Microfluidic devices methods and systems for detecting a target in a fluidic component of a sample are shown. In such devices, methods and systems, the flow resistance of various channels where the sample is introduced is adjusted to control separation of the fluidic component from the sample and/or performance of assays for the detection of the target in the fluidic component in a controlled fashion. Such performance is controlled by binding affinity of the target with capture agents or diffusion of the target in the fluidic component.02-26-2009
20090053733SIMULTANEOUS ASSAY FOR DETERMINING DRUGS - A method and kits for assaying a sample of a human or mammalian bodily fluid to simultaneously determine whether one or more of a plurality of drugs and/or metabolites thereof are present in said sample and optionally to perform a semi-quantitative assay for said drug or drugs, comprising: 02-26-2009
20090053731Method for Detection of L523S Expression in Biological Samples - The present invention discloses methods for differentiating between normal or reactive cells and malignant cells in biological samples comprising: exposing the biological sample to an antibody to L523S protein and detecting the presence of the antibody bound to L523S protein within the malignant cells, in embodiments, such methods may further comprise: exposing the biological sample to an antibody to a second protein that is a marker of cell lineage and detecting the presence of the antibody to the second protein within cells corresponding to a particular cell lineage and/or may comprise: exposing the biological sample to an antibody to a third protein which is a marker of cells that are normal or reactive and detecting the presence of the antibody to the third protein within cells that are normal or reactive.02-26-2009
20090117584Non-Human mammalian Arthritis Model Featuring Human Antibodies Against Citrul-Linated Proteins - Use of a non-human mammalian disease model, wherein the non-human mammal has been implanted with human synovial tissue or other human inflamed tissue containing anti-CCP (cyclic citrullinated peptide) antibody producing cells for (i) analyzing cellular processes in a disease associated with anti-CCP antibodies in such human synovial tissue or other human inflamed tissue, (ii) studying the role of anti-CCP antibodies in the induction and progression of a disease associated with anti-CCP antibodies, (iii) testing the efficacy of a therapeutic agent for the prevention or treatment of a disease associated with anti-CCP antibodies, and (iv) identifying a therapeutic agent useful for the prevention or treatment of a disease associated with anti-CCP antibodies. In one embodiment the non-human mammalian disease model is a mouse, such as a SCID mouse, and the disease associated with anti-CCP antibodies is arthritis, such as RA (rheumatoid arthritis).05-07-2009
20090220987Use of Intramolecularly, Covalently Cross-Linked Proteins As Binding Partners In Immunoassays - The invention concerns the use of intramolecularly, covalently cross-linked proteins and covalently cross-linked reverse transcriptase from HIV as immunological binding partners in immunoassays. It also concerns immunological test procedures for detecting an analyte in a sample in which intramolecularly, covalently cross-linked proteins are used as binding partners, and it further concerns intramolecularly, covalently cross-linked reverse transcriptase from HIV and a method for producing this reverse transcriptase.09-03-2009
20090208971Insulin promoter factor 1 as target/marker of beta cell failure - The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of IPF-1 in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes.08-20-2009
20100159472Method for Diagnosing Multiple Sclerosis - Disclosed is a method for diagnosing and prognosing multiple sclerosis and more particularly to a method for diagnosing and prognosing multiple sclerosis by measuring levels of antibodies. The levels of IgM-type anti-Glc(α1,2)Glc(α) or Glc(α1,3)Glc(α) or Glc(α1,6)Glc(α) antibodies in serum act as diagnostic markers for MS disease and as prognostic biomarkers for the conversion of CIS patients suggestive of MS to clinically definite MS (CDMS) within 24 months.06-24-2010
20090246800IMMUNOASSAY OF ANALYTES IN SAMPLES CONTAINING ENDOGENOUS ANTI-ANALYTE ANTIBODIES - The disclosure provides among other things an assay method that compensates for the presence of endogenous antibodies, e.g., autoantibodies, which might otherwise compromise the measurement of an analyte in a biological sample. In one embodiment, this method entails the use of a two labeled entities: a labeled detection agent and a labeled species-specific antibody, wherein the labeled species-specific antibody is specific for the species from which the biological sample was obtained. Sample analyte is bound by the detection agent and any anti-analyte autoantibodies present in the sample. Analyte bound by autoantibodies is detected via the species-specific antibody, optionally labeled.10-01-2009
20120142020Sample Metering Device and Assay Device with Integrated Sample Dilution - In one embodiment, the invention is to a sample metering device, comprising a sample holding chamber oriented between a sample entry port and a sample extraction unit, wherein a portion of said extraction unit defines a metered volume of a sample. A diluent may be transported over and/or through the extraction unit to form a diluted sample for sample analysis. In another embodiment, the invention is to an apparatus and method for rapid determination of analytes in liquid samples by various assays including immunoassays incorporating a sample dilution feature, capable of being used in the point-of-care diagnostic field is provided. The devices and methods of the invention preferably are well-suited for high range sample dilution.06-07-2012
20120142016Array-based bioactivated nanopore devices - A nanopore device capable of single molecule detection is described. The nanopores are formed in thin, rigid membranes and modified by a sputtered metal that forms an overhang during application. The overhang causes the pore to be narrower in a certain region, allowing passage of only a single molecule through the pore at a time, or binding to a biomolecule on the pore to be detected by a change in ionic current flow through the nanopore. Embodiments include a silicon nitride membrane formed on a silicon substrate and having a nanopore drilled with a focused ion beam system, followed by gold sputtering onto the membrane. Devices are formed with one or more nanopores and chambers having electrodes on either side of the nanopore.06-07-2012
20110143366PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY AND ENBRYOTOXICITY OF CHEMICAL SUBSTANCES - Presently, the toxicological assessment of chemicals is mainly performed in vivo using a variety of animal species and in addition taking into account human clinical, biochemical, pathological and morphological data. Over the past years it became increasingly clear that some substances are particularly harmful for children and thus there is a focus on the special vulnerability of the developing human brain. Meanwhile there is a recommendation to test substances with a known neurotoxic or teratogenic (in particular a neuroteratogenic) risk additionally for embryotoxicity. Moreover the US Environmental Protection Agency (EPA) requires embryotoxicity tests for pesticides. Further tests are required if substances shall be used as medicaments (S7A Safety Pharmacology Studies for Human Pharmaceuticals, Guidelines of the International Conference on Harmonization, ICH, 2001).06-16-2011
20090239238METHODS FOR MEASURING PRO-INFLAMMATORY SUBSTANCE LEVELS IN DIALYSIS SOLUTIONS AND DIALYSIS COMPONENTS - Methods of measuring levels of pro-inflammatory substances in dialysis solutions or specific dialysis components used to manufacture dialysis solutions are provided. In a general embodiment, the method comprises determining an IL-6 response versus a pro-inflammatory substance concentration of a reference standard containing a pro-inflammatory substance and establishing a dose-response curve of the IL-6 responses as a function of different pro-inflammatory substance concentrations of the reference standard. An IL-6 response of a test sample of a dialysis solution is determined. The corresponding pro-inflammatory substance concentration of the dialysis solution is then calculated using the dose-response curve. The IL-6 response of the reference standards and the dialysis solution can be determined using a high sensitivity PBMC IL-6 assay.09-24-2009
20090208972CYTOTOXIC PROTEIN AND UTLIZATION THEREOF - This invention relates to a new cytotoxic protein (M toxin, mucous layer devastating toxin) produced by 08-20-2009
20090117588Methods of diagnosing pre-eclampsia or eclampsia - Disclosed herein are kits for diagnosing pre-eclampsia and eclampsia or a propensity to develop pre-eclampsia or eclampsia that include agents for the detection of levels of free placental growth factor in a subject.05-07-2009
20090117587High-Affinity Monoclonal Antibodies for Botulinum Toxin Type A - High affinity antibodies for binding epitopes of BoNT/A and hybridomas that produce such antibodies are described. The antibodies may be used in a kit for detecting BoNT/A in a sample.05-07-2009
20090117586FUNGAL CELL WALL SYNTHESIS GENE - A reporter system reflecting the transport process that transports GPI-anchored proteins to the cell wall was constructed and compounds inhibiting this process were discovered. Further, genes conferring resistance to the above compounds were identified and methods of screening for compounds that inhibit the activity of the proteins encoded by these genes were developed. Therefore, through the novel compounds, the present invention showed that antifungal agents having a novel mechanism, i.e. inhibiting the process that transports GPI-anchored proteins to the cell wall, could be achieved.05-07-2009
20090117585ANTI-FUNGAL SCREENING METHOD - The present invention relates to a method for identification of anti-fungal agents and their mode of actions. In particular, it relates to cell wall disturbing anti-fungal agents and to an assay to identify them. More particularly, it relates to a screening method for the identification of an anti-fungal compound, which method comprises (i) contacting a potential anti-fungal compound with a polypeptide which is involved in cell wall synthesis; and then (ii) identifying the effect which the potential anti-fungal compound has on the activity of the polypeptide, whereby reduced polypeptide activity is indicative for anti-fungal activity of the potential anti-fungal compound. It also relates to an overexpressing host cell and to a kit for performing the assay.05-07-2009
20090258373METHODS OF CONTROLLING THE SENSITIVITY AND DYNAMIC RANGE OF A HOMOGENEOUS ASSAY - A method is disclosed for accurately determining the concentration of a target analyte utilizes reagent pairs having different affinity for the target. The different affinity provides distinct binding profiles that can be analyzed to absolutely determine the analyte concentration. The method provides an assay system having expanded dynamic range to cover a wider range of analyte concentration and can overcome the hook-effect that commonly exists in homogenous assay systems. The method utilizes distinguishable signals that allows for the analysis of multiple binding profiles and multiplex analysis.10-15-2009
20080268460Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases - The present invention relates to a method of identifying an inhibitor of a receptor tyrosine kinase that irreversibly binds to the kinase. Specifically, the method comprises using a variety of assays, either alone or in combination, to identify compounds that irreversibly bind to tyrosine kinases. More specifically, there are four assays, which are novel variations of a basic enzyme assay and identify irreversible binding inhibitors.10-30-2008
20090263822In Vitro Procedure for Diagnosis and Early Diagnosis of Neurodegenerative Diseases - An in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurogenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.10-22-2009
20090246801RAPID TEST FOR GLYCATED ALBUMIN IN BLOOD - This invention describes a rapid assay for measuring the ratio of glycated albumin to total albumin in blood. Patients with diabetes have elevated levels of glucose in their blood that can react with plasma albumin to form glycated albumin. The amount of glycated albumin formed is directly correlated with the level of plasma glucose that the albumin has been exposed to over a period of time. The ratio of glycated albumin to total albumin in blood will provide an indication of the average amount of protein glycation that occurred over the preceding 2-3 week period.10-01-2009
20090246798METHOD OF DETECTING CANCER AND EVALUATING CANCER PROGNOSIS - A method of detecting cancer in a subject is provided. One step of the method includes obtaining a bodily sample from the subject. Next, the level of pro-prion protein (pro-PrP) in the bodily sample is detected. The level of pro-PrP in the bodily sample is then compared to a control level. An increased level of pro-PrP in the bodily sample as compared to the control level indicates that the subject has cancer or an elevated risk of having cancer.10-01-2009
20090258372Detection Systems Utilizing Supported Lipid Bilayers - The invention relates to lipid bilayer coated beads and methods of using those beads in immunoassays, in analytical assay and the like.10-15-2009
20100190182DIAGNOSTIC COMPOSITION AND METHOD FOR THE DETECTION OF A TRICHINELLA INFECTION - A diagnostic composition to detect antibodies in a sample obtained from an animal or human being infected by 07-29-2010
20100047822TIMP-4 AS A BIOMARKER FOR THE DIAGNOSIS OF CARDIAC INSUFFICIENCY - The invention relates to the use of the plasma concentration of the polypeptide “tissue inhibitor of metalloproteinase-4” (TIMP-4) as a biomarker for the diagnosis of heart failure.02-25-2010
20120142018Rapid Single Cell Based Parallel Biological Cell Sorter - A disposable rapid cell sorter comprises of microfluidic chip with electrodes and sorts biological cells of interest through magnetic field and electric field based on biological cell functional antibody bonded magnetic beads and luminescent labeling.06-07-2012
20120190040CELL CONCENTRATION, CAPTURE AND LYSIS DEVICES AND METHODS OF USE THEREOF - The present invention provides a microfluidic devices and methods of use thereof for the concentration and capture of cells. A pulsed non-Faradic electric field is applied relative to a sample under laminar flow, which results to the concentration and capture of charged analyte. Advantageously, pulse timing is selected to avoid problems associated with ionic screening within the channel. At least one of the electrodes within the channel is coated with an insulating layer to prevent a Faradic current from flowing in the channel. Under pulsed application of a unipolar voltage to the electrodes, charged analyte within the sample is moved towards one of the electrodes via a transient electrophoretic force.07-26-2012
20100184084METHODS FOR MEASURING PLATELET REACTIVITY OF INDIVIDUALS TREATED WITH DRUG ELUTING STENTS - A method is provided for measuring inhibition of platelet reactivity in an individual treated with a drug-eluting stent (DES). First, a blood sample is obtained from an individual treated with a DES and a P2Y12 antagonist. The blood sample is then mixed with particles comprising an attached GPIIb/IIIa receptor ligand, adenosine diphosphate (ADP) and prostaglandin E1 (PGE1). The mixture is incubated under conditions suitable for agglutinating particles, and platelet-mediated agglutination is assessed in the mixture. The absence or reduction of agglutination indicates that the individual treated with a DES has reduced platelet reactivity. Also provided is a kit for measuring inhibition of platelet aggregation by a P2Y12 receptor antagonist that includes a GPIIb/IIIa receptor ligand immobilized on a particle, adenosine diphosphate (ADP), prostaglandin E1 (PGE1), an anticoagulant, and a buffer to maintain the anticoagulated blood in a condition suitable for platelet aggregation.07-22-2010
20100184082ANTIBODY AND IMMUNOASSAYS FOR DETERMINING THE PRESENCE OF DELTA9-TETRAHYDROCANNABINOL - Antibodies having specific binding for the parent THC (Δ07-22-2010
20130122513DETECTION OF MAGNETICALLY LABELED BIOLOGICAL COMPONENTS - A sample acquiring device for detection of biological components in a liquid sample is disclosed, comprising a measurement cavity for receiving a liquid sample and a reagent comprising an antibody linked with a magnetic particle and arranged in a dry form inside the measurement cavity. A method is further disclosed, comprising mixing the reagent with the liquid sample, introducing the liquid sample into the measurement cavity, applying a magnetic field to the liquid, wherein the magnetic particles move in the magnetic field, thereby moving the biological components to which the magnetically labeled antibodies are bound to, acquiring at least one digital image of the sample after the magnetic field has been removed, digitally analysing the at least one digital image for identifying biological components and detecting the magnetically labeled biological components in the measurement cavity. A system comprising the sample acquiring device and a measurement apparatus is also disclosed.05-16-2013
20130122514METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO05-16-2013
20130122517METHOD OF PERFORMING AN ASSAY - The present invention relates to a method and kit for performing assays like immunoassays. The assays are performed by using two different types of magnetic beads.05-16-2013
20100261196METHODS OF IDENTIFYING SMALL MOLECULES FOR RENEWALS, SURVIVAL AND MIGRATION OF CARDIAC PROGENITORS - The present invention relates to a small molecule high-throughput screening assay consisting of detectably labeled cardiac progenitor cells. The invention also describes a method of identifying small molecules from the high-throughput assay affecting cardiogenesis and/or modulating cardiac progenitor cell development. Also described are methods of stimulating maturation of cardiac progenitor cells using a GSK-3β inhibitor.10-14-2010
20090053734DETERMINATION OF AM-BINDING PROTEINS AND THE ASSOCIATION OF ADRENOMEDULLIN (AM) THEREWITH - The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies. The present invention additionally provides methods for identifying antagonists agents that inhibit the function of AM, factor H, or the AM/factor H complex. The invention also provides methods for treating conditions such as cancer or diabetes using these antagonist agents.02-26-2009
20090298088CLEAVABLE CATALYTIC BINDING AND DETECTION SYSTEM - The present invention provides a detection reagent for detection of the presence of a substance of interest in a sample. The detection reagent comprises a binding portion, a linking portion, and a catalytic portion. The linking portion comprises a cleavage site for cleavage of the binding portion from the catalytic portion. According to the method, the detection reagent is caused to bind to the substance of interest. The bound reagent is then cleaved by breaking of a bond in the linking portion. Upon cleavage, the catalytic portion is removed from the binding reaction mixture and caused to catalyze a reaction that produces a detectable product.12-03-2009
20090298089Novel method for detecting and analyzing protein interactions in vivo - The invention relates to various methods of detecting and analyzing protein interactions in a cell, which methods involve the appearance of a specific protein interaction being converted to a permanent detection signal by means of providing, in a manner dependent on said protein interaction, a recombinase activity or protease activity.12-03-2009
20100184086EARLY DETECTION OF CANINE LYME DISEASE BY SPECIFIC PEPTIDES AND ANTIBODIES - The present invention relates, in one aspect, to the detection of Lyme disease in canines by detecting the peptide or antibodies to an infection specific peptide after challenge with 07-22-2010
20100184085Prokaryotic collage-like proteins and uses thereof - The present invention provides recombinant triple helical proteins or collagen-like proteins comprising a prokaryotic protein or one or more domains of a prokaryotic protein comprising a collagen-like peptide sequence of repeated Gly-Xaa-Yaa triplets and, optionally, one or more domains from a mammalian collagen. Also provided are expression vectors and host cells containing the expression vectors to produce these recombinant proteins and methods of producing the same. Additionally, antibodies are provided that are directed against a recombinant collagen-like protein that, preferably, binds an integrin. Furthermore, a method of screening for potential therapeutic compounds that inhibit the integrin-binding or integrin-interacting activities of recombinant collagen-like proteins.07-22-2010
20100184083RELEASED CYTOKERATINS AS MARKERS FOR EPITHELIAL CELLS - The present invention is directed to methods of detecting viable epithelial cells in a sample. The method includes isolating the sample comprising cells from a patient and culturing the cells for a time sufficient for an epithelial cell-specific marker to be released from the cells. The marker includes a substantially full-length cytokeratin. The method further includes detecting the released marker. Detection of the marker indicates the presence of disseminated epithelial cells. Methods are also directed to identifying disseminated epithelial tumor cells.07-22-2010
20100261195RAPID ANTEMORTEM DETECTION OF INFECTIOUS AGENTS - Methods for detection of the presence or absence of PrP10-14-2010
20100261194NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody.10-14-2010
20100151482DIAGNOSIS OF FASCIOLOSIS BY SKIN TEST (INTRADERMOREACTION) USING THE ANTIGEN FH8 (FASCIOLIN) - Fasciolosis is an anthropozoonotic disease caused by the Trematoda 06-17-2010
20100159473Peptide Standards - The invention relates to methods for making a peptide standard for mass spectrometry said method comprising (a) identifying endopeptidase cleavage sites in a parent polypeptide sequence of interest; (b) selecting peptide sequences from said parent polypeptide which are defined by endopeptidase cleavage sites of step (a); (c) adding a C-terminal extension to each selected sequence; wherein if the endopeptidase cleavage site is C-terminal to its recognition sequence then the C-terminal extension comprises 1 to 6 amino acids, wherein if the endopeptidase cleavage site is N-terminal to its recognition sequence then the C-terminal extension comprises said recognition sequence, wherein if the endopeptidase cleavage site is within its recognition sequence then the C-terminal extension comprises the remainder of said recognition sequence C-terminal to the cleavage site; and (d) synthesising a peptide having the extended amino acid sequence of step (c). The invention also relates to peptide standards and methods of analysing samples.06-24-2010
20110059464Biomarker Panel For Prediction Of Recurrent Colorectal Cancer - The present invention provides a biomarker panel predictive of whether colorectal cancer is likely to recur or metastasize in an afflicted patient. By identifying the likelihood of recurrence, a treatment provider may determine in advance those patients who would benefit from certain types of treatment. The present invention further provide methods of identifying gene and protein expression profiles associated with the likelihood of recurrence/metastasis of colorectal cancer in a patient sample.03-10-2011
20110059463Serine and Threonine Phosphorylation Sites - The invention discloses 726 novel phosphorylation sites identified in carcinoma and leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies that specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.03-10-2011
20120196297MASS TAGS FOR MASS SPECTROMETRIC ANALYSIS OF IMMUNOGLOBULINS - The present invention is a method for the characterization or detection of one or more antibodies in a sample. The method comprises obtaining a tagged antigen comprising an antigen and a mass tag attached to the antigen. The tagged antigen has specificity for the antibody. In addition, the method comprises combining the tagged antigen with the antibody to form a tagged antigen-antibody complex. Further, the method comprises cleaving the mass tag from the tagged antigen-antibody complex. Thereafter, the method comprises analyzing the mass tag via a mass spectrometer to determine the presence of the mass tag in the sample and correlating the presence of the mass tag with a presence of the antibody in the sample.08-02-2012
20100216156CANCER MARKERS - Provided are previously uncharacterized markers of cancers, for example colorectal cancers, and uses of these as diagnostic and prognostic markers of cancers, and in particular colorectal cancers. The markers are SEQ ID NO:1—hnRNP-K; SEQ ID NO:2—HMG-1; SEQ ID NO:3—proteasome subunit alpha type 1; SEQ ID NO:4—bifunctional purine biosynthesis protein; SEQ ID NO:5—STI1; SEQ ID NO:6—annex in IV; SEQ ID NO:7—60 kDa heat shock protein; SEQ ID NO:8—T complex protein 1 beta subunit; SEQ ID NO:9—T complex protein 1 epsilon subunit; SEQ ID NO:10—mortalin; and SEQ ID NO:11—TER-ATPase. The invention further provides related methods and materials for the use of the markers in therapeutic intervention in colorectal and other cancers e.g. to specifically target neoplastic cells without causing significant toxicity in healthy tissues, and to provide methods for the evaluation of the ability of candidate therapeutic compounds to modulate the biological activity of cancerous cells from the colon, rectum and other tissues.08-26-2010
20100151487Hepcidins as Biomarkers for Impending Lupus Nephritis Flare - Biomarkers for determining a kidney flare episode in systemic lupus erythematosus are described.06-17-2010
20100221744METHOD FOR PREDICTION OF POSTOPERATIVE PROGNOSIS AND DIAGNOSIS KIT - The present invention relates to a method for predicting the postoperative prognosis of a lung adenocarcinoma patient with high sensitivity and/or specificity by identifying a protein with an expression level that specifically varies in a lung adenocarcinoma patient, comprising: step (a) of determining expression levels of myosin IIA and/or vimentin in a biological sample collected from a lung adenocarcinoma patient; and step (b) of predicting or determining a prognosis based on the expression levels of myosin IIA and/or vimentin obtained as a result of determination.09-02-2010
20100216158DIAGNOSTIC TEST FOR HEAD AND FACIAL PAIN - A diagnostic test for a head and facial pain disorder in a human patient includes providing test strip containing one or more antibodies corresponding one or more biological markers associated with the disorder or with multiple disorders. A saliva sample is collected from the human patient and applied to the test strip. The test strip is subsequently evaluated for evidence of binding of one or more of the antibodies with any biological markers present in the saliva sample. The progression of the head and facial pain disorder in the patient may be measured by collecting and evaluating additional saliva samples over time and comparing any changes in the amount of binding activity between or among samples.08-26-2010
20100255497ANALYTE DETECTION - The present invention relates to analyte detection test systems, including test systems for the oral detection of analytes in saliva. The present invention also provides compositions and methods for storing multiple assay tests and compositions and methods for measuring the concentration of analytes in a sample.10-07-2010
20100255498METHODS FOR IDENTIFYING COMPOUNDS THAT REGULATE BETA-ARRESTIN SIGNALING COMPLEXES - A method of screening a candidate compound for βArrestin mediated anti-G protein coupled receptor signaling activity is comprises: (a) contacting said candidate compound to a βArrestin signaling complex or a constituent thereof, under conditions in which a signaling complex is formed; and then (b) detecting the presence or absence of disruption of said signaling complex, disruption of said complex indicating said compound has βArrestin mediated anti-G protein coupled receptor signaling activity. Compositions and kits for carrying out the method are also described.10-07-2010
20100159476DEVICE AND METHOD FOR DETECTING THE PRESENCE OF HEMOGLOBIN IN A BIOLOGICAL SAMPLE - A device and method for detecting the presence of hemoglobin in a biological sample, more particularly, the presence of blood in a fecal sample as an indicator of upper or lower gastrointestinal tract bleeding.06-24-2010
20100240065Prolyl Hydroxylase Compositions and Methods of Use Thereof - The invention provides methods and compositions for making and using novel HIF-specific prolyl hydroxylase (HPH) enzymes from rhesus monkeys.09-23-2010
20100233726TANDEM FLUORESCENT PROTEIN CONSTRUCTS - This invention provides tandem fluorescent protein construct including a donor fluorescent protein moiety, an acceptor fluorescent protein moiety and a linker moiety that couples the donor and acceptor moieties. The donor and acceptor moieties exhibit fluorescence resonance energy transfer which is eliminated upon cleavage. The constructs are useful in enzymatic assays.09-16-2010
20120142021pH MODULATION METHODS AND SYSTEMS FOR DETECTING BINDING EVENTS - Methods and systems for detecting binding between first and second molecules using a pH-sensitive fluorophore. A change in fluorescence emission intensity of the fluorophore is indicative of binding.06-07-2012
20100209936Novel recombinant 15-kDa polypeptide and use of same in detecting human infection with Bartonella henselae - Disclosed are the cloning and expression of a novel antigen of 08-19-2010
20100209940FIBROSIS BIOMARKER ASSAY - Methods of diagnosis or of quantitation of fibrosis comprise conducting an immunoassay to measure neo-epitope containing protein fragments naturally present in a biofluid sample, and associating an elevation of said measure in said patient above a normal level with the presence or extent of fibrosis. The immunoassay is conducted by a method comprising:08-19-2010
20100136575B7-RELATED NUCLEIC ACIDS AND POLYPEPTIDES USEFUL FOR IMMUNOMODULATION - The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.06-03-2010
20100136573DIAGNOSING NEURODEGENERATIVE DISEASES - This document provides methods and materials related to determining whether or not a mammal (e.g., a human) has a neurodegenerative disease (e.g., frontotemporal dementia, AD, or amyotrophic lateral sclerosis (ALS)). For example, methods and materials for using the levels of TDP-43 polypeptides and/or TDP-43 polypeptide cleavage products (e.g., 25 kD and 35 kD TDP-43 polypeptide cleavage products) in a biological fluid (e.g., cerebrospinal fluid) to determine whether or not a mammal has a neurodegenerative disease (e.g., frontotemporal dementia, AD, or ALS) are provided.06-03-2010
20100136574METHOD FOR DETECTING A CHRONIC INFLAMMATORY-ASSOCIATED DISEASE - The present invention in one embodiment is an early detection marker for chronic or acute inflammatory-associated diseases. Chronic diseases may include atherosclerosis, Alzheimer's disease, asthma, rheumatoid arthritis, osteoarthritis, and inflammatory diseases of the bowel such as Crohn's disease, Ulcerative colitis, Irritable bowel syndrome and Inflammatory bowel disease. Acute diseases may include sepsis, acute systemic infections, acute lung injury, and acute respiratory distress syndrome.06-03-2010
20090042212DETECTION OF PRIMARY INFECTIONS WITH PATHOGENS - The present invention relates to fusion proteins: suitable as test antigens in the detection of infections with pathogens, particularly of primary infections with pathogens. Further, the invention relates to methods for detecting and differentially determining antibodies, particularly IgM antibodies resulting from an infection with a pathogenic organism. Furthermore, test reagents for carrying out these methods are provided.02-12-2009
20090075292METHODS FOR IDENTIFYING MODULATORS OF APOPTOSIS - The invention provides a method of identifying an effective compound that modulates the binding of Humanin to Bax or Bid. The invention also provides a method of identifying an effective compound that modulates an activity of Bax or Bid. In addition, the invention provides a method of identifying a Humanin-like compound that binds to Bax or Bid or modulates an activity of Bax or Bid, or inhibits the apoptotic activity of Bax or Bid. The invention further provides an isolated polypeptide containing a mitochondrial-derived form of Humanin (SEQ ID NO:3) or a functional fragment thereof where the fragment contains the methionine at position 16 of SEQ ID NO:3.03-19-2009
20090075290IMMUNOCHEMICAL DETERMINATION METHOD AND DETERMINATION REAGENT FOR CYTOCHROME - An immunochemical method for the accurate measurement of the quantity of cytochrome c in a body fluid, in particular, blood, and a kit for the measurement. The quantity of cytochrome c can be measured accurately without being affected by any interfering substrate by reacting an antibody with cytochrome c in a buffer solution in an acidic range.03-19-2009
20120142019Sample Metering Device and Assay Device with Integrated Sample Dilution - In one embodiment, the invention is to a sample metering device, comprising a sample holding chamber oriented between a sample entry port and a sample isolation unit and having a diluent introduction port disposed therebetween for introduction of a diluent into the sample holding chamber. The volume within the sample holding chamber between the diluent introduction port and the sample isolation unit defines a metered volume of a sample for analysis. In another embodiment, the invention is to an apparatus and method for rapid determination of analytes in liquid samples by various assays including immunoassays incorporating a sample dilution feature, preferably suitable for low range sample dilution, and preferably capable of being used in the point-of-care diagnostic field.06-07-2012
20120034621MICROORGANISM CONCENTRATION PROCESS AND DEVICE - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration device comprising a sintered porous polymer matrix comprising at least one concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration device with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration device.02-09-2012
20120034619METHOD OF DETERMINING THE OLIGOMERIC STATE OF A PROTEIN COMPLEX - A method of counting protein subunits to determine the oligomeric state of an oligomeric protein complex includes tagging and expressing the protein subunits with a mass/charge tag and selectively removing each mass/charge tag. The number of protein subunits of the oligomeric complex corresponds to the number of mass/charge tags removed.02-09-2012
20090286257WATER SOLUBLE NANOCRYSTALLINE QUANTUM DOTS CAPABLE OF NEAR INFRARED EMISSIONS - A novel quantum dot capable of near infrared emissions at wavelengths of 750-1100 is made by forming solid solutions of metal sulfide, metal selenide or metal sulfide selenide by incorporating a suitable amount of an additional metallic element or elements to provide an emission wavelength in the range of 750 nm to 1100 nm. The quantum dots may be enabled for bioconjugation and may be used in a method for tissue imaging and analyte detection.11-19-2009
20100062456T2R, A NOVEL FAMILY OF TASTE RECEPTORS - The invention provides nucleic acid and amino acid sequences for a novel family of taste transduction G-protein coupled receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of taste transduction G-protein coupled receptors.03-11-2010
20110236905METHOD FOR SCREENING CATTLE, CATTLE SCREENED, AND CATTLE SCREENING KIT - There are provided a method for screening individual cattle having useful economic traits in which proteins related to the economic traits of beef cattle are identified by proteomics and are used as biomarkers, and a cattle screening kit for use in the method.09-29-2011
20100015633METHODS AND KIT FOR ANALYTE DETECTION - A method includes binding a probe to an analyte present in a sample, wherein the probe comprises a binder bonded to a metal particle that is capable of releasing metal ions when contacted with a reagent solution. The method includes contacting the metal particle with the reagent solution to release the metal ions, and observing an optical signal from the released metal ions to determine a presence or amount of the analyte in the sample. An associated kit is also provided.01-21-2010
20080268461Method of Measuring Cholesterol in Remnant-Like Lipoproteins - There are provided a method and reagent for measuring cholesterol in remnant-like lipoprotein in a sample with high sensitivity by more simple operation. The method for measuring cholesterol in remnant-like lipoprotein uses a cholesterol esterase, in which the activity ratio of a lipoprotein lipase to a cholesterol esterase (lipoprotein lipase activity/cholesterol esterase activity) is from 12 to 7000 in a method for measuring cholesterol in the lipoprotein by measuring hydrogen peroxide or a reduced coenzyme obtained by allowing the cholesterol esterase and a cholesterol oxidase or a cholesterol dehydrogenase to act on a test sample containing a lipoprotein.10-30-2008
20100221746COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE - The present invention relates to pharmaceutical compositions for the treatment and/or prophylaxis of disease associated with fibrosis in a vertebrate, said composition comprising at least one activin antagonist, and optionally a pharmaceutically acceptable carrier, adjuvant and/or diluent. The invention also relates to methods of treatment of disease associated with fibrosis in a vertebrate, as well as methods for diagnosing such conditions, and kits therefor.09-02-2010
20090203036EPITOPE REGIONS OF A THYROTROPHIN (TSH) RECEPTOR, USES THEREOF AND ANTIBODIES THERETO - The present invention is concerned with epitope regions of a thyrotrophin (TSH) receptor, uses thereof and antibodies thereto.08-13-2009
20090215073Layered peptide/antigen arrays - for high-throughput antibody screening of clinical samples - A method and composition for the identification of biomolecule in a sample are disclosed. The method comprises obtaining a coated capture membrane stack comprising a plurality of capture membranes with each capture membrane coated with a different peptide. The membrane stack is exposed to a sample, and, after a given amount of time for the sample to permeate the membrane stack, the membrane stack is removed from the sample carrier and the capture membrane to which the biomolecule adheres is identified.08-27-2009
20090197278Antibodies to hADA2 - Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.08-06-2009
20090186366METHOD OF DETECTING INTERACTIONS BETWEEN PROTEIN COMPONENTS - A method of detecting protein interactions in a biological sample. Protein components in a first aliquot of a sample are labelled with a first bifunctional dye which cross-links any-interacting components. A second aliquot of said sample functions as a control sample, in which protein components are labelled with a different, mono functional dye. Thereafter, the two aliquots are mixed and all components are separated by electrophoresis. Finally, differences in luminescence of the separated dye-labelled components are detected. The two dyes should match one another with regard to charge and/or molecular weight but should emit different kinds of fluorescent light.07-23-2009
20090186364Method of Constructing Recombinant Proteoliposome for Diagnostic Use - [PROBLEMS] To provide a method for preparation of recombinant proteoliposomes suitable for diagnostic applications, a detection plate coated with the recombinant proteoliposomes, a detection kit and so on.07-23-2009
20090176246ASSAY FOR MEASURING FACTOR VIIa-ANTITHROMBIN COMPLEXES - A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed.07-09-2009
20100221740METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.09-02-2010
20090148861KIR CHANNEL MODULATORS - Provided is a three-dimensional structure of an alcohol bound to an alcohol-binding site of an inwardly rectifying potassium (Kir) channel, Kir channel alcohol modulators and methods for identifying Kir channel modulators.06-11-2009
20090142774METHOD FOR THE EARLY DETECTION OF RENAL INJURY - A method and kit for detecting the immediate or early onset of renal disease and injury, including renal tubular cell injury, utilizing NGAL as an immediate or early on-set biomarker in a sample of blood serum. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the blood serum following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctuate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the serum is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.06-04-2009
20080311588NEUROGENIN - The invention relates to novel neurogenin proteins, nucleic acids and antibodies.12-18-2008
20080286802SYSTEM AND METHOD FOR LARGE SCALE DETECTION OF HAZARDOUS MATERIALS IN THE MAIL OR IN OTHER OBJECTS - A system and method that enables early detection of hazardous materials, such as explosives and biological materials, in the early phases of mail handling or processing.11-20-2008
20080280307Chimeric Recombinant Antigens of Toxoplasma Gondii - The invention described herein relates to a method for combining antigen fragments of 11-13-2008
20080280306Immunoassay For Determining The Release Of Neurotensin Into The Circulation - The invention relates to an immunodiagnostic method for determining the release of neurotensin into the circulation of mammals based on the selective determination of an immunoreactivity of the N-terminal portion of a mammal proneurotensin (PNT immunoreactivity) m a serum or plasma sample of a mammal; this immunoreactivity is not neurotensin or neuromedin immunoreactivity.11-13-2008
20090023156Methods and reagents for quantifying analytes - The present invention relates to methods and reagents for quantifying analytes. More specifically, the present invention related to methods and reagents for measuring one or more analytes present in a sample.01-22-2009
20110111423Demethylated and / or oxidized membrane DNA - A process for the preparation of oxidized and/or demethylated antigens comprising the steps of 05-12-2011
20110117571Transporter assay - This invention concerns a non-radioactive homogenous proximity assay for cellular transport system. The assay format disclosed here takes advantageous of the fact that ABC transporters have two similar ATP binding sites, and thus allowing two ATP molecules to bind simultaneously to these adjacent sites.05-19-2011
20110129848Antibody Recognizing G Protein, and Agent and Kit Using the Same - A novel protein (Gm1) includes an amino acid sequence part having a high homology with a domain having a high homology with a GTP binding site and a GTPase site conserved among G protein α subunits and a trimer forming domain conserved among G protein α subunits. The Gm1 protein is involved in signal transduction via a G protein-coupled receptor (GPCR) stimulation. The Gm1 protein is expressed intensively in human brain, thymus, testes, spleen, small intestine, uterus and heart. A method for screening for a substance capable of regulating a cellular signal transduction employs a polynucleotide encoding the Gm1 protein06-02-2011
20100297661Diagnostic Composition and Kit for Renal Cell Carcinoma - Disclosed herein are a composition and a kit for diagnosing renal cell carcinoma. The composition and kit employ, as a renal cell carcinoma marker, nicotinamide N-methyltransferase, L-plastin, secretagogin, NM23A, CapG, which is an actin regulatory protein, and/or C4a anaphylatoxin.11-25-2010
20090042213METHODS AND COMPOSITIONS FOR DETECTING THYROGLOBULIN IN A BIOLOGICAL SAMPLE - The invention provides a method and reagents for determining the presence and/or amount of human thyroglobulin in a biological sample. In one embodiment, the method comprises (a) digesting a biological sample containing proteins to provide peptide fragments; (b) contacting the digested sample with a binding reagent comprising a plurality of antibodies that are capable of binding to at least one thyroglobulin peptide fragment; and (c) determining the presence and/or amount of the thyroglobulin peptide fragments that are bound to the binding reagent. In some embodiments, the binding reagent comprises a plurality of antibodies capable of binding to at least one thyroglobulin peptide fragment set forth in TABLE 1. In some embodiments, the binding regent comprises a plurality of antibodies capable of binding to at least one thyroglobulin peptide selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, and SEQ ID NO:5.02-12-2009
20100304398 NOVEL DIAGNOSTIC SENSOR FOR RAPID AND REPRODUCIBLE RO52 PROTEIN DOMAIN DETECTION - The present invention relates to the use of specific synthetic sensor molecules for the discrimination of proteins and protein domains involved in autoimmunity. More specifically, in one embodiment, the invention relates to the detection of antibodies which bind to specific domains of the Ro52 protein. In another embodiment, the invention relates to the use of specific synthetic sensor molecules to identify domains of the Ro52 protein with different antibody specificities. The invention also includes a method for assessing the risk that a fetus will develop congenital heart block. The invention enables the evaluation and differential diagnosis of a range of autoimmune disorders, allowing appropriate treatment or more generally medical intervention decisions to be made.12-02-2010
20100248262Anti-Fibronectin Fragment Monoclonal Antibody - A method for measuring a fibronectin fragment which is easy to handle and has excellent measuring accuracy, specificity and reproducibility is provided. An anti-fibronectin fragment monoclonal antibody which reacts with a human fibronectin fragment but does not react with human fibronectin, a measuring reagent containing the monoclonal antibody, a method for measuring a fibronectin fragment which uses the monoclonal antibody and a hybridoma which produces the monoclonal antibody are provided.09-30-2010
20100248261METHOD TO DETERMINE PROTEIN INTERACTION SITES - The invention provides improved crosslinkers which permit more efficient determination of protein interactions in biological samples.09-30-2010
20110212463HYBRID TARGET ANALYTE RESPONSIVE POLYMER SENSOR WITH OPTICAL AMPLIFICATION - Disclosed is a product that includes an optical sensor; a target-responsive hydrogel matrix on a surface of the optical sensor (where the hydrogel matrix comprises one or more target-specific receptors and one or more target analogs), and one or more high refractive index nanoparticles within the hydrogel matrix, where a detectable change occurs in a refractive index of the hydrogel matrix when contacted with one or more target molecules. Sterile packages and detection devices containing the product, and methods of detecting a target molecule using the product, are also disclosed.09-01-2011
20100304399METHOD FOR CONTINUOUSLY DETECTING GLUCOSE CONCENTRATION IN SAMPLE, KIT THEREOF AND METHOD FOR USING BIOSENSOR - The invention provides a method for continuously detecting glucose concentration in a sample, including: (a) providing a biosensor comprising a transducer and a polysaccharide covered on the surface of the transducer; (b) providing a carbohydrate binding protein solution, wherein the carbohydrate binding protein has at least one receptor, and the receptor is capable of binding to the polysaccharide and glucose; (c) mixing a sample and the carbohydrate binding protein solution to form a mixture; (d) contacting the mixture with the biosensor; (e) detecting the amount of carbohydrate binding proteins bound to the polysaccharide by the biosensor, wherein glucose concentration of the sample is inversely proportional to the amount of carbohydrate binding proteins bound to the polysaccharide; and (f) refreshing the surface of the biosensor with a high concentration glucose solution.12-02-2010
20100304397Chromogenic test kit for detecting health conditions in saliva - A device and method for detecting diseases, disorders and health conditions in saliva or other body fluid. The method employs solid phase immunoassay and similar detecting processes along with one of several bioluminescent reactions such that the presence of specific biomarkers is reported visually on a chromogenic panel incorporated directly into the test kit. The device does not require electricity or refrigeration, and results in a small, sealed diagnostic packet that can be safely discarded or stored as necessary.12-02-2010
20100248259NATRIURETIC PEPTIDE/GDF-15 RATIO FOR DIAGNOSIS OF CARDIAC DISORDERS - The present invention is concerned with methods and devices for medical diagnosis. Specifically, it relates to a method of diagnosing a cardiac disorder, the method including (a) determining the amount of a natriuretic peptide in a sample of the subject, (b) determining the amount of GDF-15 in a sample of the subject, (c) calculating the ratio (natriuretic peptide/GDF-15), and (d) diagnosing if the subject is suffering from a cardiac disorder, based of the ratio calculated in step (c). The method allows determining whether an elevated amount of GDF-15 in a sample of a subject is related to cardiac disorders, in particular myocardial dysfunction and/or heart failure, or if the elevation is related to a different pathological state Moreover, the present invention relates to a diagnostic device and a kit for carrying out the aforementioned method.09-30-2010
20100311076METHOD OF BINDING PROTEINS TO CARRIERS BY MAKING USE OF TAMAVIDINS - The present invention provides a method of binding a protein to a carrier in such a way that the protein is not impaired in its function but can be allowed to act more efficiently than when it is bound directly.12-09-2010
20100311080WATER-SOLUBLE NANOCRYSTALS THROUGH DUAL-INTERACTION LIGANDS - A dual-interaction ligand for rendering otherwise hydrophobic nanoparticles water soluble or suspendable has a hydrophilic base with a plurality of hydrophilic segments extending from a core of the base, where at least one segment or the core contains a hydrophobic groups capable of forming van der Waal interaction between hydrophobic groups of the dual-interaction ligand and other hydrophobic ligands, and at least one complexing functionality to complex a metal atom or ion of a nanoparticle. The dual-interaction ligands can be combined with hydrophobic nanoparticles, where the dual-interaction ligands can displace some or all of the hydrophobic ligands of the hydrophobic nanoparticles, to form a nanoparticle-dual interaction ligand complex that can be dissolved or dispersed readily in an aqueous solution. The dual interaction ligand can be functionalized to attach an antibody or other biomolecules such that the nanoparticle dual-interaction ligands complexes can contain biomolecules. Such biomolecules modified nanoparticle dual-interaction ligands can be used for sensing, labeling, optical imaging, magnetic resonance imaging, cell separation, and treatment of diseases.12-09-2010
20100311078IMMUNOREGULATION IN CANCER, CHRONIC INFLAMMATORY AND AUTOIMMUNE DISEASES - The present invention primarily relates to a method for analyzing the amount of immunoregulatory integrin binding factors and/or patient endogenous antibodies which are directed against such factors, the factors having the capacity to modulate the immune functions in a subject suffering from cancer or inflammatory or autoimmune diseases, by utilizing binding reagents to determine these factors and/or the patient endogenous antibodies which are directed against such factors, whereby the prognosis and/or the therapeutic efficacy of any treatment of a subject suffering from cancer or inflammatory or autoimmune diseases can be determined and/or monitored. The invention further relates to the use of therapeutically active compounds for eliminating, inhibiting or enhancing such binding factors for the manufacture of pharmaceuticals to be used in the treatment of cancer, inflammatory conditions or autoimmune diseases.12-09-2010
20100311075HUMAN SODIUM-DEPENDENT BILE ACID TRANSPORTER PROTEINS - A novel sodium-dependent bile acid transporter protein, an Na12-09-2010
20090130689Method useful for detecting encephalopathies - The invention concerns a method of detecting a TSSE Disease or prion disease. The invention further concerns a method for amplifying oligomerization of isoforms of the cellular prion PrP05-21-2009
20110129849DETECTION OF PROSTATE CANCER USING PSA GLYCOSYLATION PATTERNS - The present invention features novel methods for determining if a subject has prostate cancer. The present invention is based on the development of lectin immunosorbant assays which analyze α2,6-linked sialylation of total serum PSA by 06-02-2011
20090068680Method for Characterizing Immune Disorders - Methods for characterizing immune diseases are provided which include exposing a sample of biological fluid from a patient to a pooled population of particles, wherein a first subset of particles is bound to a reactant that binds an antibody and a second subset of particles is bound to a reactant that binds an antigen. The methods further include determining a ratio of measured amounts of the antibody and the antigen in the sample. In some cases, the ratio is compared to one or more standard ratios representing differing states of the disease to determine a state of the disease within the patient. In other embodiments, the steps of exposing and determining a ratio of antibody to antigen are repeated for one or more additional samples of biological fluid taken from the patient. In such cases, at least two ratios are compared to analyze a progression of the disease.03-12-2009
20090068678Method for identifying modulators of NOAH10 useful for treating Alzheimer's disease - Methods for identifying modulators of NOAH10 are described. The methods are particularly useful for identifying analytes that antagonize NOAH10's effect on processing of amyloid precursor protein (APP) to amyloid beta (Aβ) peptide and are useful for identifying analytes that can be used for treating Alzheimer disease.03-12-2009
20090068677BIOMARKER FOR DIAGNOSING HEART DISEASE AND THE USE THEREOF - The invention relates to the following methods [1] to [3] and to a kit for carrying out the methods:03-12-2009
20090068676Diagnostic methods for congestive heart failure - The invention provides an assay for the quantification of circulating glycophorin in biological fluid samples. The circulating glycophorin measured by this assay is a truncated glycophorin diagnostic for congestive heart failure (CHF).03-12-2009
20100143937ASSAY METHODS FOR IDENTIFYING AGENTS THAT MODIFY THE ACTIVITY OF NAPE-PLD OR Abh4 - The present invention provides methods for the detection of agents that modify the activity of the N-acylphosphatidylethanolamine-hydrolysing phospholipase D (NAPE-PLD) enzyme or the Alpha/beta-hydrolase-4 (Abh4) enzyme. The disclosed methods are configured in an assay format amenable to high throughput screening applications.06-10-2010
20090239239EUKARYOTIC AMADORIASE HAVING EXCELLENT THERMAL STABILITY, GENE AND RECOMBINANT DNA FOR THE EUKARYOTIC AMADORIASE, AND PROCESS FOR PRODUCTION OF EUKARYOTIC AMADORIASE HAVING EXCELLENT THERMAL STABILITY - Disclosed are: a eukaryotic amadoriase which is prepared by introducing a mutation into DNA encoding a eukaryotic amadoriase derived from a microorganism belonging to the genus 09-24-2009
20090035786MULTI-ANALYTE AFFINITY COLUMN - A multi-analyte column is disclosed. The column may contain at least one unit of resin having ochratoxin specific affinity and, for each unit of resin having ochratoxin specific affinity, the column further contains about 0.95 to 1.05 units of resin containing antibody having specificity for zearalenone, about 1.9 to 2.1 units of resin containing antibody having specificity for aflatoxin, about 2.35 to 2.65 units of resin containing antibody having specificity for fumonisin, about 2.8 to 3.2 units of resin containing antibody having specificity for T-2 (and/or HT-2) and about 4.7 to 5.3 units of resin containing antibody having specificity for deoxynivalenol. One unit of resin is the quantity of resin containing antibody that will bind 50 ng of aflatoxin, 500 ng of deoxynivalenol, 3300 ng of fumonisin, 50 ng of ochratoxin, 830 ng T-2 (and/or HT-2) or 1140 ng of zearalenone, respectively.02-05-2009
20100330583Compositions and methods for identification of PARP function, inhibitors, and activators - The invention provides nucleic acids encoding PARP fusion proteins, PARP fusion proteins, antibodies that bind to one or more of these PARP fusion proteins, and transgenic cells expressing one or more PARP fusion proteins. The invention also provides methods for identifying an agent as a specific PARP inhibitor or activator requiring contacting one or more PARP fusion proteins with a labeled nicotinamide adenine dinucleotide substrate and the agent and measuring the amount of labeled of ADP-ribose covalently attached to the one or more PARP fusion proteins. The invention also provides methods for identifying an agent that specifically binds to one or more PARP fusion proteins and methods for quantitating the level of one or more PARP proteins in a sample.12-30-2010
20110008799PHENOTYPIC RATIO OF SERUM AMYLOID IN PRE- AND TYPE 2 DIABETES - The present invention is directed to diagnosing, determining, and/or monitoring type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by detecting levels and modulations of Serum amyloid A protein (SAA), SAA variants and/or the phenotypic ratio of SAA. The present invention is also directed to methods for identifying and evaluating therapeutic treatments for type 2 diabetes, pre-diabetes, insulin resistance, and their related conditions by monitoring SAA, SAA variants, and/or the phenotypic ration of SAA.01-13-2011
20110033870HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to 02-10-2011
20090142772Devices and Methods for the Detection of Analytes - System and methods for detecting analytes such as pathogenic cells are described. The methods allow for the direct measurement of analytes such as pathogenic organisms without the need for sample preparation and/or PCR. The devices can be used individually as point-of-use sensors for airborne pathogens and other pathogenic organisms in foods and agriculture products.06-04-2009
20110244475MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed.10-06-2011
20110086363Method and apparatus to conduct kinetic analysis of platelet function in whole blood samples - Adhesion of platelets to blood vessel walls is the first step that promotes arrest of bleeding by interaction of the platelet receptors with various extracellular matrix proteins that become exposed on vascular injury. A flow chamber is provided for use in analyzing or studying platelet function, in whole blood, either as part of a batch process or in real time. In the flow chambers, an inert polydimethylsiloxane (PDMS) surface is plasma-activated and a homobifunctional cross-linker is used to immobilize platelet-binding proteins onto a chamber wall surface. Immobilized collagen and fibrinogen may thus be assayed by continuously monitoring the adhesion of ADP and Ca04-14-2011
20110244478Methods and Compositions for Treating Bleeding Disorders - Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) is administered to a subject to enhance blood coagulation in the subject. Also provided are methods for preparing a NASP composition having blood coagulation enhancing activity. Compositions and kits for practicing methods of the invention are also described.10-06-2011
20110244479Plasmon Resonant Particles, Methods and Apparatus - A method and apparatus for interrogating a target having a plurality of plasmon resonant particles (PREs) distributed in the target are disclosed. In the method, a field containing the target is illuminated, and one or more spectral emission characteristics of the light-scattering particles in the field are detected. From this data, an image of positions and spectral characteristic values in the field is constructed, allowing PREs with a selected spectral signature to be discriminated from other light-scattering entities, to provide information about the field. Also disclosed are a novel PRE composition for use in practicing the method, and a variety of diagnostic applications of the method.10-06-2011
20110244477ANTIBODY-SECRETING CELL ASSAY - An improved assay is described where a surface is provided with immobilized anti-Ig antibodies rather than antigen and where specific antibody-secreting cells (ASC) are detected using soluble antigen probes containing one of several possible labels. The method gives improved sensitivity with less background and is also more representative because antigen binding does not employ immobilized antigen. The assay is particularly effective for measuring antibody secreting cells against HIV, for determining whether an infection is acute as opposed to old or latent, for mapping epitopes and for measuring for ASCs against different antigens in the same reaction.10-06-2011
20110244476METHOD FOR EVALUATION OF QUALITY OF BLOOD SAMPLE - A method for evaluating the quality of a blood sample, comprising the steps of: mixing labeled anti-cortisol antibodies with a blood sample to be subjected, to conduct the antigen-antibody reaction of the labeled anti-cortisol antibody with cortisol contained in the blood sample, developing a mixture obtained in the above step on an immunochromatographic test strip having a substrate on which cortisol is immobilized to cause the antigen-antibody reaction of the labeled anti-cortisol antibodies which are free in the mixture with the cortisol immobilized on the substrate, thereby bonding the antibody to the cortisol, determining the amount of the labeled anti-cortisol antibodies bonded to the cortisol in the above step, and evaluating whether or not the blood sample has a quality suitable for suprarenal vein sampling test on the basis of the amount of the labeled anti-cortisol antibodies determined in the above step.10-06-2011
20110065122METHOD FOR ACCESSING MICROBIAL DIVERSITY - A method of interfering with quorum sensing regulation of genes to promote cell growth is disclosed. The method of is aimed at accessing microbial biodiversity. The method involves obtaining an environmental sample comprising at least one novel (uncultivated in the laboratory) microorganism, contacting the environmental sample with an effective amount of an agent or combination of agents which interferes with the quorum sensing regulation of genes, growing the treated sample in a culture medium containing the quorum sensing signal disrupting agent or agents, and analyzing the colonies of microorganisms grown to demonstrate genetic novelty.03-17-2011
20110129846PHOTONIC BIOSENSOR, PHOTONIC BIOSENSOR ARRAY, AND METHOD OF DETECTING BIOMATERIALS USING THE SAME - A photonic biosensor, a photonic biosensor array, and a method of detecting a bio-material using the same are provided. The photonic biosensor includes a light emitting diode configured to emit light, a photodiode (PD), an optical fiber configured to connect the light emitting diode with the PD, and a micro-fluidic channel disposed on the optical fiber. Bio-antibodies or aptamers are fixed to the surface of the optical fiber, and the micro-fluidic channel includes gold (Au) nanoparticles to which bio-antibodies or aptamers are fixed. The photonic biosensor may be configured using absorption of surface plasmons in Au nanoparticles with respect to light traveling through the surface of the optical fiber configured to connect the light emitting diode with the PD, thus simplifying the manufacture of the biosensor and reducing the manufacturing cost.06-02-2011
20100227333METHOD OF DETECTING INFECTION WITH UROGENITAL MYCOPLASMAS IN HUMANS AND A KIT FOR DIAGNOSING SAME - A method and a kit are provided for detecting an infection by mycoplasma, particularly an urogenital infection in humans. The presence of specific anti-mycoplasma antibodies in a biological sample of a diagnosed subject is detected by reaction with an immobilized mixture of various antigenic determinants associated with a variety of pathological states.09-09-2010
20100221745ABNORMAL PRION PROTEIN BINDER, AND METHOD FOR DETECTION OF ABNORMAL PRION PROTEIN - Disclosed are: a method for detecting pathogenic isoform of prion protein as distinguished from normal prion protein in a simple manner, rapidly, with a high degree of sensitivity and quantitatively without the need of the enzymatic treatment with protease K; and a reagent for use in the method. Specifically disclosed are: a pathogenic isoform of prion protein binder which comprises lactoferrin; and a method for detecting pathogenic isoform of prion protein by using the pathogenic isoform of prion protein binder.09-02-2010
20100221742NOVEL CANCER ASSOCIATED ANTIBODIES AND THEIR USE IN CANCER DIAGNOSIS - The present invention relates to an antibody having specificity for a polypeptide comprising an amino acid sequence of SEQ ID No:2 or an isoform thereof or a polypeptide comprising SEQ ID NO:2.09-02-2010
20100221741ANALYSIS DEVICE, AND ANALYSIS APPARATUS AND METHOD USING THE SAME - An analysis device includes: a separation cavity 09-02-2010
20110136133METHOD FOR DIFFERENTIATING BETWEEN MULTIPLE SCLEROSIS SUBTYPES - Disclosed herein is a method for differentiating between multiple sclerosis subtypes in a patient. The method comprises a) determining an amount of an IAP gene expression level in a blood sample obtained from the patient; and b) correlating the amount of the IAP gene expression level in the blood sample with the presence of a multiple sclerosis subtype in the patient.06-09-2011
20090098572BREAST CANCER RESISTANCE PROTEIN (BCRP) AND ANTIBODIES THERETO - The present invention provides a breast cancer resistance polynucleotide and protein of 04-16-2009
20100047815METHOD TO DETECT TUMOR MARKERS AND DIAGNOSIS OF UNDIFFERENTIATED TUMORS - This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of different tumor markers in a protein sample extracted from tumor tissue, which can be used for the diagnosis of undifferentiated tumors. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of monoclonal antibodies used for detecting tumor markers in a tumor tissue sample and for the diagnosis of undifferentiated tumors.02-25-2010
20100047816RAPID IMMUNOCHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a rapid immunochromatographic test device suitable to detect an antibody and/or antigen in at least one sample, uses of said device for detecting diseases in a sample, a method for the production of said device as well as a kit comprising the device.02-25-2010
20110086362High-Throughput Method for Quantifying Sialylation of Glycoproteins - Provided herein methods and kits for detecting and/or quantifying sialic acid content of glycosylated molecules that does not require purification of the glycosylated molecule of interest or purification of the labeled product. The methods and kits provided herein are fast and suitable for high-throughput use.04-14-2011
20100047814PROTEIN INTERACTION REPORTER AGENTS AND METHODS FOR USING SAME - Particular aspects provide novel protein interaction reporter (PIR) compounds (e.g., formulas I and II), comprising at least two protein reactive moieties (e.g., N-hydroxysuccinamide), each linked to a reporter moiety (e.g., mass reporter) by a covalent labile bond that is differentially cleavable with respect to peptide bonds (e.g., by a method such as collisional activation in a mass spectrometer, activation by electron capture dissociation (ECD), photoactivation, etc.), wherein the reporter moiety is operatively releasable from the PIR agent upon cleavage of the labile bonds, the released reporter moiety having a characteristic identifying property or label (e.g., m/z value). Particular PIRs comprise a mass reporter moiety, and further comprise an affinity group, (e.g., biotin), linked to the PIR (e.g., to the mass reporter moiety) by a selectively cleavable bone (e.g. photo-labile bond)). Additional aspects provide methods for characterizing intermolecular or intramolecular protein interactions using one or more inventive PIR compounds.02-25-2010
20100047813BIOLUMINESCENCE RESONANCE ENERGY TRANSFER (BRET) SYSTEMS AND METHODS OF USE THEREOF - Briefly described, embodiments of this disclosure include bioluminescence resonance energy transfer (BRET) systems, methods of detecting a protein-protein interaction, noninvasive methods for detecting the interaction of a first protein with a second protein within a living animal, methods to determine the efficacy of a test compound administered to modulate the interaction of a first protein with a second protein in a living animal, BRET vectors, kits relating to each of the above, transgenic cell or progeny thereof and/or animals relating to each of the above, and the like.02-25-2010
20090246794Methods and Kit for Detecting Breast Cancer - The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer.10-01-2009
20100047812PEPTIDE ANTIBODY DEPLETION AND ITS APPLICATION TO MASS SPECTROMETRY SAMPLE PREPARATION - The present invention relates, e.g., to a method for pre-processing a sample for mass spectral analysis, comprising cleaving proteins in the sample to peptides and immunodepleting highly abundant and/or well-ionizing and/or proteotypic peptides from the sample. Also described are methods for identifying well-ionizing peptides for use in this and other methods: analytic (diagnostic) methods using antibodies against highly ionizable peptides from a protein target of interest; and compositions kits and devices comprising antibodies of the invention.02-25-2010
20090311714Methods for the Screening of Antibacterial Substances - The present invention concerns a method for the screening of antibacterial substances comprising a step of determining the ability of a candidate substance to inhibit the activity of a purified enzyme selected from the group consisting of: (i) a D-aspartate ligase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with an amino acid sequence selected from the group consisting of SEQ ID No 1 to SEQ ID No 10, or a biologically active fragment thereof; and (ii) a L,D-transpeptidase comprising a polypeptide having an amino acid sequence possessing at least 50% amino acid identity with the amino acid sequence of SEQ ID No 11, or a biologically active fragment thereof.12-17-2009
20100047811METHOD FOR OPTIMIZING THE AUTOMATIC FLUORESCENCE PATTERN RECOGNITION IN IMMUNODAGNOSIS - The invention relates to a method for optimizing the automatic fluorescence pattern recognition in immunodiagnosis. In this method, in addition to or together with the fluorescence dye, one or more other indicator dyes for the identification of relevant structures are incubated before an image is taken with a camera.02-25-2010
20100009382METHODS AND COMPOSITIONS FOR DIAGNOSING LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ubiquilin 1 markers for cancer.01-14-2010
20100055712Oligopeptides for treatment of osteoporosis and other bone diseases and methods therefor - Methods of identifying compounds for treating Alzheimer's disease are disclosed. These methods comprise a) forming an in vitro mixture comprising i) cells expressing LDL receptor related protein 1 (LRP1), ii) an LRP1 ligand comprising a label, and iii) a candidate compound; and b) determining quantity of the label incorporated by the cells, whereby a candidate compound is deemed effective for treating Alzheimer's disease if the quantity of label incorporated by the cells exceeds that of a control in vitro mixture comprising cells expressing LRP1 and the LRP1 ligand, but not comprising the compound.03-04-2010
20100055711METHODS FOR THE IDENTIFICATION OF PI3K INTERACTING MOLECULES AND FOR THE PURIFICATION OF PI3K - The present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) incubating the phenylthiazole ligand 1-PI3K complex with a given compound, and d) determining whether the compound is able to separate PI3K from the immobilized phenylthiazole ligand 1. Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing a protein preparation containing PI3K, b) contacting the protein preparation with phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and c) detecting the phenylthiazole ligand 1-PI3K complex formed in step b). Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing two aliquots of a protein preparation containing PI3K, b) contacting one aliquot with the phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, c) contacting the other aliquot with the phenylthiazole ligand 1 immobilized on a solid support and with a given compound under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and d) determining the amount of the phenylthiazole ligand 1-PI3K complex formed in steps b) and c). Furthermore, the present invention relates to a method for the identification of a PI3K interacting compound, comprising the steps of a) providing two aliquots comprising each at least one cell containing PI3K, b) incubating one aliquot with a given compound, c) harvesting the cells of each aliquot, d) lysing the cells in order to obtain protein preparations, e) contacting the protein preparations with the phenylthiazole ligand 1 immobilized on a solid support under conditions allowing the formation of a phenylthiazole ligand 1-PI3K complex, and f) determining the amount of the phenylthiazole ligand 1-PI3K complex formed in each aliquot in step e).03-04-2010
20090035783FLUORESCENT PROTEINS AND USES THEREOF - A fluorescent sensor and methods for producing and using the fluorescent sensor. Such fluorescent sensors have broad applicability in characterizing cells and organisms, in detecting or measuring various cellular parameters, and in detecting or measuring protein-protein/peptide interactions.02-05-2009
20090148865POLYSACCHARIDE STRUCTURE AND SEQUENCE DETERMINATION - The invention provides a method for the structural analysis of a saccharide, comprising: a) providing on a surface a plurality of essentially sequence- and/or site-specific binding agents; b) contacting said surface with a saccharide to be analyzed, or with a mixture comprising a plurality of fragments of said saccharide; c) washing or otherwise removing unbound saccharide or saccharide fragments; d) adding to the surface obtained in step c) an essentially sequence- and/or site-specific marker, or a mixture of essentially sequence- and/or site-specific markers; e) acquiring one or more images of the markers that are bound to said surface; and f) deriving information related to the identity of the saccharide being analyzed from said image.06-11-2009
20100062453Method of diagnosing endometriosis in human subjects - A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to ME-5 (SEQ ID NO:3) polypeptide or a peptide comprising an epitope of ME-5 in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.03-11-2010
20100062459Tacrolimus Standard and Methods of Using Same - A composition and kit useful as a tacrolimus standard solution for immunoassays, and methods for making and using same. The composition and kits include a known amount of tacrolimus or a derivative thereof, and a non-specific protein capable of forming a complex with the tacrolimus or derivative thereof. The standard solution may be used to generate calibration curves for an immunoassay or to check the precision of an analytical instrument.03-11-2010
20110097733PROCESS FOR THE PRODUCTION OF A HYBRIDOMA AND ANTIBODY OBTAINED THEREFROM, ABLE TO RECOGNIZE MORE THAN ONE VITAMIN D METABOLITE - The invention concerns a process for the production of a hybridoma, and of a monoclonal antibody or fragments thereof able to recognize 25-hydroxyvitamin D04-28-2011
20100062452METHODS FOR DETERMINING SIGNAL TRANSDUCTION ACTIVITY IN TUMORS - The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.03-11-2010
20100068724Biomaker for ovarian and endometrial cancer: hepcidin - The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.03-18-2010
20100068729METHOD AND KITS FOR THE DIAGNOSIS OF DIABETES - Provided are methods for the detection and diagnosis of a predisposition for developing diabetes. The methods are based on the discovery that abnormal levels of the selected analyte in biological samples, typically blood samples, of patients who are at risk are supportive of a diagnosis of a predisposition for developing diabetes. At least one new biomarker for a predisposition for diabetes is thus disclosed, IGF-1. Other important biomarkers for diabetes are described, including but not limited to ZAG, clusterin, corticosteroid-binding globulin, lumican, and serotransferrin. Kits containing reagents to assist in the analysis of biological samples are also described.03-18-2010
20090215078Doxorubicin Immunoassay - Novel conjugates of doxorubicin and novel doxorubicin immunogens derived from the 13 and 14 positions of doxorubicin and antibodies generated by these doxorubicin linked immunogens all of which are useful in immunoassays for the quantification and monitoring of doxorubicin in biological fluids.08-27-2009
20090215077METHODS FOR DIAGNOSIS OF ACUTE CORONARY SYNDROME - Provided are methods for the detection and diagnosis of acute coronary syndrome or ACS. The methods are based on the discovery that abnormal levels of selected analytes in sample fluid, typically blood samples, of patients who are at risk are supportive of a diagnosis of ACS. At least two new biomarkers for ACS are thus disclosed, MMP-3 and SGOT. Altogether the concentrations of twelve analytes provide a sensitive and selective picture of the patient's condition, namely, whether the patient is suffering a heart attack. Other important biomarkers for ACS are described, including but not limited to IL-18, Factor VII, ICAM-1, Creatine Kinase-MB, MCP-1, Myoglobin, C Reactive Protein, von Willebrand Factor, TIMP-1, Ferritin, Glutathione S-Transferase, Prostate Specific Antigen (free), IL-3, Tissue Factor, alpha-Fetoprotein, Prostatic Acid Phosphatase, Stem Cell Factor, MIP-1-beta, Carcinoembryonic Antigen, IL-13, TNF-alpha, IgE, Fatty Acid Binding Protein, ENA-78, IL-08-27-2009
20090215076Methods and substances for the diagnosis and therapy of sepsis and sepsis-like systemic infections - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biomarkers in the diagnosis of sepsis.08-27-2009
20090215074Detection of the nucleolar channel system of human endometrium and uses thereof - Methods are disclosed for assaying at the light microscopic level for the presence or absence of nucleolar channel systems (NCSs) in an endometrial tissue sample, as are methods for determining whether or not a postovulatory human endometrium is in a state that is receptive for implantation of a human embryo, where the presence of NCSs indicates that the endometrium is in a state that is receptive for implantation of an embryo and the absence of NCSs indicates that the endometrium is not in a state that is receptive for implantation of the embryo, and methods for determining the effectiveness of a contraceptive in a woman, comprising assaying an endometrial tissue sample for the presence or absence of NCSs.08-27-2009
20090215072METHODS AND COMPOSITIONS RELATED TO DETERMINATION AND USE OF WHITE BLOOD CELL COUNTS - Described herein is an analyte detection device and method related to a portable instrument suitable for point-of-care analyses. In some embodiments, a portable instrument may include a disposable cartridge, an optical detector, a sample collection device and/or sample reservoir, reagent delivery systems, fluid delivery systems, one or more channels, and/or waste reservoirs. Use of a portable instrument may reduce the hazard to an operator by reducing an operator's contact with a sample for analysis. The device is capable of obtaining diagnostic information using cellular- and/or particle-based analyses and may be used in conjunction with membrane- and/or particle-based analysis cartridges. Analytes, including proteins and cells and/or microbes may be detected using the membrane and/or particle based analysis system.08-27-2009
20090215071METHODS OF TARGETING BAFF - The present disclosure provides compositions and methods relating to the structure of BAFF in solution. The disclosure includes BAFF 60-mers, BAFF trimers, methods of making BAFF 60-mers and BAFF trimers, antibodies that preferentially bind one form or the other, and methods of identifying or evaluating a compound on the basis of its relative binding to or activity towards a BAFF 60-mer and a BAFF trimer. The disclosure also provides computer-based systems and methods relating to BAFF structures.08-27-2009
20090215070Highly Sensitive Immunoassays and Antibodies for Detection of Blood Factor VIII - Disclosed are antibodies that selectively bind to blood coagulation factor FVIII, and highly sensitive immunological assays comprising these antibodies. Preferred assays can detect FVIII at about 3500-fold below the normal physiological levels, and have a wide array of applications including accurate monitoring of FVIII concentration in pharmaceutical products for treatment of blood coagulation disorders, and determination of FVIII levels in plasma of human patients, including those with blood coagulation disorders such as hemophilia.08-27-2009
20090215069Pancreatic polypeptide as target/marker of beta cell failure - The present invention relates to the monitoring of disease progression and diagnosis of beta-cell failure in diabetes by measuring levels of pancreatic hormone in a liquid sample, and to screening for novel compounds for the prevention and/or treatment of diabetes.08-27-2009
20100129831METHODS FOR DIAGNOSING HYPERSENSITIVITY REACTIONS - The invention is directed to the diagnosis of allergic reactions. Particularly, the invention is directed to in vitro assays for diagnosing systemic hypersensitivity reactions, and identifying agents causing these reactions.05-27-2010
20100267049DIAGNOSTIC DEVICES AND RELATED METHODS - Devices, systems, and methods for detecting the presence of one or more analytes in a sample are described. In some variations, a test strip may be used to detect and/or analyze one or more analytes in a sample. In certain variations, a test strip configured to receive a sample for detection of an analyte therein may comprise a substrate and a coating on a portion of the substrate, the coating comprising a combination of a first analyte capture agent configured to bind to a first analyte and a second analyte capture agent configured to bind to a second analyte that is different from the first analyte.10-21-2010
20110250613Arrayed Multiple Ubiquitin Binding Domains as Linkage-specific Polyubiquitin Affinity Reagents - Linkage-specific polyubiquitin recognition is thought to make possible the diverse set of functional outcomes associated with ubiquitination. Thus far, mechanistic insight into this selectivity has been largely limited to single domains that preferentially bind to lysine 48-linked polyubiquitin (K48-polyUb) in isolation. A mechanism is proposed herein, linkage-specific avidity, in which multiple ubiquitin-binding domains are arranged in space so that simultaneous, high-affinity interactions are optimum with one polyUb linkage but unfavorable or impossible with other polyUb topologies and monoUb. The model used herein is human Rap80, which contains tandem ubiquitin interacting motifs (UIMs) that bind to K63-polyUb at DNA doublestrand breaks. The sequence between the Rap80 UIMs positions the domains for efficient avid binding across a single K63 linkage, thus defining selectivity. K48-specific avidity is also demonstrated in a different protein, ataxin-3. Using tandem UIMs, the general principles governing polyUb linkage selectivity and affinity in multivalent ubiquitin receptors are established.10-13-2011
20110250615Methods and Compositions for Detection of Ehrlichia chaffeensis (VLPT) - The invention provides methods and compositions for the detection of 10-13-2011
20110250614METHODS AND COMPOSITIONS FOR DETECTING THE ACTIVATION STATE OF MULTIPLE PROTEINS IN SINGLE CELLS - The invention provides methods and compositions for simultaneously detecting the activation state of a plurality of proteins in single cells using flow cytometry. The invention further provides methods and compositions of screening for bioactive agents capable of coordinately modulating the activity of a plurality of proteins in single cells. The methods and compositions can be used to determine the protein activation profile of a cell for predicting or diagnosing a disease state, and for monitoring treatment of a disease state.10-13-2011
20110097734Flow Control Technique for Assay Devices - A method for controlling fluid flow in an assay device that employs a membrane is provided. Specifically, one or more recessed regions are formed in the membrane by applying a solvent treatment thereto. The solvent treatment is selected based on its particular dissolving capacity for the material used to form the membrane. For example, an alcohol-based solvent, such as methanol, may be used as a solvent for nitrocellulose membranes. Upon contact with the solvent treatment, a recessed region is formed that may serve a variety of different functions relating to flow control. In one particular embodiment, the recessed region may function as a metering channel that is capable of delivering a controlled volume of the test sample to a detection zone upon initiation of the assay.04-28-2011
20110097732NOVEL BIOMARKER FOR THE PROGNOSIS OF BREAST CANCER - The present invention relates to methods of determining the predilection for survival for an individual having breast cancer comprising: obtaining a breast tissue sample from said individual, measuring the amount of Wrap53 in the nucleus of cells in said breast tissue sample, and/or measuring the amount of Wrap53 in the cytoplasm of cells in said breast tissue sample, and wherein both the nuclear levels, the cytoplasmic levels and/or the ratio between the nuclear and cytoplasmic levels of Wrap53 may be used alone or in combination in breast cancer prognosis. The invention furthermore relates to antibodies and kits relating to Wrap53.04-28-2011
20100124755PROSTATE CANCER AND MELANOMA ANTIGENS - Methods for identifying a human subject as a candidate for further prostate cancer or melanoma examination are disclosed. Also disclosed are methods for determining whether an immune therapy has elicited a tumor-specific immune response in a prostate cancer or melanoma patient. Further disclosed are kits that can be used to practice the above methods. Methods for identifying candidate compounds for further testing as preventive or therapeutic agents for melanoma are also disclosed.05-20-2010
20110070592DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES - The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.03-24-2011
20110076691TWO STEP LATERAL FLOW ASSAY METHODS AND DEVICES - A two step lateral flow assay method for identifying IgE antibodies in a sample comprises applying a sample to a sample port of a device, wherein the device is adapted to deliver the sample to a lateral flow matrix having a plurality of IgE antigen species immobilized at respective positions at a first location; allowing the sample to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species to a second location downstream of the first location; and, after a predetermined period of time, applying liquid buffer to the lateral flow matrix to mobilize labeled reagent which is adapted to bind anti-IgE antibody and which is dried on the lateral flow matrix at a location upstream of the sample port delivery of the sample to the lateral flow matrix, and allowing labeled reagent mobilized by the liquid buffer to travel along the lateral flow matrix through the immobilized plurality of IgE antigen species and bind with any IgE antibody bound to the immobilized IgE antigen species, and to travel to a second location downstream of the first location where the mobilized labeled reagent causes a visible change to occur at the second location.03-31-2011
20110070593Conjugates of biological substances - Chemically reactive carbocyanine dyes that are intramolecularly crosslinked between the 1-position and 3′-position, their bioconjugates and their uses are described. 1,3′-crosslinked carbocyanines are superior to those of conjugates of spectrally similar 1,1′-crosslinked or non-crosslinked dyes. The invention includes derivative compounds having one or more benzo nitrogens.03-24-2011
20120202216NOVEL PHOTOACTIVABLE FLUORESCENT DYES FOR OPTICAL MICROSCOPY AND IMAGING TECHNIQUES - The present invention relates to novel photoactivable rhodamine or carbopyronine derivatives of the following general formulae G1-G4 (I), G1: A1=O, A2=N, A3=C; G2: A1=S, A2=N, A3=C; G3: A1=O, A2=O, A3=N; G4: A1=S, A2=O, A3=N; comprising UV light absorbing chromophores which after photolysis by irradiation at 254-490 nm (preferably at 375-420 nm) generate fluorescent rhodamine or carbopyronine derivatives and small non-toxic fragments such as N08-09-2012
20120149028DETECTION AND VISUALIZATION OF THE CELL CYCLE IN LIVING CELLS - The present invention relates to a nucleic acid molecule encoding a polypeptide specifically binding to proliferating cell nuclear antigen (PCNA), said nucleic acid molecule comprising a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence deviating from SEQ ID NO: 2 by conservative substitution of one or more amino acids in position 1 to 28, 38 to 52, 63 to 98 and 115 to 123 of SEQ ID NO: 2. The present invention also relates to a vector comprising the nucleic acid molecule of the invention, a host cell comprising the nucleic acid molecule of or the vector of the invention and a method of detecting the amount and/or location of PCNA in living cells, a method of screening for compounds having an effect on the cell cycle.06-14-2012
20120149029Magnetic Needle Biopsy - An apparatus and method for performing biopsies in-vivo using magnetically labeled nanoparticles is disclosed. One embodiment of the apparatus is called a magnetic needle. When used in a biopsy, one embodiment of the present invention collects diseased cells in-vivo which have been tagged with magnetic nanoparticles coated with receptors for specific diseased cells.06-14-2012
20110151479MICROFLUIDIC SYSTEMS INCORPORATING FLOW-THROUGH MEMBRANES - Disclosed is a flow-through membrane assay that takes advantage of a high surface area and rapid transport while allowing individual control over flow rates and times for each step of a multi-step assay. A microfluidic card features channels in communication with a porous membrane, channels on either side of membrane to allow transverse flow across the membrane, capturing a labeled target from the sample by flowing the sample across the membrane, or capturing a target from the sample followed by flowing a reagent containing a label that binds to the target. Fluid can be pushed or pulled through the assay membrane by external control. Air near the membrane is managed by diverting air between fluids to a channel upstream of the assay membrane, venting air between fluids through a hydrophobic membrane upstream of the assay membrane, and/or by venting trapped air through a hydrophobic membrane downstream of the assay membrane.06-23-2011
20110033868USE OF A NITRATED PROTEIN OR PEPTIDE SEQUENCE FOR THE IMPLEMENTATION OF A METHOD OF DIAGNOSIS - The present invention relates to the use of quantitative assay, in particular in vitro, in a biological sample, of the degree of nitration of tyrosine residues of a particular nitrated protein or physiological peptide sequence, for the implementation of a method of in vitro diagnosis of the state of severity and progressiveness of a chronic or acute pathology associated with nitrating stress.02-10-2011
20110033867Use of biomarkers for detecting ovarian cancer - The present invention relates to a method of qualifying ovarian cancer status in a subject comprising: (a) measuring at least one biomarker in a sample from the subject and (b) correlating the measurement with ovarian cancer status. The invention further relates to kits for qualifying ovarian cancer status in a subject.02-10-2011
20110033872METHOD AND APPARATUS FOR DETECTING UNDESIRED MEASUREMENT CONDITIONS - The invention relates to a method and apparatus for detecting undesired measurement conditions in a sample container. The method comprises measuring a fluorescent property of the sample container comprising a sample substrate with impregnated blood sample and incubation buffer to which the blood sample is to be eluted, and determining, based on temporal and/or spectral characteristics of the fluorescent property, whether the fluorescent property is characteristic to a sample container comprising a sample substrate and incubation buffer under said undesired measurement conditions or to a sample container suitable for optical measurement of analyte contained in the sample. Thus undesired measurement condition can be a floating sample substrate or a foreign body in the sample container. By means of the invention, reliability of neonatal screening, for example, can be increased.02-10-2011
20110033866Resonance Energy Transfer Assay with Cleavage Sequence and Spacer - A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.02-10-2011
20120034620COMPOSITIONS AND METHODS FOR ADHESION OF INTACT CELLS TO AN APPARATUS - Bio-adhesive compositions that include an extra-cellular matrix protein, bovine serum albumin conjugated with a fluorophore, and an aggregate are provided. The bio-adhesive composition may also include at least one component selected from the group consisting of collagen type IV, laminin, and chitosan. Also provided are methods of making the present compositions, that include taking a desired amount of extracellular matrix gel to liquid form of extracellular matrix; adding a desired amount of bovine serum albumin conjugated with a fluorophore; adding a desired amount of aggregate; and mixing. Further provided are methods for attaching cells to an apparatus using the present bio-adhesive compositions, and methods of attaching the present bio-adhesive compositions to an apparatus. Also provided are kits that include the present composition, components thereof or apparatuses, having the present composition attached thereto.02-09-2012
20100279309MICROFLUIDIC CHIPS AND SYSTEMS FOR ANALYZING PROTEIN EXPRESSION, AND METHODS OF USE THEREOF - Microfluidic chips, systems including at least one integrated microfluidic chip operably connected to hardware (e.g., docking device, high voltage electrodes, portable fluorescence microscope, computer, etc.), and methods for analyzing peptides (e.g., toxins), proteins (e.g., cancer biomarkers, recombinant human growth hormone, recombinant human erythropoietin), and protein expression in biological samples (e.g., human serum, urine, or tissue, marine organism, seafood, etc.) have been developed. On a single microfluidic chip as described herein, several sequential processes for analyzing a protein (e.g., cell culturing, cell lysis, protein enrichment, protein labeling, and protein detection) can be performed in an automated fashion. The microfluidic chips, systems, and methods described herein provide real-time, high-throughput, highly-specific detection of proteins such as recombinant erythropoietin, recombinant human growth hormone and marine biotoxins, as well as important biomarkers in the cancer signaling pathway network for early and precise cancer diagnosis.11-04-2010
20100311077Use of GPR100 Receptor in Diabetes and Obesity Regulation - We describe a method of identifying a molecule suitable for the treatment, prophylaxis or alleviation of a Gpr100 associated disease, in particular diabetes and obesity, the method comprising determining whether a candidate molecule is an agonist or antagonist of Gpr100 polypeptide, in which the Gpr100 polypeptide comprises the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 5, or a sequence which is at least 90% identical thereto.12-09-2010
20100304400DISTINGUISHING ASSAY - The current invention comprises a method for determining of an antibody against a drug antibody in a sample using an immunoassay comprising a capture drug antibody and a tracer drug antibody, wherein the method comprises providing i) a capture drug antibody, which is the drug antibody conjugated to a solid phase, ii) a tracer drug antibody, which is the drug antibody conjugated to a detectable label, contacting the capture drug antibody separately with i) the sample, ii) the sample, to which the drug antibody in monomeric form has been added, iii) the sample, to which the drug antibody in oligomeric form has been added, and determining an antibody against the drug antibody in the sample by a positive immunoassay in i) and a negative immunoassay in ii) and iii).12-02-2010
20100279310ASSAY DEVICE AND METHOD - An assay method is described, which comprises the steps of immobilizing a binding partner (e.g., an antigen or antibody) for an analyte to be detected (e.g., an antibody or antigen) on a portion of a surface of a microfluidic chamber; passing a fluid sample over the surface and allowing the analyte to bind to the binding partner; allowing a metal colloid, e.g., a gold-conjugated antibody, to associate with the bound analyte; flowing a metal solution, e.g., a silver solution, over the surface such as to form an opaque metallic layer; and detecting the presence of said metallic layer, e.g., by visual inspection or by measuring light transmission through the layer, conductivity or resistance of the layer, or metal concentration in the metal solution after flowing the metal solution over the surface.11-04-2010
20100279308RAPID LATERAL FLOW GLYCAN-DETECTING DEVICE - A glycan-detecting device containing a sample pad, a membrane in communication with the sample pad, a labeled lectin, an immobilized lectin of the same type, and an immobilized antibody specific to the lectin.11-04-2010
20100279306ANALYSIS OF PHOSPHORYLATED GLYCANS, GLYCOPEPTIDES OR GLYCOPROTEINS BY IMAC - The present disclosure provides technologies for enriching, detecting, and/or quantifying phosphorylated glycans and/or glycoconjugates (e.g., glycopeptides, glycolipids, proteoglycans, etc.). Specifically, the present disclosure provides methods that utilize immobilized metal affinity chromatography (IMAC) to isolate and/or to characterize phosphorylated glycans. The present disclosure particularly provides methods for distinguishing sulfated and phosphorylated glycans.11-04-2010
20090023157Proteome epitope tags and methods of use thereof in protein modification analysis - Disclosed are methods for reliably detecting the presence of proteins, especially proteins with various post-translational modifications (phosphorylation, glycosylation, methylation, acetylation, etc.) in a sample by the use of one or more capture agents that recognize and interact with recognition sequences uniquely characteristic of a set of proteins (Proteome Epitope Tags, or PETs) in the sample. Arrays comprising these capture agents or PETs are also provided.01-22-2009
20100255496METHODS OF ISOLATING CELLS AND GENERATING MONOCLONAL ANTIBODIES - The invention provides methods for isolating cells, particularly antibody-secreting cells that have a high likelihood of secreting antibodies specific for a desired antigen for the purpose of making monoclonal antibodies.10-07-2010
20080248491BIOMARKER FRAGMENTS FOR THE DETECTION OF HUMAN BNP - The present invention relates among other things to a composition comprising at least two (2) human BNP fragments, wherein each of the human BNP fragments of the composition are cross-linked to at least one of the other human BNP fragments of the composition.10-09-2008
20100062451Bead-ligand-nascent protein complexes - Bead-ligand-nascent protein complexes, and method of creating and detecting a bead-ligand-nascent protein complexes, are described. PCR-amplified product which is attached to a surface, e.g. of a bead, is used to generate nascent protein, which in turn is captured on the bead and detected, e.g. by fluorescence.03-11-2010
20100062454Method for predicting risk of acquiring influenza - An object of the present invention is to provide a method for predicting the risk of acquiring influenza, which is characterized by low price, low invasiveness, and applicability to total automation. The present invention provides a method for predicting the risk of acquiring influenza, which comprises measuring the ratio of anti-influenza IgA to the total IgA in a specimen collected from a subject.03-11-2010
20110151475LAB-ON-A-CHIP AND METHOD OF DRIVING THE SAME - Provided are a lab-on-a-chip and a method of driving the same. The lab-on-a-chip includes a first region where a lower substrate and an upper substrate are bonded to each other, a second region where the lower and upper substrates are not bonded to each other, a gap control member disposed at a terminal of the second region facing an interface between the first and second regions, and configured to control a gap between the lower and upper substrates at the terminal of the second region, and a pressure application member disposed at the terminal of the second region facing the interface between the first and second regions, and configured to apply pressure to the upper substrate at the terminal of the second region to reduce a gap between the lower and upper substrates in the center of the second region. Thus, binding events between a fluid sample to be analyzed and a reagent can be maximized so that a high signal can be obtained using only an infinitesimal quantity of sample.06-23-2011
20100055713CHEMILUMINESCENCE SENSOR ARRAY - Embodiments of the invention relate to integrated chemiluminescence devices and methods for monitoring molecular binding utilizing these devices and methods. These devices and methods can be used, for example, to identify antigen binding to antibodies. The devices include both a chemiluminescence material and a detector integrated together.03-04-2010
20100035275DIAGNOSIS AND RISK ASSESSMENT OF PANCREATIC DIABETES USING MR-PROADM - The invention relates to a method for diagnosis and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker mid-regional proAdrenomedullin (MR-proADM: SEQ ID No. 2) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method.02-11-2010
20110151478TRANSCRIPTIONAL BIOMARKERS AND METHODS FOR DETECTING AND ISOLATING CANCER CELLS IN BODY FLUIDS AND TISSUE SPECIMENS - The invention provides molecules that target cancer-specific transcription complexes (CSTC), compositions and kits comprising CSTC-targeting molecules, and methods of using CSTC-targeting molecules for the treatment, detection and monitoring of cancer.06-23-2011
20110151476METHOD OF DETECTION AND/OR TITRATION IN VITRO OF AN UNCONVENTIONAL TRANSMISSIBLE AGENT - The invention relates to an in vitro method for the in vitro detection and/or titration of a non-conventional transmissible agent (NCTA) or of a protein of pathological conformation, which is a marker for infectiousness related to the NCTA, in a sample, comprising: replication or propagation, in cells in culture, of the NCTA present in the sample, and then repeated incubation with a substrate which allows amplification of the NCTA or of the protein of pathological conformation, nonpathological conformer of the NCTA, before determination of the presence and/or of the amount of the NCTA or of the protein of pathological conformation in the sample.06-23-2011
20090317825ASSAY FOR PARKINSON'S DISEASE THERAPEUTICS AND ENZYMATICALLY ACTIVE PARKIN PREPARATIONS USEFUL THEREIN - The invention provides to assays for agent useful for treatment of Parkinson's Disease. Included are cell-based assays for agents that modulate the effect of Parkin proteins on proteasome function. The invention also provides recombinant, enzymatically active, Parkin protein produced in prokaryotic expression systems, such as 12-24-2009
20090286256ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES - The present disclosure relates to isolated human autoantibodies and assays and kits for detecting human autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample.11-19-2009
20120202217AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte08-09-2012
20090011428Fluid Membrane-Based Ligand Display System for Live Cell Assays and Disease Diagnosis Applications - A supported membrane based, strategy for the presentation of soluble signaling molecules to living cells is described. In this system, the fluidity of the supported membrane enables localized enrichment of ligand density in a configuration reflecting cognate receptor distribution on the cell surface. Display of a ligand in non-fluid supported membranes produces significantly less cell adhesion and spreading, thus demonstrating that this technique provides a means to control functional soluble ligand exposure in a surface array format. Furthermore, this technique can be applied to tether natively membrane-bound signaling molecules such as ephrin A1 to a supported lipid bilayer. Such a surface can modulate the spreading behavior of metastatic human breast cancer cells displaying ligands and biomolecules of choice. The SLB microenvironment provides a versatile platform that can be tailored to controllably and functionally present a multitude of cell signaling events in a parallel surface array format.01-08-2009
20090111122METHOD FOR NON-INVASIVE EXAMINATION OF NON-ALCOHOLIC STEATOHEPATITIS BY QUANTIFICATION OF CYTOCHROME-c, AND TEST KIT - It is found that blood cytochrome c levels quantified for non-alcoholic steatohepatitis patients are higher than those for healthy persons, and that the quantified blood cytochrome c values correlated with fat deposition rates in hepatocytes. It is possible to test non-alcoholic steatohepatitis by quantifying cytochrome c in serum. A test method and a test kit for the test are provided.04-30-2009
20110256551SYSTEMS AND DEVICES FOR ANALYSIS FOR SAMPLES - Systems and methods for analysis of samples, and in certain embodiments, microfluidic sample analyzers configured to receive a cassette containing a sample therein to perform an analysis of the sample are described. The microfluidic sample analyzers may be used to control fluid flow, mixing, and sample analysis in a variety of microfluidic systems such as microfluidic point-of-care diagnostic platforms. Advantageously, the microfluidic sample analyzers may be, in some embodiments, inexpensive, reduced in size compared to conventional bench top systems, and simple to use. Cassettes that can operate with the sample analyzers are also described.10-20-2011
20110256550Novel reagents for directed biomarker signal amplification - Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.10-20-2011
20110256549Novel reagents for directed biomarker signal amplification - Described herein are methods, compositions and articles of manufacture involving neutral conjugated polymers including methods for synthesis of neutral conjugated water-soluble polymers with linkers along the polymer main chain structure and terminal end capping units. Such polymers may serve in the fabrication of novel optoelectronic devices and in the development of highly efficient biosensors. The invention further relates to the application of these polymers in assay methods.10-20-2011
20100311074SWITCH-REGION: TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - The invention provides a target and methods for specific binding and inhibition of RNA polymerase from bacterial species. The invention provides methods for identifying agents that bind to a bacterial RNA polymerase, and that inhibit an activity of a bacterial RNA polymerase, through interactions with a bacterial RNA polymerase homologous switch-region amino-acid sequence. Said methods comprise preparing a reaction solution comprising the compound to be tested and an entity containing a bacterial RNAP homologous switch-region amino-acid sequence, and detecting binding or inhibition. The invention has applications in control of bacterial gene expression, control of bacterial viability, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.12-09-2010
20100323368Cytokine production-inducing antibody - The invention relates to a method of measuring the activation of an effector cell belonging to the immune system, which may or may not be transformed, using a monoclonal (AcMo) or polyclonal antibody. The invention is characterised in that it consists in: bringing into contact (i) CD16 receptor-expressing cells in a reaction medium in the presence of the antibody and (ii) the antigen of said antibody, and measuring the quantity of at least one cytokine produced by the CD16 receptor-expressing cell. The invention also relates to the selection of an antibody capable of inducing the expression of cytokines and interleukins, such as IFN? or IL2 which are intended for the treatment of autoimmune and inflammatory diseases, cancers and infections by pathogens.12-23-2010
20080213793ANTIBODIES THAT BIND RECEPTOR PROTEIN DESIGNATED 2F1 - 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.09-04-2008
20120064541N-GLYCAN CORE BETA-GALACTOSYLTRANSFERASE AND USES THEREOF - The present invention relates to new galactosyltransferases, nucleic acids encoding them, as well as recombinant vectors, host cells, antibodies, uses and methods relating thereto.03-15-2012
20120064539RESISTANCE TO AUXINIC HERBICIDES - The invention provides methods of identifying herbicidal auxins. The invention further provides auxin-herbicide-resistant plants and genes conferring auxin-herbicide resistance. This invention also provides a method of identifying other proteins that bind picolinate auxins from additional plant species. The invention further provides a method to identify the molecular binding site for picolinate auxins. The invention also includes the use of the picolinate herbicidal auxin target site proteins, and methods of discovering new compounds with herbicidal or plant growth regulatory activity. The invention also includes methods for producing plants that are resistant to picolinate herbicidal auxins. Specific examples of novel proteins associated with herbicide binding include AFB5, AFB4, and SGT1b.03-15-2012
20080254479Methods and Kits For Predicting Risk For Preterm Labor - The invention is directed to kits and methods that allow one to predict the risk for preterm labor in a pregnant woman. The inventors have discovered that various extracellular matrix components can be detected in cervical secretions. The quantification of certain extracellular matrix proteins found within cervical secretions can be used as a diagnostic for the biomechanical state of the cervix, which indicates whether preterm labor is likely. Some extracellular matrix components that can be found in cervical secretions include hyaluronic acid, thrombospondins and matrix metalloproteinases.10-16-2008
20080254484Preparation of Deallergenized Proteins and Permuteins - Modified proteins are disclosed that maintain enzymatic and insecticidal activity while displaying reduced or eliminated allergenicity. Epitopes which bind to anti-patatin antibodies were identified, and removed via site directed mutagenesis. Tyrosines were observed to generally contribute to the allergenic properties of patatin proteins. Removal of glycosylation sites was observed to reduce or eliminate antibody binding.10-16-2008
20080254480MICROCYTOXICITY ASSAY BY PRE-LABELING TARGET CELLS - The standard or original microcytotoxicity assay (OMCA) has significant advantages over other cytotoxicity assays, since it is able to detect both cell necrosis and apoptosis and it is simpler, safer, more practical, and more economical. OMCA has serious weaknesses, however, such as low accuracy, low selectivity, and low sensitivity. These drawbacks are ameliorated or eliminated by pre-labeling of target cell nuclei, for instance, with 5-bromo2′-deoxyuridine. This improved microcytotoxicity assay (IMCA) is readily adapted to a wide range of applications, such as screening of cytotoxicity drug candidates, selecting an anticancer cytotoxic therapy, detecting abnormalities including reduced tumor cell killing ability of NK cells in cancer patients, predicting outcome of cytokine therapy and immunotherapy, determining effectiveness of cytokine therapy and immunotherapy in follow up studies following treatment, determining effectiveness of anticancer cytotoxic therapy during and following therapy and ascertaining cytotoxic T cell activity during anticancer vaccination therapy.10-16-2008
20120276550MICROFLUIDICS APPARATUS AND METHODS - This invention relates to microfluidics apparatus and methods for particle concentration in sensors for sensing biological entities such as cells, spores and the like. We describe a microfluidic sensor for sensing biological particles including a particle concentration device for performing concentration of particles in three dimensions. The sensor device comprises a substrate bearing a microfluidic channel or chamber for carrying a conductive fluid bearing the particles. The channel has: first and second electrodes spaced apart on the channel or chamber for defining an electric field therebetween, and a sensing surface on an inner surface of the channel or chamber. The particle concentration device comprises means for applying an ac voltage across the electrodes to perform simultaneously: i) electrohydrodynamic generation of a convection current flow in the fluid; and ii) 3D concentration of the particles in said fluid by dielectrophoretic attraction or repulsion of the particles towards or away from a region of increased electric field, to increase a concentration of the particles at sensing surface of said sensor.11-01-2012
20120276549Photonic biosensors incorporated into tubing, methods of manufacture and instruments for analyziing the biosensors - Tubing such as clear plastic disposable tubing or glass tubing includes a photonic sensor formed in or placed within the tubing. The photonic sensors can take the form of photonic crystal sensors, distributed feedback laser sensors, and surface enhanced Raman spectroscopy (SERS) sensors, including photonic crystal enhanced SERS sensors. Detection arrangements for the sensors are described. The invention has many applications including tubing used in hospital care (e.g., urinary catheters, intravenous fluid delivery tubing, tubing used in dialysis, e.g. heparin lines or blood tubing sets), food manufacturing, pharmaceutical manufacturing, water quality monitoring, and environmental monitoring.11-01-2012
20110014626METHODS FOR MEASURING THE INSULIN RECEPTOR ALPHA SUBUNIT - Presence of free insulin receptor α-subunit in blood was discovered. Furthermore, methods for measuring the insulin receptor α-subunit was provided, the method comprising the steps of contacting the insulin receptor α-subunit in a blood sample with an antibody recognizing the insulin receptor α-subunit, and detecting the binding between the two. Measurement of the free insulin receptor α-subunit in the blood is useful for evaluating risk factors for diabetes.01-20-2011
20110020836PROCESS FOR DIFFERENTIAL POLYPEPTIDES DETECTION AND USES THEREOF - Provided herein is an affinity media and the construction and use thereof. The affinity media may be used, for example, for the detection of differential proteins/peptides by depletion of proteins/peptides similar to those in a control sample from a test sample in the search for biologically and pathologically important proteins/peptides. The detected differential proteins/peptides provide vital information for biomarker discovery, drug target discovery, and personalized medicine and treatment.01-27-2011
20110020834HIGH SENSITIVITY MECHANICAL RESONANT SENSOR - A system and method for detecting mass based on a frequency differential of a resonating micromachined structure, such as a cantilever beam. A high aspect ratio cantilever beam is coated with an immobilized binding partner that couples to a predetermined cell or molecule. A first resonant frequency is determined for the cantilever having the immobilized binding partner. Upon exposure of the cantilever to a solution that binds with the binding partner, the mass of the cantilever beam increases. A second resonant frequency is determined and the differential resonant frequency provides the basis for detecting the target cell or molecule. The cantilever may be driven externally or by ambient noise. The frequency response of the beam can be determined optically using reflected light and two photodetectors or by interference using a single photodetector.01-27-2011
20110053177MASS SPECTROMETRIC METHODS AND PRODUCTS - The invention involves assays, diagnostics, kits, and assay components for mass spectrometry and other methods to determine levels of glycated CD59 in subjects.03-03-2011
20110053176PARTICLE SUSPENSION AND REAGENT KIT FOR USE IN IMMUNOASSAY - A particle suspension for use in immunoassay, comprising: particles for use in immunoassay; and a silicone antifoam agent, is disclosed. And a reagent kit for use in immunoassay, comprising: a reagent containing particles and a silicone antifoam agent; another reagent containing an antigen or antibody capable of binding to a target substance and particles; and a further reagent containing a labeled antigen or antibody capable of binding to the target substance, is disclosed.03-03-2011
20110053175Asymmetrically branched polymer conjugates and microarray assays - A composition comprising a conjugate of a randomly and asymmetrically branched dendritic polymer.03-03-2011
20110053174Magnetic-nanoparticle conjugates and methods of use - The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms.03-03-2011
20110053173Game with detection capability - Methods and systems are described herein relating to game systems. In one aspect, a game system includes: at least one game component configured for use in a game system by an individual player; at least one sensor system operably connected to the at least one game component and configured to detect one or more analyte, the at least one sensor system including a signal transmitter; at least one signal detector configured to detect a signal transmitted from the at least one sensor system; and at least one principal game unit operably connected to the at least one signal detector, the at least one principal game unit including at least one signal transmitter configured to transmit a signal responsive to the at least one signal detector.03-03-2011
20110053172ONE STEP NANOSENSOR FOR SINGLE AND MULTIDRUG RESISTANCE IN ACUTE CORONARY SYNDROME (ACS) - An embodiment relates to a method of detecting a drug resistance in a patient comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Another embodiment relates to a method of monitoring a thrombotic risk factor in a subject in a general population comprising adding nanoparticles to sample platelets to form activated platelets containing the nanoparticles and comparing a difference in activation of the activated platelets and the sample platelets. Yet another embodiment relates to a kit comprising nanoparticles, a fluorescence dye tagged antibody and optionally a buffer, wherein the kit is configured to detect a drug resistance in a patient or a likelihood of the thrombotic risk factor in a subject in general population.03-03-2011
20110053171METHOD AND APPARATUS FOR ANTIGEN RETRIEVAL PROCESS - The invention provides a method for antigen retrieval of a formaldehyde-fixed tissue sample comprising incubating a formaldehyde-fixed tissue sample in a first antigen retrieval solution at a temperature of greater than 90° C., transferring the tissue sample to a second antigen retrieval solution, and incubating the tissue sample in the second antigen retrieval solution at a temperature of greater than 90° C. The invention also provides a kit and sample delivery device for carrying out the method.03-03-2011
20100285499HUMAN p51 GENES AND GENE PRODUCTS THEREOF - Novel human genes falling within the category of family genes relating to p53 gene which is known as a cell proliferation regulatory gene, and gene products thereof. A human p51 gene characterized by containing a base sequence encoding an amino acid sequence represented by SEQ ID NO:1; a human p51 gene having a base sequence consisting of the 145- to 1488-bases in the sequence represented by SEQ ID NO:2; vectors containing these genes; host cells transformed with these vectors; a process for producing a p51 protein having the amino sequence represented by SEQ ID NO:1; which comprises culturing the above host cells and harvesting the protein from the thus obtained culture; and the p51 protein having the amino acid sequence represented by SEQ ID NO:1.11-11-2010
20100285493METHOD FOR DETERMINING AMINO-TERMINAL PROANP IN PATIENTS HAVING A CARDIAC DISEASE OR BEING SUSPECTED OF DEVELOPING OR HAVING A CARDIAC DISEASE - The present invention relates to an in vitro method for medical diagnosis, prognosis and therapy follow-up for patients having a cardiac disease or being suspected of developing or having a cardiac disease comprising the steps of: providing a sample of a patient having a cardiac disease or being suspected of developing or having a cardiac disease, determining amino-terminal proANP or partial peptides thereof having from 12 to 98 amino acids in said sample using at least one antibody that binds specifically to a partial sequence of amino-terminal proANP, attributing the determined amino-terminal proANP level or the level of partial peptides thereof to a clinical picture wherein the attribution is carried out independent of the BMI of the patient. The present invention further concerns a rapid test assay and a kit for conducting the method of the present invention and the use of antibodies suitable for the method and assays according to the present invention.11-11-2010
20100285496Methods and Devices for the Detection of Biofilm - The present invention provides methods and kits for biofilm detection.11-11-2010
20100285500NEUROFURANS-INDICES OF OXIDANT STRESS - The invention is drawn to a new class of isoeicosanoids that have been identified as products of the oxidation of docosahexaenoic acid (DHA). The invention provides compositions and methods related to the new class of molecules.11-11-2010
20100285494COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.11-11-2010
20100285492USE OF SLIM-1 IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro comprising the steps of measuring in a sample the concentration of the marker SLIM-1, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for SLIM-1 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of SLIM-1 as a marker protein in the assessment of heart failure, a marker combination comprising SLIM-1 and a kit for measuring SLIM-1.11-11-2010
20110136131Method for measuring enzyme activity and column for use in measuring enzyme activity - A method of measuring an enzyme activity, which comprises the steps of: 06-09-2011
20110136136Methods For Detection Of Hydrophobic Drugs - Methods and reagents are disclosed for pretreating a sample suspected of containing a hydrophobic drug for conducting an assay method for detecting the hydrophobic drug. A combination is provided in a medium. The combination comprises (i) the sample, (ii) a releasing agent for releasing the hydrophobic drug and the metabolites from endogenous binding moieties, and (iii) a selective solubility agent that provides for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The selective solubility agent comprises a water miscible, non-volatile organic solvent and is present in the medium in a concentration sufficient to provide for substantially equal solubility of the hydrophobic drug and the metabolites in the medium. The medium, which may further comprise a hemolytic agent, is incubated under conditions for releasing the hydrophobic drug and the metabolites from endogenous binding moieties. For conducting an assay for the hydrophobic drug, the above pretreatment is performed and to the medium is added reagents for determining the presence and/or amount of the hydrophobic drug in the sample wherein the reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug, the presence and/or amount of the complex indicating the presence and/or amount of the hydrophobic drug in the sample.06-09-2011
20110136132IMMUNODETECTION PROBE AND METHOD OF IMMUNODETECTION USING THE SAME - An immunodetection probe comprises a needle structure having a compartment and configured to be inserted into an organic tissue, a dialysis membrane configured to isolate the compartment from the organic tissue, a detection device having a detection portion and a plurality of receptors, a first optical fiber coupled to the needle structure, and a pair of tubes connected to the compartment. The plurality of receptors are disposed on an end surface of the detection portion for conjugating a target antibody, wherein the detection portion is disposed in the compartment. The first optical fiber is configured to introduce light incident on photo-induced molecules adjacent to the end surface of the detection portion so as to cause a change in the pH level of the solution adjacent to the end surface of the detection portion. The pair of tubes is configured to transport the solution containing the photo-induced molecules into the compartment.06-09-2011
20120064540RESISTANCE TO AUXINIC HERBICIDES - The invention provides methods of identifying herbicidal auxins. The invention further provides auxin-herbicide-resistant plants and genes conferring auxin-herbicide resistance. This invention also provides a method of identifying other proteins that bind picolinate auxins from additional plant species. The invention further provides a method to identify the molecular binding site for picolinate auxins. The invention also includes the use of the picolinate herbicidal auxin target site proteins, and methods of discovering new compounds with herbicidal or plant growth regulatory activity. The invention also includes methods for producing plants that are resistant to picolinate herbicidal auxins. Specific examples of novel proteins associated with herbicide binding include AFB5, AFB4, and SGT1b.03-15-2012
20120064538IMMUNOCHROMATOGRAPHY DETECTION OF MULTIDRUG-RESISTANT STAPHYLOCOCCUS AND DIAGNOSTIC KIT - This invention provides a immunochromatography detection device that can detect PBP2′ produced specifically by a bacterium of multidrug-resistant 03-15-2012
20110081656Secreted proteins and uses thereof - The invention provides isolated nucleic acid molecules, designated TANGO 228 nucleic acid molecules, which encode secreted proteins with homology to the rat MCA-32 protein, isolated nucleic acid molecules, designated TANGO 240 nucleic acid molecules, which encode secreted proteins with homology to the 04-07-2011
20100196919PEPTIDES, ANTIBODIES AND FRAGMENTS THEREOF FOR THE TREATMENT AND DIAGNOSTIC OF CELIAC DISEASE - The present invention discloses a peptide having an amino acid sequence comprising an epitope recognized by Igs of patients with active celiac disease and not recognized by Igs of patients on gluten-free diet, antibodies directed against this peptide and methods for diagnosing the celiac disease in a subject, or to check the effect of a therapy or of a diet treatment in a celiac disease affected subject, or to assess the risk of developing celiac disease in a subject vaccinated with a Rotavirus VP7 protein.08-05-2010
20100330586METHOD FOR IDENTIFYING COMPOUNDS FOR TREATMENT OF PAIN - Methods and products for the attenuation or treatment of pain and the reduction of nociception are described. The methods and products are based on the modulation of CNS intracellular chloride levels. The methods and products may also relate to modulation of the activity and/or expression of a chloride transporter, such as the KCC2 potassium-chloride cotransporter. Also described herein are commercial packages and uses based on such modulation. Related methods for identifying or characterizing a compound for the treatment of pain, the reduction of nociception and the diagnosis and prognostication of pain are also described.12-30-2010
20100330587Annexin Proteins and Autoantibodies As Serum Markers For Cancer - The present invention relates to screening methods for diagnosis, prognosis, or susceptibility to cancer in a subject by means of detecting the presence of serum autoantibodies to specific annexin protein antigens in sera from subjects. The present invention also provides screening methods for diagnosis and prognosis of cancer in a subject by means of detecting increased expression levels of annexin proteins in biological samples of the subject. The method of the invention can also be used to identify subjects at risk for developing cancer. The method of the invention involves the use of subject derived biological samples to determine the occurrence and level of expression of annexin proteins or expression of annexin derived peptides or antigens, and/or the occurrence and level of circulating autoantibodies to specific annexin protein antigens. The present invention further provides for kits for carrying out the above described screening methods. Such kits can be used to screen subjects for increased levels of annexin proteins, or for the detection of autoantibodies to annexin proteins, as a diagnostic, predictive or prognostic indicator of cancer.12-30-2010
20100330582METHOD FOR PRODUCTION OF NOVEL NANO SILICA PARTICLE AND USE OF THE NANO SILICA PARTICLE - The present invention presents a silica particle containing at least one silica compound selected from a group consisting of mercapto-propyl-trimethoxysilane (MPS), mercapto-propyl-triethoxysilane (MPES), mercapto-propyl-methyldimethoxysilane (MPDMS), trimethoxy[2-(7-oxabicyclo[4.1.0]-hepto-3-yl)ethyl]silane(EpoPS), thiocyanatopropyltriethoxysilane (TCPS), and acryloxypropyltrimethoxysilane (AcPS), which can be provided and utilized as a label, a marker, or the like for qualitative test and quantitative test for such as prophylactic agent, therapeutic agent, diagnostic agent, diagnostic and therapeutic agent or the like in dental, medical and veterinary fields regardless of fields.12-30-2010
20110177522Methods for Producing Olfactory GPCRs - The subject invention provides a method for producing an olfactory GPCR in a cell. In general, the methods involve introducing an expression cassette containing a promoter operably linked to a nucleic acid encoding an olfactory PCR into a macroglial cell, e.g., a Schwann or oligodendritic cell, and maintaining the cell under conditions suitable for production of the olfactory GPCR. Also provided is a macroglial cell containing a recombinant nucleic acid encoding an olfactory GPCR, methods of screening for modulators of olfactory GPCR activity, and a kit for producing an olfactory GPCR in a macroglial cell. The invention finds most use in research on flavors and fragrances, and, consequently, has a variety of research and industrial applications.07-21-2011
20100159474PROGNOSIS AND RISK ASSESSMENT IN PATIENTS SUFFERING FROM HEART FAILURE BY DETERMINING THE LEVEL OF ADM AND BNP - The present invention relates to a method for prognosis of an outcome or assessing the risk of a patient suffering from heart failure and/or shortness of breath, comprising the determination of the levels of ADM or fragments thereof or its precursor or fragments thereof and BNP or fragments thereof or its precursor or fragments thereof in said sample of said patient.06-24-2010
20100159475Methods For Determination of Calcineurin Activity and Uses in Predicting Therapeutic Outcomes - The methods of the disclosure provide fluorescence-based assays for calcineurin activity, especially in isolated T cells. The methods include the stimulation of the T cells with agents that specifically target the TCR with or without influencing co-stimulatory pathways. One TCR agonist is monoclonal antibodies specific for CD3, which more precisely distinguish the inducible activity of calcineurin than does an alternative method targeting the T cell receptor (CD3) combined with CD28 costimulation. This method more accurately distinguishes between the measured level of calcineurin activity of T cells from immunosuppressed transplant recipients and normal individuals, and thus has improved diagnostic accuracy with respect to the response of an individual to immunosuppressant therapy following an organ transplant.06-24-2010
20100159471PROCESS FOR PRODUCTION OF COLLOIDAL GOLD AND COLLOIDAL GOLD - It is an object of the present invention to provide a method for producing gold colloid having a targeted particle size, a sharp particle size distribution and a uniform and perfect spherical shape. The present invention relates to a method for producing gold colloid including a nucleation step of forming nuclear colloidal particles by adding a first reducing agent to a first gold salt solution; and a growth step of growing nuclear colloid by adding a second gold salt and a second reducing agent to the solution of the nuclear colloidal particles, characterized in that the growth step is performed at least once; a citrate is used as the first reducing agent and an ascorbate is used as the second reducing agent; and the addition of the ascorbate in the growth step is performed simultaneously with addition of the second gold salt. According to the method for producing gold colloid of the present invention, gold colloid having a sharp particle size distribution and a uniform and perfect spherical shape can be obtained.06-24-2010
20100196924Method for Diagnosing Tumors - The present invention describes a method for diagnosing tumors of the reproductive organs which is characterised by determination of the afamin content in a sample of a body fluid or in a tissue sample, wherein a tumour is diagnosed if the afamin content in the sample is decreased compared to the afamin content in a sample from a person without a tumour of the reproductive organs.08-05-2010
20100196923PLURIPOTENT ADULT STEM CELLS - Disclosed herein are pluripotent adult stem cells and methods of use thereof. The cells are found in, or collected from, an adult tissue or fluid. In some embodiments, the cells are c-kit positive and SSEA-4 positive, and can he differentiated into multiple tissue types, e.g., adipogenic, osteogenic, myogenic, endothelial, neurogenic and hepatic tissues.08-05-2010
20100196922FLUORESCENT METAL ION INDICATORS WITH LARGE STOKES SHIFTS - The present invention provides fluorogenic compounds for the detection of target metal ions wherein the compounds exhibit a Stokes shift greater than 50 nm and the detectable signal is modulated by photoinduced electron transfer (PET). The present compounds consist of three functional elements, the ion sensing moiety (chelating moiety), the reporter moiety (fluorophore or fluorescent protein) and spacer or linker between the sensing and reporter moieties of the present compound that allows for PET upon binding of a metal ion and excitation by an appropriate wavelength.08-05-2010
20100196918ANALYTE SENSORS, METHODS FOR PREPARING AND USING SUCH SENSORS, AND METHODS OF DETECTING ANALYTE ACTIVITY - Embodiments of the present disclosure provide for analyte sensors, methods for producing and using the analyte sensors, methods of detecting and/or measuring analyte activity, methods for characterizing analyte cellular activity, methods of detecting pH change in a system, method of controlling the concentration of an analyte in a system, fusion proteins, polynucleotides, and vectors corresponding to the analyte sensors, kits, and the like.08-05-2010
20100196921Method for Predicting the Outcome of a Critically Ill Patient - The present invention relates to a method for predicting the outcome of a critically ill patient, said method comprising measuring the concentration of Chromogranin A or a fragment thereof in a biological sample obtained from said patient.08-05-2010
20110183351Compositions and methods for therapeutic delivery with microorganisms - Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, devices, and systems that include modified microorganisms including at least one genetic element encoding at least one therapeutic agent or environmental treatment agent.07-28-2011
20090203038Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays - The present disclosure relates to isolated antibodies that do not bind to brain natriuretic peptide that can be used as a reagent to reduce heterophilic interference in an immunoassay.08-13-2009
20090203037Anti-T. Cruzi Antibodies and Methods of Use - The present disclosure is directed to reagents and methods of using the reagents to detect epitopes of 08-13-2009
20090203039MONOCLONAL ANTIBODY TO SOLUBLE LOX-1 - It is intended to provide a monoclonal antibody that specifically recognizes human soluble LOX-1, particularly a monoclonal antibody with a dissociation constant (Kd) for human soluble LOX-1 of 1×1008-13-2009
20090203035FLUORESCENT PROTEINS WITH INCREASED PHOTOSTABILITY - The present invention relates to novel fluorescent protein variants of DsRed and eqFP578. Fluorescent protein variants having increased photostability and/or having reversible photoswitching behavior, as well as polynucleotides encoding such variants are provided herein. Methods of using these novel fluorescent protein variants and methods for constructing other fluorescent protein variants having increased photostability are also provided by the present invention.08-13-2009
20090197281METHODS FOR DIAGNOSIS AND TREATMENT OF CHRONIC IMMUNE DISEASES - Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of native Stat-1 protein and/or any lower molecular weight fragments of Stat-1 protein present. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g., to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. In certain embodiments, the assay results are also used to predict the effectiveness of a particularly treatment protocol, e.g., to determine whether an interferon based treatment protocol will be effective. In addition, methods of Stat-1 based methods of treating chronic immune disease conditions are provided. Also provided by the subject invention are kits for practicing the methods.08-06-2009
20090176248Method For Evaluating Kidney Function In A Feline - Methods for (1) evaluating feline kidney function by determining ghrelin level in feline tissue or biofluid and correlating the ghrelin level directly to kidney function and (2) diagnosing kidney disease in a feline comprises determining an observed ghrelin level in a tissue or biofluid of the feline and comparing the observed ghrelin level to a reference ghrelin level indicative of normal kidney function, wherein an observed level lower than the reference level is indicative of kidney disease or susceptibility thereto.07-09-2009
20090176245Rheumatoid Arthritis Test Method and Treating Method - It is intended to evaluate the prognosis of rheumatoid arthritis based on the evaluation of the disease severity of the patient to select a treatment method suitable for each rheumatoid arthritis patients, and to measure HSC71 protein levels of the patients before and after the administrations of therapeutic agents to determine the efficacy of various therapeutic agents for each of rheumatoid arthritis patients, and to use thereof as a remedy for preventing onset and progression of rheumatoid arthritis. It has been revealed that whether HSC71 (heat shock cognate protein 71), which is a member of the heat shock protein 70 family, shows any difference in expression between rheumatoid arthritis patients and healthy subjects. In the case where the HSC71 protein is accelerated in a rheumatoid arthritis patient the HSC71 concentrations in the serum, synovial fluid, serebrospinal fluid, urine, saliva and sputum of the patient are measured to thereby examine the disease severity of rheumatoid arthritis. Based thereon, the prognosis of the rheumatoid arthritis is evaluated and a method suitable for the patient is selected. HSC71 protein levels are measured before and after the administration of therapeutic agents to a rheumatoid arthritis patient and the efficacy of the therapeutic agents are determined. Further, Use as a remedy or preventing the onset and progression of rheumatoid arthritis is intended.07-09-2009
20090176247Determination of sFlt-1:Angiogenic Factor Complex - Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-07-09-2009
20090176249Method for detecting cardiac collateral formation - The present invention relates to a method of detecting collateral artery formation by measuring the level of NT-pro-BNP or BNP in an individual.07-09-2009
20090176243Novel monkey GPR103 and monkey QRFP and method of evaluating compound by using GPR103 - There are provided non-human primate and rat GPR103 genes and proteins and a compound evaluation method employing the genes or proteins. There are also provided highly useful novel ligands for functional analysis of the GPR103 genes and proteins and for the compound evaluation. The nucleic acids or proteins having the sequences listed as SEQ ID NOS: 1 to 4 provide non-human primate or rat GPR103 genes and proteins and information based on the genes and proteins. The genes and proteins can be used for evaluation of compounds. The nucleic acids or proteins having the sequence listed as SEQ ID NO: 5 or 6 provide a GPR103 ligand.07-09-2009
20100190185NOVEL NON-INVASIVE MARKER FOR LIVER FUNCTION AND DISEASE - A monoclonal antibody or fragment thereof, capable of specifically binding to at least one epitope of sH2a and/or being elicited by at least one epitope, and assays, kits, and methods of use thereof diagnosing liver disease or condition, detecting liver function and assessing the efficacy of therapy to a liver disease.07-29-2010
20100190184SCREENING METHOD UTILIZING NOVEL SUBSTRATE C-RET FOR GAMMA-SECRETASE - The present invention provides a method of screening for compounds which affect the processing of c-Ret by γ-secretase. The method involves contacting a first biological composition containing γ-secretase or a biologically active fragment thereof with a second biological composition containing c-Ret in the presence and absence of a candidate compound; measuring the cleavage of the c-Ret in the presence and absence of the candidate compound; selecting those candidate compounds which affect the cleavage of the c-Ret by γ-secretase; and identifying the candidate compounds selected in the previous step as compounds which affect the processing of c-Ret by γ-secretase.07-29-2010
20100190180Materials and Methods for Screening, Diagnosis and Prognosis of Conditions Associated With Stat Protein Expression - The subject invention concerns methods and materials for cancer screening using platinum complexes to detect a STAT protein biomarker. Platinum (IV) complexes interacting with STATs directly correlate with the STAT expression. In one embodiment, fluorescently-labeled and/or antibody-linked platinum (IV) complexes can be used to assess the STAT expression and define malignant potential. Other methods such as imaging (MRI, e.g.) can also be used to assess platinum-STAT interactions. The STAT protein can be, for example, STAT3.07-29-2010
20100190183PROTEIN LABELLING WITH TAGS COMPRISING ISOTOPE-CODED SUB-TAGS AND ISOBARIC SUB-TAGS - Subject of the present invention are new isotopic and isobaric tagged molecules, kits comprising them and methods of using them in mass spectrometry.07-29-2010
20110189694METHODS FOR DETECTION AND DIAGNOSIS OF A BONE OR CARTILAGE DISORDER - The present invention is directed to methods for the detection and diagnosis of bone and/or cartilage disorders, wherein the level of expression of a polypeptide in a test sample is measured by contacting the test sample with an antibody that specifically binds to said polypeptide and measuring the binding of said antibody to said test sample.08-04-2011
20110189692ASSAY FOR PATHOGENIC CONFORMERS - The invention provides methods for detecting the presence of a non-prion pathogenic conformer in a sample by contacting the sample suspected of containing a non-prion pathogenic conformer with a pathogenic conformer-specific binding reagent under conditions that allow the binding of the reagent to the pathogenic conformer, if present; and detecting the presence the pathogenic conformer, if any, in the sample by its binding to the reagent; where the pathogenic conformer-specific binding reagent is typically derived from a prion protein fragment and interacts preferentially with a pathogenic prion protein. Methods for diagnosis of conformational diseases are also provided.08-04-2011
20110143363DETERMINATION OF FREE FRACTIONS - The invention relates to methods for the determination of pharmacological properties of substances, such as, e.g., chemical substances. The invention also relates to methods and kits for use in the determination of the free fraction, fu, of pharmacologically active compounds in aqueous solutions and serum. The invention also relates to the above methods in which solid particles, coated with a lipophilic medium, are used.06-16-2011
20110136134Method for Assessing the Damage of Keratin Fibers - Method for assessing damages of keratin fibers using a cationic fluorescent compound comprising a cationic ammonium group and being free of carboxyl and/or sulfonyl groups and method for comparing the damages of different keratin fibers using said cationic fluorescent compound. Said methods are useful for quantitatively and/or qualitatively assessing the degree of damages of keratin fibers and also to compare the damages of fibers of different origin, different portions of fibers and/or fibers treated with different cosmetic, chemical and/or mechanical treatments. Said methods are also useful for supporting advertising claims about the superiority of a composition and/or a treatment versus others.06-09-2011
20110262934METHOD FOR EARLY DIAGNOSIS OF ALZHEIMER'S DISEASE USING PHOTOTRANSISTOR - Disclosed is a method for the early diagnosis of Alzheimer's disease. In the method, cells in which a biomarker characteristic of Alzheimer's disease, preferably beta-amyloid, is labeled with magnetic beads are selectively located in the channel region of a phototransistor, and a difference in photocurrent between normal cells and the cells comprising the protein biomarker labeled with magnetic beads is sensed to diagnose Alzheimer's disease at an early stage.10-27-2011
20110262935METHOD FOR DETECTING A PRION INFECTION - The invention relates to an in vitro method for detecting and/or titrating an unconventional transmissible agent (UTA) or a protein of pathological conformation which is a marker for the infectivity of the UTA, in a sample, comprising a step of concentrating the sample before and after digestion with a protease.10-27-2011
20110262933COMPOSITIONS AND METHOD FOR ISOLATING MID-LOG PHASE BACTERIA - The invention generally relates to compositions and methods for isolating mid-log phase bacteria. In certain embodiments, the invention provides a magnetic particle conjugated to an antibody that includes an epitope specific for mid-log phase bacteria.10-27-2011
20110183355POLYMER PARTICLE CONTAINING FLUORESCENT MOLECULE AND METHOD FOR PRODUCING THE SAME - Polymer particles are provided which contain fluorescent molecules with high presence ratio in a polymer layer thereof and a method for preparing thereof. Polymer particles are swelled in a non-aqueous solution excluding exclusively water preferably promotes selling of the polymer layer and transfer of the fluorescent molecules to the polymer layer could not protected by water molecules such that much more fluorescent molecule may be introduced into inside of the polymer layer. Furthermore, since the water is added to the reaction system prior to evaporation removal of the non-aqueous solvent, dry-up of the polymer particles is prevented by the water remained in the reaction system and the polymer particles including fluorescent molecules with high presence ratio of the fluorescent molecules preferably keep high dispersibility using the above described procedures.07-28-2011
20100028906REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION - The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.02-04-2010
20100028905CHARACTERIZATION OF GRP94-LIGAND INTERACTIONS AND PURIFICATION, SCREENING, AND THERAPEUTIC METHODS RELATING THERETO - The presently disclosed subject matter discloses characterization of interactions between ligands and Hsp90 proteins, including GRP94, wherein ligand binding to the N-terminal nucleotide binding domain of GRP94 elicits a conformational change that converts the GRP94 from an inactive to an active conformation, and wherein the chaperone and peptide-binding activities of the GRP94 are markedly stimulated. Also disclosed are purification, screening, and therapeutic methods pertaining to the biological activity of GRP94, and in some instances HSP90, based upon the characterization of ligand interactions of Hsp90 peptide-binding proteins, including GRP94.02-04-2010
20100028901METHOD FOR DIAGNOSING IN VITRO OR EX VIVO PSYCHIATRIC DISORDERS AND/OR INTESTINAL DYSBIOSES - The invention relates to the use of at least one of the following Formula (I) compounds:02-04-2010
20100021935Goodpasture Antigen Binding Protein and Its Detection - The present invention provides native Goodpasture antigen binding protein isoforms, monoclonal antibodies directed against such proteins, and methods for their use.01-28-2010
20100021933CELLOMICS SYSTEMS - In labeling a cell, and separating and collecting the cell according to a degree of the labeling using a cell separator, effects on the cell is minimized and the use of the collected cell is facilitated, thereby, when labeling a cell, the cell is labeled in the state where interaction of each cell is retained. In the labeling, a specific labeling material present on a surface of a target cell is taken in the cell via a transporter, and the cell is dispersed one by one to separate the same with a cell separator. Immediately after the separation, the cell is put in a solution not containing the specific labeling substance to remove the specific labeling substance taken in the cell. This series of steps is continuously conducted with a cell separation chip.01-28-2010
20100021932Method for use of microdialysis - Very accurate measurements of mass transfer can be made rapidly by permitting diffusion of an agent desired to be measured into or out of a small, very precisely known volume of a microdialysis probe, then rapidly pumping or flushing (“pulsing”) the probe with a known volume of fluid as a single pulse. The diffusion and pulsing may be repeated. The method, hereinafter called pulsatile microdialysis (PMD) to distinguish it from prior art continuous flow microdialysis, is useful for measurements in a number of processes, including protein binding, adsorption to binding agents such as activated charcoal, release from microemulsion drug delivery systems, determination of drug diffusion coefficients and concentrations, and for various other purposes.01-28-2010
20100021930APPLICATION OF SURFACE PLASMON RESONANCE TECHNOLOGY TO MATERNAL SERUM SCREENING FOR CONGENITAL BIRTH DEFECTS - This invention discloses using SPR technology to simultaneously and quantitatively detect the presence of serum markers in pregnant women for the purpose of screening for congenital birth defects. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of representative antibodies used to detect the respective serum markers in pregnant women for the purpose of maternal serum screening for congenital birth defects.01-28-2010
20100021927CHOLESTEROL LOADED INSECT CELL MEMBRANES AS TEST SYSTEMS FOR ABC TRANSPORTER PROTEINS - The invention provides for a novel cholesterol loaded insect cell membrane preparation having an increased cholesterol level as compared to physiological cholesterol levels of insect cell membranes or to control insect cell membrane preparations without cholesterol loading, wherein said cholesterol loaded membrane preparation comprises an ABC transporter protein having an increased substrate transport activity due to increased cholesterol level of the membrane. The invention also relates to reagent kits comprising the preparations of the invention. The invention also relates to methods for manufacturing said preparations and methods for measuring any type of activity of the ABC transporters present in the cholesterol loaded membranes as well as studying or testing compounds and interaction of compounds and ABC transporters, in this assay systems. The invention also provides for a test system useful for testing whether ABC transporter proteins can be activated by cholesterol in an insect cell membrane.01-28-2010
20100021928METHODS AND KITS FOR DIAGNOSING CANCER - Methods and kits for diagnosing cancer in a subject is disclosed. The method comprises determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the cancer, with the proviso that the saliva secreted marker is not circulatory carcinoembryonic antigen (CEA).01-28-2010
20100068727RAPID IMMUNOCHROMATOGRAPHIC DETECTION BY AMPLIFICATION OF THE COLLOIDAL GOLD SIGNAL - The present invention relates to a method for rapid immunochromatographic detection of a target in a sample by double sandwich immunoassay detection, wherein the target is an antibody and/or an antigen, using different colloidal gold conjugates conjugated with a first and a second specific antibody or antigen and with at least one oligonucleotide and its at least one complementary oligonucleotide and/or at least one non-specific antibody and its related non-specific antigen, to a rapid immunochromatographic detection device, to uses of the method for detecting diseases or specific conditions, and to a method for the manufacture of the device as well as to a kit which comprises the device.03-18-2010
20100209939BNP(1-32) EPITOPE AND ANTIBODIES DIRECTED AGAINST SAID EPITOPE - The present invention relates to a polypeptide carrying a human BNP(I-32) epitope according to Formula (I): a08-19-2010
20090233312METHODS AND ASSAYS TO ASSESS CARDIAC RISK AND ISCHEMIA - The invention provides methods and apparatus to assess cardiac risk and ischemia by detecting or analyzing cardiac troponin levels. Also provided are methods to detect low levels of cardiac troponin in physiological fluid samples.09-17-2009
20100136571I-PLASTIN ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of the I-Plastin tumor marker in a biological sample taken from a patient suspected of having colorectal cancer. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.06-03-2010
20080318246Deeply quenched enzyme sensors - Sensors for detecting enzyme activity are provided that include a substrate module comprising a substrate for the enzyme of interest and a fluorescent label, a quencher, and a detection module. The detection module binds to the substrate module either before or after the enzyme acts on the substrate and sequesters the label from the quencher, resulting in an increased signal from the label. Sensors for detecting enzyme activity are also provided that include a substrate for the enzyme, a label, and a quencher that quenches the label. Action of the enzyme on the substrate results in a conformational change that relieves quenching. Sensors for detecting protein-protein interactions are also provided that include a quencher and a labeled first polypeptide. Binding of the first polypeptide to a second polypeptide sequesters the label from the quencher, resulting in an increased signal from the label. Methods using the sensors to detect enzyme activity and to screen for compounds affecting enzyme activity or to detect protein-protein interactions and to screen for compounds affecting protein-protein interactions, respectively, are also described.12-25-2008
20110117572Antibody Specific to the AIMP2-DX2 - The present invention relates to a variant of AIMP2 lacking exon 2 gene, named as AIMP2-DX2 gene, which is specifically expressed in cancer cells. The AIMP2-DX2 gene and siRNA targeting AIMP2-DX2 can be successfully used in the development of diagnosis and treatment of cancer05-19-2011
20100136572METHOD OF ASSAYING APOLIPOPROTEIN AI FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - The present invention relates to a method for the in vitro diagnosis of colorectal cancer by determining the presence of the Apolipoprotein AI tumor marker in a biological sample taken from a patient suspected of having colorectal cancer, it being understood that the assay is not turbidimetric. Said method can be used for early diagnosis, screening, therapeutic follow-up and prognosis, and also for relapse diagnosis in relation to colorectal cancer.06-03-2010
20100151486OSTEOPONTIN FUNCTIONAL EPITOPES, MONOCLONAL ANTIBODIES AGAINST THE EPITOPES AND USES THEREOF - Provided are functional epitopes of osteopontin (OPN), monoclonal antibodies that specifically bind to the epitopes, immunoconjugates comprising the monoclonal antibodies and use of the monoclonal antibodies or immunoconjugates for manufacturing a medicament for the treatment of tumor. Also provided are nucleotide sequences encoding the monoclonal antibodies and vectors and host cells comprising the sequences. The monoclonal antibodies or immunoconjugates can be used for detecting the OPN, blocking the promoting metastasis-signaling pathway mediated by OPN and preventing the development and metastasis of tumor, thereby inhibiting the tumor.06-17-2010
20110039277Methods of Labeling Proteins - Methods are provided for labeling specific oxidized proteins. Methods also are provided for determining the oxidation state of a cell. Such methods are useful as diagnostic, therapeutic and screening agents.02-17-2011
20100297662ANTIBODY AND USE THEREOF - An antibody provided by the present invention has a low reactivity with amyloid precursor proteins, and has a higher reactivity with amylospheroids than with amyloid β fibrils or monomeric amyloid β-proteins. According to the present invention, an antibody is provided that has a higher reactivity with amylospheroids than with amyloid precursor proteins, and has any one or more of the following properties: (i) a higher activity with amylospheroids than with amyloid β fibrils; (ii) a higher reactivity with amylospheroids than with monomeric amyloid β-proteins; and (iii) an activity of inhibiting neuronal cell death induced by amylospheroids.11-25-2010
20090004673Method for Determining Condition of Disseminated Intravascular Coagulation - A method for determining a condition of disseminated intravascular coagulation (DIC), by analyzing the amount and/or enzyme activity of a von Willebrand factor (vWF)-cleaving protease (ADAMTS13) (preferably also the amount of vWF) in a patient suffering from DIC, and a kit for determining a condition of DIC, comprising an antibody or a fragment thereof which specifically binds to ADAMTS13, are disclosed. According to the present invention, a differential diagnosis of patients with thrombotic thrombocytopenic purpura (TTP) can be carried out from among patients with DIC, which could not be distinguished on the basis of only clinical findings or known markers.01-01-2009
20090023155Polyelectrolyte multilayer films at liquid-liquid interfaces and methods for providing and using same - The present invention is directed to methods for providing a polyelectrolyte multilayer film at a liquid-liquid interface. Such methods include steps of sequentially-depositing layers of cationic and anionic polyelectrolytes at a liquid-liquid interface that is formed between immiscible first and second liquids whereby a polyelectrolyte multilayer film is provided at the liquid-liquid interface. In certain preferred embodiments, the first liquid is an aqueous solution and the second liquid is a liquid crystal. In alternative embodiments, the first liquid is an aqueous solution and the second liquid is an oil. The invention further encompasses polyelectrolyte multilayer films provided by the disclosed methods as well as applications utilizing such materials.01-22-2009
20100173323GLYCOSYLATION ENGINEERED ANTIBODY THERAPY - The instant invention is drawn to methods of generating a glycosylation-engineered antibody, and using the glycosylation-engineered antibody for treating a patient, particularly a cancer patient or a patient with an immune disease or disorder. The instant invention is also drawn to methods of generating a glycosylation-engineered antibody for use in the treatment of patients having a polymorphism that does not respond to conventional antibody therapy. The instant invention is also drawn to methods of improving the biological activity of an antibody by glycosylation engineering. The instant invention is also drawn to methods of modulating antibody-dependent cell-mediated cytoxicity (ADCC) using a glycosylation-engineered antibody.07-08-2010
20080286803Method for the Functional Determination of Mannan-Binding-Lectin Associated Serine Proteases (Masps) and Complexes Thereof - This invention relates to the field of determining, assaying or quantifying activity of components of the complement system. More particularly, the invention relates to methods for detecting the presence or level of activity in a sample of mannan-binding-lectin associated serine proteases (MASPs) or complexes of such proteases with lectins and to detection of the particular lectins themselves. Provided is a method for determining the activity of a MASP in a sample, comprising incubating the sample with a pro-urokinase comprising at its activation site the consensus sequence Arg/Leu/Gly-Yyy-Arg/Lys-Ile/Leu/Val-Zzz-Gly-Gly cleavable by a MASP, wherein Yyy can be any amino acid and Zzz is preferably an aliphatic amino acid, and determining proteolytic activation of said pro-urokinase.11-20-2008
20130122516DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY - Particular disclosed embodiments disclosed herein concern using a one or more various mass tags, which can be specifically deposited at targets through direct or indirect enzymatic-catalyzed transformation, to provide a method for identifying targets in tissue samples. The mass tags may be labeled with stable isotopes to produce mass tags having the same chemical structure but different masses. Mass codes produced by ionizing the mass tags are detected and/or quantified using mass spectrometry. The method can be used for multiplexed detection of multiple targets in a particular sample. In some embodiments, a map divided into sections representing sections of the tissue sample may be prepared, with the map sections including data corresponding to quantification data wherein the size of a mass peak is determined and correlated with the amount of a target for the corresponding tissue sample section.05-16-2013
20130122515METHOD FOR THE SELECTIVE DETERMINATION OF PROCALCITONIN 1-116 - The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of intact procalcitonin 1-116, or procalcitonin partial peptides derived therefrom that retain amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116. The method uses antibodies that selectively bind an epitope comprising amino acids 1 and 2 of procalcitonin 1-116 (SEQ ID NO: 1) and can distinguish between intact procalcitonin 1-116 and for example, procalcitonin 3-116.05-16-2013
20100015634IN SITU LYSIS OF CELLS IN LATERAL FLOW IMMUNOASSAYS - Devices and methods incorporate lysis agents into a point-of-care testing device. The sample is loaded, and then the sample travels until it encounters a lysis agent. The lysis agent is preferably pre-loaded onto the collection device. In a preferred embodiment, the initially lysis agent is localized between the sample application zone and the conjugate zone. The lysis agent is preferably soluble or miscible in the sample transport liquid, and the lysis agent is solubilized and activated upon contact with the sample transport liquid. The sample transport liquid then contains both lysis agent in solution or suspension and sample components in suspension. Any lysis-susceptible components in a sample, then being exposed in suspension to the lysis agent, are themselves lysed in situ. The running buffer then carries the analyte, including any lysis-freed components, to the detection zone.01-21-2010
20120040369ON-BOARD CONTROL DETECTION - Embodiments disclosed herein relate to a sensor comprising an on-board control system and a testing system. The on-board system can determine viability of the control system or the testing system. Also disclosed are methods of using such a sensor.02-16-2012
20120040368MUTATED VOLTAGE-GATED SODIUM CHANNEL NAV ALPHA SUBUNIT FOR IDENTIFICATION OF MODULATORS - Reagents, methods and kits for screening for compounds that modulate the activity of voltage-gated sodium channels (NaV), such as human NaV1.5/SC-N5A/hH1 are described. The reagents, methods and kits are based on mutated NaV alpha subunit polyptides of SEQ ID NO:5 with mutations at positions 372, 898, 1419 and 1711 (the DEKA motif) and at positions 11485, 1486 and 1487 (the IFM motif) resulting in increased permeability for a group IIA divalent cation (Ca02-16-2012
20110151477METHODS FOR DETECTING ANTIBODIES IN MUCOSAL SAMPLES AND DEVICE FOR SAMPLING MUCOSAL MATERIAL - A method to detect local antibodies such as antigen-specific IgE via a brush biopsy specimen of a mucosal surface of a subject is disclosed. The method is easily performed in an office setting on both adult and pediatric patients. Also disclosed is a brush device specially designed for harvesting materials from a mucosal surface such as the medial surface of the inferior turbinate.06-23-2011
20100248260GLYCOSAMINOGLYCAN-COATED PARTICLES AND USES THEREOF - The present invention is directed to metallic particles coated with glycosaminoglycans and methods for preparing them. Methods of using such glycosaminoglycan-coated metallic particles in biomedical and other applications are also disclosed. In certain embodiments, methods for assaying glycosaminoglycan-degrading activity in biological fluids, test samples, and/or therapeutic formulations using the glycosaminoglycan-coated particles are provided. Such methods may be used, for example, in diagnostic tests for diseases such as cancer, inflammatory diseases, or autoimmune diseases and to test activity of enzymes being developed as therapeutics.09-30-2010
20100021931Fluorescence based reporter construct for the direct detection of TGF-beta receptor activation and modulators thereof - The invention comprises a fusion protein as sensor for TGF-beta receptor activity, a method for detecting receptor activity and to screening compounds for modulators of receptor activity. The fusion protein comprises a type I TGF-beta receptor, a circularly permutated fluorescent protein moiety (cpFP) and an activation state specific receptor binding domain, binding specifically to either the activated or inactive form of the TGF-beta receptor. An activation specific interaction between the receptor and the activation state specific receptor binding domain modulates the fluorescence of the cpFP inserted in between. Thus, activation of the receptor can be detected directly by a change in fluorescence of the cpFP.01-28-2010
20080268463Methods for Prognosis and Diagnosis of Chronic Prostatitis/Pelvic Pain Syndrome and Interstitial Cystitis - We have discovered that levels of specific protein biomarkers present in urine samples of subjects correlate with the presence, or absence of, chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in men or interstitial cystitis (IC) in women. These protein biomarkers are cortitropin releasing hormone (CRH), dehydroepiandrosterone (DHEA), neuropeptide Y (NPY) and Galanin. Accordingly, the invention is directed to methods for diagnosis of CP/CPPS and IC by monitoring the levels of at least one of these proteins in urine, as well as to diagnostic kits designed for diagnosis of CP/CPPS and IC.10-30-2008
20100285497MARKERS OF ENDOTHELIAL CELLS AND USES THEREOF - Use of a beta tubulin isotype that is differentially expressed between activated endothelial cells and quiescent endothelial cells for identifying an agent which inhibits or promotes angiogenesis and/or vascular function.11-11-2010
20110306057Phosphorylated RalA - Antibodies that are specific for human RalA that is phosphorylated at one or both of Ser183 and Ser194 are described as various methods such antibodies, including diagnostic methods and screening methods.12-15-2011
20100330585LATERAL FLOW ASSAY SYSTEM AND METHODS FOR ITS USE - A lateral flow test system together with methods for its use in the detection of one or more analytes, or components, of interest within a sample, such as a biological sample, is provided. The system comprises a liquid formulation of a gold conjugate and a lateral flow assay device that does not include a conjugate pad having conjugate dried thereon.12-30-2010
20100273181METHODS FOR THE DETECTION OF GLYCATED HEMOGLOBIN - Particular aspects of the present invention relate to methods for detecting glycated hemoglobin in, for example, human whole blood, that are not affected by the presence of variation in amino acid sequence that can exist in hemoglobin β chains. The methods detect all glycated hemoglobin in a sample, regardless of the form of the hemoglobin that has been glycated, and thus detect glycated human Hemoglobin A, Hemoglobin S, and Hemoglobin C.10-28-2010
20110008798Lipid insertion for antigen capture and presentation and use as a sensor platform - It has been found that moieties containing a lipophilic domain, e.g., lipophilic pathogen activated molecular patterns (PAMPs), insert into the lipid bilayer on a cell membrane to facilitate antigen recognition by the innate immune response receptors. This changes the basic understanding of antigen recognition by the innate immune system. A sensor platform for the ultra-sensitive and specific detection of moieties containing such a lipophilic domain, e.g., PAMPs, that are associated with a disease, has now been developed. To date, this approach has been validated with Lipoarabinomannan (LAM) from 01-13-2011
20110111424ANALYSIS OF UBIQUITINATED POLYPEPTIDES - The invention relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent.05-12-2011
20100178656Multiple Analysis of Blood Samples - The invention relates to a method for detecting a plurality of antigenic molecules carried by erythrocytes and/or a plurality of anti-erythrocyte antibodies of an individual, comprising bringing a sample into contact with distinguishable beads, on which are attached a) antibodies specific for said antigens, or b) erythrocytes, erythrocyte membrane fragments or blood group antigens.07-15-2010
20090148859Mtor Pathway Theranostic - This invention relates, e.g., to a method for predicting a subject's response to a chemotherapeutic agent and/or the subject's prognosis, comprising measuring the phosphorylation state of at least one member of the mTOR pathway, and/or of at least one member of an interconnected polypeptide pathway (e.g. a member of the Akt pathway or a member of the IRS pathway), compared to a baseline value, in a cancer tissue or cancer cell sample from the subject, wherein an elevated level of the phosphorylation state compared to the baseline value indicates that the subject is a non-responder to the chemotherapeutic agent and/or has a poor prognosis. Also described is a method for treating a cancer in a subject in need thereof, wherein the subject exhibits an elevated level of the phosphorylation state, comprising administering one or more inhibitors of the mTOR and/or an interconnected pathway.06-11-2009
20090197280Methods and Devices for Rapid Assessment of Severity of Injury - Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided.08-06-2009
20110111425ENHANCED IMMUNOASSAY SENSOR - Disclosed herein are devices for detecting the presence of a target analyte in a fluid sample. The biosensor device can comprise at least a reaction chamber and a detection chamber. The device can comprise a amplifying mechanism such that one target analyte molecule present in the fluid sample can lead to generation/activation of multiple detection agent molecules, and therefore, an amplified signal. Also disclosed are the methods of manufacturing and using such a biosensor device.05-12-2011
20110111422SENSOR PROTEINS AND ASSAY METHODS - The present invention relates to biosensors. In some embodiments, the biosensors are modified ligand binding molecules. In some embodiments, the modified ligand binding molecule is a phosphate binding protein (PBP). In some embodiments, the modified ligand binding molecules are labeled to be capable of RET, e.g., comprising a donor and acceptor moiety. In some embodiments of the invention, there is a detectable change in RET (e.g., FRET) when the modified ligand binding molecule binds and/or releases the ligand (e.g., phosphate). The invention also provides related methods, reactions and assays.05-12-2011
20110033871METHOD FOR THE DETERMINATION OF TRICHINELLA INFECTIONS AND DIAGNOSTIC COMPOSITION FOR SUCH METHODS - Method for the determination of 02-10-2011
20100196920NANOSCOPIC BIOMOLECULAR ABSORPTION SPECTROSCOPY ENABLED BY SINGLE NANOPARTICLE PLASMON RESONANCE ENERGY TRANSFER - The disclosure provides methods and compositions useful for measuring a target analyte in a sample with nanoparticle plasmon resonance. In particular the disclosure provides methods and compositions for measuring a target analyte comprising plasmon resonance energy transfer.08-05-2010
20110020833Method for Detecting Analytes - The subject of this invention is a process for detection of analytes from biological samples comprising the following process steps: 01-27-2011
20120301894LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS - Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group.11-29-2012
20100279307Angiogenesis Inhibiting Molecules, Their Selection, Production and Their Use in the Treatment of Cancer - The present invention relates to a method for providing molecules that are capable of inhibiting angiogenesis, comprising the steps of providing a range of molecules; testing whether these molecules can prevent interaction between JAM-B and JAM-C; testing the positive molecules for their ability to block angiogenesis in vivo; and selecting molecules that are positive in the angiogenesis test as angiogenesis inhibiting molecules. The method may further comprise the step of isolating or producing the angiogenesis inhibiting molecules. The invention further relates to the angiogenesis inhibiting molecules thus provided and produced, to their use in the treatment of cancer, to therapeutical compositions comprising them. In a particular embodiment the invention relates to monoclonal antibodies, in particular Mab H33, to soluble JAM-C and JAM-B and to small molecules.11-04-2010
20110045490BIOMARKER FOR THE PREDICTION OF RESPONSIVENESS TO AN ANTI-TUMOUR NECROSIS FACTOR ALPHA (TNF) TREATMENT - The invention refers to a method for diagnosing an individual who is to be subjected to or is being subjected to an anti-tumour necrosis factor alpha (TNFα or TNF) treatment to assess the responsiveness to an anti-TNF treatment which comprises the detection of immunoglobulin(s) against one or more biomarker proteins in a bodily fluid or an excrement of said patient, and sorting the individual into one of two categories based on detection of said immunoglobulin(s), wherein individuals are classified as NON-responder or responder. The invention refers to diagnostic kits comprising said one or more biomarker proteins and the use of these kits for assessing the responsiveness to an anti-TNF treatment of an individual who is to be subjected to or is being subjected to an anti-TNFα treatment.02-24-2011
20090042209Neoplasia-Specific tNOX Isoforms and Methods - All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity. Cancers of different cellular or tissue origins express different tNOX cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative tNOX amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression.02-12-2009
20090029388Detection of Antibodies - The present invention relates to a method for detecting antibodies against a target antigen in a sample which comprises contacting the sample with labelled target antigen, subjecting the sample to immunoprecipitation to precipitate antibodies in the sample and detecting the presence of antibodies against the target antigen in the sample by means of the presence of labelled target antigen in the immunoprecipitate, wherein the labelled target antigen is a fusion protein comprising the target antigen and a fluorescent protein label and the presence of labelled target antigen in the immunoprecipitate is detected by means of the fluorescence of the fluorescent label. The method is particularly suitable for use where the target antigen is an autoantigen and can also be used to identify autoantigens implicated in a particular autoimmune disorder by screening serum samples from patients with a clinical phenotype indicative or suggestive of an autoimmune disorder and suitable controls. The target protein may be from the cys-loop acetyl choline receptor ion channel gene superfamily, the voltage-gated calcium, sodium or potassium ion channel gene superfamily, the glutamate receptor gene family, a receptor tyrosine kinase, or other membrane associated channels such as aquaporin gene family.01-29-2009
20100143933Measurement value lowering inhibitor for immunoassay method and immunoassay method using the same - A measurement value lowering inhibitor for immunoassay method that is capable of enhancing the accuracy of immunoassay method through suppressing of any influences of interfering substances existing in an analyte sample; and using the inhibitor, an immunoassay method in which any measurement value lowering by interfering substances is suppressed and a reagent for immunoassay method. The measurement value lowering inhibitor for immunoassay method used to suppress any measurement value lowering by interfering substances is comprised of an ionic surfactant consisting of a polymer obtained by polymerization of a hydrophobic cyclic monomer having an ionic functional group, which has a molecular weight of 1000 to 10×1006-10-2010
20110318753NEW COMPOUND, PHOSPHORYLATION INHIBITOR, INSULIN RESISTANCE IMPROVING AGENT, PREVENTIVE OR THERAPEUTIC AGENT FOR DIABETES, AND SCREENING METHOD - A new compound inhibiting phosphorylation of Ser727 of STAT3, a phosphorylation inhibitor containing the new compound, an insulin resistance improving agent and a preventive or therapeutic agent for diabetes; and a screening method for at least one of the insulin resistance improving agent and the preventive or therapeutic agent for diabetes.12-29-2011
20090136965Use of antibody-ligand binding to characterise diseases - We have found that when an antibody binds to (captures) its specific ligand, the antibody-ligand complex is redirected to a route of elimination which is different from that which occurs naturally for the specific ligand that is not bound to an antibody. As a consequence, the amount of antibody-bound ligand in the blood increases over time. The increase in total ligand concentration is a property that is specific to the patient to whom the antibody is administered. Accordingly, the invention provides a method for diagnosing disease in a subject and a method for identifying the most appropriate treatment for a particular patient. Patients who produce more ligand, and thus more antibody-ligand complex, may be more likely to have a disease which is predominantly driven by that ligand. These patients should respond better to a therapy targeted against that ligand. The better understanding of the underlying malfunctions in disease biology provided by the methods of the invention, in respect of the rates of production of natural ligands in health and disease, provides a logical and targeted selection of the appropriate treatments to address specific biological abnormalities.05-28-2009
20110086364DETECTION OF CANNABIS USE - A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of 04-14-2011
20120045773CELL ADHESION INHIBITOR AND APPLICATIONS THEREOF02-23-2012
20120045772Affinity Hydrogel and Label Independent Detection Methods Thereof - A biosensor article including a substrate having polymer modified surface, the polymer comprising the formula (I)02-23-2012
20120003664METHOD FOR EVALUATING PRE-TREATMENT - The present invention relates to methods for evaluating tissue pre-treatment such as ischemic time, fixation time and alcohol time in an immunohistochemical assay by using one or more internal controls. Said internal controls may be biomarker specific or tissue specific. Also included are uses and kits comprising said internal controls.01-05-2012
20100021936Sensor for Spores - A sensor for spores, comprises spore-binding ligands and, on or within the body of the sensor, a material that is responsive to Ca-DPA (calcium-dipicolinic acid) but not to a (or another) germinant.01-28-2010
20090286258ANALYSIS OF ANTIBODY DRUG CONJUGATES BY BEAD-BASED AFFINITY CAPTURE AND MASS SPECTROMETRY - Methods to detect, characterize, and quantitate biological samples after administration of antibody conjugates, antibody-drug conjugates of Formula I, antibodies, and fragments and metabolites thereof, by immunoaffinity bead separation, chromatography, and mass spectrometry are disclosed.11-19-2009
20120208207Sample Processing Device - A floating chamber set may include a plurality of containers coupled to a frame such that each container translates vertically within a limited vertical range independent of the other containers. Each container may be perforated to allow liquid penetration.08-16-2012
20120208204Compositions and Methods for Inhibiting Tumor Growth - The invention provides methods and compositions for inhibiting p53-inactivated cancers. Cancer cells are preferentially inhibited compared to normal cells by inhibiting tumor survival kinases that are required for growth of tumor cells but not normal cells.08-16-2012
20120208206METHOD FOR PRODUCING MAST CELLS FROM PLURIPOTENT STEM CELLS - The present invention relates to a method for producing human mast cells from human pluripotent stem cells. More particularly, the present invention provides a method for producing human mast cells from human pluripotent stem cells, comprising the steps of: (a) culturing human pluripotent stem cells under a condition suitable for promoting differentiation of the human pluripotent stem cells into hematopoietic progenitor cells expressing CD34; and (b) culturing the cells obtained in step (a) in the presence of hematopoietic factors comprising thrombopoietin (TPO) and Flt3 ligand.08-16-2012
20120208205POINT-OF-CARE TEST SYSTEM AND METHOD FOR APPLYING A SAMPLE - The present invention relates to a test system or assay system (detection system) and to a test method, preferably in use in the point-of-care (PoC) field.08-16-2012
20120208202Method for the Reduction of Biological Sampling Errors by Means of Image Processing - The present invention relates to methods and devices for reducing biological sampling errors by means of image processing. Image processing techniques are used to determine the volume of sample added to a device, such as a diagnostic test, and to correct for user error in sampling techniques.08-16-2012
20120208203COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION - The present invention is directed to compositions and methods for modulating c-Rel-dependent cytokine production without materially altering the level of expression of NFκB and/or the amount of IκB. The present invention is also directed to screening for modulators of c-Rel activity as determined by assaying for altered subcellular localization of c-Rel but where the level of expression of NFκB and/or the amount of IκB is materially unaltered.08-16-2012
20090117582Diagnosis of Allergic Complaints, Atopic Diseases and/or Auto-Immune Diseases by the Identification of Antibodies Against CD28 in Human Serum - The invention relates to a method for diagnosing allergic complaints, atopic diseases and/or auto-immune diseases, according to which a sample from a patient is analysed for the presence of anti-CD28 auto-antibodies by bringing said sample into contact with CD28. If auto-antibodies bond to the CD28, this indicates the presence of an allergic complaint, atopic disease and/or auto-immune disease. The invention also relates to the use of CD28 for diagnosing said diseases and to a kit that is designed for this purpose, comprising CD28 and marked anti-immunoglobulin antibodies.05-07-2009
20100285498METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION - Methods for identifying individuals who are not yet diabetic (pre-diabetic), but who are at significant risk of developing diabetes, such as type 2 diabetes, are disclosed herein. Methods are also provided for the identification of diabetic subjects. Also disclosed are methods for identifying individuals with diabetic complications. The methods include the identification of an overall glycosylation profile of proteins in a biological fluid, such as saliva, urine, or serum. In some examples, the methods include determining the amount of one or more protein in a biological fluid or determining the glycosylation pattern of one or more proteins in a biological fluid.11-11-2010
20120009591METHOD FOR DETECTION OF AN ENZYME-SUBSTRATE REACTION - The present invention relates to a method for detection of an enzyme-substrate reaction by capturing the product of the reaction on a solid support. More closely, the invention relates to a solid phase system for enzyme characterisation and screening of enzyme-targeted drugs. The method comprises the following steps a) rapidly mixing an enzyme solution with a substrate solution to start a reaction between enzyme and substrate wherein said reaction may result in product formation; and b) monitoring any binding of the product to a capturing agent immobilised on a solid surface, wherein said capturing agent is directed against the product of the enzymatic reaction. In a preferred embodiment the method comprises a further step c) measuring the initial rate of the product binding to the capturing agent and thereby characterize the enzymatic reaction. The method may also be used for drug screening.01-12-2012
20120009590DEVICE AND NON-TOXIC COMPOSITIONS AND METHODS FOR PERMEABILIZATION OF DROSOPHILA EMBRYOS - The invention provides compositions and methods for permeabilizing insect embryos by removing the waxy layer of the shell using a solution containing a non-toxic cyclic terpene and a non-toxic surfactant, preferably a non-ionic surfactant. The invention further provides kits to practice the method of the invention. The invention also provides methods for toxicology and other high throughput screening method including the compositions and methods of embryo permeabilization provided herein.01-12-2012
20090023158Compositions and Methods for Identifying Substrate Specificity of Inhibitors of Gamma Secretase - The invention provides assays and methods for determining the substrate specificity of gamma secretase inhibitors and for identifying substrate-selective (and substrate isoform-selective) inhibitors of gamma secretase. The invention provides assays and methods for determining whether a compound inhibits gamma secretase in a site specific or substrate specific manner. The invention provides isolated polypeptide sequences comprising modified gamma secretase substrates, and polynucleotide sequences encoding the polypeptide sequences. The invention also provides compounds that inhibit gamma secretase, pharmaceutical compositions comprising such compounds, and methods of treating Alzheimer's disease using such compounds.01-22-2009
20100190181BIOMARKERS FOR PREECLAMPSIA - The present invention relates to novel biomarkers such as histidine and ketone bodies and methods of use thereof for detecting preeclampsia in pregnant individuals and for identifying individuals at risk at an early stage of pregnancy.07-29-2010
20120015374ENIGMA-MDM2 INTERACTION AND USES THEREOF - The present invention relates to Enigma (PDLIM7)-Mdm2 interaction and use thereof. More particularly, it may induce an effective apoptosis of cancer cells by inhibition of an Enigma expression or an Enigma activity which induces Mdm2 destabilization and p53 activity; it may assess the prognosis of anti-cancer therapy by determining that Enigma, which is induced by SRF, is overexpressed in cancer tissues with Mdm2; it may screen anti-cancer activity substances by selecting a factor to inhibit specific binding between Enigma and Mdm2. Enigma-Mdm2 interaction and Enigma expression regulation may be utilized usefully for preventing cancers and developing therapeutic methods and anti-cancer agents.01-19-2012
20120015375MCM6 AND MCM7 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE IN THE DETECTION OF CERVICAL DISEASE - Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.01-19-2012
20120015372METHODS AND COMPOSITIONS FOR PATHOGEN DETECTION USING FLUORESCENT POLYMER SENSORS - Compositions, methods and related apparatus, as can be used for selective pathogen detection and identification.01-19-2012
20120015373ACRIDONE DERIVATIVES AS LABELS FOR FLUORESCENCE DETECTION OF TARGET MATERIALS - Disclosed are methods for assay of an analyte employing acridone dyes having the structure:01-19-2012
20090148863Nanoparticle biosensors - Compositions which are useful in ultralow level of detection based on functionalized nanoparticles having exceptional combinations of properties including stability, brightness, binding specificity, and ability to be imaged at single nanoparticle resolution over desired period of time. The biological moieties on the nanoparticles preserve biological function. The nanoparticle surface can comprise a first monolayer component which is adapted to bind to a biological moiety. The biological moiety can be adapted to bind to an analyte. The nanoparticle surface can further comprise a second monolayer component, which is adapted to help expose the first monolayer component on the surface. Other components on the surface can help stabilize the nanoparticle. The nanoparticles are stable against aggregation, have photostability (non-photodecomposition and non-blinking), and can achieve single molecule detection in real time. Analytes can be detected at low levels both in solution and on surfaces such as cell surfaces.06-11-2009
20100173324ANTI-CD27 ANTIBODY - The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same.07-08-2010
20110165592ANTIBODIES AGAINST HUMAN EPO RECEPTOR - An antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment LDKWLLPRNPPSEDLPGPGGSVDIV (SEQ ID NO:1), CSSALASKPSPEGASAASFEY (SEQ ID NO:2), or GGLSDGPYSNPYENSLIPAAEP (SEQ ID NO:3) is useful for the analysis of EPO receptor in human tissue.07-07-2011
20110165591USE OF BIGLYCAN IN THE ASSESSMENT OF HEART FAILURE - The invention relates to a method for assessing heart failure in vitro and involves the steps of measuring in a sample the concentration of the marker biglycan, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for biglycan and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of biglycan as a marker protein in the assessment of heart failure, a marker combination comprising biglycan and a kit for measuring biglycan.07-07-2011
20110165590Vaccine Protection Assay - The present invention relates to the field of Serum Bactericidal Activity (SBA) assays for Gram negative bacteria, in particular 07-07-2011
20110165589DEVICE AND METHOD FOR SEPARATING AND ANALYZING BLOOD - The invention provides a device for detecting FABP in a blood sample from a patient, methods for analyzing blood on the presence of FABP, as well as methods and kits for the detection of FABP in a blood sample from a patient.07-07-2011
20110165588METHOD FOR QUANTIFYING PHOSPHOKINASE ACTIVITY ON PROTEINS - The invention involves a method for measuring phosphorylation of proteins at specific sites and, as such, is an indicator of the protein kinase activity of enzymes capable of phosphorylating those sites. The method involves the in vitro or in vivo phosphorylation of a target protein at a specific serine, threonine or tyrosine residue, subjecting that protein (non-phosphorylated) to reaction mixture containing all reagents, including phosphokinase which allow the creation of a phosphorylated form of protein. The phosphorylated protein is measured by contacting it with an antibody specific for the phosphorylation site(s). The invention includes antibodies useful in practicing the methods of the invention. The invention particularly relates to all proteins modified by phosphorylation and dephosphorylation as illustrated by Tau, Rb and EGFR proteins and antibodies specific for the site of phosphorylation of the Tau, Rb or EGFR proteins.07-07-2011
20110165587Method for live-cell activity assay - Provided are technologies capable of direct measurement of activity of a bioactive substance in cell using nanowires, more particularly, a method for measuring intracellular activity of a bioactive substance using a nanowire support to which cells are immobilized and a nanowire support to which target substances for the subject bioactive substance are immobilized, and a chip for measuring intracellular activity of a bioactive substance including nanowires to which cells are immobilized and nanowires to which a target substance for the subject bioactive substance is immobilized.07-07-2011
20110165586Detection Method of Bio-Chemical Material Using Surface-Enhanced Raman Scattering - Provided is a detection method of a biochemical material using surface-enhanced Raman scattering in order to detect the existence of a biochemical material in a target subject or its content therein, more particularly a detection method of a biochemical material facilitating multiplex detection with high-sensitivity, high-reproducibility, high-reliability, and high-precision owing to multiple hot spots formed on the nanowire surface of a single crystal body by the bond of multiple nanoparticles which are physically separated from each other.07-07-2011
20120115164MAMMALIAN CYTOKINES; RELATED REAGENTS - Purified genes encoding a cytokine or composite cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.05-10-2012
20100248256HEPATOCELLULAR CARCINOMA PROTEIN MARKER, AND METHOD FOR DETECTION OF HEPATOCELLULAR CARCINOMA USING THE SAME - Provided are: a method of assessing hepatocellular carcinoma by using a protein with a different phosphorylated state in hepatocellular carcinoma cells compared with non-hepatocellular carcinoma cells; and a hepatocellular carcinoma protein marker for detecting hepatocellular carcinoma formed of the protein. The hepatocellular carcinoma protein marker for detecting hepatocellular carcinoma includes tumor rejection antigen gp96 formed of the amino acid represented by SEQ ID NO: 1, and is measured for its phosphorylated state to detect the presence or absence of hepatocellular carcinoma.09-30-2010
20090208970Probe for detection and quantification of inositol-1,4,5-trisphosphate and a method for detecting and quantifying inositol-1,4,5-trisphosphate using the same - A probe for detection and quantification with high accuracy in a noninvasive manner as to where and when inositol-1,4,5-trisphosphate is generated in living cells, and a method for detecting and quantifying inositol-1,4,5-trisphosphate using the probe.08-20-2009
20120058488WIRELESS BASED MARINE PATHOGENS DETECTION SYSTEM - Embodiments of the present Invention provide antibody functionalized high electron mobility transistor (HEMT) devices for marine or freshwater pathogen sensing. In one embodiment, the marine pathogen can be 03-08-2012
20120028267METHOD FOR INCREASING SENSITIVITY USING LINKER AND SPACER IN CARBON NANOTUBE-BASED BIOSENSOR - Disclosed is a method of detecting even a very small amount of a target substance by mixing a linker and a spacer at a suitable ratio and immobilizing the mixture on the surface of carbon nanotubes in a carbon nanotube-based biosensor. This method detects a specific substance at the level of femtomoles and lowers the detection limit of conventional carbon nanotube transistor sensors. Accordingly, the method detects even a very small amount of a target substance, and thus the carbon nanotube-based biosensor is a highly useful sensor which can be used either as a medical sensor for diagnosing diseases or as an environmental sensor.02-02-2012
20120028269Methods For Detection Of Gastric Cancer - The invention is directed to non-invasive methods of detecting gastric cancer in an individual in need thereof comprising determining an expression level of inter-alpha-trypsin inhibitor heavy chain H3 (ITIH3) in the individual and comparing the expression level to a control, wherein an increase in the expression level of ITIH3 in the individual compared to the control is indicative of gastric cancer in the individual.02-02-2012
20120107829STABILIZING COMPOSITIONS FOR IMMOBILIZED BIOMOLECULES - The present invention relates to the use of a composition comprising (a) at least three different amino acids, (b) at least two different amino acids and a saponin or (c) at least one dipeptide or tripeptide for stabilizing biomolecules immobilized on a solid carrier. The invention furthermore relates to a method for producing stabilized biomolecules, comprising embedding the biomolecules in the composition according to the invention and a method of producing a solid carrier having biomolecules attached thereto. The invention furthermore relates to a solid carrier producible or produced by the method of the invention and a method of diagnosing a disease using the carrier of the invention.05-03-2012
20100291586METHOD FOR THE DIAGNOSIS OR THE SCREENING OF AN ARBOVIRUS INFECTION, REAGENTS USEFUL IN SAID METHOD AND THEIR APPLICATIONS - Method for the diagnosis or the screening of an arbovirus infection and preferably a flaviviridae infection and more preferably a flavivirus infection, reagents useful in said method and their applications. Said method comprises: (i) contacting a sample from the subject or animal with a solid support sensitized with an Ig binding protein which is directed against a specific class of Ig molecules of the subject or animal species under consideration and (ii) incubating the immunocomplex formed in (i) with a detector molecule consisting of a hybrid protein comprising at least an arboviral ED3 domain and an alkaline phosphatase (PhoA), the detection of said immunocomplex being the sign of the presence of an arbovirus in said sample.11-18-2010
20090311716METHODS TO TREAT OR PREVENT HORMONE-RESISTANT PROSTATE CANCER USING siRNA SPECIFIC FOR PROTOCADHERIN-PC, OR OTHER INHIBITORS OF PROTOCADHERIN-PC EXPRESSION OR ACTIVITY - The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and includes a kit for detecting prostate cancer in biological samples. Also covered by the invention is a transgenic non-human mammal engineered to overexpress protocadherin-PC specifically in the prostate.12-17-2009
20120156688USE AND MAKING OF BIOSENSORS UTILIZING ANTIMICROBIAL PEPTIDES FOR HIGHLY SENSITIVE BIOLOGICAL MONITORING - A biosensor and method of making are disclosed. The biosensor is configured to detect a target and may include a peptide immobilized on a sensing component, the sensing component having an anode and a cathode. The immobilized peptide may comprise an antimicrobial peptide binding motif for the target. The sensing component has an electrical conductivity that changes in response to binding of the immobilized peptide to the target. The immobilized peptide may bind one or more targets selected from the list consisting of: bacteria, Gram-negative bacteria, Gram-positive bacteria, pathogens, protozoa, fungi, viruses, and cancerous cells. The biosensor may have a display with a readout that is responsive to changes in electrical conductivity of the sensing component. The display unit may be wirelessly coupled to the sensing component. A resonant circuit with an inductive coil may be electrically coupled to the sensing component. A planar coil antenna may be disposed in proximity to the resonant circuit, the planar coil antenna being configured to provide power to the sensing component.06-21-2012
20120156686Multifunctional particles providing cellular uptake and magnetic motor effect - Preparation of novel multifunctional particles and nanomaterials having a useful combination of magnetic and optical properties and biocompatibility. The internalization efficiencies in various in vitro cell studies have been investigated, and the external magnetic motor effect on the floating cells internalized with magnetic nanoparticles were clearly observed, for the first time. The particle surfaces can be derivatized with, for example, DNA or antibodies. The system is stable, versatile, and well-controlled. Novel gene delivery can be achieved using nanoparticles as a carrier.06-21-2012
20120070844Method For Quantifying Modified Peptides - The present invention provides a method for quantifying modified peptides in a sample, the method comprising: (a) obtaining peptides from the sample; (b) adding reference modified peptides to the peptides obtained in step (a) to produce a mixture of peptides and reference modified peptides; (c) carrying out mass spectrometry (MS) on said mixture of peptides and reference modified peptides to obtain data relating to the peptides in the sample; and (d) comparing the data relating to the peptides in the sample with data in a database of modified peptides using a computer programme; wherein the database of modified peptides is compiled by a method comprising: (i) obtaining peptides from a sample; (ii) enriching modified peptides from the peptides obtained in step (i); (iii) carrying out liquid chromatography-tandem mass spectrometry (LC-MS/MS) on the enriched modified peptides obtained in step (ii); (iv) comparing the modified peptides detected in step (iii) to a known reference database in order to identify the modified peptides; and (v) compiling data relating to the modified peptides identified in step (iv) into a database.03-22-2012
20120070845METHODS, SYSTEMS AND REAGENTS FOR IMPROVED IMMUNODETECTION - The instant invention provides methods, systems and reagents for immunodetection involving novel epitope tags and antibodies which recognize these new epitope tags as well as the antibodies which detect the FLAG epitope tag. Fusion proteins comprising the epitope tags, as well as methods of purifying these proteins and kits detecting these proteins are also provided.03-22-2012
20080213795DNA sequences encoding peptide sequences specific for the hepatic stages of P. falciparum bearing epitopes capable of stimulating the T lymphocytes - The invention discloses isolated DNA sequences encoded by polypeptides characterized by the presence in their structure of one or more sequences bearing all or part of the one or more T epitopes, and possibly other epitopes, particularly B epitopes, characteristic of proteins resulting from the infectious activity of 09-04-2008
20090197279MICROTUBULE SYNTHESIS AS A BIOMARKER - Stable isotope labeling was used to measure dynamics of tubulin incorporation into microtubule subpopulations representing different neuronal compartments in the murine hippocampus. Neuronal microtubules were largely static. Basal turnover was highest in tau-associated (axona) and growth cone), lower in MAP2-associated (somatodendritic), and lowest in cold stable (axonal shaft) subpopulations. Intracerebroventricular glutamate injection stimulated label incorporation into axonal shaft and somatodendritic microtubules, the latter dependent on cAMP-PKA. Hippocampus-dependent memory formation after contextual fear conditioning was accompanied by increased assembly of MAP2- and cold stable-microtubules. Both microtubule assembly and memory formation were inhibited by the microtubule depolymerizing drug, nocodazole. This approach allows for correlation with behavioral measures of learning and memory and for the screening of candidate agents for stimulatory activities on learning memory.08-06-2009
20090081693MOLECULE ASSOCIATING WITH INTRACELLULAR C-TERMINAL DOMAIN OF RECEPTOR - Concerning intracellular signal transduction mechanism, there has been drawn a novel hypothesis that, even in the case where phosphorylation does not occur in the intracellular C-terminal domain of a receptor, an unknown molecule associates with the Pro-C terminal domain of a G protein-coupled receptor for each chemokine and thus leukocyte chemotaxis depending on the receptor is controlled. To examine this hypothesis and clarify therapeutic targets in inflammatory diseases as well as other various diseases, attempts are made to search for a CCR2-binding protein.03-26-2009
20120107830REAGENTS FOR BIOMOLECULAR LABELING, DETECTION AND QUANTIFICATION EMPLOYING RAMAN SPECTROSCOPY - The present disclosure provides isotopically substituted compounds of the formula (II):05-03-2012
20110091902METHOD OF ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN, KIT FOR ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN AND APPARATUS FOR ASSAYING PHYSIOLOGICALLY ACTIVE SUBSTANCE OF BIOLOGICAL ORIGIN - Provided is a technique whereby a physiologically active substance of biological origin such as an endotoxin or β-D-glucan can be more conveniently and accurately detected and the concentration thereof can be determined even in the case of using a sample which contains a substance affecting LAL activity. For example, a sample is brought into contact with a substance (04-21-2011
20110091901Vectors and Methods for Screening Cells for High Expression of Protein of Interest (POI) - This invention refers to industrial production of proteins. More particularly, the invention refers to a fusion protein as a novel chimeric selection marker comprising a peptide conferring resistance to an antibiotic, or a fragment, allelic variant, splice variant or mutein thereof, and at least one sequence comprising SEQ ID NO: 1, 2 or 3, preferably for producing a protein of interest (POI). The inventive chimeric selection marker exhibits: (i) a resistance to an antibiotic; and (ii) a fluorescence activity upon binding of a ligand to the sequence comprising SEQ ID NO: 1, 2 or 3. The invention further refers to nucleic acids encoding the inventive fusion protein and to expression vectors, comprising the inventive fusion protein and additionally the protein of interest (POI). Finally, uses of the inventive chimeric selection marker for screening cells for high expression of a protein of interest (POI) are disclosed.04-21-2011
20110081657CONTROLLED PLATELET ACTIVATION TO MONITOR THERAPY OF ADP ANTAGONISTS - A method is provided of determining whether an individual has reduced ability to form platelet thrombi due to inhibition of platelet activation initiation, signal transduction and/or GPIIb/IIIa blockade. A blood sample is obtained from the individual being assessed. The blood sample is mixed in combination with 1) an anticoagulant; 2) sufficient buffer to maintain the pH and salt concentration of the anticoagulated blood within a range suitable for platelet aggregation; 3) a platelet GPIIb/IIIa receptor ligand immobilized on a solid surface; 4) one or more agents to enhance a signal transduction pathway and 5) a receptor activator. The combination is incubated under conditions for agglutinating particles. Platelet-mediated agglutination is assessed in the agitated mixture. The absence of agglutination indicates that the individual has a reduced ability to form platelet thrombi.04-07-2011
20120178098WHOLE BLOOD ASSAY FOR MEASURING AMPK ACTIVATION - A method of sample analysis is provided. In certain embodiments, the method comprises: a) labeling cells of a blood sample using an antibody that specifically binds to phospho-AMPK or a phosphorylated target thereof, to produce a labeled sample; and b) measuring antibody binding by a population of blood cells of the labeled sample using flow cytometry. In particular embodiments, the method may further comprise, prior to the labeling step: contacting blood with a test agent ex vivo or in vivo; and comparing the evaluation to results obtained from a reference sample of blood cells.07-12-2012
20120252032Immunoassay Device with Improved Sample Closure - An apparatus and method for sealing a fluid sample collection device, comprising loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.10-04-2012
20110104710CONSTRUCTION OF EXPRESSION SYSTEM FOR RNA POLYMERASE DERIVED FROM INFLUENZA VIRUS, CRYSTALLIZATION OF THE RNA POLYMERASE, AND SCREENING METHOD FOR ANTI-INFLUENZA AGENT - The present invention aims to express influenza virus RNA polymerase on a large scale, to crystallize the influenza virus RNA polymerase, and to provide a method for screening a substance capable of serving as an active ingredient in anti-influenza drugs which target a protein highly conserved among influenza virus species.05-05-2011
20110104709POROUS SOLID PHASE FOR BINDING ASSAY, AND BINDING ASSAY METHOD USING THE SAME - A porous solid phase for binding assay that enables a test sample such as whole blood to be analyzed promptly, conveniently, accurately, and inexpensively without requiring a pretreatment, and a binding assay method using said porous solid phase are disclosed. At least one surfactant is incorporated into the porous solid phase for binding assay prior to addition of a test sample, the at least one surfactant being selected from the group consisting of (A) a sugar-containing surfactant that comprises a compound shown by a general formula (I), (B) a sugar-containing surfactant that comprises a sucrose fatty acid ester wherein the constituent fatty acid has 5 to 14 carbon atoms, and (C) a steroid surfactant.05-05-2011
20110104708Method for Sensing a Chemical - The present invention relates to a method for detecting an analyte (05-05-2011
20110104707Methods and products for diagnosing autoimmune disease and gastric cancer linked with atrophic gastritis - The present invention relates to a method for examining a person having symptoms and/or biomarker indicating an autoimmune disease for the presence of atrophic gastritis. The biomarker combination, which diagnoses atrophic gastritis, acts also as a part of a biomarker panel that helps diagnosis and assessment of autoimmune disease as well. The invention relates also to products used in these methods.05-05-2011
20110104705Musclin receptor and use thereof - The present invention provides a receptor of musclin and a screening system for an agonist and/or antagonist of the receptor by means of the interaction of musclin and the receptor. Hence, provided is a screening method for a substance that alters the bindability (i) a protein containing the same or substantially the same amino acid sequence as the amino acid sequence shown by SEQ ID NO:2 or a partial peptide thereof or a salt thereof and (ii) musclin or a partial peptide thereof or a salt thereof, containing using both.05-05-2011
20110104706NOVEL KINASES AND USES THEREOF - Novel kinase polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase proteins, the invention further provides isolated kinase fusion proteins, antigenic peptides, and anti-kinase antibodies. The invention also provides kinase nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.05-05-2011
20090035787ENZYMATIC SYNTHESIS OF SULFATED POLYSACCHARIDES WITHOUT IDURONIC ACID RESIDUES - Iduronic acid (IdoUA)-free heparan sulfate (HS)-like compounds are provided. Also provided are methods of synthesizing IdoUA-free HS-like compounds. The methods can include providing at least one O-sulfotransferase (OST) enzyme and a reaction mixture comprising 3′-phosphoadenosine 5′-phosphosulfate (PAPS); and incubating a polysaccharide substrate with the at least one OST and the reaction mixture, whereby the HS-like compounds are synthesized. Also disclosed are methods of synthesizing a library of HS-like compounds and methods of determining the mechanism of activity of HS-like compounds.02-05-2009
20100092992LYSINE ACETYLATION SITES - The invention discloses 322 novel acetylation sites identified in various cancers, peptides (including AQUA peptides) comprising a acetylation site of the invention, antibodies specifically bind to a novel acetylation site of the invention, and diagnostic and therapeutic uses of the above.04-15-2010
20100092999XANTHURENIC ACID DERIVATIVE PHARMACEUTICAL COMPOSITIONS AND METHODS RELATED THERETO - The present invention relates to diuretic pharmaceutical compositions and methods and in particular to certain derivatives of the formula I:04-15-2010
20100092998METHODS AND COMPOSITIONS RELATING TO E3 RING-E2 FUSION PROTEINS - Compositions are provided according to embodiments of the present invention which include an isolated fusion protein including an E3 protein RING motif bonded to an UCE E2 protein. In preferred embodiments, the C-terminus of the E3 protein RING motif is bonded to the N-terminus of the UCE E2 protein by an intervening peptide linker. Optionally, the peptide linker is 5-50 amino acids. Preferred is a peptide linker of 15-20 amino acids. Methods of identifying ubiquitylation modulators are provided according to embodiments of the present invention which include contacting an isolated fusion protein including an E3 protein RING motif bonded to an UCE E2 protein with a ubiquitylation substrate in the presence of a test substance. Ubiquitylation of the ubiquitylation substrate is then detected to determine the effect of the test substance on ubiquitylation of the ubiquitylation substrate.04-15-2010
20100092996MICROELECTRONIC SENSOR DEVICE FOR DETECTING LABEL PARTICLES - The invention relates to a microelectronic sensor device for the detection of target components that comprise label particles, for example magnetic particles (04-15-2010
20100092993QUANTITATIVE ANALYZING METHOD - This invention discloses an analyzing method for detecting a specific analyte in a fluid sample. The method comprises the following steps. First, a substrate is provided. The substrate has a channel provided concavely on an upper surface thereof. The channel comprises a first area, a second area and a third area, and these three areas are connected sequentially. Each of the second and the third areas comprises a nitrocellulose layers containing a reaction material and formed at the bottom thereof. The nitrocellulose layer of the third area can absorb a fixed volume of the fluid sample. Second, the fluid sample is applied to the first area and delivered by the second area and then to the third area. Finally, the reaction material reacts with the specific analyte in the fluid sample to produce a signal for detection.04-15-2010
20120315646OLIGOTHIOPHENE DERIVATE AS MOLECULAR PROBES - The present invention relates to oligothiophene derivatives binding specifically to neural stem cells and neural cancer stem cells. More specifically, the invention relates to methods for detecting neural stem cells or neural cancer stem cells using said oligothiophene derivatives in a biological sample, as well as uses and kits relating thereto.12-13-2012
20120315647Immunoassay Reagent Composition - An apparatus and method for sealing a fluid sample collection device, comprising loading a fluid sample collection device with a fluid sample, said device comprising a housing having at least one substantially planar surface that includes an orifice in fluid communication with an internal fluid sample holding chamber which terminates at an internal capillary stop; and slidably moving a sealing element over at least a portion of said substantially planar surface in a way that displaces any excess fluid sample away from the orifice, seals the fluid sample within said holding chamber, and inhibits the fluid sample from prematurely breaking through the internal capillary stop.12-13-2012
20120315645MULTIPLE REACTION MONITORING LC-MS/MS METHOD TO DETECT THERAPEUTIC ANTIBODIES IN ANIMAL SAMPLES USING FRAMEWORK SIGNATURE PEPTIDES - Methods are disclosed to detect, characterize, measure, and quantitate human and humanized antibodies, and their conjugates, present in pre-clinical animal biological samples, including plasma/serum and tissue samples.12-13-2012
20120315644ANTI-NPC2 MONOCLONAL ANTIBODIES AND A METHOD OF DETECTING FATTY LIVER TISSUE, CANCER CELLS OR CANCER TISSUE BY USING THEM - The present invention is related to anti-NPC2 monoclonal antibodies, which against NPC2 or glycosylated-NPC2; and is related to a method of detecting fatty liver tissues, cancer cells or cancer tissues by evaluating the expression level of NPC2 or glycosylated-NPC2 in the cells or tissues.12-13-2012
20090130690METHOD FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS - The present invention relates to a novel diagnostic marker useful for the diagnosis of rheumatoid arthritis comprising the autoantibodies of mannose binding lectin protein and a process thereof.05-21-2009
20120237946MESENCHYMAL STEM CELL AND THE METHOD OF USE THEREOF - Demyelinated axons were remyelinated in the demyelinated rat model by collecting bone marrow cells from mouse bone marrow and transplanting the mononuclear cell fraction separated from these bone marrow cells.09-20-2012
20100248255NOVEL PEPTIDES - The present invention provides novel peptides with circulation-modulating activity. These peptides are useful as circulation-modulating agents and vasopressors because of their circulation-modulating activity, and can be used for treating diseases of the circulatory system such as myocardial infarction, ischemic heart disease, cerebral infarction, or the like.09-30-2010
20100248258Immunoassay biochip - The present invention is about a microfluidic chip for rapid detection of different target proteins and a method for using the same. The microfluidic chip utilizes antibody-conjugated magnetic beads to bind to the target proteins to form a magnetic complex, and then use the signal labeled-antibodies that can recognize said magnetic complex. Purifying said magnetic complex by the micro-magnetic field on biochip, and introducing said purified magnetic complex into the fluorescent detection area on the chip to detect the amount of the target protein in said purified complex immediately.09-30-2010
20100248257Compiled Methods for Analysing and Sorting Samples - The present invention relates to the fields of analysis, diagnostics, prognostics, standardization, characterization and enumeration of entities such as biological cells, as well as therapeutical applications. Accordingly, the present invention in preferred aspects is directed to methods for the detection and/or analysis and/or isolation and optionally further manipulation of entities, such as cells, particles, and supra-molecular structures.09-30-2010
20110183356METHOD TO IDENTIFY PATIENTS AT RISK FOR LUNG TRANSPLANT REJECTION - Various embodiments include methods for diagnosing and treating medical conditions that involve an autoimmune response to connective tissue such as collagen found in organs such as the lung. In one method pulmonary disease and disorders such as Idiopathic Pulmonary Fibrosis (IPF) are diagnosed by analyzing fluid or tissue samples obtained from a patient for evidence of an autoimmune response to various types of collagen including, for example, Type V. One type of assay for evidence of an autoimmune response to Type V collagen comprises the steps of obtaining a fluid or tissue sample from a patient, contacting at least a portion of the sample with antigen to anti-Type V collagen antibody and monitoring the mixture of sample and antigen for changes indicative of the presence of anti-Type V collagen in the sample. Another embodiment includes treating pulmonary diseases such as IPF by administering a therapeutically effective dose of epitopes of various collagens including Type V collagen.07-28-2011
20110183354HUMAN Fc GAMMA RECEPTOR III - The present invention relates to the field of human immunoglobulin receptors, specifically the glycostructure of a human Fc gamma receptor IIIa recombinantly expressed in human embryonic kidney cells and Chinese hamster ovary cells.07-28-2011
20110183353COMPOSITION AND METHOD FOR DIAGNOSING FUNGAL DISEASE - Methods of diagnosing a fungal infection using anti-glycan antibodies alone or in combination with other anti-fungal diagnostic tests are described. Laminaribioside and chitobioside are used as antigens to detect human antibodies.07-28-2011
20110183352Configurable Diagnostic Systems and Methods for Performing Assays - A method and system for configuring an analyzer is disclosed. The analyzer receives a strip identifier from a strip or a vial identifier from a vial. The parameter module in the analyzer determines the parameters corresponding to the received strip identifier or the vial identifier. The parameter module then configures the analyzer to perform a test with the strip using the determined parameters. In one embodiment, the diagnostic test module determines the test corresponding to the received strip identifier or the vial identifier and the diagnostic test module configures the analyzer to perform the determined test with the strip. In another embodiment, the association determination module determines if the received strip identifier and vial identifier are associated with each other. If not, the analyzer renders an error requesting a correct strip.07-28-2011
20120164658Transcription Factor Modulator - The present invention relates to novel agents that are useful for modulating transcription factor activity. In particular, the present invention relates to a transcription factor modulator comprising (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof or pharmaceutical composition thereof or (ii) a compound or composition capable of regulating the endogenous levels of HLS-5 or its activity; or (iii) combinations thereof.06-28-2012
20120164659HUMAN HCV-INTERACTING PROTEINS AND METHODS OF USE - The present invention generally relates to a method for identifying and cloning nucleic acid molecules encoding a new class of proteins or fragments thereof, capable of interacting with proteins associated with the Human Hepatitis C virus (HCV) and thus being suitable either alone or in complex with the HCV protein for serving as a target for the development of antiviral drugs. In this context, the present invention provides novel HCV-interacting proteins and complexes as well as antibodies which specifically recognize and bind to the complex or to specific domains of HCV proteins.06-28-2012
20120164657Method of detecting botulinum neurotoxin and antibodies that neutralize botulinum neurotoxin action - A highly sensitive method of analyzing a sample for the presence or activity of botulinum neurotoxin (BoNT) or antibodies specific for botulinum neurotoxin is disclosed. In one embodiment, the method comprises the steps of preparing primary non-human mammalian or avian spinal cord cells, and exposing the cells to a test sample, in parallel with a control sample, and examining the extent of cleavage of the intracellular neuronal target protein in both the test and control sample.06-28-2012
20100209937FLUORESCENCE MICROSCOPE IN A MICROWAVE CAVITY - The present invention relates to an optical imaging system communicatively connected to a microwave energy producing source wherein the combination provides for increases in chemical reaction times and the ability to monitor the reactions in real time with sufficient resolution to view the location of intracellular components labeled with luminescent molecules as well as interaction with other biomolecules and responses to localized environmental variables in living cells and tissues during the application of a microwave field.08-19-2010
20100209938METHODS AND SYSTEMS FOR DETECTION OF STOICHIOMETRY BY FORSTER RESONANCE ENERGY TRANSFER - Methods to detect stoichiometries of protein complexes and/or interactions between proteins based on detection and quantification of FRET and related systems and compositions.08-19-2010
20120135420Method for detecting the presence of target bacteria or a target component carbohydrate antigen thereof - A process is disclosed for separating a carbohydrate antigen from a Gram-positive or Gram-negative bacteria in a purified form that contains no more than 10% protein. The separated antigen is coupled to an affinity column, over which polyclonal antibodies to the same bacteria are chromatographed and recovered in a purified form that exhibits high specificity and sensitivity in immunoassays for the raw carbohydrate antigen corresponding to the purified antigen on the column. A particularly preferred form of rapid immunochromatographic assay employing the purified antibodies, which assay is very useful as an aid to rapid diagnosis of diseases caused by bacteria, is disclosed.05-31-2012
20090075293Methods for predicting embryo viability - The present invention provides methods for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence or absence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample. In many instances, the invention is applicable to embryos generated by in vitro fertilization techniques, for instance, to embryos developing in a growth media. The present invention further provides methods for determining the amount of a pregnancy associated markers such as molecular isoforms of hCG (hCG) in a sample. The present invention also provides a diagnostic kit for predicting the viability of an embryo or for predicting the likelihood of a negative outcome during pregnancy by identifying the presence of or determining the amount of one or more pregnancy associated markers such as molecular isoforms of hCG in a sample.03-19-2009
20090258371METHOD OF DETECTING VERY LOW LEVELS OF ANALYTE WITHIN A THIN FILM FLUID SAMPLE CONTAINED IN A THIN THICKNESS CHAMBER - A method and apparatus for the detection and quantification of very low levels of a target analyte using an imaging system is provided. In the case of some analytes such as certain hormones, for example TSH, their levels may be as low as several tens of thousands of molecules per micro liter. These extremely low levels can be measured by using the present invention to count the individual molecules of analyte. The invention also has the advantage of being a primary quantitative method, which is one which needs no standardization.10-15-2009
20100173322Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways - The invention discloses nearly 219 novel phosphorylation sites identified in signal transduction proteins and pathways underlying Anaplastic Large Cell Lymphoma (ALCL) involving the NPM-ALK translocation/fusion, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose.07-08-2010
20100173327NONHUMAN MODEL ANIMAL LACKING THE ABILITY TO CONTROL LYMPHOCYTE MIGRATION - The present invention provides a animal model useful in identifying a molecule controlling in a lymphocyte-specific manner migration and thus elucidating immune-related diseases and pathogenic conditions such as allergy, autoimmune diseases, GvH and graft rejections at a molecular level, or in developing a novel therapy. A nonhuman animal model such as a DOCK2 knockout mouse, in which the function to control lymphocyte migration has been deleted or suppressed, is generated by deleting DOCK2 gene on the chromosome. In this DOCK2 knockout mouse, the function of activating Rac to mediate actin cyteskeleton, the lymphocyte migration function in response to stimuli with chemokines such as SLC, SDF-1, BLC, the homing function to secondary lymphoid organs such as spleen, lymph nodes and Peyer's patches, and the function of emigrating mature thymic T cells into peripheral blood in response to stimulus with chemokine ELC are impaired, and as a result of this, immune responses are suppressed.07-08-2010
20100173325Composition and Method for Analysis of Target Analytes - A method of detecting analytes includes providing a mixture containing analytes to be analyzed and microparticles coated with competitive inhibitors of the analytes. First antibodies are reacted with the analytes and the competitive inhibitors under competitive binding conditions. The first antibodies bound to the competitive inhibitors are measured using flow cytometry.07-08-2010
20100173326SUBSTRATE AND METHOD FOR PRODUCING THE SUBSTRATE - A self assembling monolayer formed by the self assembling molecules is caused to bond onto the surface of a base material, and chelators are caused to bond onto the self assembling monolayer, to produce a substrate, in which the chelators are bound to the self assembling monolayer at a density within a range from 0.4/nm07-08-2010
20120252031COMPOSITIONS AND METHODS FOR REGULATING SAS1R - The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females. Together, the results suggest SAS1R is a proteolytically active, oocyte and early embryo specific oolemmal metalloprotease receptor for the sperm intra-acrosomal ligand SLLP1 and is a target for regulating fertilization and as a contraceptive.10-04-2012
20120171695SPONTANEOUSLY CONTRACTING FISH CELL AGGREGATES, USE THEREOF AND METHOD FOR THE PRODUCTION THEREOF - The invention relates to an in vitro method for producing spontaneously contracting fish cell aggregates, to the fish cell aggregates obtained thereby, and to the use thereof, in particular for testing biological active substances and pharmaceuticals. The in vitro method according to the invention for producing contracting fish cell aggregates comprises the following steps: a) mechanical comminution and/or partial enzymatic digestion of fish embryos or fish larvae; b) transfer of the comminuted and/or partially digested fish tissue into an enzyme-free medium and removing the supernatant by centrifuging to obtain a cell pellet; c) re-suspension of the cell pellet in a cell culture medium; d) culturing the cells, with the medium being changed at least once, until spontaneously contracting cell aggregates form.07-05-2012
20120252035GDF-15 and/or Troponin T for Predicting Kidney Failure in Heart Surgery Patients - The present disclosure relates to the field of laboratory diagnostics. Specifically, means and methods are disclosed for determining a patient's risk of suffering from acute kidney injury after a surgical procedure based on the detection of GDF-15, troponin T and/or a natriuretic peptide.10-04-2012
20120252034QUALITY ASSAYS FOR ANTIGEN PRESENTING CELLS - The present invention provides methods for evaluating the quality of a preparation of antigen presenting cells, such as dendritic cells. Assays for antigen-independent co-stimulation of T cells and for presentation of predetermined antigen by APCs are provided10-04-2012
20120077206Rapid Microbial Detection and Antimicrobial Susceptibility Testing - A method for the detection of microorganisms in a sample comprising contacting said sample with a biosensor concentration module, allowing microorganisms to grow for a first period of time and detecting growth of discrete microorganisms as an indication of the presence of said microorganisms.03-29-2012
20120315648METHOD OF IDENTIFICATION OF CELLS THAT SHOW SENSITIVITY TO MODULATION OF SIGNALING MEDIATED BY A FIBROBLAST GROWTH FACTOR RECEPTOR OR A VARIANT THEREOF - The invention is based on the finding that cells that show (especially tyrosine) phosphorylation of FGF-R substrate 2 (FRS-2), in contrast to cells that lack such phosphorylation, allow a prediction that treatment with a modulator, especially an inhibitor, of Fibroblast Growth Factor-Receptor signaling will be successful in cells e.g. from biological samples from patients that show such phosphorylation. Therefore, the phosphorylation of FRS-2 can serve as a biomarker for the possibility of successful treatment. The invention relates to various methods, uses, kits and reagents useful in applying this biomarker.12-13-2012
20090117580Structure of prl-1 protein crystal and the method of crystallization thereof - The present invention relates to a crystal structure of PRL-1 (Phospatase of Regenerating Liver) protein and a method of crystallization thereof. It has been found that the PRL-1 protein has a tertiary structure having 5 strands of beta-sheet surrounded by 6 alpha-helices and well-arranged active site with closed P-loop, and monomers form a trimer through farnesylation site in the C-terminus of said protein. Thus intra-cellular migration and membrane localization can be achieved. The said crystal structure of PRL-1 protein of the present invention is very useful for the development the agent which inhibits carcinogenesis and metastasis of the cancer.05-07-2009
20100047820DETECTING METHOD, DETECTING APPARATUS, DETECTION SAMPLE CELL, AND DETECTING KIT - A sample is supplied onto the sensor portion of a sensor chip. An excitation light beam is irradiated to generate an enhanced optical field to be generated on the sensor portion. Fluorescent labels are excited, and the amount of a detection target substance is detected, based on the amount of light which is generated due to excitation of the fluorescent labels. A first electric charge is present on the surface of the sensor portion. A fluorescent substance having fluorescent pigment molecules which are enveloped in a light transmitting material that transmits fluorescence generated by the fluorescent pigment molecules, the surfaces of which are charged with second electric charges opposite the first electric charge on the surface are employed as the fluorescent labels. The fluorescent substance is attracted to the sensor portion by static electric interactions between the two charges.02-25-2010
20100047818DIAGNOSIS OF CARCINOMAS - The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.02-25-2010
20120219962HUMAN EMBRYONIC STEM CELL METHODS AND PODXL EXPRESSION - A method of identifying an undifferentiated human embryonic stem cell in a sample which may contain such cells, the method comprising identifying the cell or cells within the sample that express podocalyxin-like protein (PODXL) on their surface. A method of isolating an undifferentiated human embryonic stem cell from a sample containing such cells, the method comprising isolating the cell or cells within the sample that express PODXL on their surface. Typically, the methods use an antibody which binds to PODXL. Undifferentiated human embryonic stem cells isolated by the method may be useful in cell therapy. Also, in particular, compositions of cells differentiated from a human embryonic stem cell but which composition has been depleted of undifferentiated human embryonic stem cells are provided which are useful in cell therapy.08-30-2012
20120219961Methods of running assays using intrachain fluorophore-quencher FRET-aptamers - The present invention describes methods for the production and use of single chain (single-stranded) fluorescence resonance energy transfer (“FRET”) DNA or RNA aptamers containing fluorophores (F) and quenchers (Q) at various loci within their structures, such that when its specific matching analyte is bound and the FRET-aptamers are excited by specific wavelengths of light, the fluorescence intensity of the system is modulated (increased or decreased) in proportion to the amount of analyte added. F and Q are covalently linked to nucleotide triphosphates (NTPs), which are incorporated by various nucleic acid polymerases such as Taq polymerase during the polymerase chain reaction (PCR) and then selected by affinity chromatographic, size-exclusion or molecular sieving, and fluorescence techniques. Further separation of related FRET-aptamers can be achieved by ion-pair reverse phase high performance liquid chromatography (HPLC) or other types of chromatography. Finally, FRET-aptamer structures and the specific locations of F and Q within FRET-aptamer structures are determined by digestion with exonucleases and mass spectral nucleotide sequencing analysis.08-30-2012
20120178097METHODS AND DESIGN OF MEMBRANE FILTERS - The present invention provides methods for designing a filtration systems for capturing viable tumor cells, such as circulating tumor cells at high efficiency and high viability. The methods involve development of a set of “key engineering design parameters” that are crucial to achieve high tumor cell viability. These important design parameters include the filter geometry design, fluid delivery method, transfilter pressure and total filtration time.07-12-2012
20100273177Methods and Devices for Testing Saliva - Provided are methods and devices for performing sensitive, rapid antigen testing of saliva, which yield sensitivity comparable to both rapid antigen tests and saliva culture.10-28-2010
20100273183DIAGNOSTIC ASSAY FOR ANTI-VON WILLEBRAND FACTOR CLEAVING PROTEASE (ADAMTS13) ANTIBODIES - This invention relates to a kit to be used in an assay system for determination of an anti-von Willebrand Factor-cleaving protease (“anti-vWF-cp”) antibody in a sample. The kit comprises vWF-cp and/or vWF-fragment(s) immobilized on a solid phase. The kit can be used in a method for determination of anti-vWF-cp antibodies from a patient, for the diagnosis of disorders associated with the occurrence of anti-vWF-cp-antibodies, and the differentiation of various forms of thrombotic microangiopathy.10-28-2010
20100273182Truncated Proteins As Cancer Markers - Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2X10-28-2010
20100273180DECORIN POLYPEPTIDE AND METHODS AND COMPOSITIONS OF USE THEREOF - The present invention provides methods for decreasing expression of a decorin polypeptide in a cell, methods for identifying an agent that alters, preferably decreases, the distribution of decorin polypeptide in a cell, and methods for determining a prognosis for oral cancer in a subject through the use of a compound that binds decorin polypeptide. Also provided are antibodies that specifically bind decorin polypeptides and double stranded polynucleotides, for instance, dsRNAs, that inhibit expression of a polynucleotide encoding a decorin polypeptide.10-28-2010
20100273179METHOD FOR TESTING OR SCREENING PROTEIN SYNTHESIS INHIBITORS - This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.10-28-2010
20100273178Affinity selected signature peptides for protein identification and quantification - A method for protein identification in complex mixtures that utilizes affinity selection of constituent proteolytic peptide fragments unique to a protein analyte. These “signature peptides” function as analytical surrogates. Mass spectrometric analysis of the proteolyzed mixture permits identification of a protein in a complex sample without purifying the protein or obtaining its composite peptide signature.10-28-2010
20100009379Nanoparticle-Textured Surfaces and Related Methods for Selective Adhesion, Sensing and Separation - Textured heterogeneous surfaces and related articles as can be used in conjunction with methods for selective sensing and/or separation.01-14-2010
20100009381Compositions and methods for detection and isolation of phosphorylated molecules - The present invention relates to phosphate-binding compounds that find use in binding, detecting and isolating phosphorylated target molecules including the subsequent identification of target molecules that interact with phosphorylated target molecules or molecules capable of being phosphorylated. A binding solution is provide that comprises a phosphate-binding compound, an acid and a metal ion wherein the metal ion simultaneously interacts with an exposed phosphate group on a target molecule and the metal chelating moiety of the phosphate-binding compound forming a bridge between the phosphate-binding compound and a phosphorylated target molecule resulting in a ternary complex. The binding solution of the present invention finds use in binding and detecting immobilized and solubilized phosphorylated target molecules, isolation of phosphorylated target molecules from a complex mixture and aiding in proteomic analysis wherein kinase and phosphatase substrates and enzymes can be identified.01-14-2010
20100009378Mass Spectrometric Methods and Products - The invention involves assays, diagnostics, kits, and assay components for mass spectrometry and other methods to determine levels of glycated CD59 in subjects.01-14-2010
20090068679Binding partners of the placental growth factor, especially antibodies directed against the placental growth factor, and production and use thereof - The invention relates to binding partners of the placental growth factor (or placenta growth factor, PIGF), especially antibodies directed against the placental growth factor, and production and use thereof.03-12-2009
20100285490DETECTION APPARATUS - The present invention relates to, in part, methods, reagents and apparatuses for the detection of agents. The present invention also relates, in part, to compositions including, but not limited to, flow cells, assay chambers, reagent reservoir delivery units and devices for holding an assay chamber. The present invention also provides various components and combinations of components for various detection apparatuses. The present invention also relates to a portable agent detection apparatus that can be used in the field or at a point of care and is not limited to specialized laboratories or limited to use by highly skilled users.11-11-2010
20090061458Heterooligomeric Taste Receptor - Newly identified mammalian taste-cell-specific G protein-coupled receptors which function as hetero-oligomeric complexes in the sweet taste transduction pathway, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in sweet taste signaling as hetero-oligomeric complexes, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for identifying putative taste modulating compounds using such hetero-oligomeric complexes also described, as is a novel surface expression facilitating peptide useful for targeting integral plasma membrane proteins to the surface of a cell.03-05-2009
20090061456Method for predicting progression free and overall survival at each follow-up time point during therapy of metastatic breast cancer patients using circulating tumor cells - A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.03-05-2009
20090061455Use of Glycosaminoglycans to Reduce Non-Specific Binding in Immunoassays - An immunoassay reagent is provided which comprises an analyte binding agent in a diluent, and a glycosaminoglycan in an amount sufficient to reduce non-specific binding in an assay of a sample for the analyte. Provided is such an immunoassay reagent in which the analyte is troponin I, the analyte binding agent is a biotinylated anti-troponin I antibody, and the glycosaminoglycan is chondroitin sulfate. A sample composition is also provided which comprises a sample to be assayed for the presence of an analyte, an analyte binding agent, and a glycosaminoglycan other than heparin. Further provided is a method of detecting an analyte in a sample, in which non-specific binding is reduced in the method using a glycosaminoglycan.03-05-2009
20120225436Immuno-Based Botulinum Toxin Serotype A Activity Assays - The present specification discloses SNAP-25 compositions, methods of making α-SNAP-25 antibodies that bind an epitope comprising a carboxyl-terminus at the P09-06-2012
20120225435NANOPIPETTE APPARATUS FOR MANIPULATING CELLS - Disclosed herein are methods and systems for controlled ejection of desired material onto surfaces including in single cells using nanopipettes, as well as ejection onto and into cells. Some embodiments are directed to a method and system comprising nanopipettes combined with an xyz controller for depositing a user defined pattern on an arbitrary substrate for the purpose of controlled cell adhesion and growth. Alternate embodiments are directed to a method and system comprising nanopipettes combined with an xyz controller and electronic control of a voltage differential in a bore of the nanopipette electroosmotically injecting material into a cell in a high-throughput manner and with minimal damage to the cell. Yet other embodiments are directed to method and system comprising functionalized nanopipettes combined with scanning ion conductance microscopy for studying molecular interactions and detection of biomolecules inside a single living cell.09-06-2012
20120258466FILTRATION DEVICE FOR ASSAYS - A device and method for filtering blood is disclosed herein. The device can filter blood and attach analytes within the blood to magnetic particles. The analytes can then be strongly bound to an analyzing device by a magnetic force. The analytes can then be counted by the analyzing device and the result can be displayed.10-11-2012
20120082998DETECTION OF BACTERIAL INFECTIONS IN SUBJECTS SUFFERING FROM DYSPNEA - The field of the present invention is the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea. It is a subject of the present invention to provide a method for the diagnosis and/or prediction and/or therapy follow-up of bacterial infections in subjects suffering from dyspnea.04-05-2012
20120258467TRANSDERMAL SYSTEMS, DEVICES, AND METHODS TO OPTICALLY ANALYZE AN ANALYTE - The invention provides transdermal optical analysis systems, test sensors, methods, and kits for determining the presence and/or concentration of at least one analyte in a fluid sample. The system includes a transdermal test sensor including an aqueous material including at least one analyte selective reagent and at least one optically active moiety. The optical system preferably uses fluorescent spectroscopy to correlate fluorescent emission or adsorption from a dye with the analyte concentration of the sample. An optical light source and/or detector may be housed with the aqueous material in a housing or external to the housing of the aqueous material.10-11-2012
20120190041METHODS, IMMUNOASSAYS AND DEVICES FOR DETECTION OF ANTI-LIPOIDAL ANTIBODIES - Compositions, methods and devices for the detection of anti-lipoidal antibodies and the diagnosis of disease, for example, syphilis, are described. In particular, a method for immobilizing a lipoidal antigen, comprising cardiolipin, lecithin, and cholesterol, on a solid support (such as a nitrocellulose membrane) is described. The ability to immobilize a lipoidal antigen on a membrane satisfies a long-felt need for membrane-based assay for the detection of anti-lipoidal antibodies. Also described are immunoassay devices for concurrently performing treponemal and non-treponemal tests for syphilis.07-26-2012
20120329068FLUORESCENT DYES, FLUORESCENT DYE KITS, AND METHODS OF PREPARING LABELED MOLECULES - The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners.12-27-2012
20110124008NOVEL Au/Ag CORE-SHELL COMPOSITE USEFUL FOR BIOSENSOR - In accordance with an aspect of the present invention, there is provided an Au/Ag core-shell composite including an Au nanoparticle; an Ag nanoparticle layer surrounding the Au nanoparticle; and a receptor having a target material recognition site bondable or reactable with a target material, wherein one end of the receptor is bonded on the surface of the Au nanoparticle, so that a portion of the receptor is embedded into the Ag nanoparticle layer, and the target material recognition site is exposed to the outside of the Ag nanoparticle layer. The Au/Ag core-shell composite can provide a stable bond between Au nanoparticle and organic molecule, and superior optical characteristics of Ag nanoparticle. Thus, a biosensor using the composite in accordance with an aspect of the present invention can effectively and efficiently detect target bio material and be variously used in medical and pharmaceutics.05-26-2011
20110124006METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR CANCER - A screening method for a therapeutic agent for cancer, the method including: a step of measuring an interaction between NLRR1 and EGFR under each condition of being in the presence of a test substance and in the absence of a test substance; and a step of determining that the test substance is a therapeutic agent for cancer when the interaction between NLRR1 and EGFR in the presence of the test substance is weaker than the interaction between NLRR1 and EGFR in the absence of the test substance.05-26-2011
20120231472METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE - The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of C—C motif chemokine 23, Transmembrane glycoprotein NMB, Brain-derived neurotrophic factor, Cathepsin S, Transforming growth factor beta-2, Urokinase-type plasminogen activator, Angiopoietin-2, Matrilysin, Carcinoembryonic antigen-related cell adhesion molecule 1, Creatine kinase MB, Insulin, Immunoglobulin M, Immunoglobulin E, Macrophage migration inhibitory factor, Galectin-3, Transforming growth factor beta-3, Heparan sulfate, soluble Cadherin-3, Complement C5, Platelet factor 4, Platelet basic protein, and Stromelysin-2 as diagnostic and prognostic biomarkers in renal injuries.09-13-2012
20120231473FLOW CYTOMETRY METHOD THROUGH THE CONTROL OF FLUORESCENCE INTENSITIES - Provided is a flow cytometry method including adjusting cell populations targeted by antibodies conjugated with a same-color fluorochrome to show different fluorescence intensities according to types of the antibodies. Unlike a conventional flow cytometry method capable of classifying a positive and negative of one target using one antibody per color, the flow cytometry method adjusts several types of antibodies conjugated with a single-color fluorochrome to respectively show different fluorescence intensities, or adjusts the amounts of antibodies conjugated with a fluorochrome differently according to types of the antibodies, thereby classifying a positive and negative of multiple targets using one color. Accordingly, even when a current flow cytometer capable of classifying a limited number of colors is used, it is possible to classify a variety of cell populations to be clinically examined.09-13-2012
20120231470METHODS AND SYSTEMS ASSOCIATED WITH DETECTION OF FATTY ACID ELONGATION IN A CELL - Methods and systems to identify compounds capable of altering a fatty acid elongation pathway and for identifying conditions under which fatty acids elongation can occur in a cell are described. The methods and systems comprise labeled fatty acid precursors and cells capable of elongating fatty acids. Methods for providing suitable components of an assay for identifying compounds capable of altering a fatty acid elongation pathway are described.09-13-2012
20120231469FORMALIN-FIXED ISOTOPE-LABELED REFERENCE STANDARDS AND METHODS FOR FABRICATION AND USE THEREOF - One or more cells are labeled with minor stable isotopes, characterized, and preserved for subsequent use as a bio-specimen reference standard. The one or more cells are grown in culture media supplied with minor stable isotopes in concentrations substantially different from normally occurring concentrations, thereby supplanting major stable isotopes that would normally be incorporated into the proteins of the cells. The proteins of the cells are thus labeled by the minor stable isotopes and can be used in proteomic characterization of the cells. The cells are preserved by fixation as a reference standard. Cells of the reference standard are mixed with the sample and subject to mass spectrometry evaluation, whereby the labeled proteins of the reference standard can be used in determining the proteome of the sample.09-13-2012
20120231471MARKER ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS - Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.09-13-2012
20100233724MARKERS OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND METHODS OF USE THEREOF - Novel methods for assessing the level of triglycerides in the liver of a subject are described, comprising determining the amount of a lipid metabolite in a sample from a body fluid of the subject. The methods may be used, for example, in diagnosing and monitoring liver disorders such as steatosis, NAFLD and NASH.09-16-2010
20100323369Diagnostic Testing Process - A method and apparatus for use in a flow through assay process is disclosed. The method is characterised by a “pre-incubation step” in which the sample which is to be analysed (typically for the presence of a particular protein), and a detection analyte (typically one or more antibodies bound to colloidal gold or a fluorescent tag) which is known to bind to the particular protein may bind together for a desired period of time. This pre-incubation step occurs before the mixture of sample and detection analyte come into contact with a capture analyte bound to a membrane. The provision of the pre-incubation step has the effect of both improving the sensitivity of the assay and reducing the volume of sample required for an assay. An apparatus for carrying out the method is disclosed defining a pre-incubation chamber for receiving the sample and detection analyte having a base defined by a membrane and a second membrane to which a capture analyte is bound. In one version the pre-incubation chamber is supported above the second membrane in one position but can be pushed into contact with the membrane carrying the capture analyte thus o permitting fluid transfer from the incubation chamber through the capture membrane. In another version the membrane at the base of the incubation chamber is hydrophobic and its underside contacts the capture membrane and when a wetting agent is applied to the contents of the pre-incubation chamber fluid transfer occurs.12-23-2010
20120264137TECHNIQUES FOR BUFFERLESS LYSING OF CELLS AND SEPARATION OF CELLULAR COMPONENTS USING MODIFIED MEMBRANES - A porous membrane for lysis of a cell population enriched from a biological sample, and isolation of cellular components is provided. The porous membrane contains embedded lysing agents to perform lysing. The biological sample is brought into contact with the membrane. Lysis occurs through the action of the embedded lysing agents on the biological sample. The pores of the porous membrane are designed to have dimensions to allow only a desired type of cellular component(s) resulting from lysis to pass through the membrane, thereby achieving isolation of the desired cellular component(s). The action of lysing agents is combined with the filtration properties of porous membranes resulting in an easy-to-use and cost-effective technique.10-18-2012
20120322079METHOD FOR TESTING OR SCREENING PROTEIN SYNTHESIS INHIBITORS - This invention provides methods for screening an inhibitor of protein synthesis by measuring the level of relocalization of an SMN complex component from the cytoplasm to the nucleus. Additionally, the invention provides a kit and a system for screening protein synthesis inhibitors in a cell.12-20-2012
20110045493Hydrophilic, High Protein Binding, Low Fluorescence, Western Blotting Membrane - Hydrophilic membrane particularly suited for blotting applications, preferably Western blotting. A pre-wet hydrophobic membrane substrate, preferably made of PVDF, is contacted with a monomer solution and subjected to a UV-initiated free radical polymerization step to render the substrate permanently hydrophilic. The resulting membrane exhibits low background fluorescence, high protein binding, excellent retention of protein sample spot morphology, and extended dynamic range (high signal-to-noise ratio, enhanced sample detectability). The membrane demonstrates comparable or higher performance in Western blotting applications than conventional nitrocellulose Western blotting membranes, particularly for protein detection at low sample concentrations, and is directly water-wettable, eliminating the need for an alcohol pre-wet step prior to use.02-24-2011
20110212464PACAP AS A MARKER FOR CANCER - The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the proapoptotic caspase adaptor protein (=PACAP) as a universal marker of different types of cancer. PACAP aids in the assessment of pulmonary or lung cancer (LC), particularly of non-small cell lung carcinoma (NSCLC), but also of other specific types of cancer. Such specific types of cancer are e.g. colon, bladder, cervix, ovary, endometrial, head and neck, breast, melanoma, pancreas, kidney, prostate, esophagus, stomach or bile duct cancer. Furthermore, the present invention especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring PACAP in said sample. Measurement of PACAP can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.09-01-2011
20110212461PREDICTION OF CARDIOTOXICITY - The likelihood that a compound will exhibit cardiotoxicity in an in vitro or in vivo assay predicted by the ability of the compound to inhibit at least one kinase from a selected group.09-01-2011
20110236906SECRETORY PROTEIN BIOMARKERS FOR HIGH EFFICIENCY PROTEIN EXPRESSION - The instant invention relates to the field of protein production, and in particular is relates to compositions and processes for improving the production levels of recombinant proteins expressed in host cells.09-29-2011
20110236904DETECTION OF TUMOR STEM CELLS AND TUMOR CELLS IN EPITHELIAL-MESENCHYMAL TRANSITION IN BODY FLUIDS OF CANCER PATIENTS - The present invention relates to the detection of tumor stem cells and tumor cells in epithelial-mesenchymal transition and uses of such methods.09-29-2011
20100173321Making a diagnosis in cases of cardiac disease using a combination of markers - The present invention concerns methods for diagnosing myocardial infarction, for performing risk stratification of myocardial infarction, for making a prognosis of a disease course in a myocardial infarction patient, for identifying a patient with elevated risk of myocardial infarction, or combinations thereof, wherein a determination of at least three markers is performed on a patient sample. Furthermore, kits for performing the methods are provided.07-08-2010
20100203551MONOCYTE ACTIVATION TEST BETTER ABLE TO DETECT NON-ENDOTOXIN PYROGENIC CONTAMINANTS IN MEDIAL PRODUCTS - An improved monocyte activation test is described that is better able to detect non-endotoxin pyrogens in medical products, in which a sample is incubated with a monocyte-containing reagent in an assay system comprising at least one surface comprising polypropylene. The invention also concerns assay systems for use in these tests that include at least one microtiter well having at least one interior surface comprising polypropylene and having a shape such that monocyte-containing reagent is concentrated in the well to provide greater cell to cell contact. The invention also relates to a diagnostic kit that can be used to test for the presence of non-endotoxin pyrogens in a sample.08-12-2010
20100203550METHOD OF PERFORMING AN IMMUNOASSAY IN BLOOD - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and 08-12-2010
20100203549CALIBRATED RPMA ASSAY - This invention relates, e.g., to a set of calibrants for determining the amount in a sample of an analyte (e.g., a protein, such as a protein that has been post-translationally modified), comprising a plurality of calibrants, which contain a range of amounts (e.g., defined amounts and/or serial dilutions) of the analyte, spanning the expected amount of the analyte in the sample. In each of the calibrants, a defined amount of the analyte is present in the same suitable, biological diluent (e.g., a cell or tissue lysate, or a bodily fluid). In one embodiment of the invention, the diluent reflects the same or a similar biological milieu (proteins, lipids, serum proteins, serum matrix proteins, etc.) as that in the sample in which the analyte to be measured is present. In embodiments of the invention, a single calibrant (e.g., a cell lysate) may comprise as many as hundreds of analytes, and can be used for the quantification of those hundreds of analytes in a sample. Methods are described for performing an assay (e.g. RPMA analysis), in which the calibrants of a set of calibrants of the invention are immobilized on each of the surfaces to which samples to be analyzed are immobilized, thereby providing an internal calibration curve for quantifying an RPMA assay.08-12-2010
20100233728METHOD AND KIT FOR DETECTING THE EARLY ONSET OF RENAL TUBULAR CELL INJURY - A method and kit for detecting the early onset of renal tubular cell injury, utilizing NGAL as an early urinary biomarker. NGAL is a small secreted polypeptide that is protease resistant and consequently readily detected in the urine following renal tubule cell injury. NGAL protein expression is detected predominantly in proximal tubule cells, in a punctate cytoplasmic distribution reminiscent of a secreted protein. The appearance NGAL in the urine is related to the dose and duration of renal ischemia and nephrotoxemia, and is diagnostic of renal tubule cell injury and renal failure. NGAL detection is also a useful marker for monitoring the nephrotoxic side effects of drugs or other therapeutic agents.09-16-2010
20100233727MARKER FOR ARRHYTHMIA RISK - The present invention relates to markers and methods for determining risk of ventricular arrhythmia in an African American or woman patient. By using the markers of the present invention, individual with high risk of ventricular arrhythmia can properly be detected and treated. The present inventors have discovered that, in African American and women, IL-6 and/or DROMs and/or CRP have strongly positive correlation with the risk of ventricular arrhythmia.09-16-2010
20100233725IMMUNOASSAYS EMPLOYING NON-PARTICULATE CHEMILUMINESCENT REAGENT - Methods and reagents are disclosed for conducting assays. Embodiments of the present methods and reagents are concerned with chemiluminescent reagents for determining the presence and/or amount of an analyte in a sample suspected of containing the analyte. The reagent is non-particulate and comprises a binding partner for the analyte and a chemiluminescent composition comprising an olefinic compound and a metal chelate. In embodiments of an assay, a combination is provided that comprises a sample suspected of containing the analyte, a chemiluminescent reagent as described above and a sensitizer reagent capable of generating singlet oxygen. The combination is subjected to conditions for binding of the analyte to the binding partner for the analyte. The sensitizer is activated and the amount of luminescence generated by the chemiluminescent composition is detected wherein the amount of luminescence is related to the amount of the analyte in the sample.09-16-2010
20100233723DRY STICK DEVICE AND METHOD FOR DETERMINING AN ANALYTE IN A SAMPLE - The present invention relates to a dry stick test device for the determination of an analyte in a sample by means of a chemical assay. The device comprises: (i) optionally a solid support, (ii) at least one reagent pad comprising a reagent capable of reacting with the analyte, a derivative of said analyte or an indicator compound for said analyte to provide a detectable signal when in moistened state, and (iii) a development pad which is located in contact with the at least one reagent pad, optionally between the solid support and the at least one reagent pad, said development pad comprises at least one controlling compound capable of providing a condition required for the reagent to react with the analyte to provide a detectable signal, wherein the at least one reagent pad and the development pad are arranged to avoid precipitation of sample component(s) on the top-face of the device.09-16-2010
20110262932COMPOSITIONS - The invention generally relates to compositions that include magnetic particles bound to pathogens in a body fluid.10-27-2011
20120088251MASS SPECTROMETRIC METHODS AND PRODUCTS - The invention involves assays, diagnostics, kits, and assay components for mass spectrometry and other methods to determine levels of glycated CD59 in subjects.04-12-2012
20110287442Tumor Antigen Protein, Gene, or Peptides from Topoisimerase 2 Alpha - Provided is a tumor antigen protein, gene, or peptides derived from topoisomerase 2 alpha. As it is discovered that topoisomerase 2 alpha binds to an MHC class I or II antigen, thereby forming a complex, and the complex is recognized by cytotoxic T lymphocytes, the tumor antigen can be used in tumor immunotherapy.11-24-2011
20100216157IMMUNOGLOBULIN PEPTIDES AGAINST HEATED BOVINE BLOOD - The present invention is related to immunoglobulin peptides that recognize a thermostable antigen from bovine blood. The invention also provides methods for determining the presence of bovine blood in a food sample or an animal feed sample.08-26-2010
20120100557SAMPLE PREPARATION DEVICE AND ASSOCIATED METHOD - A sample preparation device and associated method is provided for preparing samples according to an assay protocol. A cell deposition module deposits a sample on each a plurality of assay devices supported by a support device. An epitope retrieval module deposits a reagent on each of the samples. Each of the samples is brought to a selected temperature. A heating device, corresponding to each of the assay devices, directly interacts with the corresponding assay device may be used to heat each assay device to the selected temperature, in conjunction with the epitope retrieval module depositing the reagent on each of the samples. A staining module deposits a staining reagent on each of the samples, and removes excess staining reagent. The staining, epitope retrieval, and cell deposition modules cooperate with the support device and heating devices to form a unitary sample preparation device.04-26-2012
20120288870Means for the inhibition of anti-beta1-adrenergic receptor antibodies - Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-β1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.11-15-2012
20090291453Method for Testing Alzheimer's Disease by Measuring Degradation Rate of B-Amyloid in Blood and Diagnostic Reagent - Provided is a method of testing Alzheimer's disease using serum or plasma as a sample. It is found that a β-amyloid peptide added to a blood sample is degraded. The degradation activity thereof was compared between the blood samples of normal subjects and Alzheimer's disease patients, and it is also found that the degradation activity is significantly higher in the blood of the normal subjects.11-26-2009
20090098571METHODS AND SUBSTANCES FOR THE DIAGNOSIS AND THERAPY OF SEPSIS AND SEPSIS-LIKE SYSTEMIC INFECTIONS - Uses of recombinant procalcitonin 3-116 in the diagnosis and therapy of septic diseases and the measurement of prohormones other than procalcitonin, and of dipeptidyl peptidase IV, as biormarkers in the diagnosis of sepsis.04-16-2009
20100167308METHOD FOR MEASURING AN ANALYTE IN BLOOD - An electrochemical immunosensor system with reduced interference, comprising: a first immunosensor that generates an electrochemical signal based on the formation of a sandwich between an immobilized antibody, a target analyte and a labeled antibody, wherein a portion of the signal arises from non-specific binding of the labeled antibody in the region of the first immunosensor, and 07-01-2010
20100167309APPARATUS AND METHOD FOR ANALYTE DETECTION - Disclosed is a testing device and methods for the identification of an analyte of interest in a sample. In a preferred embodiment, the testing device includes a front panel having at least one sample application aperture; a rear panel having at least one solvent application aperture; a sample collection matrix disposed between the rear panel and the front panel, the sample collection matrix being in communication with the sample and solvent application apertures of the front and rear panels; and at least one insertable test strip containing a reagent enabling detection of the analyte of interest.07-01-2010
20130011852COMPOUNDS THAT INTERACT WITH KINASES - A method of inhibiting or effecting the activity of protein kinase activity which comprises contacting a protein kinase with a compound of formula (I) being a derivative of a furanose or pyranose form of a monosaccharide, or a pharmaceutically acceptable salt thereof.01-10-2013
20130011853ANTI-HEDGEHOG ANTIBODIES - The invention relates to anti-hedgehog antibodies, their use in the detection of hedgehog expression in tissue, and to the use of such detection in the treatment of cancer.01-10-2013
20130011856CARTRIDGE FOR AUTOMATIC MEASUREMENT AND MEASURING DEVICE USING THE SAME - An object of the present invention is to provide a cartridge for automatic measurement used in an automatic measuring device, capable of automatically performing measurement including heat treatment of a sample, and a measuring device using the cartridge.01-10-2013
20130011851Lateral Flow Immunoassay With Encapsulated Detection Modality - A lateral flow immunoassay featuring encapsulated metal particles. The encapsulated particles may use SERS nanotags as the detection modality. The use of encapsulated particles as a detection modality, in particular encapsulated SERS tags increases the sensitivity of an LFI prepared for visual reading and introduces the ability to obtain substantially more sensitive qualitative results or quantitative results through the analysis of a SERS spectrum read from an LFI prepared in accordance with the present invention. The use of SERS as detection modality also enhances the ability of an LFI device to be used for a multiplexed test. Other aspects of the present invention include LFI devices specifically configured to test whole blood, a reader for the detection and interpretation of a multiplexed assay and the hardware and software components used to implement the reader.01-10-2013
20130011855Methods for Determining Aged Based Accumulation of Senescent Cells Using Senescense Specific DNA Damage Markers - One disclosure provides a method for determining a senescence based disorder by detection of cells with senescence specific DNA damage markers which includes the step of providing a sample with one or more cells. It also includes the steps of identifying with immunodetection the presence of activated DNA damage response proteins that are shown to be activated with senescence and identifying with immunodetection the inactivation of DNA damage response proteins that are shown to be inactive in senescence.01-10-2013
20100129829USE OF PLASMA HSP90 RELATED TO MALIGNANCY - The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.05-27-2010
20100129830Label Independent Detection Biosensor Composition and Methods Thereof - A biosensor article including a substrate; a tie-layer attached to the substrate surface; and a nanometer scale cross-linked acryloyl copolymer layer attached, for example, by copolymerization, to the tie-layer, as defined herein. Methods for making the biosensor article or cell culture article and methods for performing an assay of a ligand with the target derivatized biosensor article are also disclosed.05-27-2010
20130017554SUMO-SPECIFIC AFFINITY TAG - A new SUMO-specific affinity tag is described herein, based on the amino acid sequence from 403-621 of the SUMO protease Ulp1, and containing a crucial substitution of serine for cysteine. This affinity tag is particularly useful for a range of applications, including detection and affinity purification of sumoylated proteins from cell extracts.01-17-2013
20130017555FACS-BASED METHOD FOR OBTAINING AN ANTIBODY SEQUENCE - In certain embodiments, the method may comprises: a) contacting a population of permeabilized, cross-linked antibody-producing cells with a labeled antigen to produce a labeled sample in which cells that produce an antibody that specifically binds to said antigen are intracellularly labeled; b) using FACS to isolate cells that are intracellularly labeled, thereby producing labeled cells; c) uncrosslinking said labeled cells to produce uncrosslinked cells; and d) amplifying heavy and light chain-encoding nucleic acid from individual uncrosslinked cells, thereby obtaining nucleic acid that encodes the variable domain of antibody that specifically binds to said antigen.01-17-2013
20130017553PIPETTES, METHODS OF USE, AND METHODS OF STIMULATING AN OBJECT OF INTEREST - The present invention features a freestanding microfluidic pipette with both solution exchange capability and fluid re-circulation, enabling highly localized and contamination- free fluid delivery within a confined volume in the vicinity of the pipette exit. Preferably, the device features direct positioning, so the pipette can be directed at a point or object of interest, such as a biological or artificial cell, a defined surface area or a sensor element within an open volume, using micro- or nanopositioning techniques. One aspect of the invention provides a free-standing pipette. The free-standing pipette includes a microfluidic device comprising one or more channels with exits leading into an open-volume and a positioning device programmed to hold the microfluidic device at an angle from a horizontal axis.01-17-2013
20090035784NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF - The present invention provides a novel gene, designated herein as “NPC1L1”, that is associated with lipid or glucose metabolism. The invention further provides the use of the NPC1L1 gene and its corresponding protein to diagnose a lipid condition in a cell or tissue and to screen for novel therapeutic compounds useful for treating lipid disorders and other NPC1L1-associated or mediated diseases or disorders. The invention further provides specific inhibitors of NPC1L1.02-05-2009
20100167307NOVEL METHODS FOR THE ASSAY OF TROPONIN I AND T AND COMPLEXES OF TROPONIN I AND T AND SELECTION OF ANTIBODIES FOR USE IN IMMUNOASSAYS - Assay systems and specialized antibodies for the detection and quantitation of troponin I and troponin T in body fluids as an indicator of myocardial infarction. Since troponin I and T exist in various conformations in the blood, the ratios of the monomeric troponin I an T and the binary and ternary complexes, as well as which form of troponin present in the blood, may be related to the metabolic state of the heart. Disclosed is a system to determine the presence of a troponin form or a group of troponin forms in a sample of whole blood, serum or plasma.07-01-2010
20110159518METHOD FOR THE DIAGNOSIS OF THE PRESENCE OF AN OVARIAN CANCER - The invention provides an isolated antigen polypeptide that can be expressed in a subject with ovarian cancer. Also provided is the diagnosis of ovarian cancer by using the antigen polypeptide of the invention and the prevention and/or treatment of ovarian cancer by suppressing the gene of the antigen polypeptide of the invention.06-30-2011
20110159517Zinc binding compounds and their method of use - The present invention provides a metal chelator and methods that facilitate binding, detecting, monitoring and quantitating of zinc ions in a sample. The metal chelating moiety of the zinc-binding compound is an analog of the well-known calcium chelator, BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid), wherein the chelating moiety has been modified from a tetraacetic acid moiety to a tri- di- or monoacetic moiety. This change in acetic acid groups on the metal chelating moiety results in the selective bindings of zinc ions in the presence of calcium ions, both of which are present in biological fluids and intracellular cytosolic fluid and organelles.06-30-2011
20110159516PCan065 Antibody Compositions and Methods of Use - The invention provides isolated anti-PCan065 antibodies that bind to PCan065. The invention also encompasses compositions comprising an anti-PCan065 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-PCan065 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-PCan065 antibodies. The invention encompasses a method of producing the anti-PCan065 antibodies. Other aspects of the invention are a method of killing an PCan065-expressing cancer cell, comprising contacting the cancer cell with an anti-PCan065 antibody and a method of alleviating or treating an PCan065-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-PCan065 antibody to the mammal.06-30-2011
20110159515COMPOSITIONS AND METHODS FOR THE RAPID GROWTH AND DETECTION OF MICROORGANISMS - The invention relates to assay methods for use in detecting specific materials such as core oligosaccharides derived from microorganisms, particularly pathogenic microorganisms, in a test sample. The invention further relates to compositions and methods for the rapid growth of such microorganisms enabling detection of same significantly earlier than is currently possible. In particular embodiments the invention is directed towards the rapid growth and/or detection of 06-30-2011
20110159514BIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF - The invention relates to the identification of a biomarker whose abundance in biological sample is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases.06-30-2011
20080254483In Vitro Method for Diagnosing and Monitoring Renal Cell Carcinoma (Rcc) Using Mmp-7 as Humoral Biomarker for Rcc - The present invention relates to the use of matrix metalloproteinase 7 (MMP-7) and/or its precursors and fragments with MMP-7 immunoreactivity, or of circulating anti-MMP-7 antibodies, as humoral biomarkers in diagnostic in vitro methods for the detection, early detection, monitoring and/or prognosis of renal cell carcinoma (RCC) in human patients.10-16-2008
20080254482AUTOIMMUNE DISEASE BIOMARKERS - Provided herein are novel panels of biomarkers for the diagnosis of autoimmune diseases, and methods and kits for detecting these biomarkers in samples of individuals suspected of having an autoimmune disease. Also provided are methods of monitoring the progression of an autoimmune disease and methods of monitoring the efficacy and side effects of a treatment for an autoimmune disease.10-16-2008
20080254481METHODS AND KITS FOR DETECTING PROSTATE CANCER BIOMARKERS - Provided herein are novel autoantibody biomarkers, and panels for detecting autoantibody biomarkers for prostate cancer, and methods and kits for detecting these biomarkers in the serum of individuals suspected of having prostate cancer.10-16-2008
20080248490Reagents for the detection of protein phosphorylation in Leukemia signaling pathways - The invention discloses nearly 288 novel phosphorylation sites identified in signal transduction proteins and pathways underlying human Leukemia, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Adaptor/Scaffold proteins, Cytoskeletal proteins, Cellular Metabolism enzymes, G Protein/GTPase Activating/Guanine Nucleotide Exchange Factor proteins, Immunoglobulin Superfamily proteins, Inhibitor proteins, Lipid Kinases, Nuclear DNA Repair/RNA Binding/Transcription proteins, Serine/Threonine Protein Kinases, Tyrosine Kinases, Protein Phosphatases, and Translation/Transporter proteins.10-09-2008
20080248489METHODS AND COMPOSITIONS FOR DIRECTED MICROWAVE CHEMISTRY - The present invention concerns a novel means by which specific chosen reactions can be accelerated through the use of a new type of artificial enzyme. The invention allows specific reactions to occur at an accelerated rate, even in the presence of other non-chosen molecules, which may be very similar in structure to the chosen reactant. The reactions may be stoichiometric or catalytic.10-09-2008
20080248488Platelet-Derived Microparticles as a Novel Diagnosis Maker for a Cardiovascular Disease - The present invention relates to a diagnosis maker for a cardiovascular disease comprising platelet-derived microparticles. The present invention also relates to a method for diagnosing a cardiovascular disease in a subject with symptoms of cardiovascular disease or suspected of having cardiovascular disease, wherein said method comprises: (a) obtaining a sample from said subject; (b) reacting an antibody to platelet-derived microparticles or a fragment thereof with a biological sample; (c) detecting a presence or an absence of the platelet-derived microparticles or a fragment thereof in said sample; and (d) diagnosing cardiovascular disease in said subject having said symptoms when said platelet-derived microparticles or a fragment thereof are detected in said sample.10-09-2008
20080248487MODULATION OF PROTEIN FUNCTIONALITIES - New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the method comprises the steps of identifying a switch control ligand forming a part of a particular protein of interest, and also identifying a complemental switch control pocket forming a part of the protein and which interacts with said switch control ligand. The ligand interacts in vivo with the pocket to regulate the conformation and biological activity of the protein such that the protein assumes a first conformation and a first biological activity upon the ligand-pocket interaction, and assumes a second, different conformation and biological activity in the absence of the ligand-pocket interaction. Next, respective samples of said protein in the first and second conformations are provided, and these are screened against one or more candidate molecules by contacting the molecules and the samples. Thereupon, small molecules which bind with the protein at the region of the pocket maybe identified. Novel protein-modulator adducts and methods of altering protein activity are also provided.10-09-2008
20080248486Type Pept1 Protein Assay - The present invention relates to a type PepT1 protein assay and in particular a process for identifying a substrate and/or a modulator of the PepT1 protein.10-09-2008
20080248485Radiolabeled 3-[3- (Benzoyl-Amido) Benzyloxy] Aspartic Acid Derivative and Method of Producing the Same - The present invention provides a radiolabeled ligand which is highly selective and potent for glutamate transporters and is usable in specifically detecting the glutamate transporter.10-09-2008
20080241856Glycoproteomic probes for fluorescent imaging of fucosylated glycans in vivo - The disclosure provides a method of labeling of cellular glycans bearing azide groups via a fluorescent labeling technique based on Cu(I)-catalyzed [3+2]cycloaddition (click activation) of a probe comprising an alkynyl group. The method entails generating a fluorescent probe from a nonfluorescent precursor, 4-ethynyl-N-ethyl-1,8-naphthalimide, by Cu(I)-catalyzed [3+2]cycloaddition of the alkyne group of the probe with an azido-modified sugar. The disclosure further provides a method of incorporating an azido-containing fucose analog into glycoconjugates via the fucose salvage pathway. The disclosure provides a method of fluorescent visualization of fucosylated cells by flow cytometry when cells treated with 6-azidofucose are labeled with the click-activated fluorogenic probe or biotinylated alkyne. A method of visualizing the intracellular localization of fucosylated glycoconjugates by fluorescence microscopy is also disclosed.10-02-2008
20080241855Method for simultaneously detecting an antigen of, and an antibody against, an infectious microorganism - The invention relates to a method for detecting, in vitro, an infection with a microorganism, such as the hepatitis C virus, in a biological sample, by simultaneously detecting an antigen of this microorganism and the antibodies against this same antigen, and also to the reagents and kits implementing this method.10-02-2008
20080241854KITS AND METHODS FOR EVALUATING HAIR - The invention relates to kits and methods for analyzing hair, particularly for determining the amount of damage to hair, including placing hair into a solution containing at least one metal ion so that an amount of the metal ion is attached to the hair, removing the hair from the solution, determining the amount of metal ion attached to the hair, and determining the amount of damage to the hair based upon the amount of metal ion attached to the hair.10-02-2008
20080241853MICROTITER SPIN ARRAY - An improvement in heterogeneous immunoassays in microtiter plates to significantly reduce assay time, from as much as 50% up to 90% of what used to be typical assay times. The improvement involves the rotation of the liquid in a microtiter plate and during incubation times for antigen capture and during incubation times for sample labeling. This is accomplished through the insertion of fluted cylindrical stirrers in each well, and the use of a conventional, commercially available, microtiter vortexer.10-02-2008
20080241852Compositions, kits, and methods for identification, assessment, prevention, and therapy of endometriosis - The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided.10-02-2008
20080241851Cartilage intermediate layer protein 2 C1 and its use to differentiate osteoarthritis from rheumatoid arthritis and non-disease conditions - A method for differentiation of osteoarthritis from rheumatoid arthritis and non-disease conditions in a sample, comprising measuring in the sample the concentration of human cartilage intermediate layer protein 2(CILP-2) in body fluids and more specifically, measuring in the sample the concentration of the N-terminal part of CILP-2 (2C1) or fragments thereof.10-02-2008
20080241850Method of Protein Measurement - The present invention relates to a technique of measuring a protein based on a degree of coloring in a liquid sample mixed with a protein measurement indicator. In the present invention, information reflecting creatinine concentration in the liquid sample is obtained, and then an influence quantity caused by creatinine to the protein concentration measurement is eliminated based on the information.10-02-2008
20090081694Modified well plates for molecular binding studies - Microtiter plates modified to permit their use for molecular binding studies.03-26-2009
20080233596CHIMERIC HUMAN T1R1 TASTE RECEPTOR POLYPEPTIDES AND COMPOSITIONS CONTAINING SAME - Newly identified mammalian taste-cell-specific G protein-coupled receptors, and the genes and cDNA encoding said receptors are described. Specifically, T1R G protein-coupled receptors active in taste signaling, and the genes and cDNA encoding the same, are described, along with methods for isolating such genes and for isolating and expressing such receptors. Methods for representing taste perception of a particular tastant in a mammal are also described, as are methods for generating novel molecules or combinations of molecules that elicit a predetermined taste perception in a mammal, and methods for simulating one or more tastes. Further, methods for stimulating or blocking taste perception in a mammal are also disclosed.09-25-2008
20080233595METHOD FOR DIAGNOSING INTERTILITY - The invention relates to methods for diagnosing conditions characterized by altered expression of a pregnancy related serine protease (PRSP) protein in a mammal. Such conditions include infertility caused by an inability to achieve or sustain embryo implantation, an inability to sustain a pregnancy, early abortion, insufficient placentation, pre-eclampsia, or intrauterine growth restriction. The methods include detecting expression of PRSP, such as SEQ ID NP33. Detection may be accomplished using a PRSP-specific antibody.09-25-2008
20080233594Method For Detecting An At Least Bivalent Analyte Using Two Affinity Reactants - A method for the determination of an analyte which is a) present in a liquid sample 1 suspected of containing the analyte, and b) at least bivalent with respect to simultaneous affinity binding of at least two binding structures BSs. The method comprises formation of an affinity complex that comprises the analyte and an affinity reactant 1 that is immobilized to a solid phase. The method comprises the steps of: (i) providing a microfluidic flow path that comprises a reaction cavity containing a solid phase to which affinity reactant 1 is immobilized, (ii) providing sample 1 upstream of the cavity and flowing it through the cavity for the formation of the affinity complex under flow conditions, (iii) measuring the amount of complex formed in the solid phase by a) incorporating an analytically detectable and soluble affinity reactant 2 that comprises a binding structure BS into the complex subsequent to step (ii), and b) measuring the amount of affinity reactant 2 incorporated.09-25-2008
20090098568Method for immobilizing proteins - This invention provides a method for immobilizing proteins comprising: step 1 of purifying target proteins to be immobilized, which have a first tag portion and a second tag portion, with the use of the first tag portion; step 2 of activating reactive groups capable of covalently binding to the proteins on a carrier for immobilization; and step 3 of allowing a solution containing the proteins purified in step 1 to react with the carrier after step 2, wherein, in step 3, the proteins are immobilized on the carrier via interactions between the second tag portion and the site of the carrier to which the second tag portion binds and via covalent binding between the reactive groups and the proteins. This method enables the stable immobilization of various types of target proteins on a carrier regardless of the amounts of target proteins and without nonspecific immobilization of contaminating proteins.04-16-2009
20090280503Method for detecting and treating skin disorders - The invention provides for methods of detecting and treating diseased tissue, particularly in skin diseases or disorders, such as psoriasis, scleroderma, eczema or atopic dermatitis tissue. The method involves administrating a composition comprising an antibody specific to the diseased tissue to a patient. After administration, the antibody in the composition binds to the exposed cell surface antigen (epitope) and allows the detection and/or disrupts the growth of the diseased tissue. In addition, this invention provides methods of treating psoriasis, scleroderma, eczema or atopic dermatitis by eliciting an immune response in an individual against an antigen which is only exposed to antibody detection in tissues affected by these disorders11-12-2009
20080227113Methods, Antibodies and Kits for Detecting Cerebrospinal Fluid in a Sample - The present disclosure relates to detection of the presence or absence of cerebrospinal fluid (CSF) in a sample, in particular to the analysis of the CSF protein lipocalin-type prostaglandin D2 synthase (L-PGDS). The present disclosure provides assays for the analysis of L-PGDS indicating the presence or absence of CSF in a sample.09-18-2008
20080227112Global polyclonal antibodies, process for depleting commonly shared proteins by same, devices using same - A method for removing abundance proteins from a biological sample comprises passing the biological sample through a support. The support is coated with an avian polyclonal antibody. The avian polyclonal antibody is capable of binding to substantially all proteins in the biological sample with concentrations higher than a predetermined value. The method for removing abundance proteins from a biological sample further comprises collecting the pass-through fractions of the biological sample.09-18-2008
20080227111REAGENT KIT AND METHOD FOR MEASURING HCV ANTIBODY - A reagent kit for measuring an HCV antibody is described herein. This reagent comprises a first and second reagents. The first reagent comprises an HCV synthetic peptide antigen which has a solid phase binding site. The second reagent comprises a solid phase. On the solid phase is immobilized a binding substance and/or an HCV recombinant HCV antigen. The binding substance can bind to the solid phase binding site.09-18-2008
20080227110Human Genes, Sequences and Expression Products - Human polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for therapeutic purposes. Antagonists against such polypeptides and their use as a therapeutic are also disclosed. Also disclosed are diagnostic methods for detecting disease which utilize the sequences and polypeptides.09-18-2008
20080220443Methods of Screening for Modulators of h2-Calponin Activity - The invention provides methods for identifying modulators of mammalian, e.g., human, h2-calponin, the calponin isoform of relatively neutral pI. H2-calponin exerts an effect on the migration and proliferation of a variety of muscle (smooth muscle) and non-muscle cells and is an actin filament-associated regulatory protein influencing the structure of the actin cytoskeleton. Modulators of the activity levels of this protein are useful in preventing, ameliorating, or treating a variety of diseases, disorders or conditions characterized by aberrant cell migration and/or cell proliferation.09-11-2008
20080220442Difference detection methods using isoelectric focusing chips - The present invention provides an isoelectric focusing difference detection method, as well as an isoelectric focusing chip and device. The method entails labeling proteins in the first sample with a first label, and labeling proteins in the second sample with a second, different label, wherein each label has ionic and pH characteristics whereby, upon isoelectric focusing, relative migration of a protein labeled with the first label is substantially the same as relative migration of the same protein labeled with the second label. The samples are subjected to isoelectric focusing to produce a pattern of separated proteins from both samples, which is then detected to compare the protein composition of the samples. The method can be carried with a novel isoelectric focusing chip including a substrate comprising a channel for carrying out isolectric focusing. The substrate includes a non-fluorescent or low-fluorescence material in a detection region of the channel, facilitating direct detection of the pattern of separated proteins, which makes the chip particularly useful for clinical applications, including use disease diagnosis and monitoring.09-11-2008
20080220441Advanced drug development and manufacturing - X-ray fluorescence (XRF) spectrometry has been used for detecting binding events and measuring binding selectivities between chemicals and receptors. XRF may also be used for estimating the therapeutic index of a chemical, for estimating the binding selectivity of a chemical versus chemical analogs, for measuring post-translational modifications of proteins, and for drug manufacturing.09-11-2008
20080220440Waveguide sensors optimized for discrimination against non-specific binding - A system for interferometrically detecting the present of bound material using a wave propagating waveguide and the influence on propagation time of bound material in the proximity of the waveguide. The waveguide layer thickness and the radiation wavelength λ are selected so that the effects on phase difference between the two radiations applied in the beam are minimal in the region directly adjacent the surface of the waveguide, so as to unmask the influence of the more distant bound materials.09-11-2008
20130143228ACTIVITY BASED PROBES (ABPs) INTERACTING WITH GLYCOSIDASES - An activity based probe (ABP) comprising a glycosidase inhibitor, and a detection-group. The ABPs of the inventions are used for diagnosing storage disorder for screening of compounds suitable for preventing and/or treating a storage disorder, for monitoring of therapeutic enzymes for lysosomal storage disorders, and for ultra-sensitive visualization of glycosidase-fusion proteins in molecular imaging.06-06-2013
20130143229REAGENT FOR ASSAYING ANTI-TREPONEMA PALLIDUM ANTIBODY - To provide a reagent for assaying anti-06-06-2013
20130143230MICROFLUIDIC-BASED CELL-CULTURING PLATFORM AND METHOD - A microfluidic-based platform with cultured three-dimensional tissues simulates major human physiological systems for rapid evaluation of individual drugs prior to clinical testing or for personalized medical applications. The platform integrates the circulatory and lymphatic systems in a physiologically correct manner. The physiological systems may be simulated in the platform by microfluidic tissue culture devices which accommodate various tissues and provide integrated microvascular and lymphatic systems. Biomimetic nanofiber meshes or microfiber structures may be used to provide the cells with a physiologically relevant substrate. Each device may have an on-board detection system utilizing optical fiber bundles for microarray multiplexing of biomarkers, label-free SERS measurement of drugs, and microendoscopic confocal imaging of cells and tissues.06-06-2013
20130143231MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY - The present invention relates to prostate cancer (PCa). More specifically, the invention provides a MST1 phosphothreonine (pMST1-T120) antibody that can be used in various assays to study correlations between Mst1 function and T120 site phosphorylation. The present invention can also be used to determine disease development and/or progression of prostate cancer in a subject using the antibodies disclosed herein.06-06-2013
20090176244METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF CROHN'S DISEASE - The present invention provides methods and materials, including kits, to evaluate Crohn's disease, including to diagnose, monitor, or determine the efficacy of treatment for Crohn's Disease. The methods involve determining the presence, absence, or level of zonulin in a subject sample. In certain embodiments, the need for more laborious and/or invasive tests to monitor disease state is minimized or obviated.07-09-2009
20130171658ISOLATION AND DEGLYCOSYLATION OF GLYCOPROTEINS - The invention provides more rapid and cost-effective methods of deglycosylating target glycoproteins. In methods of the invention, the target glycoprotein is isolated from initial samples, which may contain multiple other glycoproteins, by subjecting the initial sample to a solid phase containing an affinity ligand, such as a deglycosylated antibody, that interacts specifically with the target glycoprotein. Once separated from the sample, the target glycoprotein can be deglycosylated in situ, or eluted from the solid phase, quantitated, and then deglycosylated.07-04-2013
20120252033SUBSTANCE DETERMINING APPARATUS - The invention relates to a substance determining apparatus and method for determining a substance within a fluid. Particles attach to the substance and bind to a binding surface (10-04-2012
20090280501A Method And A Kit For Diagnosing Type 2 Diabetes, Metabolic Syndrome, Sub Clinical Atherosclerosis, Myocardial Infarct, Stroke Or Clinical Manifestations Of Diabetes - A method and a kit for diagnosing or prognosing susceptibility to develop type 2 diabetes, the metabolic syndrome, sub clinical atherosclerosis, myocardial infarct, stroke or clinical manifestations of diabetes in a subject. The method comprises detecting and quantifying the amount of bound protein (s), (apoCIII, apoCI, apoA1 or apoE) on small dense low density lipoproteins (sdLDL) particles in a blood sample from said subject.11-12-2009
20080213796GFP-SNAP25 Fluorescence Release Assay for Botulinum Toxin Protease Activity - The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.09-04-2008
20130137115HOMOGENEOUS DETECTION METHOD - The invention relates to methods for the quantitative or qualitative detection of an analyte in an assay and adequate reagents therefor, particularly a homogeneous binding test. According to the invention, an analyte-specific binding partner R1 comprises more than one specific binding point for a specific binding partner X that is associated with a component of a signal-forming system while a second analyte-specific binding partner R2 comprises more than one specific binding point for a specific binding partner Y which is also associated with a component of a signal-forming system.05-30-2013
20130177922METHODS AND APPARATUS FOR TREATING SAMPLES WITH ACOUSTIC ENERGY - This invention relates to systems and methods for applying acoustic energy to a sample. According to one aspect of the invention, a system comprises a housing, a chamber for receiving the sample, an acoustic energy source for providing a focused acoustic field to the sample according to a treatment protocol, a processor for determining the treatment protocol, a sensor for detecting information about the sample, and a user interface for communicating with a user.07-11-2013
20130115618PHOSPHOLIPID PROFILING AND CANCER - In general, the present invention provides prognostic and predictive methods and kits for determining the lipogenicity of a tumor in a subject, by making use of phospholipid profiling, whereby a relative increase in mono-unsaturated phospholipid species in combination with a relative decrease in poly-unsaturated phospholipid species is indicative for a more resistant and aggressive lipogenic cancer phenotype.05-09-2013
20130095501LEGIONELLA TEST - A device and method for qualitatively and/or quantitatively detecting 04-18-2013
20130095500AUTOMATED DEVELOPER FOR IMMUNO-STAINED BIOLOGICAL SAMPLES - Disclosed herein are systems and methods for the developing of immuno-stained biological samples. The systems disclosed herein are automated and are configured to control one or more steps of the developing procedure. Reagents may be added using automatic syringe dispensing. Reagent temperature, reagent stirring, and wash procedures are programmable and can be separately controlled for separate immuno-staining procedures that are performed at the same time.04-18-2013
20130095499Methods, compositions and kits for imaging cells and tissues using nanoparticles and spatial frequency heterodyne imaging - Methods, compositions, systems, devices and kits are provided herein for preparing and using a nanoparticle composition and spatial frequency heterodyne imaging for visualizing cells or tissues. In various embodiments, the nanoparticle composition includes at least one of: a nanoparticle, a polymer layer, and a binding agent, such that the polymer layer coats the nanoparticle and is for example a polyethylene glycol, a polyelectrolyte, an anionic polymer, or a cationic polymer, and such that the binding agent that specifically binds the cells or the tissue. Methods, compositions, systems, devices and kits are provided for identifying potential therapeutic agents in a model using the nanoparticle composition and spatial frequency heterodyne imaging.04-18-2013
20130115620Novel Hemopoietin Receptor Protein, NR10 - The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system.05-09-2013
20130115619UBIQUITINATION ASSAY - The present invention related to a method of assaying ubiquitination in a sample by combining ubiquitin and two or more of E1, E2, E3 and a substrate protein in a sample under conditions suitable for ubiquitination to take place, exposing the sample with a labelled binding partner which is specific for the ubiquitin and measuring the amount of labelled ubiquitin bound to any one of the components in the sample, wherein one or more of the components in the sample comprises an immobilisation tag which facilitates its immobilisation onto a solid surface.05-09-2013
20130102008Method for Screening for S1P Lyase Inhibitors Using Cultured Cells - To provide a method for screening using cultured cells, intended to find a compound which increases the amount of sphingosine-1-phosphate or dihydrosphingosine-1-phosphate by SPL inhibitory activity rapidly, simply and highly sensitively. Provided are: a rapid and simple measurement method employing a scintillation proximity assay (SPA); a method with greatly improved detection sensitivity to the activity of a compound by controlling the concentration of the vitamin B04-25-2013
20130115617METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY - Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.05-09-2013
20130130273METHOD FOR DETECTING INTERACTIONS BETWEEN TWO AND MORE BIOLOGICAL MACROMOLECULES - Disclosed is a novel method for detecting interactions of biomolecules. More particularly, the disclosed method includes (a) preparing a cell comprising (i) a first construct comprising a bait, a first labeling material and a translocation module; and (ii) a second construct comprising a prey and a second labeling material; (b) detecting the distribution of the first construct and the second construct in the cell. the present invention provides a method capable of detecting bindings and interactions occurring in a living cell in real time, and a method for screening a material that alters the binding and the interaction. The method of the present invention overcomes the disadvantages including inaccuracy and complexity of existing biomaterial interaction detection techniques. By labeling both constructs to promote accuracy, the present invention provides a novel real-time, antibody-free analysis.05-23-2013
20130130272METHOD, REAGENT, AND APPARATUS FOR DETECTING A CHEMICAL CHELATOR - A method for detecting a first chelator (shown in the figure as dipicolinic acid DPA (05-23-2013
20130130274DETECTION METHOD - A method of analysis of a hydrocarbon fuel for the presence of a micro-organism comprises contacting a fuel sample with an aqueous diluent and with an antibody reactive with the micro-organism, or reactive with a metabolite of breakdown product produced by the micro-organism, to detect the presence or absence of the micro-organism.05-23-2013
20090035785IMMUNOASSAY METHOD AND REAGENT THEREFOR - The present invention provides a novel immunoassay method with high reaction specificity and high sensitivity. The present invention also provides a method for immunoassaying a target antigen utilizing reactivation of an apoenzyme, which includes simultaneously or sequentially adding a test sample to an antibody specific to the target antigen, the target antigen labeled with a coenzyme, an apo-D-amino acid oxidase, a D-amino acid, and a reagent for detecting a hydrogen peroxide produced by the oxidase.02-05-2009
20090311715IDENTIFYING CORONARY OR SOFT TISSUE CALCIFICATION - This document relates to methods and materials involved in identifying calcification (e.g., coronary calcification or soft tissue calcification) in mammals and assessing thrombotic risk in mammals. For example, methods and materials involved in using microvesicles as a marker to determine whether or not a mammal (e.g., a human) has calcification or an elevated risk of thrombosis are provided. In addition, methods and materials for determining the amount and source of microvesicles are provided.12-17-2009
20090117589SYSTEMS AND METHODS FOR ANALYZING PERSISTENT HOMEOSTATIC PERTURBATIONS - This invention is in the field of homeostasis analysis. More particularly, it relates to systems and methods for analyzing persistent homeostatic perturbations, i.e. chronic stress, by measuring levels of biomarkers that are related to chronic stress. This invention is also directed to systems and methods for analyzing the molecular mechanisms of chronic stress.05-07-2009
20110212462ULTRA-SENSITIVE DETECTION OF MOLECULES USING DUAL DETECTION METHODS - Described herein are systems and methods for the detection of and/or determination of a measure of the concentration of analyte molecules or particles in a fluid sample. In some cases, the systems and methods employ techniques to reduce or limit the negative effects associated with non-specific binding events. Certain methods of the present invention involve associating the analyte molecules at least a first type of binding ligand and at least a second type of binding ligand, and spatially segregating the analyte molecules into a plurality of locations on a surface. The presence of an analyte molecule at or in a location may be determined by determining the presence of both the first type of binding ligand and the second type of binding ligand.09-01-2011
20080199882METHOD FOR DETECTION OF BIOMARKERS FOR EXPOSURE TO STACHYBOTRYS - A method of determining exposure of an individual to a macrocyclic trichothecene comprises isolating a sample of at least a portion of a naturally occurring protein from an individual, and detecting a reaction of the sample with a macrocyclic trichothecene. The macrocyclic trichothecene may be a product of 08-21-2008
20080199881MN Gene and Protein - Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter, and which vectors preferably further encode a cytokine. The MN gene promoter is characterized, and the binding site for a repressor of MN transcription is disclosed.08-21-2008
20080199880SPIN ARRAY METHOD - An improvement in heterogeneous immunoassays to significantly reduce assay time, from as much as 50% up to 90% of what used to be typical assay times. The improvement involves rotating the captured substrate during incubation times for antigen capture and during incubation times for sample labeling.08-21-2008
20080199879Method of Assaying Alzheimer's Disease and Diagnostic Reagent - The present invention is intended to devise a process of measuring β-amyloid in a biological sample such as blood and to apply the process to diagnosis of Alzheimer's disease.08-21-2008
20110223614TOXIN DETECTION METHOD - According to the present invention, an antibody against a Panton-Valentine leukocidin toxin contained in 09-15-2011
20110223612Magnetic Sensor Based Quantitative Binding Kinetics Analysis - Methods for quantitatively determining a binding kinetic parameter of a molecular binding interaction are provided. Aspects of embodiments of the methods include: producing a magnetic sensor device including a magnetic sensor in contact with an assay mixture including a magnetically labeled molecule to produce a detectable molecular binding interaction; obtaining a real-time signal from the magnetic sensor; and quantitatively determining a binding kinetics parameter of the molecular binding interaction from the real-time signal. Also provided are systems and kits configured for use in the methods.09-15-2011
20110223611LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS - Novel conjugates and immunogens derived from lenalidomide and antibodies generated by these immunogens are useful in immunoassays for the quantification and monitoring of thalidomide and lenalidomide in biological fluids.09-15-2011
20130203071PEPTIDE APTAMERS FOR MANIPULATING PROTEIN FUNCTION - Peptide aptamers and the methods to produce cassettes including the aptamers and manipulating them, are described. The peptide aptamer cassettes are useful to, e.g., inhibit protein function such as proteins necessary for the transformation of plants, or to replicate cells.08-08-2013
20130203072APPARATUS FOR PROCESSING BIOLOGICAL SAMPLES AND METHOD THEREOF - The present invention provides devices, apparatuses and methods for automated processing of biological samples. This invention provides automated devices and automated methods of sequentially treating a biological sample with processing fluids in more than one washing basin. In some embodiments, the invention provides automated devices and automated methods of western blot processing. In some embodiments, the invention provides automated devices and automated methods of Southern blot processing. In some embodiments, the invention provides automated devices and automated methods of northern blot processing. In some embodiments, the invention provides automated devices and automated methods of staining biomolecules on solid supports. In some embodiments, the invention provides automated devices and automated methods of nucleic acid separation and isolation.08-08-2013
20130137113Photoreactive Regulator of Protein Function and Methods of Use Thereof - The present invention provides a synthetic regulator of protein function, which regulator is a light-sensitive regulator. The present invention further provides a light-regulated polypeptide that includes a subject synthetic regulator. Also provided are cells and membranes comprising a subject light-regulated polypeptide. The present invention further provides methods of modulating protein function, involving use of light. The present invention further provides methods of identifying agents that modulate protein function.05-30-2013
20130137112DYES FOR ANALYSIS OF PROTEIN AGGREGATION - Provided are dyes and compositions which are useful in a number of applications, such as the detection and monitoring protein aggregation, kinetic studies of protein aggregation, neurofibrillary plaques analysis, evaluation of protein formulation stability, and analysis of molecular chaperone activity.05-30-2013
20130137114Bioprobe, Method of Preparing the Bioprobe, and Analysis Apparatus and Method Using the Bioprobe - The present invention relates to a bioprobe including a substrate and inorganic nanoparticles attached to the surface of the substrate, a method of preparing the bioprobe, and an analysis apparatus and method using the bioprobe. In the bioprobe according to the present invention, inorganic nanoparticles introduced to the substrate serve as a linker to which a target-specific substance such as an antibody can be bound, and they also increase the surface area of the substrate, thus increasing a surface area where a target substance to be detected can contact the substrate. In this regard, the bioprobe can be effectively used for detection, dosing, or analysis of various biomolecules or other chemical substances.05-30-2013
20130149712FOLLISTATIN-LIKE PROTEIN-1 AS A BIOMARKER FOR INFLAMMATORY DISORDERS - The present invention relates to methods and compositions for diagnosis of inflammatory disorders, and in non-limiting embodiments, of inflammatory disorders associated with elevated interleukin-1β (“IL-1β”), based on increased levels of follistatin-like protein 1 (“FSTL-1”). In particular non-limiting embodiments, the invention further provides for methods of identifying subjects with systemic onset juvenile idiopathic arthritis (“SOJIA”) who are at increased risk for developing macrophage activation syndrome (“MAS”) comprising detecting, in said subjects, hyper-increased levels of FSTL-1. In additional non-limiting embodiments, the invention provides for methods of identifying subjects with Kawasaki disease who are at increased risk of developing aortic aneurysms comprising detecting, in said subjects, hyper-increased levels of FSTL-1.06-13-2013
20090111121METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE - A method for characterizing oxidative stress. The method includes dosing a ratio of HNE-to-DHN-protein in blood; comparing the ratio of HNE-to-DHN-protein in blood to a predetermined interval of ratio values associated with a predetermined level of oxidative stress; and classifying the oxidative stress as having reached the predetermined level if the ratio of HNE-to-DHN-protein in blood is within the predetermined interval of ratio values.04-30-2009
20110275093NOVEL USE OF ADENOVIRUSES AND NUCLEIC ACIDS THAT CODE FOR SAID VIRUSES - The present invention is related to the use of a virus, preferably an adenovirus, for the manufacture of a medicament, whereby the virus is replication deficient in cells which do not have YB-1 in the nucleus, and the virus codes for an oncogene or oncogene product, in particular an oncogene protein, which transactivates at least one viral gene, preferably an adenoviral gene, whereby the gene is selected from the group comprising E1B55kDa, E4orf6, E4orf3 and E3ADP.11-10-2011
20110275092METHOD FOR DETECTING BIOLOGICAL MARKERS BY AN ATOMIC FORCE MICROSCOPE - A method for detecting biological markers involves preparing sample slices using a hard granular labeling material such as hard nano-gold granular material. The sample slices are fixed to sample patches. The sample is scanned using the atomic force microscope (AFM) in tapping mode to collect the height, amplitude and phase data of the hard granular material. The hard labeling material is mainly determined through changes in discrepancies in phase diagram color, while height and amplitude diagrams are used to provide auxiliary evidence of sample morphological features. Integrating these data with the state of the biological target object can thus determine the existence of a marked object.11-10-2011
20110275091USE OF PRECURSORS OF TACHYKININS AND/OR THEIR FRAGMENTS IN MEDICAL DIAGNOSTIC - The present invention relates to the use of protachykinin and/or fragments thereof that can be isolated from body fluids, tissues or other bioiological samples and therefore, serves as a marker peptide for medical diagnosis of diseases/disorders of the central nervous system, including Alzheimer's disease, Parkinson's disease, depression and/or conditions of pain, neurological, endocrinological, cerebral, muscular, local, systemic, chronic, inflammatory diseases, infectious diseases comprising bacterial and viral infections, meningitis, sepsis, Crohn's disease, colitis ulcerosa, sickle cell anemia, ischemia, amyotrophic lateral sclerosis, arthritis comprising rheumatoid arthritis, bronchitis, hyperalgesia, asthma, intoxication comprising bacterial intoxication, immunological disorders, poly/-trauma comprising cranio-cerebral trauma, tumors/cancer, stroke, stress, atopis dermatitis, HIV, Huntington's disease, burns, schizophrenia, Hirschsprung's disease, allergies, familial dysautononmia (Riley Day syndrome), hematopoietic disorders, gliomas comprising glioblastomas and astrocytomas, disorders of the blood brain barrier. The invention further provides antibodies for binding to certain proteins and their fragments, more specifically protachykinin and protachykinin peptides. In accordance with the invention, a kit useful for the above-mentioned diagnosis is also provided.11-10-2011
20090325189Tyrosine phosphorylation sites - The invention discloses 443 novel phosphorylation sites identified in leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.12-31-2009
20100285501METHODS FOR DIAGNOSING ENDOMETRIOSIS - Provided herein is a method for diagnosing and monitoring endometriosis in a subject by measuring levels of the β-subunit of fibrinogen.11-11-2010
20100285495COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL - The present invention concerns combination of an amount of a GPR119 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-1 level in a subject over that provided by the amount of the GPR119 agonist or the amount of the DPP-IV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-1 level. The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-1 secretagogues.11-11-2010
20100291587BIOMARKER FOR DIAGNOSING HEART DISEASE AND THE USE THEREOF - The invention relates to the following methods [1] to [3] and to a kit for carrying out the methods:11-18-2010
20090280499METHOD AND KIT FOR DETECTING, OR DETERMINING 3,4- METHYLENEDIOXYMETHAMPHETAMINE - The invention provides a hapten, an immunogen comprising the hapten coupled to an antigenicity-conferring carrier material, a conjugate comprising the hapten coupled to a labelling agent, as well as, antibodies raised against the aforementioned immunogen and capable of binding with MDMA.11-12-2009
20090061457Apolipoprotein E3 protein as a biomarker of Parkinson's disease - The present invention relates to an Apolipoprotein E3 protein as a biomarker for neurodegenerative disease, including Parkinson's disease, and the related diseases. More specifically, the present invention relates to the identification of an Apolipoprotein E3 protein, useful for the screening, diagnosis, and differentiation of Parkinson's disease from Alzheimer's disease, other neurodegenerative diseases, and normal controls.03-05-2009
20100304401YS68 GENE INVOLVED IN PRIMITIVE HEMATOPOIESIS - A novel gene, dubbed “YS68”, involved in primitive hematopoiesis was successfully isolated from cDNA derived from mouse yolk sacs. In addition, a human gene corresponding to this gene was successfully isolated. Expression characteristics of these genes suggested their involvement in primitive hematopoiesis. The proteins of this invention and genes encoding the proteins may be utilized as tools for drug development against diseases, such as hematological disorders.12-02-2010
20100311079ASSAY FOR CARDIAC TROPONIN AUTOANTIBODIES - The invention provides among other things methods and kits based on assaying for cardiac troponin autoantibodies, either in conjunction with an assay for cardiac troponin and/or as an independent indicator of cardiac pathology, such as myocarditis, cardiomyopathy, and/or ischemic heart disease. Assay methods of the invention can be employed among other things to identify cardiac pathology, or risk thereof, in subjects who have an autoimmune disease or who are related to an individual with an autoimmune disease. In particular embodiments, the invention also provides a method of determining whether a subject having, or at risk for, a cardiac pathology is a candidate for immunosuppressive therapy or immunoabsorption therapy. The invention also provides kits and kit components that are useful for performing the methods of the invention.12-09-2010
20100317027SULFENIC ACID-REACTIVE COMPOUNDS AND THEIR METHODS OF SYNTHESIS AND USE IN DETECTION OR ISOLATION OF SULFENIC ACID-CONTAINING COMPOUNDS - The present invention provides compounds of Formula I:12-16-2010
20100317026VMP-Like Sequences Of Pathogenic Borrelia - The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic 12-16-2010
20100317025Diagnostic Method for Celiac Sprue - Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue.12-16-2010
20100317024DERIVATIVES, REAGENTS, AND IMMUNOASSAY FOR DETECTING LEVETIRACETAM - Levetiracetam (LEV) derivatives, methods for synthesizing LEV derivatives, and immunodiagnostic assays for LEV. The synthesis methods described herein include chirally-selective, liquid-phase synthesis steps to produce selected LEV derivatives in high-yield. LEV derivatives can include operative groups, such as: immunogenic moieties that can be used to prepare anti-LEV antibodies; antigenic moieties that can be used in immunodiagnostic assays for LEV; or tracer moieties that can be used in immunodiagnostic assays. Additionally, the LEV derivatives can be used in immunodiagnostic assays to compete with LEV for anti-LEV antibodies.12-16-2010
20100317023BIOCHEMICAL MARKERS FOR CVD RISK ASSESSMENT - A method of diagnosis of cardiovascular disease (CVD) an immunoassay to measure aggrecan fragments in said sample, and association of an elevation above a normal level with the presence of CVD, is conducted by contacting aggrecan fragments in said sample with an first antibody reactive with an N-terminal first epitope formed by cleavage of aggrecan by a proteinase and with a second antibody reactive with a second aggrecan epitope which is present in aggrecan at a location in the C-terminal direction from the location of said N-terminal epitope, and measuring the extent of simultaneous binding of both antibodies.12-16-2010
20100317022METHODS OF DIAGNOSING TISSUE FIBROSIS - The present invention provides a method of diagnosing the presence or severity of tissue fibrosis in an individual by detecting α2-macroglobulin (α2-MG) in a sample from the individual; detecting hyaluronic acid (HA) in a sample from the individual; detecting tissue inhibitor of metalloproteinases-1 (TIMP-1) in a sample from the individual; and diagnosing the presence or severity of tissue fibrosis in the individual based on the presence or level of α2-MG, HA and TIMP-1.12-16-2010
20100317021FLUIDIC ANTIBODY-CONTAINING DEVICES AND METHODS - The invention relates to devices and methods for analyzing a sample (and preferably preparing a sample), which is particularly used in analysis, such as analysis of a sample for a bacterium of interest.12-16-2010
20130157287BIOLOGICAL SUBSTANCE DETECTION METHOD - A biological substance detection method for detecting a biological substance specifically in a pathological specimen, comprising a step of immunologically staining the pathological specimen using a fluorescent label, a step of staining the pathological specimen with a staining reagent for morphology observation purposes (eosin) to observe the morphology of the pathological specimen, a step of irradiating the stained pathological specimen, with excited light to cause the emission of a fluorescent and detecting the biological substance in the pathological specimen. In the step of immunologically staining the pathological specimen, a special fluorescent particle for which the excitation wavelength appears in a region that is different from the excitation wavelength region of eosin is used as the fluorescent label.06-20-2013
20130157281Factor IXa Crystals, Related Complexes and Methods - The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.06-20-2013
20130157282CHEMILUMINESCENCE COMPACT IMAGING SCANNER - Systems, devices, and methods for accurately imaging chemiluminescence and other luminescence are disclosed. A compact, flat-bed scanner having a light-tight enclosure, one or more detector bars of linear charge-coupled device (CCD) or complementary metal oxide semiconductor (CMOS) imaging chips, and high working numerical aperture (NA) optics scans closely over a sample in one direction and then the opposite direction. Averages or other combinations of intensity readings for each pixel location (x, y) between the two or more passes are averaged together in order to compensate for luminescence that varies over time. On-chip pixel binning and multiple clock frequencies can be used to maximize the signal to noise ratio in a CCD-based scanner.06-20-2013
20130157283RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD - A microfluidic device of a diagnostic and detection system includes an inlet port connected by one or more microchannels to an outlet port and includes a capture and visualization chamber (CVC) connected to at least one microchannel. A fluid to be analyzed can be mixed with magnetic microbeads that have an affinity to become bound to target components, such as pathogens in the fluid. The fluid including the magnetically bound target components can be injected through the microfluidic device. Magnetic field gradient, such as provided by permanent or electro-magnets, can be applied to the fluid and the magnetically bound target components flowing through the microfluidic device to cause the magnetically bound target components to migrate into the (CVC) and become separated from the fluid. The magnetically bound target components can be analyzed and tested using various techniques to detect the presence of specific organic and inorganic materials, such as pathogens in bio-fluids and contamination in liquid food sources (e.g. water). The device and method provide a system for rapidly detecting pathogens and contamination in relatively small fluid samples.06-20-2013
20130157284COLORIMETRIC AND FLUORESCENT PROTEINS - The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.06-20-2013
20130157285IDENTIFICATION OF INVASIVE AND SLOW-GROWING TUMORIGENIC CELL SUBSETS IN TUMORS - HA-based functional probes and a multiplexed targeting strategy for detection and isolation of invasive subpopulations in breast cancer cell lines. Methods for using HA metabolism for profiling and sorting breast cancer heterogeneity. As such, HA-based functional probes have appropriate targeting capacity and safety profiles for development as imaging and therapeutic agents for following repair and neoplastic disease processes such as breast cancer.06-20-2013
20130157286FLUIDIC CONNECTORS AND MICROFLUIDIC SYSTEMS - Fluidic connectors, methods, and devices for performing analyses (e.g., immunoassays) in microfluidic systems are provided. In some embodiments, a fluidic connector having a fluid path is used to connect two independent channels formed in a substrate so as to allow fluid communication between the two independent channels. One or both of the independent channels may be pre-filled with reagents (e.g., antibody solutions, washing buffers and amplification reagents), which can be used to perform the analysis. These reagents may be stored in the channels of the substrate for long periods amounts of time (e.g., 1 year) prior to use.06-20-2013
20130183681DEVICE AND METHOD OF MONITORING A PATIENT - A device for remote management of patients suffering or likely to suffer from heart failure that can measure the amplitude and frequency changes of one or more biomarkers. The device aids in predicting the need for medical intervention in such patients. The device may further aid in monitoring the efficacy and safety of treatment in such patients.07-18-2013
20120282626Selective Incorporation of 5-hydroxytryptophan into Proteins in Mammalian Cells - This invention provides methods and compositions for incorporation of an unnatural amino acid into a peptide using an orthogonal aminoacyl tRNA synthetase/tRNA pair. In particular, an orthogonal pair is provided to incorporate 5-hydroxy-L-tryptophan in a position encoded by an opal mutation.11-08-2012
20120282625MICROFLUIDIC DEVICE COMPRISING MICROCHANNEL WHERE PROTRUSIONS ARE FORMED ON BOTTOM SURFACE - Disclosed is a microfluidic device comprising a microchannel through which fluid can flow. Protrusions are formed on the bottom surface of the microchannel. The microfluidic device increases detection sensitivity by improving optical characteristics and enhances the reactivity of biochemical reaction by slowing down the velocity of fluid flowing inside the microchannel.11-08-2012
20130183682Detection and Measurement of Blood-Feeding Activity - This invention provides compositions and methods for detection of hematophagous ectoparasitic activity in an enclosure or area. The compositions comprise a reagent or reagents which are reactive against antigens or markers as they appear in the excrement or other ectoparasitic materials. Such markers or antigens may be produced by the ectoparasite itself or may have been introduced into the ectoparasite because of its blood feeding activity. The method of the present invention comprises collecting from the enclosure or area, a sample comprising environmental dust or materials and subjecting the sample to tests for detecting the presence of hematophagous ectoparasitic markers, host markers or both.07-18-2013
20130183680ASSAYS AND METHODS FOR THE DIAGNOSIS OF POST-STREPTOCOCCAL DISORDERS - Provided are methods for diagnosing a disease in a subject with a previous streptococcal infection by determining the presence or absence of one or more autoantibodies in a biological sample from the subject, wherein the one or more autoantibodies recognize an antigen from a protein selected from the group consisting of ELAVL2, ELAVL3, ELAVL4, Nova-1, Nova-2, Cdr1, Cdr2; and Cdr3. The presence of such autoantibodies is indicative of a positive diagnosis for a post-streptococcal disease such as PANDAS, post-GABHS glomerulonephritis, rheumatic fever, autism and Syndenham's chorea.07-18-2013
20090092999METHODS OF PREDICTING THERAPEUTIC RESPONSE IN ATOPIC DERMATITIS TO IL-31 ANTAGONISTS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.04-09-2009
20130189705MONOCLONAL ANTIBODIES AGAINST PCBP-1 ANTIGENS, AND USES THEREFOR - The present invention provides and includes monoclonal antibodies (MoAbs or mAbs) specific or preferentially selective for PCBP-1 antigens, hybridoma lines that secrete these PCBP-1 antibodies or antibody fragments, and the use of such antibodies and antibody fragments to detect PCBP-1 antigens, particularly those expressed by cancer cells. The present invention also includes antibodies that are specific for or show preferential binding to a soluble form of PCBP-1. The present invention further includes chimeric and humanized antibodies, processes for producing monoclonal, chimeric, and humanized antibodies using recombinant DNA technology, and their therapeutic uses, particularly in the treatment or diagnosis of cancer progression. The present invention further includes methods and kits for the immunodetection and immunotherapy of cells for samples which express PCBP-1 antigens.07-25-2013
20120288871Modified Carbocyanine Dyes and Their Conjugates - Chemically reactive carbocyanine dyes incorporating an indolium ring moiety that is substituted at the 3-position by a reactive group or by a conjugated substance, and their uses, are described. Conjugation through this position results in spectral properties that are uniformly superior to those of conjugates of spectrally similar dyes wherein attachment is at a different position. The invention includes derivative compounds having one or more benzo nitrogens.11-15-2012
20120015371Methods for Measuring Concentrations of Biomolecules - The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.01-19-2012
20120021434METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS - The invention relates to a method for treating B-cell regulated autoimmune disorders using compounds that modulate the activity of c-Rel.01-26-2012
20120021433REDUCING OPTICAL INTERFERENCE IN A FLUIDIC DEVICE - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. In particular, the medical device reduces interference with an optical signal which is indicative of the presence of an analyte in a bodily sample.01-26-2012
20120021432Phosphorylated NF45 Biomarkers, Antibodies And Methods Of Using Same - The present invention relates to isolated phosphorylated NF45 peptides and isolated phosphorylation site-specific antibody or antigen-binding portion thereof that specifically binds a phosphorylated NF45 protein. The present invention also relates to methods of utilizing these antibodies to determine the therapeutic efficacy of a candidate compound and methods for screening for candidate compounds that increase the phosphorylation of NF45 protein in a cell.01-26-2012
20120021431DIAGNOSTIC METHODS USING BNP - The present invention provides a new method and kit for determining the overload of atrium or ventricle in a subject comprising at least a step of measuring levels of proBNP-108 in a sample from the subject. The disclosed methods and kits are useful, for example, in the diagnosis, prevention and/or treatment of cardiac diseases, particularly heat failure, aortic stenosis, aortic regurgitation, mitral stenosis, mitral regurgitation, and atrial fibrillation.01-26-2012
20120021430FUNCTIONAL LIPID CONSTRUCTS - The invention relates to methods for effecting qualitative and quantitative changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional lipid constructs for use in such methods. In particular, the invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is a carbohydrate, peptide, chemically reactive group, conjugator or fluorophore.01-26-2012
20120028273Particle Analysis Assay for Biomolecular Quantification - A method is provided for carrying out multi-step separations of objects bearing at least two binding sites. In the first step, a first binder/bead composition is bound to objects that bear the first binding site, and then unbound objects, i.e. objects not bearing the first binding site, are separated from bound objects. In the second step, a second binder/bead composition is bound to the remaining objects that bear the second binding site, and then the objects that are bound to both beads are removed from those objects that are bound to only one bead. The beads can differ in magnetic responsiveness, charge, size, color, and the like, and these differences can be used to carry out the separation steps.02-02-2012
20120028272DEVICE AND METHODS FOR ISOLATING CELLS - The invention provides a device and methods for separating and isolating cells.02-02-2012
20120028271Methods and Kit for Detecting Breast Cancer - The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer.02-02-2012
20120028270METAL-ENHANCED BIOLUMINESCENCE: AN APPROACH FOR MONITORING BIOLOGICAL BIOLUMINESCENT PROCESSES - The present invention relates to surface plasmon-coupled bioluminescence, wherein bioluminescent emission from a bioluminescent chemical reaction couples to surface plasmons in metallized particles thereby enhancing the signal. Importantly, these plasmonic emissions emitted from metallic particles generated without an external excitation source but instead from induced electronically excited states caused by the bioluminescent chemical reaction.02-02-2012
20120028268METHOD OF PREDICTING ACUTE APPENDICITIS - Embodiments of the invention provide method and devices for predicting the likelihood of acute appendicitis without invasive exploratory medical procedures. Several protein biomarkers: leucine-rich α-2-glycoprotein (LRG); S100-A8 (calgranulin); α-1-acid glycoprotein 1 (ORM); plasminogen (PLG); mannan-binding lectin serine protease 2 (MASP2); zinc-α-2-glycoprotein (AZGP1); Apolipoprotein D (ApoD); and α-1-antichymotrypsin (SERPINA3); are increased in the urine of patients with appendicitis. The method and devices comprise detecting the levels of these biomarkers and comparing with reference levels found in healthy individuals.02-02-2012
20120028266DISCOVERY OF CANDIDATE BIOMARKERS OF IN VIVO APOPTOSIS BY GLOBAL PROFILING OF CASPASE CLEAVAGE SITES - The present invention relates to the discovery of novel biomarkers of in vivo apoptosis based on a large number of caspase-like cleavage sites. These biomarkers are useful for detection and quantification of apoptosis in a biological sample. The invention also provides synthetic peptides and proteins corresponding to neo-epitopes created by proteolytic processing of these cleavage sites. The synthetic peptides can be used as standards to enable identification and quantitation of these biomarkers using mass spectrometry. The synthetic proteins can be used to generate antibodies and other binding reagents specific for these biomarkers. Methods for detecting apoptosis as well as for diagnosing or for providing a prognosis for a disease or disease state characterized by apoptosis are also provided herein. Finally, the invention provides compositions and kits for performing the methods of the invention.02-02-2012
20120028265METHODS OF USING RET NANOSENSORS - The present invention provides methods for detecting and monitoring metabolite concentrations, which comprise detection and measurement of Fluorescence Resonance Energy Transfer upon ligand binding. The methods of the present invention are useful for real time monitoring of changes in metabolite levels in living cell cultures.02-02-2012
20130196339SLIDE POCKET - A slide pocket includes a first shell portion having a slide well with a depth suitable for accepting a sample-containing portion of a slide thereby positioning a sample affixed to the sample-containing portion of the slide within the slide well. The slide well has a plurality of beveled interior walls, the beveled portions functioning to prevent the sample affixed to the sample-containing portion of the slide from contacting any surface of the slide well during insertion. The slide pocket has a second shell portion, mateable in fluid tight engagement with the first shell portion. The second shell portion has a slide well. The first and second shell portions engage to define a single continuous slide chamber, a fluid input channel and fluid input port in communication with the single continuous slide chamber, and a fluid output channel and fluid output port in communication with the single continuous slide chamber.08-01-2013
20130196336TRANSGLUTAMINASE 6 AS A DIAGNOSTIC INDICATOR OF AUTOIMMUNE DISEASES - The embodiments relate to the diagnosis of disorders or dysfunctions characterised by autoimmune responses to a novel antigen, transglutaminase 6, by the detection of autoantibodies to the novel antigen.08-01-2013
20130196337N-ACETYL-D-GLUCOSAMINE FOR ENHANCED SPECIFICITY OF STREP A IMMUNOASSAY - Methods, compositions and kits for detecting Group A 08-01-2013
20130196338DETECTION OF BIOMARKERS AND BIOMARKER COMPLEXES - The invention features methods and devices for the detection of biomarker complexes and their components and for the sequential detection of multiple epitopes of a biomarker. The invention also features methods for diagnosing disease and evaluating the efficacy of treatment of a subject with a disease.08-01-2013
20130196340EX VIVO PLASMA ENZYME ACTIVITY ASSAY USING INHIBITORS AS A NEGATIVE CONTROL - An improved assay for enzyme activity in bodily fluids which permits the influence of other components of the fluid to be accounted for is improved by using a negative control where the enzyme is inactivated or bound.08-01-2013
20130196341METHODS AND COMPOSITIONS FOR DETECTION OF ANALYTES - Disclosed are methods and compositions for detecting analytes, including proteins, polysaccharides, viruses, nucleic acids and cells. The methods and compositions utilize a reporter probe, suitably a multivalent reporter probe, to detect the presence of the analytes. The methods and compositions can be used for non-enzymatic detection of nucleic acids.08-01-2013
20090123936CONFORMATIONALLY ABNORMAL FORMS OF TAU PROTEINS AND SPECIFIC ANTIBODIES THERETO - The invention relates to antibodies with a specificity to an abnormally truncated form of tau protein, which is conformationally different from normal tau, and does not bind to normal tau protein, conformationally different tau proteins (“tauons”) and diagnostic and therapeutical aspects in relation to Alzheimer's disease and related tauopathies.05-14-2009
20130203065METHOD FOR ELECTROCHEMICAL DETECTION OF BINDING REACTIONS - A method for performing homogeneous immunoassay formats with electrochemical detection in solution includes combining two different conjugates as reagents with a sample or a sample/buffer mixture, one conjugate including a redox marker and an analyte molecule and the second conjugate including an anti-redox marker antibody or a specifically binding fragment thereof and a molecule specifically binding the analyte.08-08-2013
20130203066METHOD FOR DETECTING INVASIVE MICROVESCLES DERIVED FROM TUMOR CELLS - The present application relates to the isolation and analysis of populations of microvesicles and the identification of invasive microvesicles in the populations such as populations of microvesicles that are shed by tumor cells. Invasive microvesicles from tumor cells contain a variety of specific proteins, such as ARF6.08-08-2013
20130203067DETECTION OF INTRACELLULAR BINDING EVENTS BY MEASURING PROTEIN ABUNDANCE - Methods and compositions are provided to measure the binding of a test compound to a target peptide by measuring the effect of the compound on the abundance of the target peptide inside a cell. The target peptide may bind the test compound at an active site or an allosteric site, and it has been found that such binding may stabilize the target peptide against cellular degradation. The target peptide will preferably comprise a destabilizing mutation which shortens the half life of the target peptide within the cell, typically a mammalian cell. Test compounds, including small molecules, have been found to stabilize target peptides. Also provided are systems and kits for use in practicing the methods.08-08-2013
20130203069Dynamic Assay for Maintenance and Disruption of Tissue Level Organization and Architecture - A micropatterning approach, systems and methods that confine cells to a specified geometry combined with an algorithm to quantify changes of cellular distribution over time to measure the ability of different cell types to self-organize relative to each other and detect loss of cellular self-organization.08-08-2013
20130203070METHODS OF USING IL-31 ANTAGONISTS IN DISEASES MEDIATED BY CUTANEOUS LYMPHOCYTE ANTIGEN POSITIVE T CELLS - The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.08-08-2013
20130203068DUAL-ACCEPTOR TIME-RESOLVED-FRET - Methods for determining the presence or absence of a plurality of analytes in a sample with dual-acceptor time-resolved fluorescence resonance energy transfer are provided.08-08-2013
20120301893Analyte Detection Devices, Multiplex and Tabletop Devices for Detection of Analyte, and Uses Thereof - Devices and methods for the detection of analytes are disclosed. Devices and methods for detecting food-borne pathogens are disclosed.11-29-2012
20130095498NOVEL GROUP B STREPTOCOCCUS ANTIGENS04-18-2013
20120094306PREDICTIVE EVALUATION OF THE RESPONSE TO TAXANE-INCLUDING CHEMOTHERAPY - The present invention relates to methods and kits for a predictive evaluation of the effectiveness of a taxane-including treatment of a tumour or of cancer cells.04-19-2012
20120094305Methods For Treating And Diagnosing Fibrotic And Fibroproliferative Diseases - The present invention provides compositions and methods for diagnosing and treating fibrotic lung disease. In one embodiment the diagnostic method comprises determining the amount of circulating CXCL-12 in a patient relative to a control.04-19-2012
20120094304METHOD OF PREPARING HUMAN LUNG TISSUE STEM CELLS AND METHOD OF INDUCING DIFFERENTIATION INTO HUMAN ALVEOLAR EPITHELIAL CELLS - Provided are: a method of preparing cells that simultaneously express a type II alveolar epithelial cell marker and a stem cell marker, including a process of isolating and extracting constituent cells from human lung tissue, and a process of separating and culturing lung tissue stem cells from the obtained isolated cells; human lung tissue stem cells that are obtained from the method of preparation and are able to differentiate into alveolar epithelial cells; a method of inducing differentiation into human lung epithelial cells, consisting of culturing the human lung tissue stem cells; human alveolar epithelial cells prepared through the method of inducing differentiation; and a method of screening that uses the human lung tissue stem cells or human alveolar epithelial cells.04-19-2012
20120094303DEVICE FOR ASSAYING ANALYTES IN BODILY FLUIDS - A device for determining the presence and/or quantity of one or more analytes in a sample of human body fluid has a container for receiving a sample of body fluid, with an interior that is delimited by a base and by a circumferential surface. It further comprises at least one test strip and a holding element for receiving and holding the one or more test strips. The holding element is designed such that it has a shape corresponding and adapted to the peripheral circumferential surface of the container. The device further comprises an elongate sampling element having an absorbent sampler that takes up the sample of body fluid and by means of which the sample of body fluid is transferred into the container. Further, the base of the container has a central elevation via which the sample of body fluid can be conveyed from the sampler, by compression thereof on the elevation, to the at least one test strip.04-19-2012
20130210026BIOLOGICAL MARKERS PREDICTIVE OF ANTI-CANCER RESPONSE TO KINASE INHIBITORS - The present invention provides diagnostic and prognostic methods for predicting the effectiveness of treatment of a cancer patient with inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Based on the surprising discovery that tumors cells after having undergone an EMT, while being mesenchymal-like, still express characteristics of both epithelial and mesenchymal cells, and that such cells have altered sensitivity to inhibition by receptor protein-tyrosine kinase inhibitors, in that they have become relatively insensitive to EGFR kinase inhibitors, but have frequently acquired sensitivity to inhibitors of other receptor protein-tyrosine kinases such as PDGFR or FGFR, methods have been devised for determining levels of specific epithelial and mesenchymal biomarkers that identify such “hybrid” tumor cells (e.g. determination of co-expression of vimentin and epithelial keratins), and thus predict the tumor's likely sensitivity to inhibitors of EGFR kinase, PDGFR kinase, or FGFR kinase. Improved methods for treating cancer patients with EGFR, PDGFR or FGFR kinase inhibitors that incorporate such methodology are also provided.08-15-2013
20130210027TEST SYSTEM AND METHOD - The present invention relates to an apparatus for detecting compounds, the apparatus having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices. Further the present invention relates to a method for determining compounds comprising providing an apparatus for detecting compounds having a device defining a disk-shaped geometry, the device having a centre, a plurality of fluid channels each comprising a fluid inlet positioned at a first distance from the centre and a fluid channel end at a second distance from the centre, the second distance being larger than the first distance, one or more sensors arranged at each fluid channel, wherein the sensors each comprise at least one optical detectable member, the test apparatus further comprising one or more optical sensing devices arranged for sensing the at least one optical detectable member of the one or more sensors, and a rotation device adapted for rotating the device so that the sensors pass over the one or more optical sensing devices, the method comprising: providing a fluid at an inlet near the centre of the device, rotating the device, and obtaining properties of the sensors using the optical sensing devices.08-15-2013
20130059339Apparatus and Methods for Cell Culture - A bioreactor (03-07-2013
20080311625Immortal Pluripotent Stem Cell Line, Cell Lines Derived Therefrom, Methods of Preparing Thereof and Their Uses - The present invention relates to immortal pluripotent stem cells derived from a human leukaemia cell line, preferably a human monocytoid cell line and more preferably the human monocytoid cell line, THP1. The present invention further relates to cell lines derived from the immortal pluripotent stem cell line having the phenotype of cell strains characteristic of human tissues, particularly having a human hepatocyte phenotype, as well as the methods for preparing thereof. The present invention further relates to the use of the derived cell line with a human hepatocytic phenotype for the production of albumin and blood coagulation factors.12-18-2008
20100184147METHOD FOR CONTROLLING pH, OSMOLALITY AND DISSOLVED CARBON DIOXIDE LEVELS IN A MAMMALIAN CELL CULTURE PROCESS TO ENHANCE CELL VIABILITY AND BIOLOGIC PRODUCT YIELD - Methods for controlling the level of dissolved carbon dioxide and limiting osmolality in a mammalian cell culture process to enhance cell growth, viability and density, and increase biologic product concentration and yield are provided. Such control of the level of dissolved carbon dioxide and pH as well as the resulting ability to limit osmolality in a mammalian cell culture process is achieved by adopting alternative pH control strategies and CO07-22-2010
20080318277Expression of human milk proteins in transgenic plants - The invention is directed to seed and seed extract compositions containing levels of a human milk protein between 3-40% or higher of the total protein weight of the soluble protein extractable from the seed. Also disclosed is a method of producing the seed with high levels of extractable human milk protein. The method includes transforming a monocotyledonous plant with a chimeric gene having a protein-coding sequence encoding a protein normally present in human milk under the control of a seed maturation-specific promoter. The method may further includes a leader DNA sequence encoding a monocot seed-specific transit sequence capable to target a linked milk protein to a storage body.12-25-2008
20090111147Compositions Containing, Methods Involving, and Uses of Non-Natural Amino Acids and Polypeptides - Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.04-30-2009
20100221783Expression Cloning Method Suitable for Selecting Library Clones Producing a Polypeptide of Interest - The present invention relates to methods for producing a recombinant polypeptide of interest, the method comprising the steps of: a) providing a polynucleotide library encoding one or more polypeptides of interest, wherein the library was prepared in an expression cloning vector comprising at least the following elements: i) a polynucleotide encoding a selectable marker; ii) a fungal replication initiation sequence, preferably an autonomously replicating sequence (ARS); and iii) a polynucleotide comprising in sequential order: a promoter derived from a fungal cell, a cloning-site into which the library is cloned, and a transcription terminator; b) transforming a mutant of a parent filamentous fungal host cell with the library, wherein the frequency of non-homologous recombination in the mutant has been decreased compared to the parent; c) culturing the transformed host cell obtained in (b) under conditions suitable for expression of the polynucleotide library; and d) selecting a transformed host cell which produces the polypeptide of interest.09-02-2010
20110020872MICROORGANISM PRODUCING CYCLIC COMPOUND - A microorganism which produces compounds useful as an antifungal agent, particularly a therapeutic agent for deep-seated mycoses, such as mycotic sinusitis, is provided. The present inventors have conducted intensive studies on naturally-occurring microorganisms as a research for antifungal compounds, and found a fungus 01-27-2011
20110053224NOVEL COMPOSITION OF MATTER AND METHOD FOR STIMULATING THE GROWTH OF BENEFICIAL MICROORGANISMS - The invention describes a novel composition of matter obtained from the leaves of green plants, which is useful in promoting the growth of beneficial microorganisms. Specifically, that the invention describes a hydrolysate prepared from plant leaf biomass (leaf biomass hydrolysate or ‘LBH’) which dramatically stimulates the growth of beneficial microorganisms. Use of LBH as a fermentation substrate can also stimulate rapid production of organic acids and other organic compounds. LBH can be used as a substrate to promote the fermentation-based production of biobased industrial chemicals or biofuels, LBH can be utilized as a prebiotic to promote the growth of beneficial probiotic organisms, hi addition, LBH may also be useful in stimulating the fermentation-based production of other products, examples of which include preservatives, antibiotics, antigens, vaccines, amino acids, vitamins, recombinant proteins, bioremediation treatments, and immobilized enzymes.03-03-2011
20100279353Process of producing fibrinolytic enzyme from mushroom - A fibrinolytic enzyme isolated from a culture broth of a mushroom has a characteristic of degrading a fibrin and a fibrinogen without activating an activity of a plasminogen. The plasminogen is activated to generate a plasmin to degrade the fibrin and/or fibrinogen, so that the fibrinolytic enzyme be used for the thrombosis-related diseases to degrade the fibrin and fibrinogen of blood clots without activate the plasminogen, so as to avoid a hemorrhage due to the over activation the plasminogen to over generate the plasmin.11-04-2010
20120149062High Purity Lipopeptides - The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of 06-14-2012
20120156726VELOCITY FACTOR - The current invention is directed to the velocity factor. Based on the velocity factor antibodies can be classified, i.e. antibodies can be characterized on their binding properties as e.g. entropic or enthalpic antigen binder. A velocity factor based classification does not require detailed thermodynamic determinations and/or calculations. The velocity factor is the ratio of the antigen-antibody complex association rate constants ka determined at 37° C. and 13° C. As only two experimental determinations are required to calculate the velocity factor this is a fast and high-throughput suited method.06-21-2012
20100093037GROWTH OF MICROORGANISMS IN MEDIA CONTAINING SOY COMPONENTS - The present invention provides novel methods of growing of microorganisms in cell culture media comprising soy components (e.g., soy molasses) as a carbon source. The present invention further provides novel cell culture media comprising soy components (e.g., soy molasses) as a carbon source. In certain embodiments, inventive cell culture media substantially lack a carbon source other than soy molasses (e.g., the media substantially lack glucose and glycerol). In certain embodiments, inventive cell culture media comprise soy components (e.g., soy molasses) as the sole carbon source.04-15-2010
20100273216METHODS FOR PROTEIN REFOLDING - Provided herein are methods for refolding proteins. The methods involve covalently modifying a denatured protein with a nonproteinaceous polymer and then renaturing the modified protein.10-28-2010
20120258498HIGH YIELD ANTIBIOTICS PRODUCING FUNGUS STRAIN, PREPARATION METHOD AND USE THEREOF - High yield antibiotics producing fungus strain, preparation method and use thereof are provided. The fungus strain is a mutant derived from 10-11-2012
20100203591Bioreactor, in particular for NMR spectroscopy - A description is given of a bioreactor (08-12-2010
20110236930CHEMOSELECTIVE LIGATION - The present invention features a chemoselective ligation reaction that can be carried out under physiological conditions. In general, the invention involves condensation of a specifically engineered phosphine, which can provide for formation of an amide bond between the two reactive partners resulting in a final product comprising a phosphine moiety, or which can be engineered to comprise a cleavable linker so that a substituent of the phosphine is transferred to the azide, releasing an oxidized phosphine byproduct and producing a native amide bond in the final product. The selectivity of the reaction and its compatibility with aqueous environments provides for its application in vivo (e.g., on the cell surface or intracellularly) and in vitro (e.g., synthesis of peptides and other polymers, production of modified (e.g., labeled) amino acids).09-29-2011
20120100576PERFUSION BIOREACTOR - The present invention pertains to a system for culturing cells comprising a culturing bag and a continuous flow centrifuge wherein the cells are continuously separated from the supernatant and are recycled into the culturing bag. Further provided are methods for culturing cells and for producing a biological substance using the device for culturing cells, and the use of a bag for culturing cells in said device or said methods. In particular, a perfusion system for culturing cells is provided wherein the wave technology for culturing cells is combined with continuous flow centrifugation for separating the medium from the cells.04-26-2012
20080254513Cell Culture Medium - The invention relates to nutrient media, in particular cell culture media, which contain at least one substance selected from the group comprising citric acid, succinic acid, malic acid, α-keto-glutaric acid, fumaric acid, oxalacetic acid, isocitric acid, oxalosuccinic acid, tartaric acid, lactic acid, adipic acid and mixtures thereof and salts, derivatives or complexes of these acids. The invention further relates to the use and methods of production of said cell culture media, methods of cultivation of a cell culture in a cell culture medium according to the invention and cells that can be obtained by said methods.10-16-2008
20080227158NOVEL POLYPEPTIDE, NOVEL DNA AND NOVEL ANTIBODY - The present invention relates to a polypeptide having an activity of suppressing aging; DNA encoding the polypeptide; a method for improving livestock, using the DNA; a recombinant DNA prepared by inserting the DNA into a vector; a transformant harboring the recombinant; a method for preparing the polypeptide of the present invention, using the transformant; an antibody which recognizes the polypeptide; a ligand for the polypeptide of the present invention; a compound inhibiting specific binding between the polypeptide and ligand of the present invention; a compound enhancing the expression of an aging-suppressing gene encoding the aging-suppressing polypeptide of the present invention; an oligonucleotide comprising a sequence of 10 to 50 nucleotides in the nucleotide sequence of the DNA; and a therapeutic agent for a syndrome resembling premature aging, a therapeutic agent for adult diseases or an aging-suppressing agent, using the same.09-18-2008
20110212489CULTURE MEDIUM FOR EUKARYOTIC CELLS - A proteolysate of a seed material derived from a plant species of the Asteraceae family, such as sunflower, has improved properties as a constituent of a culture medium for culturing eukaryotic, in particular animal cells. The seed material is defatted and is hydrolysed to a degree of 10-50% and subsequently separated from insolubles. The cells are particularly cultured for producing desired protein products.09-01-2011
20080199913Production of Recombinant Il-18 Binding Protein - The invention relates to a process for the production of IL-18 binding protein (IL-18BP), and to a composition comprising IL-18BP characterized by a specific glycosylation pattern.08-21-2008
20080199912Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides - The invention provides yeast strains, and polypeptides encoded by genes of such yeast strains, that have enantiospecific internal epoxide hydrolase activity. The invention also features nucleic acid molecules encoding such polypeptides, vectors containing such nucleic acid molecules, and cells containing such vectors. Also embraced by the invention are methods for obtaining optically active internal epoxides and corresponding optically active internal diols.08-21-2008
20080199911VP1 OF FOOT-AND-MOUTH DISEASE VIRUS - A pure, water-soluble polypeptide containing one or more monomers of a VP1 protein of a foot-and-mouth disease virus; or a pure, water-insoluble polypeptide comprising two or more monomers of a VP1 protein of a foot-and-mouth disease virus. Also disclosed are a vaccine containing the polypeptide, a method of producing the polypeptide, and a method of inducing an immune response in a subject by administering to the subject an effective amount of the polypeptide.08-21-2008
20080199910Production of recombinant insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) in transgenic monocots - Two important human proteins, insulin growth factor I (IGF-I) and insulin growth factor binding protein 3 (IGFBP-3) have been produced in monocots. The recombinantly produced proteins exhibit the known activities of the native forms.08-21-2008